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Abstract 
The aims of this thesis were two-fold. Firstly, to develop a robust method to 
create a fully integrated, national surveillance dataset for human 
immunodeficiency virus (HIV) infections by linking records from three 
independent, national HIV case reporting systems. Secondly, to apply statistical 
techniques, more commonly used in cohort study research, to the integrated 
dataset to yield more of the potential from the constituent information and 
increase the public health utility of the data. This demonstrated that an 
integrated dataset can reduce missing information in each surveillance system 
and improve information use by combining different data that was previously 
available only in separate databases.  
Using the integrated dataset, I achieved the following: accounted for missing 
information; described the frequency of CD4 count measurements and 
associated factors; determined characteristics associated with late diagnosis 
and consequent mortality; estimated the national incidence of acquired 
immunodeficiency syndrome (AIDS) and death and the influencing factors; 
assessed information about the date of starting therapy for each individual; and 
assessed factors associated with immune defence recovery after the start of 
treatment. These analyses will be/have been integrated into national 
surveillance processes as appropriate and used to publish academic papers. 
Lessons have been learnt for surveillance methodology with regards sharing 
information and ensuring that data are representative of the whole population.  
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The large size, wide coverage and prospective nature of the integrated dataset 
mean that national (and local) policy decisions can be based on information that 
reflects the national picture rather than unrepresentative and time-bound 
studies. The dataset also has the power to unpick differences within small 
population groups. For example, evidence about late diagnoses and mortality 
has been used to promote the need for earlier HIV diagnosis and is updated 
annually and used to target local needs and to monitor improvements. 
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Chapter 1. Introduction 
1.1 Summary information about surveillance data 
Surveillance data are usually less detailed than research data but are collected 
routinely over time. Such data are therefore useful for describing the spread of 
infection, planning public health responses and allocating resources. 
Surveillance data for Human Immunodeficiency Virus (HIV) infections are very 
comprehensive in the United Kingdom (UK) and include individual-level data (no 
names), reported voluntarily, for most people diagnosed with HIV infection. 
Surveillance systems to provide epidemiological information about HIV 
infections in the UK have been in place since September 1982. These were 
initiated following the first case of Acquired Immunodeficiency Syndrome (AIDS) 
in the UK, diagnosed in a homosexual man and reported in December 19811. 
Surveillance now consists of several complementary systems that provide 
information about different aspects of the HIV epidemic in the UK. The 
complexity of certain aspects of HIV infection, including the long term nature of 
the infection, diagnosis at different stages of clinical progression, the high cost 
of treatment and care, and the stigma associated with infection, all demand that 
complex, complementary and confidential surveillance systems are in place to 
understand the epidemiology. Many of these systems involve assimilation of 
data that are routinely collected for clinical purposes on a long-term, national 
basis to provide timely public health information. However, the surveillance 
systems are separate because the primary sources of routine data are different; 
clinics, virology laboratories and immunology/haematology laboratories. HIV 
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surveillance systems in England, Wales and Northern Ireland (E,W&NI) are co-
ordinated by the Health Protection Agency’s Centre for Infections (HPA, CfI) 
and are integrated with those of Scotland and the National Study of HIV in 
Pregnancy and Childhood. HIV and AIDS surveillance data are used to help 
target and inform public health strategy, to help allocate resources for treatment 
and care, and to describe the nature of the epidemic. 
HIV surveillance systems in E,W&NI include the following: reporting of new HIV 
diagnoses, new AIDS diagnoses and deaths; annual cross-sectional surveys of 
all HIV-infected individuals attending for HIV-related care; reporting of CD4 cell 
counts of HIV-infected individuals; pregnancies in HIV-infected women and 
babies born to HIV-infected women (managed by the Institute of Child Health); 
testing samples to identify likely recent infection (still in initial phase); collation of 
laboratory viral sequence data from suspected resistance cases (managed by 
the Medical Research Council); and the Unlinked Anonymous laboratory testing 
of blood sample residues. The Unlinked Anonymous programme is unique 
because it provides data that are used to gain understanding of undiagnosed 
infection (and hence estimates of the undiagnosed and overall population 
prevalence). Such information is irreversibly unlinked from patient identifiers 
before HIV testing and therefore not used for direct patient management2. 
Monitoring reports on HIV-infected individuals is fundamental for the 
determination of the number of newly diagnosed HIV infections and newly 
diagnosed AIDS patients, the number of deaths among HIV-infected individuals, 
the number of diagnosed HIV-infected individuals seen for care during a 
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calendar year, and the level of immunosuppression of these individuals. 
Surveillance data from E,W&NI that provide this information are available from 
the following databases: 
 HIV and AIDS Reports database (HARS database), which collates reports 
from virology laboratories of all antibody positive individuals diagnosed with 
HIV for the first time at that laboratory (lab reports), reports from physicians 
of HIV-infected individuals newly diagnosed (on clinician report forms 
(CHRs) since January 2000), reports from physicians of new AIDS 
diagnoses (AIDS reports that have been adapted into CHRs since January 
2000), and reports of deaths among individuals living with HIV from both 
physicians and the Office of National Statistics (ONS); 
 CD4 Surveillance Scheme database (CD4 database) that collates reports 
from haematology and immunology laboratories of longitudinal CD4 cell 
counts for HIV-infected adults (men and women aged 15 or more); 
 Database of the Survey of Prevalent HIV Infections Diagnosed (SOPHID 
database), which collates reports of attendees of facilities providing statutory 
HIV-related treatment and care. 
1.2 Confidentiality in sexual health care and HIV surveillance 
The National Health Service (NHS) of the UK is a tax funded healthcare system 
with universal coverage, which is generally free at the point of care. HIV 
treatment and care is provided by open access and confidential (anonymous if 
requested) genitourinary medicine (GUM) clinics or specialist HIV clinics 
because sexual health and HIV remain stigmatised3.  
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Due to stigma, HIV surveillance systems in the UK are not based on statutory 
notifications (like many other infections) but voluntary and ‘pseudonymised’ HIV 
surveillance is permitted (Appendix A.1). Although reports pertain to an 
individual, the data received by the HPA do not contain patient names but a 
code based on the surname (but not unique to a given name) and date of birth 
and are therefore referred to as ‘pseudonymised’ (i.e. partially anonymised). To 
ensure confidentiality, all HIV-related data are stored on restricted and secure 
databases at the HPA, with strict adherence to the Data Protection Act and 
Caldicott Guidelines4. No patient-level data are ever released by the HPA, 
except back to clinics who have reported that information, and aggregate data 
are only published after ensuring that deductive disclosure cannot occur.  
1.3 Background to HIV infections 
1.3.1 Overview of HIV natural history and transmission 
HIV was first identified in 1983 as the causative agent of AIDS5-10 two years 
after AIDS was first recognised among homosexual men11. HIV is a chronic 
infection that appears to be terminal in all cases in the absence of treatment. 
Acute infection has been identified as a short phase of unspecific symptoms 
(fever, rash and sore throat) in 40-90% of adult cases but these symptoms are 
not usually recognised as primary HIV infection12. There often follows an 
extended period (sometimes many years) without symptoms before the 
development of serious clinical events and/or death. During this period the 
infected individual becomes progressively more immunodeficient until 
opportunistic infections cause illness and eventual death. AIDS represents the 
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late clinical stage of HIV infection and is clinically defined as a spectrum of 
opportunistic infections, cancers, neurological complications and other disorders 
(Appendix A.2)13;14. Not all infected individuals who die with HIV infection have 
developed AIDS, although the vast majority did so prior to the availability of 
effective treatment.  
The exact mechanism by which HIV infection impairs the human immune 
system remains unclear and it is likely that a combination of proposed 
mechanisms is involved. However, between 1981 and 1987 the CD4 molecule 
on the surface of T helper lymphocytes was identified as the receptor for the 
HIV virus15-17, the immunodeficiency associated with AIDS was shown to be due 
to a progressive loss of these CD4 cells due to HIV infection18-23, and CD4 cell 
counts were shown to be predictive for the development of AIDS24-28. CD4 cell 
counts (absolute T-helper lymphocyte count as a concentration per cubic 
millimetre of blood) are therefore most frequently used as markers of 
immunodeficiency and the risk of progression. Declining CD4 counts as a 
function of time are illustrated in Figure 1.1, which represents the natural history 
of HIV infection. The literature suggests that this trend is best described by a 
curve, which is linear in the square root or logarithm of the CD4 cell count29-35. 
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Figure 1.1. Natural history of infection shown by declining CD4 counts* 
 
 
The function of the CD4 cells and the ability of the thymus to generate CD4 
cells in the presence of HIV infection may be important determinants of the rate 
of progression of infection36;37. Decreasing thymic function with age has been 
recognised as a major cause of increased progression with age38-41. However, 
CD4 cell function is infrequently studied in the routine medical care of HIV-
infected individuals. 
                                            
* Reproduced from Cozzi Lepri et al. Journal of Infectious Diseases 1997;175:775–80 29 
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1.3.2 CD4 cell counts prior to HIV infection and measurement 
error 
CD4 cell counts tend to be stable for each adult without HIV infection over long 
periods of time42. Yet, there is a wide range of CD4 cell counts among 
uninfected adults (studies indicate medians between 591 and 1116 cells/mm3 
with large inter-quartile ranges [IQR])42-47. Women have higher CD4 cell counts 
than men43;44;48-53 but there is no consensus on whether these differences are 
maintained among HIV-infected individuals or whether they are associated with 
an effect on the rate of progression to AIDS or death among untreated 
individuals49;54-56 (the similar progression rates for men and women suggest 
that the difference becomes less pronounced over time since infection49). 
There is also evidence that CD4 counts may be up to 30% lower during 
pregnancy but that the trend is u-shaped and CD4 counts recover to previous 
levels after delivery50;57. There is some evidence for differences in the CD4 cell 
counts of uninfected individuals by geography/race/ethnicity. Most comparisons 
have been between summary results of studies and largely indicated lower 
CD4 counts among Asians, Africans, Middle-Eastern and Chinese than among 
Caucasians42;53;58-64 although similar studies have contradicted these findings65-
69. Studies that directly compared racial/ethnic groups either did not control for 
possible confounding factors70-75, did not find any differences by 
race/ethnicity76, or found no differences by race/ethnicity after controlling  for 
other factors77. It is important to note that even if there are differences between 
races/ethnicities in CD4 cell counts prior to HIV infection, these do not have 
any significant clinical effect on the rate of progression to AIDS or death 
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because of faster CD4 decline for those with higher CD4 counts 63;78-83. 
Furthermore, CD4 cell counts prior to infection are rarely known for HIV-
diagnosed individuals. Therefore, CD4 cell counts prior to infection are not 
used at the population or individual-level to vary the immunologic threshold for 
initiation of antiretroviral therapy. 
Other factors are associated with CD4 cell counts among adults without HIV 
infection but only account for a small proportion of the observed variability. 
There is a diurnal variation such that CD4 cell counts increase during the day48, 
and pregnancy, use of the contraceptive pill, smoking, illness (including 
tuberculosis and viral infections such as influenza), and trauma have all been 
associated with temporarily diminished CD4 cell counts42-46.  
There is likely to be significant measurement error in the determination of CD4 
cell counts as there is considerable variability both within an individual and 
between laboratories48. This variation is likely to have decreased over time as 
more reproducible laboratory techniques have developed. 
1.3.3 Transmission, viral loads and viral types/subtypes 
Susceptibility to HIV infection appears to be universal although host factors, co-
infections and medical interventions can affect the risk. Documented routes of 
infection are sexual exposure, exposure to blood or tissues and breast feeding 
with infectivity correlated with the amount of virus (viral load) in the bodily fluid.  
Often in the second week after infection, a peak is seen in the viral load 
followed by the development of a specific immune response84;85. There is 
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continuing debate as to whether the viral load tends to fluctuate around a stable 
‘set point’ for some years or whether viral load levels progressively increase 
over the subsequent years of infection86-90. One theory suggests that the ‘set-
point’ varies significantly between individuals reflecting different steady-state 
levels of viral replication. Subsequent increases in viral load, related to a failure 
of the immune system to keep viral replication in check, often then predict the 
development of symptomatic disease. The contrasting theory suggests that viral 
loads rise progressively, and with it, the risk of AIDS and death88;91-93. 
There are three main types of HIV virus, HIV-0, HIV-1 and HIV-2, which are 
serologically and geographically relatively distinct with numerous subtypes. HIV-
1 is most commonly found in the UK whereas HIV-0 and HIV-2 remain mainly 
confined to West Africa. By the end of 2007, there were 121 diagnoses of HIV-2 
infection in individuals without HIV-1 infection reported in the UK and a further 
22 diagnoses of HIV-1 and HIV-2 dual infections. HIV-1 is more pathogenic than 
HIV-0 or HIV-2 with a faster rate of CD4 cell count decline, a faster rate of 
disease development and shorter survival94-96. There is also evidence that 
infection with HIV-1 subtype D or some recombinant subtypes is associated 
with a higher risk of death and faster CD4 cell count decline than subtype A 
infection80;97-103. However, HIV types will not be considered in this thesis 
because HIV testing strategies do not always seek to distinguish types and 
subtypes and because surveillance lacks good data in this area. 
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1.3.4 Detection of HIV/HIV tests/diagnosis 
Detection of the HIV virus has been widely carried out since 1984 using the 
enzyme-linked immunosorbent assay (ELISA), which detects antibodies specific 
to HIV in venepuncture serology samples. ‘4th generation’ HIV tests, which 
include antigen detection to increase sensitivity are now the standard of care. 
Point-of-care testing kits, which use blood from fingerpricks or mouth swabs and 
provide results within minutes, can facilitate HIV testing where laboratory testing 
is not feasible or when results are required promptly. However, these currently 
do not detect antigen and have lower specificity. Independent assays should be 
used to confirm all positive HIV test results104;105. 
In the UK, HIV testing has been primarily available at sexual health, HIV and 
antenatal clinics. Prior to 1999, HIV testing was largely a result of individuals 
requesting an HIV test. Subsequently, HIV testing increased with the 
recommendations that the following groups should be offered a test: all 
pregnant women (1999); all GUM attendees (2001); all individuals with 
symptoms indicative of HIV infection attending healthcare settings (2001); all 
individuals with a high risk of infection* (2008); all adults registering in primary 
care and all general medical admissions where diagnosed HIV prevalence 
estimates in the local population exceed 2 in 1000 (2008)105-111. 
                                            
*
 all men and women reporting a history of IDU, all individuals known to be from a high 
prevalence country or who report sexual contact with individuals from areas of high HIV 
prevalence, and all men who have disclosed sexual contact with other men 
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1.3.5 Key risk groups for HIV infection 
Men who have had sex with men (MSM), injecting drug users (IDU) and 
individuals from areas of high HIV prevalence, particularly sub-Saharan Africa 
(SSA), are preferentially offered HIV testing because these groups are 
disproportionally affected by HIV infection in the UK. Estimated overall HIV 
prevalence among individuals aged 15 to 44 years in England, Wales and 
Scotland in 2006 was 5.36% among MSM, 0.43% among IDU, 2.86% among 
women born in SSA, 1.57% among men born in SSA, 0.04% among women 
born elsewhere and 0.03% among men born elsewhere (unpublished HPA data 
using Multi-Parameter Evidence Synthesis methodology112-114). Additionally, 
many individuals were unaware of their infection (Table 1.1)115. 
Table 1.1. Estimated* number of adults (15-59 years) with HIV in the UK in 2006 
Exposure category Number diagnosed
†
 Number undiagnosed Total 
MSM 20,900  (20,300, 21,500) 9,200  (6,800, 12,800) 30,100  (27,600, 33,700) 
IDU 1,600  (1,400, 1,900) 1,100  (700, 1,600) 2,700  (2,300, 3,300) 
Heterosexuals  25,300  (24,500, 26,100) 11,100  (7,600, 16,200) 36,400  (32,900, 41,400) 
          Men 9,100  (8,800, 9,400) 5,600  (3,600, 9,300) 14,700  (12,700, 18,400) 
African born  5,700  (5,500, 5,900) 3,200  (1,600, 6,400) 8,900  (7,300, 12,100) 
Non-African born  3,400  (3,200, 3,500) 2,400  (1,600, 3,900) 5,800  (5,000, 7,300) 
          Women 16,200  (15,700, 16,800) 5,400  (3,700, 7,500) 21,600  (20,000, 23,700) 
African born  12,100  (11,700, 12,500) 3,500  (2,000, 5,300) 15,600  (14,100, 17,400) 
Non-African born  4,200  (4,000, 4,300) 1,800  (1,200, 3,000) 6,000  (5,300, 7,200) 
Grand total 47,800  (46,500, 49,100) 21,600  (17,000, 27,800) 69,400  (64,800, 75,500) 
                                            
*
 Numbers of prevalent infections (rounded to the nearest 100) with credible ranges were estimated using 
Multi-parameter Evidence Synthesis, in an extension of the method described in Goubar A et al 
112 
†
 Numbers diagnosed exclude individuals aged 15-59 living with HIV in 2006 infected through blood or 
blood products or tissue (466) or through mother to infant transmission (233). Numbers diagnosed include 
individuals with unknown exposure, allocated according to the distribution of those with known exposure. 
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1.3.6 Treatment of HIV-infected individuals 
Daily therapy with a combination of antiretroviral drugs can reduce the viral load 
below the level of quantification, increase CD4 cell counts, and reduce the risk 
of opportunistic infections and the development of AIDS, which prolongs life116. 
However, insufficient adherence allows viral mutations to develop that can 
promote resistance to antiretroviral drugs and loss of the benefits of 
treatment117. It is often difficult for patients to adhere sufficiently even if they do 
not suffer from any side effects of therapy, but these are common and can 
cause significant morbidity, discouraging patients from starting or continuing 
treatment. Therefore, treatment of an HIV-infected individual must balance the 
advantages of attaining viral suppression with the risks of drug toxicities and 
viral resistance. Even assuming no resistance or toxicities, it would take an 
estimated 73 years to eliminate HIV from the body with currently available 
therapies because of a latent reservoir of HIV in resting memory CD4 cells118-
120. Thus, it is unlikely that HIV clearance will be achieved and therapy is 
expected to be lifelong. Yet, the majority of patients can tolerate antiretroviral 
therapy (ART) well for years and treatment can be effective even after detection 
of resistance121;122. 
There are currently five classes of antiretroviral HIV drugs approved in the UK: 
nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs), non-
nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), 
fusion (or entry) inhibitors and an integrase inhibitor. Most effective regimens 
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consist of a combination of drugs, referred to as ‘highly active antiretroviral 
therapy’ (HAART), and often made up of two NRTIs and either an NNRTI or PI. 
There is much debate about the optimum time to start therapy due to the need 
for a balance between viral suppression and the risks of drug toxicities, viral 
resistance and long-term damage to the immune system. Treatment guidelines 
recommend that HAART be initiated fairly late in the course of infection, 
primarily based on CD4 cell counts, but before the patient has become at 
markedly increased risk of AIDS or death123. Cohort studies have shown that 
the short-term risk of AIDS or death is higher for individuals starting treatment 
with CD4 cell counts below 200 cells/mm3 than for those with counts over 200 
cells/mm3 and that there is little further decline in the risk as counts increase to 
over 350 cells/mm3 or over 500 cells/mm3 124;125. Therefore, British guidelines 
between 2001 and 2006 recommended that individuals start treatment before 
CD4 counts fell below 200 cells/mm3 but that treatment was deferred for most 
until counts were below 350 cells/mm3 (also that treatment be initiated 
immediately for individuals with AIDS defining illnesses and considered for 
individuals with high viral loads or rapid loss of CD4 cells) (Table 1.2). However, 
the recommended threshold changed over time as new evidence informed the 
point at which the benefits of treatment were likely to outweigh its risks126;127. 
Randomised controlled trials to determine the optimal time to initiate therapy 
have not yet been completed. In 2008 and 2012 (after the period for which this 
thesis analyses data), these guidelines were updated again. In 2008, the 
guidelines were updated to recommend the initiation of treatment for all 
individuals with CD4 count below 350 cells/mm3 and also for those with CD4 
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count between 350 and 500 cells/mm3 with higher risk of clinical events* 123. 
These guidelines remained very similar in 2012 except that CD4 counts close to 
the threshold of 350 cells/mm3 were included in the recommendation for 
initiation of treatment and the limit of 500 cells/mm3 was removed for individuals 
indicated treatment for hepatitis B and for patients wishing to reduce the risk of 
transmission128. 
Table 1.2. Recommended CD4 thresholds for initiating ART. 
Year guidelines 
published 
CD4 threshold 
(cells/mm3) 
Recommendation (paraphrased) 
1997129 <300 
Consider at all levels. No evidence to indicate the 
optimum time to start therapy. 
1998130 >350 
Should begin before irreversible damage has 
occurred to the immune system such as at a CD4 
count above 350 cells/mm3. 
2000131 <350 
Treat when CD4 count is less than 350 cells/mm3. 
Consider when CD4 count is 350-500 cells/mm3.   
2001132 200-350 Start treatment within 200-350 cells/mm3 range. 
2003133 201-350 
Most individuals should start therapy when the CD4 
count is in the range 201-350 cells/mm3. 
2005134 200-350 
Recommended that the majority of people initiate 
therapy with CD4 counts of 200 to 350 cells/mm3 
2006135 200-350 
Treatment should start before CD4 cell count has 
fallen to below 200 cells/mm3. Majority of patients 
with CD4 cell counts greater than 350 cells/mm3 
should continue to defer treatment. 
2008123 ≤350 
Treat as soon as possible when CD4 count is less 
than 350 cells/mm3. Consider in specific situations 
when CD4 count is 350-500 cells/mm3.   
2012128 ≤350 
Treat when CD4 count is less than 350 cells/mm3 or 
close to this threshold. Consider in specific situations 
when CD4 count is >350 cells/mm3.  
                                            
*
 any HIV-related co-morbidity, hepatitis B or C co-infection, low CD4 percentage, established 
CVD or a very high risk of cardiovascular events, or if a patient wished to reduce the risk of 
transmission. 
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Treatment, although expensive, is free to patients in the UK (although only free 
for undocumented migrants in emergency situations). It is provided from open-
access, voluntary and confidential HIV-specific clinics in most areas and often 
integrated with genitourinary medicine clinics, which provide sexual health 
services136. 
1.4 Summary of aims of this thesis 
The aims of this thesis were firstly, to develop a robust method to create a fully 
integrated, national surveillance database for HIV infections by developing 
methods to link records from three independent, national HIV case reporting 
systems. And secondly, to apply statistical techniques, more commonly used in 
cohort study research, to the enhanced database to enable the constituent 
information to be analysed to its full potential, increasing the public health utility 
of the data. 
In chapter 2, I describe the methodology of the three national HIV case 
reporting systems, compare these systems to those of other developed 
countries, and describe the epidemiology of diagnosed HIV infections in 
E,W&NI using the national surveillance data. In chapter 3, I describe how I 
linked records from the three surveillance systems by comparing patient-
specific information (such as year of birth) between datasets using a 
hierarchical algorithm. This allowed for some clerical errors in the data and only 
retained links between the datasets that were reliable enough for use in 
analyses. Chapter 4 describes how an integrated dataset containing a single 
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patient record consisting of a coherent sequence of events was created from 
the linked records by triangulation and data validation. Chapter 5 shows how I 
investigated potential sources of bias that could affect subsequent analyses. 
These were inclusion bias and bias due to differential CD4 cell count 
monitoring, loss to follow-up (LTFU) and informative censoring. The aim of 
chapter 6 was to investigate the frequency of ‘late diagnosis’ of HIV infection 
and its consequent effect on mortality within a year of HIV diagnosis by 
analysing CD4 cell counts at the time of HIV diagnosis (as a marker of 
diagnosis after the recommended time for treatment initiation). In chapter 7, I 
use longitudinal CD4 cell counts for each individual to allocate follow-up time 
and to estimate the national incidence of AIDS and death and the influencing 
factors, considering specifically the first six months after HIV diagnosis. In 
chapter 8, I investigated a number of algorithms to estimate the time of starting 
ART based on changes in the CD4 cell count, with the aim of supplementing 
surveillance data for individuals for whom this data had not been reported. 
Chapter 9 describes the rate of change of CD4 cell counts after the initiation of 
ART and the determination of factors associated with these rates. Chapter 10 
provides a brief summary of the thesis with lessons learnt and further work 
indicated. 
The work included in this thesis was conducted over a number of years, over 
which time the epidemiology of HIV in the UK changed markedly and new data 
fields were added to the dataset.  Thus, all data and results were updated in 
2008. 
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Chapter 2. HPA case report systems and HIV epidemiology in 
England, Wales and Northern Ireland 
2.1 Introduction 
This chapter describes the data and case report systems used for monitoring 
HIV infections among adults in England, Wales and Northern Ireland (E,W&NI). 
The systems are the HIV and AIDS Reporting System (HARS), the Survey of 
Prevalent HIV Infections Diagnosed (SOPHID), and the CD4 Surveillance 
Scheme (CD4 Surveillance), which receive data from clinics, virology 
laboratories and immunology laboratories. 
The second section uses data received by these systems to describe the HIV 
epidemic. It highlights the limitations of surveillance and the conclusions that 
can be drawn by making informed assumptions about the data. It shows that 
MSM have continuously been diagnosed in large numbers but that estimated 
numbers of MSM living with HIV in the UK have recently been almost matched 
by black African heterosexuals from sub-Saharan Africa. As well as showing 
geographical foci of the epidemic, case reports indicate that prevalence has 
increased markedly in association with increasing numbers of new diagnoses, 
and decreasing numbers of deaths due to treatment. 
Section three summarises HIV case reporting in other countries with similar HIV 
epidemics to provide context and a wider understanding of HIV surveillance.  
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2.1.1 Data analysed: HIV infections among adults in E,W&NI to 
the end of 2007 
The data analysed throughout this thesis was derived from reports of HIV 
infections among adults (aged 15 years or more) from clinics or laboratories in 
E,W&NI. Transmission of HIV from mother to child was first recognised in 
1982137 and case reports due to this route of infection were originally included in 
the remit of the HPA but taken on by the Institute for Child Health in the late 
1980s. Reports are added to the HPA databases on a regular basis and 
included in UK surveillance reports. However, missing patient identifiers on 
reports for children limits the possibilities for data linkage across surveillance 
systems. Additionally, the natural history of infection among children is quite 
different than it is among adults.  
Case reports from Scotland are made to Health Protection Scotland and 
aggregate data are included in UK surveillance reports. However, only 
disaggregate data on new diagnoses in Scotland have been historically 
incorporated into the HPA database so Scottish data was not included in the 
data analysed. Analyses were updated in 2008, when data were practically 
complete for 2007 so events after the end of 2007 were not considered.  
2.1.2 Key data used to link records from the same individual 
Key data for HIV case report surveillance systems in E,W&NI include the 
‘pseudonymised’ patient identifiers: soundex code, date of birth, firstname initial, 
area of residence (reported as postcodes [Appendix A.3]), local patient 
identification (ID) number, and demographic information on probable route of 
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infection (subsequently referred to as risk group) and ethnicity. These data are 
fundamental to individual-based HIV surveillance systems and to this thesis 
because, in combination, they are considered specific enough to link records 
from the same individual while maintaining confidentiality because no names 
are collected.  
The soundex is a four-character alphanumeric code of the patient’s surname 
(e.g. C316 for Chadborn [Appendix A.4]) based upon phonetic grouping of its 
consonants, which is not unique to a surname due to redundancy in the coding 
system (only 6,734 possible soundex codes are available). Therefore, it is not 
possible to decode a soundex code to a specific surname (to reverse the 
function) with any certainty. Soundex codes were originally developed with the 
aim of matching equivalent surnames that had been spelt differently over time 
or because of clerical errors138. 
Local patient ID numbers (also known as clinic numbers but not to be confused 
with numbers identifying clinics) are assigned by HIV and sexual health clinics 
to uniquely and anonymously identify patients locally. HIV surveillance systems 
use these numbers to identify reports from the same individual originating from 
the same clinic or hospital. Local patient ID numbers do not have a nationally 
standardised format although many are alphanumeric codes that include an 
incremental number, which increases as new patients are added to the clinic 
cohort, and prefixes and/or suffixes, which may denote the patients’ sex, year of 
first attendance at the clinic and/or the clinic within the hospital (e.g. 
GUM99M00132). 
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The frequently long delay between infection and diagnosis means that 
individuals often do not know exactly when or from whom they acquired 
infection. To understand the epidemiology of HIV in the UK, reports to the HPA 
are categorised by their most likely route of infection according to a hierarchy 
(Appendix A.5) related to the decreasing risk of transmission (assigned 
according to data on reports). Individuals categorised as having acquired their 
infection heterosexually are sub-categorised according to the risk group of their 
partner(s) following the same hierarchy. Those presumed heterosexually 
infected by a partner presumed also to have acquired infection heterosexually 
are again sub-categorised. This sub-categorisation is according to whether the 
exposure occurred abroad or in the UK, and then by world region of exposure 
(ranked by HIV prevalence). Exhaustive follow-up is attempted for all individuals 
who cannot be categorised from data initially reported (Sections 2.2.9 and 
2.4.3). 
The ethnicity of HIV-infected adults was requested on all AIDS reports, on all 
HIV reports since 2000 (since 1993 for individuals infected abroad) and on all 
clinician reporting forms (CHRs). Ethnicity was not routinely followed-up if 
missing but was requested if follow-up of other data was undertaken. It was 
categorised as follows: i) White, ii) Black African, iii) Black Caribbean, iv) Black 
– other, v) Indian\Pakistani\Bangladeshi, vi) Other/mixed. 
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2.2 Reporting of HIV and AIDS diagnoses and deaths  
2.2.1 Background 
A report to provide detailed information about AIDS in the UK was proposed in 
August 1982139 following a case* of AIDS in a homosexual man in December 
19811. In September 1982 a voluntary clinical reporting system was initiated by 
requesting consultant dermatologists and venereologists from E,W&NI to report 
new diagnoses of AIDS to the HPA’s Centre for Infections141. In November 
1982, microbiologists were asked to include age, sex and sexual orientation on 
their reports of Kaposi’s sarcoma and severe opportunistic infections when the 
condition appeared to fit the definition of AIDS. Also in 1982, the Office of 
National Statistics (ONS) began to provide the HPA with details of deaths due 
to Kaposi’s sarcoma or AIDS on a weekly basis.  Although the case definition of 
AIDS has been revised since the early 1980s, these original methods remain 
essential to the surveillance of HIV and AIDS in the UK today (Figure 2.1). 
HIV antibody tests became available at the HPA’s Virus Reference Laboratory 
in the UK in late 1984142 and voluntary HIV serosurveillance was added to 
national surveillance in March 1985 (Section 2.2.2). Virologists who receive 
specimens for HIV testing have since been asked to report to the HPA all 
                                            
*
 based on a working definition of AIDS among adults developed by the Centers for Disease 
Control and Prevention, Atlanta, for the purposes of epidemiologic surveillance 
140
. Cases were 
defined “as illness in a person who (1) has either biopsy-proven Kaposi’s sarcoma or culture-
proven, life-threatening opportunistic infection, (2) is under age 60 and (3) has no history of 
either immunosuppressive underlying illness or immunosuppressive therapy”. 
46 
 
individuals when they are first identified as HIV positive in their laboratory. 
Detection of HIV also enabled retrospective HIV diagnoses from stored samples 
such as those from haemophiliacs. Information about these HIV infections was 
collated in the database of the United Kingdom Haemophilia Centre Doctors’ 
Organisation and epidemiological data on new diagnoses were sent to the HPA. 
A timeline of the development of the various surveillance methods for reporting 
HIV and AIDS diagnoses and deaths is shown in Figure 2.1. The methods and 
forms used are described in more detail in the following sections. 
Figure 2.1. Timeline of the introduction and modification of the various 
surveillance methods for reporting HIV and AIDS diagnoses and deaths.  
 
The HARS database is managed by a team of epidemiologists and data 
management staff at the HPA. This usually consists of a two data entry clerks, 
two graduate scientists and a research nurse led by a Masters-level 
epidemiologist and overseen by a medical consultant epidemiologist. 
Jan-1980 Jan-1984 Jan-1988 Jan-1992 Jan-1996 Jan-2000 Jan-2004
Laboratory HIV reporting Clinician HIV/AIDS reporting Clinician AIDS reporting ONS death reports
Form 30 Form 30A Form 2 Form D95 Form L0001Laboratory HIV 
reporting
Clinician AIDS 
reporting
ONS reports 
of deaths
Indicates a revision of the form used to report to HPA
Form D93 Form L3 Form L4
Clinician HIV/AIDS reporting
Form C3Form C0001 Form C2
Jan-2008
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2.2.2 Ascertainment of reports of HIV and AIDS diagnoses 
HIV and AIDS reporting have always been voluntary and in strict medical 
confidence so as not to deter individuals from being tested. Whilst largely 
complete, an estimated 10-20% of new diagnoses were not reported to the HPA 
in the first decade of the epidemic143. However, this compared favourably with 
the completeness of surveillance for infections made officially notifiable144. 
Information as to why reports are not sent is not available and the proportion 
under-reported has not been robustly determined.  
2.2.3 The HARS database 
Databases have been used to support the surveillance of HIV/AIDS since the 
establishment of AIDS reporting in 1982 and data have been transferred 
between databases at the time of each upgrade (every five years since 1985) 
(Appendix A.6). A separate HIV database was created with the advent of HIV 
serosurveillance in 1985 but since 1995 the HIV and AIDS databases have 
been unified. These databases were patient-based with a single integrated and 
coherent record for each patient linked to reports of HIV diagnoses, AIDS 
diagnoses and deaths. Integration of the AIDS and HIV databases allowed 
simple production of national figures of the number of individuals reported as 
HIV-diagnosed. The structure of the database, showing the main data tables 
and their relationships at the end of December 2007 is shown in Figure 2.2. 
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Figure 2.2. Main data tables and their relationships in the database of HIV 
diagnoses, AIDS diagnoses and deaths for HIV-infected individuals: 2007. 
 
The ‘patient’ table forms the basis of the database with a single integrated and 
coherent record from each patient containing data from potentially a number of 
sources. This source information is recorded, as reported, in the supporting 
tables according to the source and type of form: the ‘lab report’ table stores 
minimal data about newly detected positive HIV test results that are reported on 
laboratory HIV reporting forms from virology laboratories; the ‘AIDS diagnosis’ 
table stores data about new AIDS diagnoses reported on AIDS forms by 
clinicians; the ‘CHR’ table stores both data on new HIV infections and new AIDS 
AIDS Diagnosis 
Patient ID 
CHR 
Patient ID 
Patient 
Patient ID 
Lab Report 
Patient ID 
Death Record 
Patient ID 
FUP* 
Patient ID 
FUP* Interview 
Patient ID 
ONS 
Patient_ID 
* FUP = follow-up 
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illnesses diagnosed by clinicians that are both reported on CHRs; the ‘death 
record’ table stores a single integrated and coherent record from each patient 
who is known to have died irrespective of the source of that information; the 
‘ONS’ table stores records of deaths reported to ONS that have been linked to 
records of HIV-infected individuals in the ‘patient’ table; the ‘FUP’ (follow-up) 
table stores records of reports that require follow-up due to incomplete 
information; the ‘FUP interview’ table stores information from interviews of 
patients conducted to ascertain that incomplete information. The ‘patient ID’ 
links all records from the same patient. 
On addition of new reports to the database, data are merged if reports are 
complementary (HIV and AIDS reports, HIV and death reports, AIDS and death 
reports, or HIV, AIDS and death reports). If the same event is reported more 
than once then only the report with the earliest date of event is retained in the 
patient record. However, any different demographic information on the report to 
be deleted is used to update missing data on the report that is retained. 
Conflicting information is dealt with individually and on an ad-hoc basis as new 
report forms are received.  If a clear majority of reports concur and differ from 
the new information then the new information is not used to update the patient 
record. However, demographic data reported directly from clinicians is assumed 
to be more dependable than data routed through laboratories. If a clear decision 
cannot be made then follow-up is undertaken to resolve the inconsistency.  
Since 1997, an additional and separate flat table, called ‘XLatest’ has been 
created in the database at the end of every quarter (biannually since January 
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2008). This aggregates key elements of all reports received to date into one 
record per individual and is therefore more comprehensive than the ‘patient’ 
table (Appendix A.7). The ‘earliest event date’ in this table is understood to be 
the earliest reported date of confirmed HIV-infected status for the individual 
whether it comes from a laboratory report, a clinician report or a death report 
(assuming complete reporting of events). For the large majority of records, this 
reflects the first positive result from voluntary testing. In a few cases this is the 
date of clinical AIDS diagnosis prior to an HIV test (in particular for those cases 
diagnosed before the availability of antibody tests) and in even fewer, a date of 
death where post-mortem investigation reveals evidence of HIV-infection. 
Related information, such as the ‘earliest organisation’ that reported the event 
and the ‘age at earliest event’ are extracted from the relevant forms, which are 
recorded in the ‘earliest event code’. The first reported date of birth and 
soundex code are assigned to the patient record, unless subsequently reported 
or found through follow-up to be incorrect.  
2.2.4 Laboratory reporting of HIV and AIDS diagnoses 
In 1984, microbiologists began to report newly diagnosed HIV infections 
individually on pre-existing forms for the reporting of other infections (Appendix 
Table B.1 and Appendix Forms B.1a – B.1i). After HIV serosurveillance was 
initiated in March 1985, an HIV-specific form was used until 1989 that allowed 
the reporting of up to 9 cases per sheet and was accompanied by a specific 
guide for completion. However, it was not until September 1993 (after 
reincorporation into the standard laboratory reporting form for individual cases) 
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that the first dedicated HIV form with accompanying guidance sheet was 
introduced. This was used with minor modifications until January 2000 when 
clinician reporting of newly diagnosed HIV infections was introduced. As many 
diagnoses would subsequently be reported by clinicians it was therefore no 
longer justifiable to request information that was not readily available in the 
laboratory and was expected to be duplicated on the clinician HIV form (CHR). 
However, laboratories were asked to continue reporting newly diagnosed HIV 
infections to indicate diagnoses that were not reported by clinicians and to 
provide preliminary information in the case of delayed clinician reporting. 
Multiple records of an HIV diagnosis for an individual are expected because all 
laboratories are asked to report the first time that they diagnose an individual 
even if they know that the patient was previously diagnosed elsewhere. This is 
to maximise the completeness of surveillance and to save reporters from 
enquiring whether patients have been diagnosed elsewhere. However, if 
patients are known to have been diagnosed elsewhere, the form requests the 
date and place of earliest diagnosis to help identify and link related reports. 
A total of 417 laboratories (serving 621 clinics) in E,W&NI had been involved in 
reporting newly diagnosed HIV infections among adults to the HPA to the end of 
June 2008 (Map 2.1). By the end of June 2008, 206 laboratories (serving 311 
clinics) had reported new HIV/AIDS infections that were diagnosed during 2007. 
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Map 2.1. Location of laboratories and clinics that have reported data to HARS 
 
  
 
Key: 
Reference laboratories 
that reported data 
Laboratories/clinics that 
reported data in 2007 
Laboratories/clinics that 
reported data previously 
but not in 2007 
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2.2.5 Clinician reporting of HIV and AIDS diagnoses and deaths 
In September 1982 clinicians began to confidentially report newly diagnosed 
cases of AIDS to the HPA141. Due to the progressive nature of infection without 
effective antiretroviral therapy, individuals are considered to be AIDS cases 
from the first diagnosis of AIDS-defining illness. The status of the patient does 
not revert with successful treatment of or spontaneous recovery from the illness.  
The form used to report AIDS cases was revised with each revision of the AIDS 
case definition in 1985, 1987, 1989, 1993 and 1996 and additional minor 
changes were made in 1997 and 1998 to add further questions about 
antiretroviral therapy (Appendix Table B.2 and Appendix Forms B.2a – B.2g). 
These forms have also requested the date of death of HIV-infected patients who 
are known to have died. In January 2000, the AIDS report form was adapted to 
also allow clinicians to report newly diagnosed HIV infections (Appendix Table 
B.3 and Appendix Forms B.3a – B.3c). Clinicians are not requested to report 
HIV-infected individuals they see for the first time if they know them to have 
been diagnosed previously as these are expected to be reported by the 
laboratories if not by the previous clinician. 
Since 1987, both AIDS forms and CHRs have requested that clinicians notify 
the HPA by telephone or letter of the date and cause of death of patients who 
die after being reported on an AIDS form or CHR. 
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2.2.6 ONS files of death certificates 
ONS has provided notifications of deaths occurring in HIV-infected individuals to 
complement the reporting of newly diagnosed HIV infections, since 1982. These 
add to the reports clinicians are asked to make when a patient dies, may 
identify some previously unreported cases (see below), and may provide 
causes of death not otherwise reported.  
On a monthly, quarterly and annual basis, files of deaths are compared with 
HARS to see whether any further deaths in HIV-infected individuals can be 
identified. Monthly files, received since 1982, contain a report of every death 
notified in the previous month on which HIV, AIDS, Pneumocystis pneumonia, 
Kaposi’s Sarcoma or conditions suggestive of these as a cause of death were 
recorded. Quarterly files contain notifications of all individuals aged less than 60 
years who have died in the previous quarter to allow record linkage to deaths 
where HIV-related conditions have not been reported. Quarterly files have been 
received prospectively since 1997 but historical files were used at that time to 
update HPA records of deaths occurring between January 1993 and December 
1996. Although this information is timely, not all deaths are included due to 
delayed notifications (for example, notifications awaiting a coroner’s 
investigation). Therefore, annual files are also requested, which contain the final 
underlying cause of death information (which is not part of the public death 
certificate) for all deaths in those aged less than 60 years by calendar year of 
death. Restricting the data to those dying at age less than 60 years provides a 
manageable data set while including the majority of those who might have been 
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HIV-infected. Annual datasets are produced from the ONS ‘Statistics’ file on 
which their outputs are made; these are complete but not timely as this process 
is not finalised until autumn in the year following the date of death. Annual ONS 
files were first received in 2002 for individuals dying in 2000. 
Figure 2.3 shows how quarterly and annual ONS files improved the 
ascertainment of deaths in 1993 and 2000 respectively. 
Figure 2.3. Source of first received death report by year of death 
  
A death record is added for any death report that can be identified as relating to 
an individual with both HIV and AIDS reports. Follow-up to ascertain whether 
the patient ever had AIDS is carried out for any death report that is linked to an 
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HIV report without a linked AIDS report. Where there is no link to existing 
reports but the ONS report indicates an HIV-related death or an illness usually 
associated with HIV, follow-up for both HIV and AIDS information is carried out. 
For follow-up, a physician at the site that reported the death is written to and 
asked to complete and return a CHR form (AIDS form before 2000). This 
confirms the HIV status and usually provides earlier dates of HIV and/or AIDS 
diagnoses. In recent years, about 100 further deaths have been assigned to 
patient records in HARS from annual ONS files. 
2.2.7 Delayed reporting of HIV diagnoses, AIDS and deaths 
A considerable number of reports of HIV diagnoses, AIDS diagnoses and 
deaths continue to be received months and years after the events occur. Just 
less than a third of the HIV diagnoses that were reported (by 2008) to have 
occurred in the first quarter of 2003 were received in the same quarter as the 
diagnosis occurred (Table 2.1). Almost 15% were received after more than one 
year and almost 5% were received after more than two years. The equivalent 
percentages for AIDS and deaths, respectively, were 21% and 18% reported 
after more than one year and 8% and 13% reported after more than two years. 
The greater percentage of death reports delayed by more than two years and 
the peak in the number of death reports delayed by 10 quarters reflects the 
timeliness of ONS files of deaths rather than clinician or laboratory reporting. 
Similar reporting delay affects surveillance systems in other countries145. 
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Table 2.1. Numbers of HIV diagnoses, AIDS diagnoses and deaths (with or 
without AIDS) reported (by the end of 2007) to have occurred in the first quarter 
of 2003 by the number of quarters before reports were received 
Number of 
quarters delayed 
Number (%) of events that occurred in the first quarter of 2003 
HIV diagnoses AIDS diagnoses Deaths 
0 615  (31.4) 60  (26) 43  (31.2) 
1 747  (38.1) 63  (27.3) 59  (42.8) 
2 172  (8.8) 28  (12.1) 6  (4.3) 
3 124  (6.3) 31  (13.4) 5  (3.6) 
4 39  (2) 11  (4.8) 2  (1.4) 
5 118  (6) 8  (3.5) 4  (2.9) 
6 34  (1.7) 8  (3.5) 1  (0.7) 
7 22  (1.1) 3  (1.3) 0  (0) 
8 23  (1.2) 6  (2.6) 1  (0.7) 
9 11  (0.6) 4  (1.7) 0  (0) 
10 33  (1.7) 1  (0.4) 15  (10.9) 
11 2  (0.1) 0  (0) 0  (0) 
12 1  (0.1) 1  (0.4) 0  (0) 
13 3  (0.2) 1  (0.4) 2  (1.4) 
14 2  (0.1) 2  (0.9) 0  (0) 
15 5  (0.3) 2  (0.9) 0  (0) 
16 6  (0.3) 2  (0.9) 0  (0) 
17 0  (0) 0  (0) 0  (0) 
18 2  (0.1) 0  (0) 0  (0) 
19 1  (0.1) 0  (0) 0  (0) 
Total 1,960 (100) 231  (100) 138  (100) 
 
2.2.8 Under-reporting of HIV and AIDS diagnoses and deaths 
Under-reporting of HIV diagnoses, AIDS diagnoses and deaths to HARS is 
suspected because a number of records reported to CD4 Surveillance, SOPHID 
or ONS cannot be linked to HARS. Under-reporting of AIDS and deaths have 
also been frequently reported in the literature146-156. However, the degree of 
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under-reporting of these events has not been determined due to the difficulty in 
confirming whether the unlinked records represent different individuals or 
individuals that have already been reported to HARS but with different patient 
identifiers. Additionally, because of the passive nature of HARS reporting, it is 
difficult to ascertain whether these events would have been reported in the 
future to distinguish between delayed reporting and under-reporting. For deaths, 
doctors may be reluctant to record HIV on what is essentially a public 
document, reducing the number of deaths among individuals with a prior AIDS 
diagnosis that are identifiable from this source as HIV-infected148;152;157-161. In 
addition, some HIV cases may not be detected at death if the post-mortem did 
not indicate HIV infection. In particular, there were deaths that were not 
associated with an AIDS illness prior to the availability of effective combination 
therapy and non-AIDS related deaths have accounted for an increasing 
proportion of all deaths among HIV-infected individuals since then152;162. 
2.2.9 Follow-up of missing information 
Follow-up is carried out for missing patient identifiers and missing CD4/viral 
load information. Clinics are telephoned for any missing data on the following: 
 Soundex code, date of birth, sex (the few reports without these pieces of 
information have not been added to the database since January 2000); 
 Any CD4 cell counts, CD4 cell count measurement dates, viral loads or viral 
load measurement dates missing from CHRs. 
If the local patient ID number and/or risk group are missing then those data are 
also requested during follow-up for the above information. 
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Follow-up is also carried out to reduce the proportion of records with missing 
route of infection data. Incomplete information makes determination of the 
number of new diagnoses acquired through uncommon routes difficult, may 
mask trends, and introduce selection bias to analyses. 
Follow-up is carried out for reports of all individuals who cannot initially be 
assigned to a route of infection category. This includes all those with no known 
route of infection (Figure 2.4 – category ‘undetermined’) and heterosexuals for 
whom information is missing on partner’s risk group or likely country of infection 
(if the partner is presumed to have been heterosexually infected) (Figure 2.4 – 
category ‘heterosexual undetermined’)163. To monitor onward heterosexual HIV 
transmission in E,W&NI, follow-up is also carried out for clarification of risk 
group where it was reported to be heterosexual and where the sexual contact 
took place in the UK with a partner not known to be from a country where 
heterosexual transmission is common and not known to be at high risk of HIV 
infection163. 
The missing information is requested from microbiologists and/or clinicians or 
by data extraction from patient notes or databases at clinical centres where 
necessary.  In-depth interviews with patients are sought, with the consent and 
facilitation of the clinician, when the likely route of transmission is otherwise 
unresolved. Any other missing information such as ethnicity is collected where 
possible if follow-up is undertaken for the reasons outlined above. 
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The graphs below show reports of new diagnoses in E,W&NI between 1997 and 
2007, before and after follow-up. Follow-up was required for 12,607 reports with 
‘undetermined’ route of infection and 9,223 reports with ‘heterosexual 
undetermined’ route of infection. Route of infection remained undetermined 
after follow-up for 24% and 17% of these records respectively. Follow-up was 
continuing for 17% (3,649) and abandoned for 2% (541) of cases. Cases were 
closed because patients had died (17%), patients were lost to follow-up (69%), 
clinicians advised against interviewing the patient (5%), patients refused 
interview (8%) or a route of transmission still could not be assigned after 
interview (1%). 
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Figure 2.4. Number of new HIV diagnoses in E,W&NI by risk group (a) before 
and (b) after follow-up 
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*includes sex between men, injecting drug users, all blood exposures, mother to infant and other. 
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2.2.10 Deduplication of reports from the same individual 
Linking reports from the same individual is important to collate information about 
events reported on different forms and to limit duplication of records of the same 
individual in the database. These may be reports of different events that are 
received at different times or from different sources. 
Deduplication occurs when a new report form is added to the database. Patient 
identifiers and demographics are compared using a multiplicative scoring 
system and likely duplicates are manually assessed by two users before reports 
are merged into a single consistent master patient record (Appendix A.8). 
Quarterly deduplication is also carried out on the whole database by identifying 
potential duplicate records for the same individual with matching dates of birth, 
sex and forename initial that may have been reported with different soundexes. 
The ‘master’ record in the patient table stores the demographic details from the 
report with the earliest date of HIV diagnosis and the earliest date of HIV 
diagnosis, AIDS and death. Records are not deduplicated if information is 
inconsistent unless follow-up confirms which data are correct. 
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2.3 The CD4 Surveillance Scheme 
2.3.1 Background 
The national CD4 Surveillance Scheme was initiated in 1993 to augment the 
epidemiological information collected through the reporting of HIV/AIDS 
cases164. Laboratories performing CD4 cell counts and participating in the UK 
National External Quality Assessment Scheme are requested to provide all CD4 
cell counts of HIV-infected adults (aged 15 years or more) to monitor trends in 
the prevalence of various levels of immunosuppression in E,W&NI. 
2.3.2 Coverage of laboratories 
Three laboratories initially reported CD4 cell counts in 1993 but by the end of 
1996 50 laboratories had sent data to the scheme. On enrolment, laboratories 
were requested to send retrospective data to improve the completeness of the 
archive. A total of 72 laboratories had reported data by the end of 2007 
although 10 of these no longer reported in 2007.  Of these ten, seven had 
contracted this work to another laboratory included in the CD4 Surveillance 
Scheme; one was too busy, one had computing problems and one had staffing 
issues. Two laboratories reporting in 2007 could not provide data for 2005 or 
2006 due to computing problems.  An additional seven laboratories contacted 
had never sent data to the CD4 Surveillance Scheme; two were too busy, two 
did not respond, one only did clinical trials, one was not interested, and one was 
about to start reporting data in 2008. Incomplete data are usually available 
retrospectively in subsequent years. 
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The database therefore contains the majority of the CD4 cell counts performed 
on HIV positive individuals in E,W&NI between 1990 and 2007 and achieves 
substantial national coverage (Map 2.2). 
Map 2.2. Geographic distribution of CD4 Surveillance Scheme participants 
 Key: 
Laboratory reporting ≥100 
individuals in 2007 
 
Laboratory reporting previously 
but not in 2007 
Laboratory reporting <100 
individuals in 2007 
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2.3.3 Data collected and data processing 
Variables collected with each CD4 cell count include: soundex code, date of 
birth, initial, sex, primary local patient ID number, secondary local patient ID 
number (if provided), date CD4 cell count measured, absolute CD4 cell count, 
total lymphocyte count, percentage of lymphocytes that are CD4 cells, doctor 
requesting the CD4 count and the local clinic or hospital source of the sample. 
However, some laboratories cannot send soundex and date of birth information 
because they do not receive it with the sample to ensure confidentiality. 
Information about individuals is used to populate a ‘patient’ table whereas the 
data about the CD4 cell counts is used to populate a ‘counts’ table (Figure 2.5). 
The patient table stores only the first reported set of demographic information 
for each patient regardless of whether that patient was subsequently reported 
with different demographics. Each record in the patient table is linked to as 
many records in the counts table as there are CD4 counts for that individual. 
CD4 cell counts are added to the database using the primary local patient ID 
number and reporting laboratory identifier. If the ID number matches an existing 
patient ID number on the database from the same laboratory, then the new 
counts are added to the counts table relating to that patient. The only change 
made to the patient table on addition of counts to an existing patient is to update 
missing information if that is present in the new report. If a patient number is 
reported that does not match an existing patient number on the database from 
the same laboratory then a new patient record is created and the new counts 
are added to the counts table relating to the new patient record. 
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Figure 2.5. Structure of the CD4 Surveillance database 
 
CD4 Surveillance data are managed by a graduate scientist, led by a Masters-
level epidemiologist, and overseen by a medical consultant epidemiologist. 
2.3.4 Deduplication process 
The process of importing data to CD4 Surveillance results in patients appearing 
more than once in the database if they are reported from different laboratories 
or with different patient ID numbers. This may occur if the patient has blood 
samples sent from different clinics to the same laboratory, if the patient attends 
a clinic that uses a different laboratory, if clinics change their administration 
systems, or if clerical errors result in a change in format of the laboratory 
identifier (e.g. M034746, 99M034746 and M34746). Therefore, every year after 
all of the previous years’ counts have been received, the patient records are 
Key: 
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deduplicated by matching patient identifiers such that all CD4 counts from 
duplicate records are attributed to a master record. The deduplication 
methodology was improved between 2004 and 2005 (Appendix A.9) based on 
the hierarchical algorithm developed for record linkage between the CD4 
Surveillance and SOPHID databases (Section 3.6). In 2002, 1,664 records were 
deduplicated of which the majority had matching soundex and date of birth 
which probably identified individuals who had counts performed in different 
laboratories. In 2005, 7,561 records were deduplicated and the majority of these 
had missing or discordant soundex codes indicating greater sensitivity. 
2.3.5 Record linkage to HARS 
It is clear that some of the records for patients in CD4 Surveillance are 
duplicates of other patients or are from HIV-negative patients. By the end of 
2007, there were a cumulative total of 1.3 million CD4 cell counts from over 
104,761 adults on the database. However, only 87,193 HIV-infected adults 
(aged 15 years or more) had been reported as newly diagnosed in E,W&NI to 
HARS by June 2008. Although laboratories are asked to report only CD4 cell 
counts from HIV-infected adults, some do not exclusively perform CD4 cell 
counts on HIV-infected individuals and do not have the resources or information 
to exclude CD4 cell counts of uninfected individuals from surveillance data.  
To ensure that CD4 counts analysed are from HIV-infected individuals, record 
linkage is carried out annually between the CD4 and HARS databases 
(Appendix A.10). This process also relates CD4 counts to data such as date of 
HIV diagnosis, ethnicity, date of AIDS diagnosis, and risk group.  
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Record linkage related about four in five of records in HARS to records in the 
CD4 Surveillance database from the mid-1990s when national coverage of CD4 
Surveillance was achieved (Figure 2.6). Incomplete linkage may have been due 
to individuals reported to HARS not having CD4 cell counts, having CD4 counts 
that were not reported to CD4 Surveillance or having CD4 counts that were 
reported to CD4 Surveillance but with patient identifiers that did not match. 
Individuals with positive HIV test results may not have had CD4 cell counts if 
they did not return for their results or were lost to follow-up once they received 
their result. However, this was likely to account for only a minority of the non-
linked reports because most people are likely to return for care as clinical 
symptoms become increasingly significant. Only a relatively small number of 
people were likely to have died or emigrated before returning for care165;166. 
Figure 2.6. Proportion of HARS records linked to CD4 records (Sept. 2008) 
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Some of the incomplete linkage was likely to be due to CD4 cell counts not 
having been reported to CD4 Surveillance. However, between 1998 and 2007, 
there were only 620 reports of new HIV diagnoses from HARS clinics that 
related to laboratories that had never reported to the CD4 Surveillance Scheme. 
These accounted for only 1.1% (378/55,338) of reports of HIV diagnoses. 
Different or incomplete reporting of patient identifiers was therefore likely to 
account for the majority of non-linkage. Although there were very few reports of 
new HIV diagnoses with missing patient identifiers during this period, this was 
relatively common in reports to CD4 Surveillance (about one in four soundex 
codes and one in twelve dates of birth). It was clear that a minority of reports 
that linked between the databases had different patient identifiers, which was 
assumed to be largely due to coding errors either locally or at HPA. It was 
assumed that only a few reports would have even more dissimilar patient 
identifiers in the HARS and CD4 Surveillance databases as the likelihood of 
these, more extensive coding errors, would be even lower. Therefore, it was 
assumed that most individuals reported to both surveillance systems but not 
linked were due to missing soundex code or date of birth in CD4 Surveillance. 
Each year, after record linkage, the proportion linked was consistently lower for 
the most recent years. This may be due to delayed reporting of HIV diagnoses 
(Section 2.2.7) or the temporary loss to follow-up of some recently-diagnosed 
patients as they take time to come to terms with their diagnosis167-171. Patients 
diagnosed towards the end of the most recent calendar year may not have had 
their first CD4 cell counts until the next calendar year.  
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2.4 The Survey of Prevalent HIV Infections Diagnosed 
2.4.1 Background 
The Survey of Prevalent HIV Infections Diagnosed (SOPHID) has carried out 
annual cross-sectional surveys of every individual who attended for HIV-related 
care at NHS hospitals in E,W&NI during the previous calendar year since 
1995172. The objective of the SOPHID surveys is to provide accurate 
information on the current number and distribution of individuals aged 15 years 
or more who have received HIV-related care from statutory services for use in 
funding allocation, health-care planning and health promotion. The key aspect 
of these data is the current area of residence (Appendix A.11) of the individuals 
reported. The Department of Health for England originally funded the national 
survey for allocation of ring-fenced HIV funding although this information has 
been increasingly used locally for residence-based cross-charging by HIV 
commissioners. This information cannot be obtained from reports of new 
HIV/AIDS diagnoses because patients’ place of residence and treatment often 
change after diagnosis173. A key aspect of the SOPHID surveys is that data 
collection does not finish until all reporters have submitted and validated data – 
therefore, there is no delayed reporting and records from previous years are not 
updated. 
2.4.2 Methodology 
Local co-ordinators collate data (Appendix A.12) for their area/hospital/clinic 
(Map 2.3) and send it to the HPA. Originally, one co-ordinator, with a good 
knowledge of the local area, was identified in each Health Authority (Appendix 
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A.11) but progressively data providers have been identified for each reporting 
hospital/clinic to improve the communication process. Overall, 332 clinics in 
E,W&NI had reported to SOPHID to the end of 2007 with 246 of those reporting 
in 2007 (Map 2.3). In London and East Sussex (referred to as the London 
survey) the SOPHID surveys have been carried out biannually since 1998 and 
in other areas (referred to as the national survey) once a year.  
SOPHID data are managed by two graduate scientists, two Masters-level 
epidemiologists, and overseen by a medical consultant epidemiologist. 
The collection of information used to link reports from the same patient within 
and between surveys have always included soundex code of the surname, date 
of birth and sex. First name initial has been requested since 2000 in the national 
surveys and since 2002 in the London surveys to help clarify links between 
records. Local patient ID number has been collected for individuals seen for 
care in London since the start of the London SOPHID surveys in 1998 but has 
only been requested outside London since 2003. This was due in part to 
recognition that soundex codes and dates of birth were sometimes reported 
differently for the same individual (due to either clerical errors or 
misunderstanding/miscalculation of the soundex algorithm) and were indeed 
expected for the majority of women who married and changed their surnames 
(Chapter 3). 
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Map 2.3. Geographic distribution of hospitals/clinics that reported data to 
SOPHID 
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Clinic reporting ≥100 individuals 
in 2007 
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not in 2007 
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Collection of information about the stage of HIV infection developed over time. 
CD4 cell count was added to the data collection request in 2000. ‘Vital status’ 
(either alive or dead at the end of the year) was collected until 1999 but since 
2000, most advanced clinical stage has been collected in five categories of: 
asymptomatic, symptoms pre-AIDS, AIDS, death in a patient with AIDS, and 
death in a patient who has never had AIDS. 
The national and London surveys were standardised and new variables were 
added in 2005 after I became responsible for managing the SOPHID surveys in 
May 2005. Collection of Health Authority of residence in the London survey was 
discontinued at this time. Datepos was added to the data request in the national 
survey (it was requested since the start of the London surveys in 1998). 
However, its definition was changed from the first ever date of a positive HIV 
test or HIV diagnosis to the first date positive or date of first attendance at that 
site. This was to reduce duplication between the reporting requests of new 
diagnoses and individuals accessing care and to provide information on 
transfers between sites. The new variables requested were latest viral load, 
viral load date, previous care, date of starting ART and date of AIDS diagnosis 
(since the second half of 2005 in the London surveys).  
2.4.3 Data processing, validation and follow-up 
SOPHID data were originally requested to be sent to the HPA on paper forms 
for fewer than 20 reports, or on diskette if numbers were greater. Paper reports 
were manually entered into a single flat file database table by a single user. 
Progressively, data have been sent in Excel spreadsheets and since 2006, the 
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spreadsheet has included integral validation for each variable. This provides 
pop-up messages to the user indicating the format of the information required, 
and pop-up error messages if the data entered are inconsistent with the 
expected formatting (e.g. numbers in text fields, dates not in dd/mm/yyyy 
format). The pop-up error messages appear on manual data entry. If data are 
copied and pasted into the spreadsheet, a macro circles in red all data that are 
inconsistent with the expected formatting for attention prior to submission of the 
dataset. The data are also re-validated on entry to the national database and up 
to two follow-ups are made with the local co-ordinators to minimise missing or 
inconsistent data if necessary.  
2.4.4 Deduplication 
Although data providers are asked to report each of their patients only once to 
each survey, deduplication is necessary for two reasons. Firstly, they may not 
have the resources to do that locally, and secondly patients may visit more than 
one site within a survey period.  Data for the London surveys are deduplicated 
at the end of each six-month data-collection period and are used to produce 
epidemiological information for participants. London datasets from the same 
calendar year are amalgamated and deduplicated within reporting sites (those 
with soundex, date of birth, sex and SOPHID site matching) to leave the last 
attendance in the year at each site of care. This dataset is then appended to the 
national survey for the same calendar year and the combined dataset is 
subsequently deduplicated, such that only the last attendance during the 
calendar year for each individual remains in the annual dataset. Records are 
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considered to be potential duplicates from the same patient if the soundex code, 
date of birth and sex match. Additional data fields such as infection route, 
ethnicity, and postcode are then considered to prevent aggregation of data from 
truly different individuals. If records are found to be duplicates then the record 
with the latest date seen for care is retained while the other is excluded. 
Information provided in the excluded record that is missing from the retained 
record is used to update the record that is kept. 
2.4.5 Amalgamated SOPHID dataset 
A longitudinal dataset was created (initially by Brian Rice) by amalgamating the 
annual cross-sectional surveys from 1997 to 2002 and assigning an individual 
patient ID number to all records. Records from different survey years were 
assumed to originate from the same patient and linked if the soundex code, 
date of birth and sex matched.  Where a combination of soundex code, date of 
birth and sex occurred more than once in a survey year indicating truly different 
individuals these were deduplicated manually to prevent incorrect linkage. 
2.4.6 SOPHID patient and report tables 
I devised and supervised the creation of a SOPHID ‘report table’ by appending 
together in one dataset all original files of reported data. This contained all the 
variables that were in the SOPHID reports as well a patient-specific number 
relating records from the same individual. This patient number was assigned 
according to criteria in a record linkage algorithm that required the matching of 
at least two of the three main patient identifiers (soundex, date of birth or local 
patient ID number) and then considered matches using the full postcode or 
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postcode sector+ (all but the last character of the postcode) (Table 2.2). All 
records that matched on any of the criteria shown were linked and considered 
to relate to an individual. Because of the high specificity expected from 
matching with local patient ID number and to allow for some coding errors, year 
of birth was used instead of date of birth in two of the matching criteria.  
Table 2.2. Matching criteria in the record linkage algorithm for de-duplication of 
SOPHID records to create the SOPHID report table ( = exact match) 
Match 
score 
Postcode Clinic 
Local 
patient ID 
Soundex Date of birth Sex 
1       
2     Year of birth  
3       
4 Full postcode      
5 Postcode sector+   
First three 
characters 
Year of birth  
 
The SOPHID report table in 2008 contained 574,913 records from 1995 to 
2007, of which 562,130 were from 79,596 adults (aged 15 years or more) 
according to the record linkage algorithm. If the same data were deduplicated 
according solely to exact soundex, date of birth and sex matches then it would 
have appeared that there were 89,076 adults overall and more in each year 
(Appendix A.13). 
In the SOPHID patient table, the last reported soundex code, date of birth and 
sex are assigned to the patient record to reflect the most up-to-date situation 
and because information which changes for an individual between surveys are 
validated with the reporting clinic. 
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2.5 HIV epidemiology from case reporting 
2.5.1 Overview 
HARS data were originally collected to directly inform public health policy about 
transmission, as reflected by new diagnoses of HIV infections, and about the 
resource requirements for health services, as reflected by AIDS diagnoses. The 
characteristics of these can differ due to the long incubation period of infection. 
A total of 95,627 HIV infections were newly diagnosed in the UK by the end of 
December 2007 (reported by the end of December 2008). This figure includes 
some records of the same individuals who could not be deduplicated because 
of differences in the information supplied, some records of individuals who left 
the country at some date after diagnosis and many records of individuals who 
have died. The total number of individuals reported to SOPHID as seen for care 
in the UK in 2007 was 56,377. Estimates including undiagnosed HIV infections 
suggest that there were a total of 77,400 individuals living with HIV in the UK in 
2007. This equated to an overall HIV prevalence of 127 per 100,000 population.  
The HIV epidemic in the UK is not equally distributed throughout the population 
but focused in risk groups (Section 1.3.5). Different epidemic trends have been 
observed in each group. The overall breakdown, to the end of December 2007, 
was as follows: 
 44.5% (42,525) sex between men 
 43.5% (41,619) heterosexual sex 
 5.1% (4,876) IDU  
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 2.0% (1,893) blood or tissue transfer or use of blood products 
 1.8% (1,696) transmission from mother-to-infant  
 3.2% (3,018) other or undetermined 
The geographical distribution of HIV-infected individuals within the UK is 
heterogeneous. The focus of the epidemic, in each exposure category, is 
London, which accounted for 49.2% (27,741/56,377) of all reported diagnosed 
HIV-infected UK residents when last seen for care in 2007. 
2.5.2 Trends in new HIV diagnoses in E,W&NI reported to HARS 
The earliest evidence of HIV infections diagnosed in E,W&NI comes from 
retrospective samples stored in 1979. The introduction of laboratory tests for 
HIV in late 1984 resulted in a rapid rise in the number of new diagnoses as 
asymptomatic, prevalent infections were detected. These infections were mostly 
due to sex between men and transmission due to the transfer of blood, tissues 
and blood products (Figure 2.7). Following the initial diagnosis of infections from 
the prevalent pool, the number of newly diagnosed infections acquired through 
sex between men was relatively stable until 2000 (around 1,500 per year) but 
then increased to a record 2,526 in 2007. There was a sharp decline in newly 
diagnosed infections acquired from blood, tissues and blood products after 
1985 largely associated with the introduction of methods to screen and heat 
treat blood factor. More recent diagnoses due to these sources are most likely 
infections acquired in countries where these sources are less safe. Numbers of 
newly diagnosed infections acquired through IDU declined from 166 in 1988 to 
98 in 2000 but then increased to previous levels by 2007.  
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Figure 2.7. The number of newly diagnosed HIV infections among adults (aged 
15 years or above) by year of diagnosis and risk group: reported in E,W&NI by 
June 2008. 
It is important to note that diagnoses often do not equate to incident infections 
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Numbers acquired through heterosexual infection increased to 733 in 1992, 
stabilised until 1996, and then rapidly increased to peak at 4,544 in 2003 before 
falling off to 3,435 in 2007. It is important to note that the number of new 
diagnoses, particularly for recent years, will rise as further reports are received. 
There were few diagnoses each year attributed to other routes of infection or 
that remained undetermined. These numbers for recent years will fall as follow-
up continues. 
The breakdown of newly diagnosed infections acquired heterosexually shows 
that the vast majority of individuals acquired their infection from partners who 
themselves were presumed to have been infected heterosexually (Table 2.3). 
The relatively small number of diagnoses among heterosexuals infected by a 
high-risk partner did not fall between 1990 and 2006 but accounted for a 
decreasing proportion of newly diagnosed infections acquired heterosexually.  
Table 2.3. The number of HIV infections acquired heterosexually by year of 
diagnosis and heterosexual sub-category: reported in E,W&NI  by June 2008. 
Year of 
diagnosis 
Heterosexual sub-category 
Total High-risk 
partner 
Heterosexual 
partner 
Partner exposure undetermined 
investigation 
continuing 
investigation 
closed 
prior to 1990 206  (22%) 742  (78%) 0  (0%) 9  (1%) 957 
1990 51  (10%) 445  (89%) 1  (0%) 3  (1%) 500 
1991 54  (9%) 545  (91%) 0  (0%) 3  (0%) 602 
1992 69  (9%) 659  (90%) 2  (0%) 3  (0%) 733 
1993 66  (9%) 661  (91%) 0  (0%) 2  (0%) 729 
1994 55  (7%) 698  (92%) 1  (0%) 4  (1%) 758 
1995 57  (7%) 737  (92%) 3  (0%) 5  (1%) 802 
1996 54  (7%) 739  (92%) 3  (0%) 3  (0%) 799 
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1997 67  (7%) 885  (92%) 3  (0%) 8  (1%) 963 
1998 68  (6%) 1,043  (93%) 3  (0%) 3  (0%) 1,117 
1999 42  (3%) 1,346  (96%) 15  (1%) 6  (0%) 1,409 
2000 40  (2%) 1,916  (97%) 7  (0%) 9  (0%) 1,972 
2001 70  (2%) 2,772  (97%) 24  (1%) 6  (0%) 2,872 
2002 63  (2%) 3,681  (97%) 44  (1%) 8  (0%) 3,796 
2003 60  (1%) 4,403  (97%) 75  (2%) 6  (0%) 4,544 
2004 59  (1%) 4,339  (96%) 128  (3%) 11  (0%) 4,537 
2005 65  (1%) 4,128  (93%) 224  (5%) 9  (0%) 4,426 
2006 54  (1%) 3,493  (87%) 447  (11%) 8  (0%) 4,002 
2007 32  (1%) 2,497  (73%) 902  (26%) 4  (0%) 3,435 
Total 1,232  (3%) 35,729  (92%) 1,882  (5%) 110  (0%) 38,953 
 
Further analysis of newly diagnosed infections acquired heterosexually from 
partners who themselves were infected heterosexually shows that the majority 
had had sexual partners in Africa (Table 2.4). It has been shown that these 
sexual exposures were mainly occurring in Uganda and Kenya in the early 
1990s, but that although the number of infections attributed to Uganda and 
Kenya increased to 2002, Zimbabwe was the source of the majority of 
exposures in more recent years174. Data on year of arrival, collected since 
January 2000, have also shown that there was a sharp peak in 2002 in the 
number of individuals infected with HIV in Africa who arrived in the UK. 
Evidence that the majority of heterosexually-infected individuals diagnosed in 
the UK acquired their infection abroad means that sex between men is the most 
common route of acquisition of HIV in the UK115. 
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Table 2.4. The number of HIV infections acquired heterosexually from heterosexuals by year of diagnosis and sub-category: 
reported in E,W&NI by June 2008. 
Year of 
diagnosis 
Region of exposure 
Exposure abroad Exposure in the UK 
Africa 
Latin 
America / 
Caribbean 
Asia 
North 
America 
Europe Australasia 
country(ies) 
not known 
outside 
Europe 
within 
Europe 
country(ies) 
not known 
prior to 1990 554 (75%) 16 (2%) 18 (2%) 25 (3%) 38 (5%) 3 (0%) 18 (2%) 36 (5%) 30 (4%) 4 (1%) 
1990 361 (81%) 11 (2%) 5 (1%) 7 (2%) 23 (5%) 1 (0%) 3 (1%) 14 (3%) 19 (4%) 1 (0%) 
1991 437 (80%) 12 (2%) 16 (3%) 10 (2%) 22 (4%) 1 (0%) 0 (0%) 16 (3%) 31 (6%) 0 (0%) 
1992 511 (78%) 23 (3%) 23 (3%) 14 (2%) 34 (5%) 1 (0%) 1 (0%) 27 (4%) 25 (4%) 0 (0%) 
1993 497 (75%) 24 (4%) 28 (4%) 16 (2%) 32 (5%) 2 (0%) 0 (0%) 19 (3%) 41 (6%) 2 (0%) 
1994 526 (75%) 26 (4%) 19 (3%) 9 (1%) 36 (5%) 0 (0%) 0 (0%) 40 (6%) 42 (5%) 0 (0%) 
1995 543 (74%) 13 (2%) 35 (5%) 8 (1%) 43 (6%) 2 (0%) 2 (0%) 50 (7%) 36 (5%) 5 (1%) 
1996 544 (74%) 24 (3%) 44 (6%) 7 (1%) 40 (5%) 1 (0%) 6 (1%) 42 (6%) 31 (4%) 0 (0%) 
1997 635 (72%) 31 (4%) 46 (5%) 9 (1%) 45 (5%) 2 (0%) 3 (0%) 75 (8%) 38 (4%) 1 (0%) 
1998 741 (71%) 32 (3%) 72 (7%) 14 (1%) 38 (4%) 3 (0%) 14 (1%) 88 (8%) 40 (4%) 1 (0%) 
1999 997 (74%) 69 (5%) 71 (5%) 7 (1%) 49 (4%) 5 (0%) 0 (0%) 99 (7%) 48 (4%) 1 (0%) 
2000 1,489 (78%) 72 (4%) 110 (6%) 8 (0%) 42 (2%) 2 (0%) 2 (0%) 139 (7%) 51 (3%) 1 (0%) 
2001 2,274 (82%) 97 (3%) 94 (3%) 8 (0%) 48 (2%) 4 (0%) 0 (0%) 184 (7%) 51 (2%) 12 (0%) 
2002 3,028 (82%) 148 (4%) 123 (3%) 7 (0%) 67 (2%) 4 (0%) 0 (0%) 258 (7%) 35 (1%) 11 (0%) 
2003 3,592 (82%) 168 (4%) 143 (3%) 7 (0%) 93 (2%) 5 (0%) 1 (0%) 317 (7%) 69 (2%) 8 (0%) 
2004 3,434 (79%) 148 (3%) 174 (4%) 10 (0%) 95 (2%) 0 (0%) 1 (0%) 385 (9%) 63 (1%) 29 (1%) 
2005 3,183 (77%) 106 (3%) 177 (4%) 15 (0%) 93 (2%) 3 (0%) 3 (0%) 415 (10%) 81 (2%) 52 (1%) 
2006 2,551 (73%) 92 (2%) 176 (5%) 9 (0%) 113 (3%) 1 (0%) 1 (0%) 374 (11%) 88 (3%) 88 (3%) 
2007 1,716 (69%) 48 (2%) 131 (5%) 10 (0%) 86 (3%) 2 (0%) 0 (0%) 318 (13%) 80 (3%) 106 (4%) 
Total 27,613 (77%) 1,160 (3%) 1,505 (4%) 200 (1%) 1,037 (3%) 42 (0%) 55 (0%) 2,896 (8%) 899 (3%) 322 (1%) 
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2.5.3 Trends in HIV diagnoses and deaths in E,W&NI reported to 
HARS by risk group  
Since 1990, the overall numbers of new HIV diagnoses and deaths have been 
dominated by infections acquired sexually. From 1990 to 1995 the number of 
deaths increased while the number of newly diagnosed infections remained 
relatively stable. The steep rise in the number of newly diagnosed, sexually-
acquired infections and a dramatic fall in the number of deaths among MSM 
(Figure 2.8) resulted in rapidly increasing numbers of patients accessing care 
after 1995. 
2.5.4 Trends in AIDS diagnoses and deaths in E,W&NI reported 
to HARS 
HARS only captures the first diagnosis of AIDS for each individual. Trends in 
the number of first AIDS diagnoses reported to HARS are similar to trends in 
deaths.  Following gradual increases in the number of AIDS diagnoses between 
the early 1980s and mid-1990s, there were marked decreases as HAART 
became widely available (Figure 2.9). However, there was an increase in the 
number of first AIDS diagnoses reported between 2001 and 2003. 
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Figure 2.8. Number of new diagnoses by year of diagnosis and deaths by year of death: reported in E,W&NI by June 2008. 
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Figure 2.9. Trends in the number of first AIDS diagnoses by year of diagnosis 
and deaths by year of death. 
 
 
 
 
 
 
 
 
 
2.5.5 Number of diagnosed HIV-infected individuals accessing 
care in E,W&NI reported to SOPHID 
There were 53,673 diagnosed HIV-infected patients seen for care in E,W&NI in 
2007. Sex between men accounted for 42.7% (22,935) of these infections, sex 
between men and women for 50.5% (27,131), injecting drug use 2.1% (1,111) 
and other/unknown exposures, 4.7% (2,496). 
Almost all (99.1% [53,180]) individuals accessing care in 2007 had a reported 
ethnic group. Of those who acquired HIV infection through sex between men, 
87.5% were white, 7.2% were of Asian, Oriental, Indian/Pakistani/Bangladeshi 
or mixed ethnicity and 4.5% were of black ethnicity. In contrast, the ethnic 
breakdown of individuals heterosexually infected was 68.4% of black African 
ethnicity, 18.7% white, 6.0% Asian, Oriental, Indian/Pakistani/Bangladeshi or 
mixed ethnicity and 6.4% of black Caribbean or other black ethnicity.  
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In 2007, 71.1% (37,699/52,997) of individuals were on therapy (excluding 676 
individuals without a reported level of antiretroviral therapy). The number of 
individuals seen for care in E,W&NI increased by 9.0% between 2006 and 2007 
(from 49,219) and nearly tripled between 1999 and 2007 (from 19,127). 
2.6 HIV case report surveillance in other countries with 
similar epidemics 
HIV case report surveillance in other countries with low-level or concentrated 
epidemics is based on similar principles to that in E,W&NI related to the nature 
of the epidemic. Case-based surveillance systems originated for the reporting of 
clinical AIDS diagnoses. Most of these systems were developed by addition of 
reports of HIV diagnoses and some furthermore by monitoring laboratory data 
such as CD4 cell counts and/or viral loads. The SOPHID methodology of 
repeated cross-sectional surveys of prevalent, diagnosed HIV-infected 
individuals accessing care is unique but equivalent information can be derived 
from longitudinal or cohort data. 
The mechanisms of reporting (including whether voluntary or mandatory), the 
degree of integration of systems, the range of data variables collected and the 
national coverage of surveillance vary substantially175-178. Yet, HIV case report 
surveillance can be broadly grouped into five categories based upon these 
factors: i) systems with national coverage of patient-specific HIV and AIDS case 
reporting, which may also have introduced the monitoring of laboratory markers 
such as in Scotland, E,W&NI and Australia; ii) systems with national coverage 
that were limited to AIDS case reporting until the recent introduction of HIV case 
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reports such as in France, the United States and Ireland; iii) systems with 
national coverage of patient-specific AIDS case reporting but anonymous 
reporting of HIV cases such as in Denmark and Germany; iv) systems with 
national coverage of patient-specific AIDS case reporting but no national HIV 
case reporting such as in Italy and Spain (France before 1998 and the United 
States before 2008); v) national cohorts such as in the Netherlands and Austria. 
HIV surveillance systems in Scotland are similar to those in E,W&NI as 
described earlier. Reporting of CD4 cell counts from laboratories was added to 
HIV and AIDS surveillance in the 1980s to monitor the immunological status of 
diagnosed HIV-infected individuals179-181. In contrast to the development of the 
SOPHID survey in E,W&NI, CD4 cell count monitoring was also used to monitor 
access to care. In addition to these case reporting systems, Scotland also 
introduced the voluntary reporting of all HIV testing in 1988 (including 
individuals testing HIV negative) and so may record time points before infection 
enabling the identification of seroconversion182.  Furthermore, HIV surveillance 
in Scotland includes subtype monitoring and country of infection for greater 
characterisation of the epidemic (but until recently recorded nationality instead 
of ethnicity)183. In Australia, HIV and AIDS case surveillance is very similar to 
the HARS surveillance system in E,W&NI (no equivalent of CD4 Surveillance or 
SOPHID). Separate report forms and databases are used for HIV diagnoses 
and AIDS diagnoses but records can be linked between these if sufficient 
patient identifiers are available184-187. 
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The availability of effective HAART in 1996 was the catalyst for many countries 
to develop HIV case reporting because back-calculation from AIDS diagnoses 
could no longer be used to estimate the time of infection. This issue was 
recognised in France but the development of confidential reporting systems 
delayed the introduction of HIV case reporting from 1999 until March 2003. 
Subsequently, virologists in France have reported all HIV diagnoses with 
epidemiologic and clinical information completed by a physician. Physicians 
only report AIDS diagnoses. The variables collected include nationality, country 
of residence, country of birth, occupation, reason for attending screening, 
previous HIV serology, route of transmission, and clinical stage but not country 
of infection or ethnicity. Reporting is anonymised using a unique irreversible 
code for each individual to maintain confidentiality but multiple reports from an 
individual can be linked for epidemiological monitoring. However, despite 
mandatory reporting and follow-up for missing epidemiologic information, under-
reporting was estimated to be 30-40%188. Yet, France also introduced the 
voluntary, anonymous submission of sera from newly diagnosed individuals to 
test for recent infections to better inform HIV prevention strategies189;190 
(surveillance of recent infections was introduced in E,W&NI in 2008). 
In the United States, HIV surveillance systems were not standardised across 
states and were largely limited to passive reporting until April 2008191;192. Until 
then, the variety of mandatory HIV surveillance across states included name-
based reporting of all HIV-infected individuals (but allowing anonymous HIV 
testing), name-based reporting of symptomatic HIV-infected persons only and 
anonymous reporting. Other states relied on voluntary reporting systems. 
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Deduplication of reports was not carried out in all states with name-based 
reporting resulting in a significant proportion of duplicate reports193. The varied 
sources of HIV reports included state public health laboratories, private 
laboratories, private physicians, and other health-care providers194;195. HIV 
surveillance has been enhanced since 2007 by development of the Medical 
Monitoring Project, which will survey random samples of HIV-infected persons 
accessing care to provide detailed information of the need for care services196. 
Denmark, in the early 1990s, introduced a mandatory but anonymous HIV 
reporting system. Laboratory staff reported directly to the national surveillance 
unit but also via clinicians in order to collect patient data and to ensure 
maximum completeness of the reports. Serial numbers were used to link 
records but maintain anonymity, as long as records originated from the same 
laboratory or clinical source197;198. National HIV surveillance was very similar in 
Germany, with AIDS cases reported since 1982 and anonymous HIV reporting 
from laboratories since 1987199 (unspecific record linkage was possible in 
Germany using date of birth only176).  
Italy and Spain do not have national HIV surveillance systems despite long-
running national AIDS case reporting and some regional collation of HIV 
reports176. In Italy, record linkage procedures with non-name based identifiers 
are used to identify newly diagnosed HIV and AIDS cases and to integrate HIV 
surveillance data from a variety of local sources such as hospital registers and 
death notifications200-202. In Spain, there is no possibility of record linkage due to 
anonymous reporting of HIV infections (only the initials were reported)176.  
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The Netherlands started a new HIV reporting system in 2002 using name-based 
identifiers176. This is based on a national cohort of HIV-infected individuals 
founded in 2001, which was itself based upon a national cohort research study 
of adults receiving antiretroviral therapy undertaken from 1998 to 2000203.  
2.7 Summary 
HIV case reporting systems in E,W&NI have developed over time to provide 
comprehensive, detailed and valid information about the HIV epidemic. The 
data include all diagnosed HIV infections in E,W&NI since the first identified 
case and are derived from reports submitted from clinics, laboratories and 
national death records. The completeness of the data is maximised by active 
follow-up for missing reports and missing information from reports. Validation 
and follow-up also maximise the consistency of the data. Individual-level data 
allow detailed presentation of data cross-tabulated by numerous different 
variables. Data collection balances timeliness with appropriateness such that 
most HARS reports are received within six months of diagnosis/death but 
SOPHID and CD4 reports are only expected once or twice a year. 
HIV surveillance in E,W&NI is more comprehensive than surveillance in many 
other countries with similar HIV epidemics due to: the ability to link records from 
the same individual over time while maintaining confidentiality; the early 
monitoring of new HIV diagnoses; and the additional monitoring of prevalent 
diagnosed infections and levels of immunosuppression. The data are not as 
comprehensive as the Dutch cohort but surveillance systems have the potential 
to be linked to produce comparably rich information for analysis. 
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Chapter 3. Bilateral record linkage between three                         
independent HIV surveillance systems 
3.1 Introduction 
The main methodological aim of this thesis was to develop a valid method to 
create a fully integrated, national HIV surveillance database by linking records 
from three independent HIV case reporting systems. This would allow 
corresponding information, which was missing from one database but not 
another, to be shared and allow investigation of a wider range of issues by the 
simultaneous analysis of data from the integrated HIV surveillance systems. 
This chapter briefly describes the theory of record linkage, and then, the 
detailed approach taken to bilaterally link records. This approach was based on 
comparisons of patient-specific information between datasets and the 
subsequent use of an algorithm to identify reliable bilateral links between two 
datasets at a time (allowing for some coding errors in the data). Triangulation of 
these bilateral links for full integration is described in chapter 4. As HARS (HIV 
and AIDS Reports database) and CD4 Surveillance data were already routinely 
linked, this chapter focuses on the record linkage between HARS and SOPHID 
(Survey of Prevalent HIV Infections Diagnosed) and separately between 
SOPHID and CD4 Surveillance. 
The record linkage algorithm was developed over time as more information was 
collected through SOPHID and as the SOPHID data were more completely 
linked over time. Therefore, the results are described in sections showing the 
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lessons that were learnt as the methodology developed: validation of record 
linkage based on soundex codes, dates of birth and sex; evaluation of record 
linkage including local patient ID numbers (included nationally in SOPHID 
reports for 2003); and record linkage between datasets using multiple records 
per individual.  
3.2 Aims of this chapter 
a) To develop a thorough understanding of the key variables used in the 
record linkage process. 
b) To assess the use of different combinations of variables in the matching 
process to determine how best to link the databases allowing for some 
coding errors in the data to maximise sensitivity while maintaining high   
accuracy by only retaining reliable links between the datasets.  
c) To identify factors associated with record linkage in order to consider the 
potential for bias to be introduced by the record linkage process, to aid 
the interpretation of subsequent analyses. 
3.3 Introduction to the record linkage process 
3.3.1 Background to record linkage 
Record linkage between two databases is increasingly used, as electronic 
information systems proliferate, to make use of data that are already held 
elsewhere rather than duplicate its collection in different systems. In relation to 
HIV, it has been used with census data, cancer and tuberculosis (TB) registries 
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and vital statistics information to estimate mortality, cancer and TB-coinfection 
rates204-210. It has also been used in capture-recapture studies to estimate 
numbers of deaths among HIV-infected adults, cumulative numbers of HIV 
diagnoses, and the underreporting of AIDS cases211-213. If unique and reliable 
identifiers were available to allow every record in the datasets to be matched 
(often the aim of relational databases) then record linkage would be simple. 
However, record linkage is complicated by unreliable reporting, redundancy of 
information and changes over time. 
Record linkage has employed a variety of methodologies depending on the 
aims and the information available. However, there are currently two principal 
conceptual strategies that are utilised. Deterministic record linkage looks for 
exact agreement between one or more (or combined) matching variables. 
Coding errors in the variables in one dataset are likely to result in records from 
the same individual not being linked. However, variables can be subdivided to 
find exact agreement between parts of variables, known as fuzzy matching, 
which can allow record linkage between variables despite coding errors (for 
example, the day, month and year of birth instead of the date of birth or the 
surname initial instead of the soundex code). In contrast, probabilistic record 
linkage tends to use a greater number of matching variables and considers the 
probability that two records are from the same person even if some of the 
variables differ, by taking into account the expected frequency of each of these 
variables in the dataset (i.e. rarer instances of a variable mean that it is more 
likely to result in record linkage if it matches with the variable from the other 
dataset). These methods can also be combined together or combined with 
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manual reviews depending on the aims of the project. Both methods involve a 
degree of subjectivity because cut-offs for an acceptable link between the 
datasets need to be decided by the user. Deterministic linkage is simple to 
understand, situation-specific and maintains a high positive predictive value214. 
Probabilistic linkage, on the other hand, is likely to result in greater sensitivity 
but usually requires prior input of variable frequencies from a reference 
population or an iterative process to estimate these frequencies from the study 
population214-216. Deterministic record linkage (or probabilistic linkage with 
careful manual review) is therefore recommended when making inferences at 
the individual-level based upon combined data214;217. Probabilistic linkage, on 
the other hand, tends to be used for larger population-based studies to estimate 
a statistical rate or prevalence218-222. 
3.3.2 Background to record linkage in HARS, SOPHID and CD4 
Surveillance 
The accuracy and completeness of the information reported to the HPA directly 
impact on the collation of data from different sources for each individual and 
therefore on the precision of the results that are disseminated. These are reliant 
on the processes of record linkage.  
Record linkage within each of the three databases is referred to in this thesis as 
deduplication and is carried out to link reports from the same individual in order 
to limit over-counting and to collate information on that individual (Sections 
2.2.9, 2.3.4, 2.4.4). Inability to link multiple reports of the same individual over 
time within each individual database (insensitive deduplication) due to incorrect 
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identifiers will result in an inflation of the true number of individuals and events 
reported. Incorrect linkage of reports from different individuals within the same 
database (non-specific deduplication) due to non-unique identifiers will result in 
the assimilation of data from different individuals and may produce 
inconsistencies within the dataset and lead to a reduction of the true number of 
individuals and events reported. Deduplication within each of the three HIV 
surveillance systems is deterministic although a wide array of criteria is used to 
allow consideration of non-unique and unreliable identifiers. Manual review of 
weak matches is carried out to ensure high sensitivity is not gained at the 
expense of specificity. 
Insensitive or non-specific record linkage between datasets can have similar 
effects to deduplication, such as over-estimating under-reporting and producing 
inconsistencies by linking data from different individuals. 
Record linkage between databases can link reports from the same individual 
that are separately held in HARS, SOPHID and CD4 Surveillance. Record 
linkage between HARS and CD4 Surveillance is routinely carried out to 
determine levels of immunosuppresion at HIV diagnosis (Section 2.3.5). 
Temporary matching used to be routinely carried out between SOPHID and 
HARS and between SOPHID and CD4 Surveillance to estimate under-reporting 
to SOPHID172;223 and to determine the last date on which the individual was 
known to have been alive for newly diagnosed individuals224. Yet, the annual 
SOPHID datasets were not previously combined for matching purposes and 
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temporary matches were not used to create permanent links between the 
datasets. Nor were any formal analyses of the matched data undertaken. 
Record linkage of SOPHID to HARS had the potential to link SOPHID and CD4 
Surveillance via HARS. However, separate record linkage between SOPHID 
and CD4 Surveillance was undertaken because it had the potential to link a 
large number of CD4 Surveillance records that had not previously been linked 
to HARS records. This potential was conferred by the availability of local patient 
ID numbers requested for all biannual London SOPHID surveys and also for the 
national SOPHID survey since 2003. Linkage of these datasets also allowed 
triangulation of CD4 Surveillance, SOPHID and HARS records (Chapter 4). 
3.3.3 Development of methodology 
Deterministic methodology was selected as appropriate for the aims of 
achieving an integrated and robust dataset. This also allowed full utilisation of 
in-house expertise with the deterministic algorithms and software already used 
in the surveillance systems. 
Record linkage between HARS and SOPHID originally only considered matches 
between patient-based tables where the soundex, date of birth and sex were 
exactly the same and only created unique, one-to-one links between datasets 
(Figure 3.1a). Fuzzy matching between HARS and SOPHID was used to 
improve the sensitivity of the record linkage as was incorporation of local patient 
ID numbers after I expanded their collection in the SOPHID surveys to areas 
outside London for data from 2003 (Figure 3.1a). In 2004, I devised the 
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SOPHID ‘Report Table’, which included all records reported since 1995, and 
developed the methodology for deduplicating these data and assigning a 
patient-specific number (Section 2.4.5). This ‘Report Table’ was then used to 
consider matches between multiple combinations of reported patient identifiers 
for the same individual and assess potential duplicates (Figure 3.1b). In 2008, 
methods were integrated and simplified, based on what had been learnt, and 
Report Tables were used for record linkage of data to the end of 2007. After this 
final process, triangulation between the three datasets was carried out to check 
the validity of multiple links to the same record and links that formed only two 
sides of the triangle. I carried out all of the record linkage between SOPHID and 
HARS and the original record linkage between SOPHID and CD4 but a 
colleague undertook the record linkage of SOPHID and CD4 after 2004 under 
my supervision (Figure 3.1a/b). 
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Figure 3.1 a/b. Timeline showing development of the record linkage algorithm 
between a) HARS and SOPHID and b) SOPHID and CD4 Surveillance 
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3.4 Key data used for deduplication and record linkage 
3.4.1 Soundex codes 
There were 5,043 different genuine soundexes reported in data to the end of 
December 2007 (4,467, 4,522, and 4,471 in HARS, SOPHID and CD4 datasets 
respectively). Within each database, about a fifth of soundexes were unique but 
few occurred more than 200 times (Table 3.1). 
Table 3.1. Distribution of the frequency of reported soundex codes in HARS, 
SOPHID and CD4 Surveillance 
Frequency HARS SOPHID CD4 Surveillance 
1 895  (20.0%) 948  (21.0%) 901  (20.2%) 
2 545  (12.2%) 524  (11.6%) 501  (11.2%) 
3 355  (7.9%) 332  (7.3%) 318  (7.1%) 
4 254  (5.7%) 282  (6.2%) 281  (6.3%) 
5 204  (4.6%) 218  (4.8%) 241  (5.4%) 
6-50 1,799  (40.2%) 1,803  (39.9%) 1,798  (40.2%) 
51-100 240  (5.4%) 246  (5.4%) 250  (5.6%) 
101-200 121  (2.7%) 116  (2.6%) 121  (2.7%) 
201-300 33  (0.7%) 34  (0.8%) 33  (0.7%) 
>300 30  (0.7%) 19  (0.4%) 27  (0.6%) 
Total 4,476  (100%) 4,522  (100%) 4,471  (100%) 
 
Whereas 377 (0.5%) of 79,736 individuals reported to SOPHID and 856 (1.0%) 
of 87,654 individuals reported to HARS had never had a genuine soundex code 
reported, there were 20,225 (19.3%) of 104,619 individuals reported to CD4 
Surveillance for whom all reports over time lacked soundex codes. Two-thirds 
(67.1% [253]) of individuals reported to SOPHID without soundex codes were 
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young adults (aged 15-19 years) reported from the National Study of HIV in 
Pregnancy and Childhood, which requests but does not require soundex codes.  
A greater number and proportion of new HIV diagnoses reported only from 
laboratories (822 [2.4%]) were missing soundex codes than reports from 
clinicians (31 [0.9%] individuals reported on an AIDS form only; 2 [0.4%] on a 
death form only; 1 [<0.01%] on both a laboratory form and a clinician report 
form; all other combinations of reports included a soundex code) (Figure 3.2). 
Almost all missing soundex codes were for records of new HIV diagnoses 
between 1985 and 1993 because only one of either soundex or local patient ID 
number were requested on the laboratory forms that were used at the time 
(Appendix B). Almost a half (47.2% [404/856]) of the individuals reported to 
HARS without a soundex code were reported from two London clinics* and, 
independently, almost a fifth (18.5% [158/856]) had no date of birth reported. 
A high percentage of individuals with their first CD4 cell count reported to CD4 
Surveillance in 2006 or 2007 were missing soundex codes (37.5% [3,534/9,433] 
and 40.5% [5,415/13,359] respectively compared to an average of 13.5% where 
the first CD4 cell count was between 1990 and 2005). These individuals 
accounted for 44.2% [8,949/20,225] of all individuals reported to CD4 
Surveillance without soundex codes. There was no clear association between 
the location or size of the laboratory and the proportion of missing soundexes. 
                                            
*
 However, these records only accounted for 3.7% and 4.8% of all records from these two 
London clinics, which were not the highest percentages from London clinics. 
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Figure 3.2. HARS reporting over time* by type of report# and availability of soundex code  
(AIDS = AIDS report, LAB. = HIV report from laboratory)   
* the first HIV infection diagnosed in the UK was in 1991 but retrospective diagnoses were made based on historical samples 
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In each database, there were many individuals who had more than one 
soundex code reported: 5,308 (6.7%) of 79,359 individuals reported to SOPHID; 
2,702 (3.1%) of 86,798 individuals reported to HARS; 6,493 (7.7%) of 84,469 
individuals reported to CD4 Surveillance (Table 3.2). Although people may 
change their surnames, particularly women who marry, manual inspection 
showed that many individuals with multiple soundex codes had very similar 
codes indicating that they were likely to be due to coding errors. This was 
expected because records are linked due to exactly or closely matching patient 
identifiers. Records with substantially different soundex codes are unlikely to be 
linked unless they have matching dates of birth and local patient ID numbers. 
Table 3.2. Distribution of the frequency of different soundex codes per individual 
in HARS, SOPHID and CD4 Surveillance 
Frequency HARS SOPHID CD4 Surveillance 
1 84,096  (96.9%) 74,051  (93.3%) 77,976  (92.3%) 
2 2,634  (3.0%) 4,878  (6.1%) 5,568  (6.6%) 
3 65  (0.1%) 390  (0.5%) 751  (0.9%) 
4 2  (<0.01%) 35  (0.04%) 125  (0.1%) 
>4 1  (<0.01%) 5  (0.01%) 49  (0.1%) 
Total 86,798 79,359 84,469 
 
3.4.2 Dates of birth 
Fewer reports were missing dates of birth than were missing soundex codes. 
There were 140 (0.2% of 79,736) individuals reported to SOPHID and 377 
(0.4% of 87,654) individuals reported to HARS without dates of birth compared 
to 7,667 (7.3% of 104,619) individuals reported to CD4 Surveillance. 
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As with soundex codes, dates of birth were more likely to be missing in HARS 
for individuals diagnosed in the late 1980s (Figure 3.3). All but seven of these 
(370 [1.1% of all individuals who were only reported on a laboratory form]) were 
only reported on a laboratory form as either age or year of birth could be 
reported instead of date of birth on laboratory forms until 1993 (Form D93 – 
Appendix B.1). Two in five (39.8% [150/377]) of individuals with no date of birth 
were reported from three London clinics, two of which were the same London 
clinics that reported many individuals without soundex codes. 
Figure 3.3. Percentage of newly diagnosed individuals without a reported date 
of birth. 
 
The majority of individuals reported to SOPHID without a date of birth were only 
reported once between 1997 and 1999 (68.6% [96/140]). Almost a quarter 
(22.9% [32/140]) were reported from one of five clinics in Oxford. Only three of 
the 140 had no soundex code reported. 
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Individuals reported to CD4 Surveillance without a date of birth largely had their 
first CD4 cell count before 2000, although there were also a substantial number 
without dates of birth who were first reported in 2006 (which may have been 
due to changes in clinic computing systems) (Figure 3.4). There was wide 
variability in the reporting of dates of birth by laboratory: 75.3% of the 
individuals without dates of birth were reported from three large laboratories in 
London but there were no clear trends by location or size and there was wide 
variation around the average of 3.6% with missing dates of birth.  
Figure 3.4. Percentage of individuals reported to CD4 Surveillance without a 
reported date of birth. 
 
There were 22,460 different dates of birth reported to the end of 2007 (17,940, 
16,986, and 21,316 to HARS, SOPHID and CD4 Surveillance). Within each 
dataset, 22-26% were unique and few occurred more than 15 times (Table 3.3).
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Table 3.3. Distribution of the frequency of reported dates of birth in HARS, 
SOPHID and CD4 Surveillance 
Frequency HARS SOPHID CD4 
1 3,929  (21.9%) 3,695  (21.8%) 5,635  (26.4%) 
2 2,636  (14.7%)   2,512  (14.8%) 2,976  (14.0%) 
3 1,965  (11.0%) 1,870  (11.0%) 2,188  (10.3%) 
4 1,600  (8.9%) 1,478  (8.7%) 1,766  (8.3%) 
5 1,416  (7.9%) 1,345  (7.9%) 1,499  (7.0%) 
6-10 4,790  (26.7%) 4,433  (26.1%) 5,105  (23.9%) 
11-15 1,372  (7.6%) 1,411  (8.3%) 1,782  (8.2%) 
16-20 198  (1.1%) 204  (1.2%) 300  (1.4%) 
>20 34  (0.2%) 38  (0.2%) 65  (0.3%) 
Total 17,940 16,986 21,316 
 
To examine the frequencies of reported dates of birth by individual, the date of 
birth in the master record of each individual in each database was considered. 
This was the date of birth from the earliest HIV diagnosis event reported in 
HARS, the first reported date of birth in CD4 Surveillance and the last reported 
date of birth in SOPHID. Where dates of birth were reported without a specific 
day of birth they were recorded as “15/xx/xxxx” if missing a day of birth and 
“01/01/xxxx” (some as “15/06/xxxx”, “30/06/xxxx”, or “01/07/xxxx” due to change 
of staff and misunderstandings) if missing both a day and month of birth. Lack 
of both day and month of birth was much more frequent than just a missing day 
of birth. In HARS, for each year of birth there was a median of 232 individuals 
with dates of birth on the same day and month. However, there were 855 
individuals recorded as born on “01/01/xxxx”, more than twice as many as the 
next most frequent day and month of birth combination (401 individuals born on 
the “10/10/xxxx”). The “15/06/xxxx” was fifth most frequently reported (367 
individuals) whereas “01/07/xxxx” and the “30/06/xxxx” were the 20th and 31st 
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most frequently reported combinations (289 and 281 individuals respectively). 
Dates associated with memorable or auspicious dates were also more 
frequently reported (e.g. Christmas Day)225. Dougan et al. suggested that the 
increased frequency of certain dates of birth, particularly among black Africans, 
reflected disproportionate duplication of records in HARS225. It may be more 
likely that these reported dates of birth are the dates of birth used consistently 
by separate individuals even if they are not exact dates of birth. In contrast with 
the conclusion of Dougan et al., I suggest that the use of these dates of birth for 
deduplication of records should not be compromised when used in combination 
with soundex codes and other patient identifiers. Similar patterns of dates of 
birth were evident in both the SOPHID and CD4 Surveillance databases. 
In each database many individuals had more than one valid date of birth 
reported: 3,176 (4.0%) of 79,596 individuals reported to SOPHID; 1,984 (2.3%) 
of 87,277 individuals reported to HARS; 3,825 (3.9%) of 97,094 individuals 
reported to CD4 Surveillance (Table 3.4). Multiple dates of birth must be due to 
coding errors or inconsistent reporting of dates of birth by the individuals 
themselves (only few were also reported with missing information). For 
example, one individual’s date of birth was reported as 21/01/19xx, 02/01/19xx 
and 20/01/19xx. The first two dates were reported from the same clinic with the 
same local patient ID number but slightly different soundex codes. The latter 
two dates were reported with the same soundex code but from different clinics.  
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Table 3.4. Distribution of the frequency of different dates of birth per individual 
in HARS, SOPHID and CD4 Surveillance 
Frequency HARS SOPHID CD4 Surveillance 
1 85,293  (97.7%) 76,420  (96.0%) 93,269  (96.1%) 
2 1,950  (2.2%) 3,008  (3.8%) 3,585  (3.7%) 
3 32  (0.04%) 160  (0.2%) 222  (0.2%) 
4 1  (<0.01%) 6  (<0.01%) 15  (0.02%) 
>4 1  (<0.01%) 2  (<0.01%) 3  (<0.01%) 
Total 87,277 79,596 97,094 
 
3.4.3 Summary of key data used for record linkage and 
deduplication 
Dates of birth were more specific to an individual than soundex codes. About a 
fifth of both soundex codes and dates of birth were unique, but fewer individuals 
were reported with the same dates of birth than with the same soundex codes. 
However, between one in 25 and one in 50 individuals had more than one date 
of birth and/or soundex code reported. There were few missing soundex codes 
or dates of birth in both HARS and SOPHID but a significant proportion of 
missing dates of birth and a substantial proportion of missing soundex codes in 
CD4 Surveillance. The latter is likely to have resulted in incomplete record 
linkage of measurements of CD4 cell counts in CD4 Surveillance and therefore 
gaps in patient follow-up. 
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3.5 Record linkage between SOPHID and HARS 
3.5.1 Matching soundex, date of birth and sex: 1997 to 2002 data 
This was carried out in 2003 prior to the collection of local patient ID numbers 
from outside London and prior to the development of the SOPHID Report Table. 
Therefore, only one combination of soundex, date of birth, sex, date of 
diagnosis/date last seen, ethnic group and risk group for each individual existed 
in the datasets for record linkage. 
First, record linkage was carried out where soundex, date of birth and sex 
matched exactly. There were only a very small number of records with the same 
combination of soundex, date of birth and sex in each database, which had 
been determined to represent separate individuals. Matching of other data 
between HARS and SOPHID was compared to quantitatively determine 
whether there was evidence to support and validate this record linkage.  
Second, fuzzy matching was investigated for the remainder of records where 
soundex, date of birth and sex did not exactly match and algorithms were 
developed to identify further links. 
Finally, factors associated with record linkage were determined to help 
understand any potential biases for analyses of integrated data. 
3.5.1.1 Methods 
The data fields from SOPHID and HARS that were used for matching are 
shown below (Table 3.5).  
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 Table 3.5. Variables in SOPHID and HARS that were used for matching. 
 
Record linkage used a hierarchical algorithm of mutually exclusive and 
progressively less specific criteria (Table 3.6) and scores were assigned 
accordingly. As HARS records were linked they were excluded from further 
matching. Exact matches () were required for the soundex, date of birth and 
sex variables. Less specific matches included missing (m) or discordant (X) 
Name (and code) 
of variable 
Description of data 
HIV 
report to 
HARS 
AIDS 
report to 
HARS 
SOPHID 
Soundex (sdex) 
Soundex codes consist of the first letter 
of the surname followed by 3 digits 
assigned to consonants in the surname 
   
Date of birth (dob) In the form dd/mm/yyyy    
Sex Male, female or unknown    
Ethnic group (eth) 
Selected from the following options:                    
 White, black-Caribbean, black-African,  
black-Other, 
Indian/Pakistani/Bangladeshi, 
other/mixed 
   
Risk group 
Selected from the following options:                   
homosexual sex, heterosexual sex, 
injecting drug use, mother to child, 
haemophilia or blood/tissue recipient, 
other, unknown 
   
Site of care 
Name of hospital or centre providing 
HIV-related care 
   
HIV hospital 
The abbreviated name of the hospital 
where the patient gave the specimen for 
HIV testing 
   
Laboratory 
The abbreviated name of the institution 
or site of the laboratory that carried out 
the HIV test 
   
AIDS hospital 
The abbreviated name of the hospital 
where the patient was newly diagnosed 
with AIDS 
   
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ethnicity, risk group or location information. Matching of locations was first 
carried out requiring exact matches. For locations outside London this was then 
repeated requiring only the first four letters of the abbreviated location name to 
match (L) as matching reports from outside London were more likely to relate to 
the same person. 
Visual FoxPro 5.0 was used for the analysis. 
3.5.1.2 Data preparation 
There were 128,345 records relating to 43,189 individuals in the SOPHID 1997-
2002 amalgamated dataset. A total of 1,872 individuals were excluded because 
not all of date of birth, soundex and sex were reported (19 were missing sex). 
Fourteen (0.03%) individuals had the same soundex, date of birth and sex 
combinations in the remaining dataset of 41,317 individuals but had been 
determined to represent separate individuals at the time of deduplication.  
Individuals reported to be newly diagnosed in Scotland were excluded from an 
‘XLatest’ extract of HARS created at the end of March 2003. Also excluded 
were reports of individuals who were newly diagnosed after 31 December 2002 
or who were known to have died before 1 January 1997. Of the remaining 
40,274 individuals, 1,034 were excluded because not all of date of birth, 
soundex and sex were reported. 96 (0.2%) individuals had matching soundex, 
date of birth and sex combinations in the remaining dataset of 39,240 
individuals but had been determined to represent separate individuals. 
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3.5.1.3 Results 
Table 3.6 shows the number of records that were linked by each individual 
match score, the number of records that were linked according to grouped 
match scores, and cumulative numbers as matches became less specific. For 
example, there were 1,250 links with a match score of 2 with exactly matching 
risk group and ethnicity and matching town/city outside London (in addition to 
exactly matching soundex, date of birth and sex). The locations for these 
records were not exact matches as these would have been linked with a match 
score of 1. The 713 records linked with match score 5 were less specific as 
information about ethnicity was missing. However, information about ethnicity 
was often missing in HARS and these matches were considered to be more 
likely than if ethnicities were discordant (match score 12).  
There were 28,680 HARS records that were linked to SOPHID records as exact 
soundex, date of birth and sex matches (only 28,670 SOPHID records were 
linked to HARS records as 10 SOPHID records matched to two records in 
HARS with the same level of confidence) (Table 3.6). These links accounted for 
69% (28,670/41,317) of records in SOPHID and 73% (28,680/39,240) of 
records in the HARS dataset. Ninety nine per cent of links also had matching 
risk group, ethnicity or location to suggest that these were indeed the same 
individual (match scores 1-16). In addition, 43% (12,441/28,680) of all links had 
complete matching information (match scores 1-2) and 79% (22,724/28,680) 
had at least two of ethnicity, risk group or location that matched (match scores 
1-5, 7, 9-12). 
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Table 3.6 also shows the number of records that were linked according to 
grouped match scores. From the top, these links had: 
 Exactly matching risk group and ethnicity (17,667; 62%) 
 Exactly matching risk group but missing ethnicity (8,343; 29%) 
 Exactly matching ethnicity but missing risk group (334; 1%) 
 Exactly matching ethnicity and location but discordant risk group (389; 1%) 
 Exactly matching risk group and location but discordant ethnicity (796; 3%). 
There were 74 records in HARS that had soundex, date of birth and sex 
matching records in SOPHID but were not linked because they had already 
been linked to other records. None of these records were denoted in HARS as 
not being duplicates and so were flagged for future follow-up. 
Of the 28,680 linked records, 93.6% (26,856) had the same risk group reported, 
0.9% (245) were missing risk group information in both datasets, and a further 
2.2% (645) were missing risk information in one dataset (of which, 88% 
(565/645) were missing in HARS). There were 933 links (3.3% of the total) with 
discordant risk groups (Table 3.7a).  
Of the 28,680 linked records, 62.3% (17,885) had the same ethnicity reported 
and 2.4% (690) were missing ethnicity information in both datasets (Table 3.7b). 
In contrast to the risk group information, 31% (8,910) were missing information 
in only one dataset, of which over 99% (8,853) were missing ethnicity 
information in HARS. The HARS records with missing ethnicity were more likely 
to be white individuals such that 54% of those with known ethnicity in the linked 
dataset were white and 37% black African compared to 60% and 30% 
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respectively when SOPHID ethnicities were included. This is because missing 
ethnicity information is not routinely followed-up for completion of the HARS 
dataset. There were 1,191 links (4.2% of the total) with discordant ethnicity. 
Table 3.6. Results of record linkage ( = exact match, L = location outside 
London town/city match, M = missing data in HARS, X = discordant 
information). 
Match 
Score 
Sdex
1
 DOB
2
 Sex 
Risk 
group 
Eth
3
 Location 
Links Grouped links 
n cumulative n (%) cumulative 
1       11,191 11,191 
17,667 
(62%) 
17,667 
(62%) 
2      L 1,250 12,441 
3      X 5,226 17,667 
4     M  2,907 20,574 
8,343 
(29%) 
26,010 
(91%) 
5     M L 713 21,287 
6     M X 4,723 26,010 
7    M   252 26,262 
334 
(1%) 
26,344 
(92%) 8    M  X 82 26,344 
9    X   351 26,695 389 
(1%) 
26,733 
(93%) 10    X  L 38 26,733 
11     X  756 27,489 796 
(3%) 
27,529 
(96%) 12     X L 40 27,529 
13    X X  308 27,837 374 
(1%) 
27,903 
(97%) 14    X X L 66 27,903 
15    X  X 185 28,088 
185 
(1%) 
28,088 
(98%) 
16     X X 295 28,383 
295 
(1%) 
28,383 
(99%) 
17    X X X 297 28,680 
297 
(1%) 
28,680 
(100%) 
1
 Soundex code 
2
 Date of birth 
3
 Ethnicity 
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Tables 3.7 a/b. Results of record linkage by a) risk group and b) ethnicity. 
a) 
 
 
 
 
 
b) 
 
 
 
 
 
* I/P/B = Indian/Pakistani/Bangladeshi 
 
Of the linked records with no reported ethnicity in HARS, 93% (8,853/9,543) 
had a reported ethnicity in SOPHID. Attributing the SOPHID ethnicity to those 
linked HARS records reduced the overall proportion with missing ethnicity in the 
HARS dataset from 33% (9,543/28,680) to 2% (690/28,680).  
Sex between  
men 
Injecting drug  
use 
Blood or  
tissues 
Heterosexual  
sex 
Not  
reported/not  
known 
Total 
Sex between men 14,277 54 4 146 144 14,625 
Injecting drug use 77 941 1 81 16 1,116 
Blood or tissues 7 1 501 50 11 570 
Heterosexual sex 316 150 46 11,137 394 12,043 
Not reported/not known 32 13 2 34 245 326 
Total 14,709 1,159 554 11,448 810 28,680 
 
S
O
P
H
ID
  
HARS 
White Other/mixed Black  
Caribbean Black African Black other I/P/B Not reported Total 
White 9,819 83 34 69 10 5 6,637 16,657 
Other/mixed 298 464 26 55 15 37 515 1,410 
Black Caribbean 17 2 557 62 12 1 192 843 
Black African 51 52 77 6,688 41 19 1,312 8,240 
Black other 29 32 34 88 126 1 120 430 
I/P/B 10 16 1 17 232 77 353 
Not reported 17 9 9 11 5 6 690 747 
Total 10,241 658 738 6,990 209 301 9,543 28,680 
S
O
P
H
ID
  
HARS 
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Tables 3.8 a/b. Risk group and ethnicity of individuals newly diagnosed who 
were linked to SOPHID a) before record linkage and b) after record linkage. 
a) 
 
 
 
 
 
b) 
 
 
 
 * I/P/B = Indian/Pakistani/Bangladeshi 
 
When the 10,560 HARS records that did not link to SOPHID were included in 
the assessment of missing ethnicity information, SOPHID data reduced the 
proportion with missing ethnicity in HARS from 42% (16,314/39,240) to 19% 
(7,461/39,240). The percentage missing ethnicity information by risk group was 
reduced from: sex between men, 50% to 20%; heterosexual sex, 25% to 12%; 
injecting drug use, 60% to 37%; blood transfusions/blood or tissue transfer, 
67% to 20%; not known, 62% to 41%. 
Sex between  
men 
Injecting drug  
use 
Blood or  
tissues 
Heterosexual  
sex 
Not  
reported/not  
known 
Total 
White 12,719 1,030 435 2,335 359 16878 
Other/mixed 733 48 18 343 31 1173 
Black Caribbean 360 16 8 518 28 930 
Black African 173 24 51 7,753 301 8302 
Black other 167 8 0 142 12 329 
I/P/B 107 4 26 230 11 378 
Not in HARS or SOPHID 450 29 16 127 68 690 
Total 14,709 1,159 554 11,448 810 28,680 
Ethnicity 
Route of infection 
Sex between  
men 
Injecting drug  
use tissues 
Heterosexual  
sex 
Not  
reported/not  
known 
Total 
White 7,602 590 124 1,713 212 10241 
Other/mixed 345 21 11 265 16 658 
Black Caribbean 248 11 6 454 19 738 
Black African 116 19 34 6,648 173 6990 
Black other 90 7 0 107 5 209 
I/P/B 81 4 15 191 10 301 
Not reported to HARS 6,227 507 364 2,070 375 9543 
Total 14,709 1,159 554 11,448 810 28,680 
Route of infection 
Ethnicity 
Blood or  
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3.5.1.4 Investigation of the subset not yet linked at one site 
A ‘small’ site with 62 SOPHID records and 53 HARS records was selected for 
further investigation of records that had not yet been linked. The aim was to 
determine whether HARS records that had not yet been linked were also 
reported to SOPHID but with a different soundex, date of birth or sex. There 
were 13 HARS records that were not linked to SOPHID records on the basis of 
exact soundex, date of birth and sex. Records reported to SOPHID were 
trawled for records matching HARS records on either the date of birth or 
soundex. Six of these records could be identified in SOPHID with a high degree 
of confidence (Table 3.9). This indicated that the maximum sensitivity of record 
linkage using exactly matching soundex, date of birth and sex was only 87% 
(40/46). Further matches that were not identified, due to either different soundex 
and date of birth reported or because patients were reported from elsewhere, 
would reduce this sensitivity. 
Table 3.9. Matches at one ‘small’ site between HARS and SOPHID without all 
of soundex, date of birth and sex matching   ( = exact match) 
Number 
matched 
Soundex Date of birth Sex Risk group Ethnicity Location 
1       
1 First letter      
1 
Numbers correct 
Letter wrong 
     
2  1 digit incorrect in day     
1  1 digit incorrect in day   
Missing in 
SOPHID 
 
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This brief investigation showed the potential for fuzzy matching and therefore 
algorithms were developed to identify further links for the remainder of the 
HARS and SOPHID records that had not previously been linked. 
3.5.1.5 Record linkage of the unlinked with fuzzy matches 
Fuzzy matching was carried out in a similar manner to the hierarchical record 
linkage based on matching soundex, date of birth and sex described above. 
However, for the first four match scores, discordant sex was allowed for records 
with exactly matching soundex and date of birth (Table 3.10). Subsequently, 
records were linked with only either date of birth or soundex matching exactly. 
The other of these patient identifiers was allowed to differ slightly between 
linked records. For these fuzzy matches, additional matching information was 
considered essential to limit false links. As before, less specific links with other 
information missing or discordant were allowed as the match score increased.  
As dates of birth have less redundancy than soundex codes in these databases 
(Section 3.4.3) matches were sought with the same date of birth prior to 
matches with the same soundex. Due to the redundancy of soundex codes, 
soundex matches required a fuzzy date of birth match whereas some date of 
birth matches were allowed with completely discordant soundex if there was 
sufficient supporting information. Some manual checking of individual records 
was carried out to limit false links. 
A total of 1,925 HARS records were linked to SOPHID records using fuzzy 
matching. The majority (1,139; 59%) of these fuzzy matches had exactly 
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matching soundex and sex but slightly different dates of birth. Most of the 
records linked with fuzzy date of births had two parts of the date of birth 
matching but a different day, month or year. Only 5% of the records linked with 
fuzzy matching had exact soundex and date of birth but different sex. 
Fuzzy matches linked 18.2% of the 10,560 previously unlinked HARS records 
(39,240 records with soundex and date of birth minus 28,680 linked records) 
and accounted for 6.3% (1,925/30,605) of the total number of links made 
between the datasets. However, fuzzy matching only increased the proportion 
of linked records in HARS from 73% (28,680/39,240) to 78% (30,605/39,240). 
Of the 1,925 fuzzy matches, 88.9% (1,712) had the same risk group reported, 
which was a similar proportion to that for the exact soundex, date of birth and 
sex matches. There were 98 links (5.1% of the total) with discordant risk groups 
(compared to 3.3% for exact matches), 11 (0.6%) with missing risk group 
information in both datasets, and 104 (5.4%) missing information in one dataset. 
Similar proportions of the 1,925 fuzzy matches as exact matches had matching 
ethnicity: 56.3% (1,083) had the same ethnicity; 3.0% (57) had missing ethnicity 
information in both datasets; 3.5% (68) had discordant information; and 37.2% 
(717) were missing information in only one dataset, of which 96.0% (688) were 
missing ethnicity in HARS. Of the newly linked records with no reported 
ethnicity in HARS, 92.3% (688/745) had a reported ethnicity in SOPHID. 
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Table 3.10. Results of fuzzy matching ( = exact match, L = location outside London town/city match, X = discordant information, 
empty cell = not considered). 
Match 
score 
Soundex Date of birth Sex 
Risk 
group 
Ethnicity Location Links 
Cumulative 
totals 
Grouped 
totals (%) 
1   X    43 43 
90      
(5%) 
2   X  X  18 61 
3   X X   15 76 
4   X X X  14 90 
5 First letter and following two numbers      139 229 
696  
(36%) 
6 First letter      or L 254 483 
7 Three numbers only      or L 80 563 
8 X      or L 30 593 
9 First letter and following number    missing  or L 69 662 
10 First letter and following two numbers    missing  57 719 
11 First letter and following number    missing X 67 786 
12  
Americanised date of birth 
    32 818 
1,139  
(59%) 
13    X  23 841 
14   X X  10 851 
15  Switched day (i.e. 12 vs 21)     or L 19 870 
16  Switched month (i.e. 12 vs 21)     or L 19 889 
17  Switched year (i.e. 12 vs 21)     or L 8 897 
18  
Discordant month of birth 
    99 996 
19    X  107 1,103 
20   X X  or L 35 1,138 
21  
Discordant day of birth 
    189 1,327 
22    X  171 1,498 
23   X X  or L 57 1,555 
24  
Discordant year of birth 
    156 1,711 
25    X  149 1,860 
26   X X  or L 65 1,925 
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Of all 30,605 linked records, 11 (0.04%) HARS records had dates of death prior 
to being first reported to SOPHID, of which 5 were fuzzy matches. Five of the 6 
records linked with exact soundex, date of birth and sex were also reported 
from matching clinics and all were recorded to have died in 1997. This suggests 
that errors occurred in record linkage between HARS and ONS records in 1997, 
which was the first year that ONS quarterly files were used. The five fuzzy 
matches all had different dates of birth between HARS and SOPHID and were 
reported from different clinics suggesting incorrect record linkage. 
Additionally, 95 (0.3%) individuals were recorded in HARS as having died in a 
calendar year prior to being last reported to SOPHID, of which 11 were fuzzy 
matches. Later investigation of some of the individuals last reported to SOPHID 
in 2002 indicated that they continued to be seen for care after 2002 suggesting 
that most of these HARS dates of death were likely to be incorrect. 
In addition, of the linked records, 521 (1.7%) records were in HARS as newly 
diagnosed in a calendar year after being first reported to SOPHID, of which 62 
(12%) were fuzzy matches. There was a mean of 2.0 years between the year 
first reported to SOPHID (1997-2002 dataset) and the year first reported to 
HARS. Although it is clear that some of these differences may be due to 
incorrect record linkage, it is likely that the majority reflect errors in HARS due to 
failure to deduplicate HARS records sufficiently (linking the matched HARS 
record to an earlier HARS report), coding errors or delayed reporting with 
incorrect dates of HIV diagnosis. However, there were only 41 of cases where 
 121 
 
the first report received was from a clinician at the time of an AIDS diagnosis 
and there was no previous report of a new HIV diagnosis from the laboratory. 
3.5.1.6 Factors associated with record linkage 
The third aim of this chapter was to identify factors associated with record 
linkage in order to consider the potential for bias to be introduced into analyses 
of the integrated data by the record linkage process. Therefore the associations 
between epidemiologic factors and record linkage were considered by 
multivariable logistic regression analysis with successful and unsuccessful 
record linkage as the binary outcome (Table 3.11). All of the following factors 
were included in the adjusted model. This showed the following: 
 The proportion linked increased with increasing period of HIV diagnosis 
 Fewer individuals aged over 39 years were linked compared to those aged 
30-34 years.  Although numbers were small, a higher proportion of patients 
aged younger than 15 years were linked than for other age groups. 
 IDU and heterosexuals were about half as likely to be linked as MSM. 
Individuals infected through ‘other/not known’ transmission were less likely 
to be linked (adjusted odds ratio [AOR] 0.17; 95% CI 0.15, 0.20). 
 Slightly more individuals diagnosed outside London were linked compared to 
individuals diagnosed in London (AOR 1.16; 95% CI 1.10, 1.23). 
 White individuals were more likely than individuals of other ethnicities to be 
linked. A lower proportion of individuals of unknown ethnicity were linked 
than individuals of white ethnicity (AOR 0.29; 95% CI 0.27, 0.31).  
 122 
 
Table 3.11. Number and percentage of HARS records linked to SOPHID 
 
Number of 
linked HARS 
patients   
n    
(distribution, %) 
All newly 
diagnosed 
patients 
n    
(distribution, %) 
Percentage 
of newly 
diagnosed 
patients 
linked 
% 
Multivariable 
adjusted        
odds ratio       
(95% confidence 
interval) 
        
    Period of HIV diagnosis     
1979-1984 285  (0.9) 378  (1) 75 0.18  (0.14,  0.24) 
1985-1989 2,533  (8) 4,999  (13) 51 0.12  (0.11,  0.13) 
1990-1994 5,274  (17) 8,228  (21) 64 0.24  (0.22,  0.27) 
1995-1999 10,670  (35) 12,308  (31) 87 0.77  (0.71,  0.84) 
2000-2002 11,843  (39) 13,327  (34) 89 - 
     
   Age group at diagnosis     
<15 154  (0.5) 170  (0.4) 90 4.21  (2.40,  7.38) 
15-24 4,063  (13) 5,497  (14) 74 1.07  (0.98,  1.17) 
25-29 7,050  (23) 9,236  (24) 76 1.04  (0.96,  1.12) 
30-34 7,495  (24) 9,454  (24) 79 - 
35-39 5,394  (18) 6,757  (17) 80 0.93  (0.85,  1.01) 
40-44 2,862  (9) 3,624  (9) 79 0.88  (0.80,  0.98) 
45+ 3,587  (12) 4,502  (11) 80 0.82  (0.74,  0.90) 
     
   Risk group     
MSM 15,517  (51) 19,585  (50) 79 - 
IDU 1,257  (4) 2,080  (5) 60 0.46  (0.41,  0.51) 
Blood/blood products 598 (2) 743  (2) 80 1.91  (1.53,  2.40) 
Heterosexual men 4,880  (16) 6,170  (16) 79 0.51  (0.47,  0.55) 
Heterosexual women 7,496  (24) 9,140  (23) 82 0.58  (0.54,  0.63) 
Other/not known 857  (3) 1,522  (4) 56 0.17  (0.15,  0.20) 
     
   Region of diagnosis     
London 19,053  (62) 24,950  (64) 76 - 
Outside London 11,552  (38) 14,290  (36) 81 1.16  (1.10,  1.23) 
     
   Ethnicity     
White  10,741  (35) 11,988  (31) 90 - 
Black African 7,565  (25) 8,622  (22) 88 0.71  (0.64,  0.79) 
Black Caribbean 782  (3) 887  (2) 88 0.71  (0.57,  0.88) 
Black Other 210  (0.7) 242  (0.6) 87 0.62  (0.42,  0.91) 
Indian\Pakistani\Bangladeshi 322  (1) 389  (1) 83 0.57  (0.43,  0.76) 
Other/mixed 697  (2) 807  (2) 86 0.63  (0.50,  0.78) 
Not known 10,288  (34) 16,305  (42) 63 0.29  (0.27,  0.31) 
     
    Total 30,605  (100) 39,240  (100) 78 - 
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In addition, the proportion linked was determined for various patient identifiers 
(Appendix A.14). Analysis showed that decade of birth was a factor associated 
with record linkage but confounded by the period of diagnosis. Older individuals 
diagnosed between 1985 and 1989 were less likely to be reported to SOPHID. 
This trend became less evident as the period of diagnosis became more recent 
suggesting that it may have been related to survival (Figure 3.5). 
Figure 3.5. Percentage of HARS records linked to SOPHID records by decade 
of birth for different periods of diagnosis (1985 to 2002). 
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The site (HIV hospital) that reported the HARS record was also considered as a 
factor associated with record linkage. For individual sites, the range in the 
percentage linked was 15% to 100%. Reports were grouped together according 
to the total number of reports received from each site to investigate whether 
there were trends by size of site. The percentage linked increased with the 
number of patients reported except for the largest sites (Table 3.12). 
 The percentage of reports linked was also considered as a function of the 
SOPHID reporting site. For individual sites the proportion linked ranged from 
7% to 99%. A similar but more marked trend in the percentage linked was seen 
when grouped by the number of patients reported than for HARS sites (Table 
3.12). As for HARS sites, the percentage linked was low for the largest sites. 
 Table 3.12. Percentage of records linked by the total number of reports per site 
 
 HARS records linked to SOPHID SOPHID records linked to HARS 
Total number of 
reports 
Number of    
reporting sites  
Percentage of 
patients linked 
Number of    
reporting sites  
Percentage of 
patients linked 
        
1-9 294 72% 85 53% 
10-24 112 73% 52 59% 
25-49 66 75% 58 66% 
50-74 33 77% 29 71% 
75-99 16 77% 22 71% 
100-149 22 76% 25 74% 
150-199 15 81% 11 75% 
200-499 22 80% 31 78% 
500+ 10 75% 15 73% 
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3.5.1.7 HARS reports with missing soundex, date of birth or sex 
The 1,034 records in HARS with missing soundex, date of birth or sex were 
added to the 8,635 HARS records that did not link and the 30,605 records that 
did link to examine the proportion of all HARS records linked to SOPHID 
records (Figure 3.6). A higher proportion (92% in 1998) of individuals recently 
diagnosed was linked to SOPHID than those diagnosed earlier (42% in 1988). 
Furthermore, the 1,034 individuals missing soundex, date of birth, or sex were 
mostly diagnosed in the mid-1980s and could not be linked to SOPHID records 
to confirm their survival. Many of these individuals may have died but even if 
their deaths were reported to HARS, it will not have been possible to link these 
events to their diagnoses due to the missing patient information.  
Figure 3.6. Percentage of HARS records linked to SOPHID records by year of 
diagnosis (1985 to 2002). 
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3.5.1.8 Discussion 
Exact soundex and date of birth matches linked almost three-quarters of 
records in the HARS and SOPHID datasets that could be potentially matched. 
Almost all the linked records with exactly matching soundex and date of birth 
also had additional matching information to suggest that these were indeed the 
same individual. In addition, almost a fifth of the HARS records that did not 
match on soundex, date of birth and sex were linked with good confidence 
using fuzzy matches. There was little discordance of sex, risk group, ethnicity or 
dates of diagnosis/death between linked records but many records in the HARS 
dataset were missing ethnicity information (Section 3.5.1.3). A benefit of record 
linkage is that much of the missing ethnicity information can be gathered from 
SOPHID. Discordant risk groups were expected because information collected 
through confidential follow-up for HARS may differ from information in clinic 
records. However, it is likely that much of the discordant information (5% or 
fewer of linked records) was due to clerical errors in the data collection or data 
transcription process. The discordance could also be explained as false links 
between datasets or false deduplication but it is likely that the use of exact 
soundex, date of birth and sex, which are duplicated few times within a dataset, 
conferred a high specificity. The low number of matching HARS and SOPHID 
records that were not linked because one of the records had already been 
linked provides supporting evidence for this high specificity. For example, it is 
unlikely that an error in the date of birth would lead to a match with another 
individual with the same soundex. However, discordant dates of death 
suggested that some false links were created by fuzzy matching.  
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Although the matching process was limited to individuals with complete 
soundex, date of birth and sex information who were expected to feature in both 
datasets, over a fifth of HARS records could not be linked to SOPHID. Reasons 
for this may be that individuals with HARS records had died without our 
knowledge or emigrated prior to 1997, individuals had changed names since 
their original diagnosis or provided false information to maintain anonymity, that 
individuals were reported to HARS but not to SOPHID (under-reporting to 
SOPHID), or that patient identifiers were reported differently and so could not 
be linked. All of these factors may account for part of the large number of 
unmatched records but are considered in more detail below: 
 Most deaths should have been determined through matching records to 
ONS records if they were not reported directly from physicians. However, 
over 1,000 individuals mostly diagnosed in the mid-1980s had insufficient 
identifiers reported to confirm their death or survival; 
 Relatively few individuals were expected to have changed their names 
between HIV diagnosis and inclusion in SOPHID surveys; 
 The number of individuals who provided false information to maintain 
anonymity is likely to have been minimised because of the confidential 
service that GUM clinics provide226. False names may have been more 
frequently used in the 1980s and early 1990s when there was more fear 
about disclosure of a terminal disease, in particular, due to restrictions for 
life insurance227;228. However, patient and NHS websites advise people of 
the confidentiality of GUM services and of the option of using a false name 
but emphasise the need to use that same false name again when 
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reattending. I could not find any similar advice about the use of false dates 
of birth. If individuals continued to use the same false information, record 
linkage would still have been effective but this consistency may be less likely 
if patients change clinics; 
 If individuals diagnosed in England and Wales had emigrated before 1997 
they would have appeared in HARS but not in SOPHID. However, a similar 
number of SOPHID and HARS records were considered for record linkage. 
If many individuals had emigrated, substantial under-reporting to HARS or 
over-counting in SOPHID must have balanced these numbers; 
 A substantial number of individuals reported to HARS but not to SOPHID 
was unlikely because a similar number of SOPHID records were not linked 
to HARS. It was unlikely that there was such a degree of under-reporting to 
both surveillance systems, in particular, because SOPHID data are used to 
allocate funding on the basis of the number of individuals reported; 
 Coding errors that became evident through fuzzy matching accounted for a 
fifth of the links that did not link on exact soundex, date of birth and sex. 
Coding errors were also likely to account for most of the discordant risk 
groups and ethnicity from linked records. It is likely that many other links 
could not be identified through fuzzy matching. 
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3.5.2 Use of local patient ID numbers in the SOPHID 1997-2003 
dataset for record linkage to HARS data (2004) 
3.5.2.1 Data preparation 
Data preparation for record linkage in 2004 between SOPHID and HARS was 
the same as in 2003 (Section 3.5.1.2) except that local patient ID numbers were 
available for the majority of individuals reported to the 2003 SOPHID survey 
and included in the amalgamated dataset. Of the 34,260 records in the 
deduplicated SOPHID dataset for 2003 with all of date of birth, soundex and sex 
reported, 99.8% (19,434/19,473) of records from the London survey and 88.5% 
(13,093/14,787) from outside London had local patient ID numbers reported. 
The dataset from the 2003 SOPHID survey was appended to the previous 
amalgamated dataset with the additional local patient ID numbers available for 
matching and amalgamated as previously. There were 158,459 records relating 
to 49,197 individuals in the SOPHID 1997-2003 dataset. Records for 107 
individuals were excluded because not all of date of birth, soundex and sex 
were reported to leave a dataset of 49,090 individuals. There were 32,484 
(66.2%) records with a local patient ID number of which 29,249 (90.0%) were 
longer than four characters (to provide at least some additional specificity for 
records containing ‘GUM.....’ or similar at the start of their local patient ID 
number [Section 2.1.2]) and could be used for reliable matching.  
The HARS dataset from the end of June 2004 included records for 47,349 
individuals, 1,027 were excluded for whom not all of date of birth, soundex and 
sex were reported to leave a dataset of 46,322 individuals.  
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3.5.2.2 Record linkage process 
Local patient ID numbers were included in this process as it was found to be 
very effective in record linkage between SOPHID and CD4 Surveillance. 
Reports in the SOPHID and HARS databases were linked as previously using 
exact and fuzzy matched patient information, but including local patient ID 
numbers. However, the process was streamlined because the results of the 
previous record linkage strategy suggested that many records could be linked 
with high confidence. For example, all records with matching soundex code, 
date of birth and sex were linked without considering risk group, ethnicity or 
location. Matches were not considered for record linkage if they had a date of 
death in HARS prior to the year that they were first reported to SOPHID. Visual 
FoxPro 5.0 was used for the analysis. 
3.5.2.3 Results 
There were 38,975 records linked between the SOPHID and HARS datasets 
(Table 3.13). These accounted for 79.4% of the 49,090 SOPHID records and 
84.1% of the 46,322 HARS records. Of the total, 34,783 (89.2%) were linked by 
exact soundex, date of birth and sex, 1,360 (3.5%) were linked using the local 
patient ID number but did not have exact soundex, date of birth and sex 
matching, 701 (1.8%) were linked by exact date of birth and sex but fuzzy 
soundex and 2,131 (5.5%) by exact soundex and sex but fuzzy date of birth. 
Nine per cent (1,360) of the 15,045 patient ID number matches did not have 
matching soundex, date of birth and sex but some of these could have been 
linked with fuzzy soundex and date of birth. Local patient ID numbers only 
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corroborated 39.1% (13,685) of the 34,973 exact soundex, date of birth and sex 
matches and only half (15,045/29,249) of the SOPHID records with a sufficiently 
long patient ID number were linked. It is important to note here that the patient 
ID number from the clinic at the time of HIV diagnosis was being matched to the 
patient ID number from the clinic of last attendance in 2003. 
There were eight links where an individual was reported to SOPHID in a 
calendar year after the year of death in HARS. These were investigated 
individually and all dates of death were subsequently believed to be incorrect. 
There were 32 links where the individual was reported to SOPHID as having 
died and the last year reported to SOPHID was earlier than the year of death 
reported to HARS.  However, these HARS deaths were all reported to be in 
January or February of the year after they were last reported to SOPHID and 
the links were therefore believed to be reliable. There were also three links 
where the year of death reported to SOPHID was earlier than the year of 
diagnosis reported to HARS and all of these linked incorrectly with a fuzzy date 
of birth. There were 60 additional links where the last year of report to SOPHID 
(but no death reported) was earlier than the year of diagnosis reported to 
HARS. Half (32) of these were linked incorrectly with a fuzzy date of birth (31) 
or fuzzy soundex code (1), a different reporting clinic and no matching local 
patient ID number. The other 28 were believed to be correct links, mostly 
accounted for by HARS reports that were not linked to previous HARS reports, 
but where SOPHID reports had been linked over time (through deduplication). 
However seven of these 28 appeared to be because diagnoses in early January 
were reported to SOPHID as seen at the end of the previous calendar year. 
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3.5.2.4 Discussion 
Local patient ID numbers provided a highly specific match with only additional 
soundex or date of birth matching needed to ensure that records with similar 
patient ID numbers at different clinics/centres were not linked. However, 
although patient ID numbers provided confirmation of true links with discordant 
soundex or date of birth, they did not substantially increase the number of 
records linked between HARS and SOPHID datasets. This is likely to be 
because local patient ID numbers are specific to a clinic and the majority of 
reports from a clinic are likely to have matching soundex codes and dates of 
birth. Links based on soundex code and date of birth but with different local 
patient ID numbers were most likely to be due to patients changing clinic 
between diagnosis and when last seen for care. Links between SOPHID and 
HARS records were not reliable if the year of death reported to SOPHID was 
earlier than the year of diagnosis reported to HARS. However, if the individual 
was reported to SOPHID after the date of death recorded in HARS, the link was 
reliable and the date of death was not. Although the numbers of probable 
incorrect links (found through analysis of discordant dates) was small, all of 
these were based on fuzzy matches, indicating that the additional sensitivity 
gained is not worth the probable loss of specificity. 
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Table 3.13. Results of record linkage ( = exact match, X = discordant 
information, L = town/city match outside London, missing = ethnicity missing in 
HARS dataset, empty boxes not considered). 
Match 
Score 
Sdex
1
 Dob
2
 Sex Risk Eth
3
 Loc
4
 
Patient 
number 
Individual links Grouped links 
n cumulative n (%) cumulative 
1        11,060 11,060 
34,783 
(89%) 
34,783 
(89%) 
2       Fuzzy  2,625 13,685 
3       X 21,098 34,783 
4   X     41 34,824 
1,360 
(3%) 
36,143 
(93%) 
5 X       516 35,340 
6  X      353 35,693 
7 X X    /L  62 35,755 
8       Fuzzy  248 36,003 
9       Fuzzy  140 36,143 
10        130 36,273 
701  
(2%) 
36,844 
(95%) 
11 1,3
5
       111 36,384 
12 1,1
5
     /L  190 36,574 
13 2,3
5
     /L  87 36,661 
14      /L  26 36,687 
15 1,2
5
    missing /L  79 36,766 
16 1,3
5
    missing   78 36,844 
17  Am dob
6
      77 36,921 
2,131 
(5%) 
38,975 
(100%) 
18  Flip dD
6
    /L  25 36,946 
19  Flip mM
6
    /L  20 36,966 
20  Flip yY
6
    /L  0 36,966 
21  Dd/--/Yy
6
      151 37,117 
22  Dd/--/Yy
6
   X   263 37,380 
23  Dd/--/Yy
6
  X    36 37,416 
24  --/Mm/Yy
6
      273 37,689 
25  --/Mm/Yy
6
   X   480 38,169 
26  --/Mm/Yy
6
  X    54 38,223 
27  Dd/Mm/--
6
      238 38,461 
28  Dd/Mm/--
6
   X   463 38,924 
29  Dd/Mm/--
6
  X    51 38,975 
1 
Soundex, 2 Date of birth, 3 Ethnicity, 4Location 
5 
Substring of soundex code: 1,3 = first letter and following two numbers, 1,2 = first letter and following 
number, 1,1 = first letter, 2,3 = second number and following two numbers 
6 
Fuzzy date of birth: Am dob = Americanised date of birth, flip = switched number (i.e. 12 vs 21), Dd/--/Yy
 
= 
discordant month of birth, --/Mm/Yy = discordant day of birth, Dd/Mm/-- = discordant year of birth 
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3.5.3 Record linkage between HARS and SOPHID using multiple 
records for each individual: 2008 
While the central methodology of record linkage between HARS and SOPHID 
remained the same in 2008, the datasets were modified. These datasets 
included all reports to HARS and SOPHID (Report Tables) rather than 
deduplicated data with records unique to each patient. The aim was to 
maximise the record linkage between the databases by enabling matching 
between multiple reports of an individual rather than only between unique 
aggregated records for each individual. When using an aggregated record for 
an individual, a single soundex, date of birth and local patient ID number must 
be chosen to represent the patient. However, using all reports for a patient 
meant that all different combinations of the patient identifiers were considered 
for record linkage.  
A key difference to the record linkage strategy in 2008 was that the algorithm 
was not mutually exclusive and records were not excluded from subsequent 
matching. Therefore, records could be linked a number of times between the 
datasets. This identified probable duplicates and therefore, an additional step of 
deduplicating records in the HARS and SOPHID matching tables was 
incorporated in the process. This resulted in unique one-to-one links between 
the final datasets. 
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Figure 3.7. Schema summarising how bilateral links between HARS and 
SOPHID were deduplicated 
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records could still be linked despite missing information. There were no 
individuals with matching patient identifiers in the final SOPHID dataset as 
these were all deduplicated. 
The HARS reports used for record linkage included data from a combined 
extract of the XLatest and Report Tables at the end of June 2008. For every 
individual, this incorporated every unique combination as reported. Reports of 
individuals who were diagnosed when aged less than 15 years, who were newly 
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diagnosed after 31 December 2007 or who were known to have died before 1 
January 1995 were excluded. There were reports from 79,192 individuals 
among the remaining 130,492 records, of whom 728 individuals did not have all 
of date of birth, soundex and sex reported. There were 59 (0.08%) individuals 
with matching soundex, date of birth and sex combinations in the remaining 
dataset, of which 11 had matching ethnicities and risk groups. 
3.5.3.2 Record linkage process 
Reports in the SOPHID and HARS databases were linked as previously using 
exact and fuzzy matched patient information (Section 3.5.2.2). However, the 
process was streamlined even further so that only robust links were included in 
line with the SOPHID deduplication algorithm of the Report Table (Section 
2.4.6). However, this strategy did not incorporate fuzzy soundex code and date 
of birth matching as the additional yield was not considered worth the possible 
loss of specificity without manual inspection of these potential links. As 
previously, matches were not considered if they had a date of death in HARS 
prior to the year that they were first reported to SOPHID. Matches were not 
considered if the SOPHID year of death was earlier than the year of HIV 
diagnosis reported to HARS (Section 3.5.2.4). 
As noted above, this process was not mutually exclusive and records were not 
excluded from subsequent matching, which therefore required additional 
deduplication in the HARS and SOPHID datasets.  
Microsoft Access 2003 was used for the analysis.  
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3.5.3.3 Results 
After record linkage, there were 65,676 links between the SOPHID and HARS 
datasets (Table 3.14). This was after deduplicating 3,903 records from HARS 
where more than one record matched a single SOPHID record to leave 1,923 
linked records. Similarly, 2,795 records from SOPHID, where more than one 
record matched a single HARS record, were deduplicated to leave 1,383 linked 
records. The algorithm linked 82.5% (65,676/79,596) of SOPHID records and 
85.1% (65,676/77,212) of HARS records. 
Almost all (97.6% [64,089]) of the records were linked with exact soundex code, 
date of birth and sex. Over half (55.1% [36,170]) of all links were corroborated 
by matching local patient ID number and clinic. A slightly higher percentage 
(61.2%) had matching risk group and ethnicity. Comparison of the records 
linked between XLatest and the SOPHID patient table showed that there were 
3,804 (5.8%) for whom soundex codes did not match, 2,076 (3.2%) for whom 
dates of birth did not match, and 251 (0.4%) for whom sex did not match. 
There were 367 (0.6%) links where the individual was reported to HARS as 
having died in a calendar year earlier than the individual was last reported to 
SOPHID. Over a third (36.8% [135]) of these 367 individuals were reported to 
HARS to have died in the year before they were last reported to SOPHID but 
over a quarter (26.7% [98]) were reported to have died more than five years 
before being last seen and 5.4% (20) more than ten years before.  
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For 26 of the 135 who had a date of death reported to HARS in 2006 but were 
last reported to SOPHID in 2007, the dates of death were thought to be 
incorrect. However, for the remaining 109 of the 135 records, the date of death 
appeared to be correct and was sometimes also reported to SOPHID, but a 
SOPHID report was inappropriately received for these individuals in the year 
after their death. 
Examination of the latter 20 links with date of death in 1995 or 1996 indicated 
that all links between HARS and SOPHID were valid. Either the date of death 
was incorrectly reported (sometimes to both HARS and SOPHID), records were 
incorrectly deduplicated in SOPHID, the individual was subsequently reported 
by the clinic many years after their death (sometimes continuously), or the clinic 
had subsequently reported the same patient identifiers for a different individual.  
Investigation of many of the remaining 212 records with more than one year 
difference between the year of death reported to HARS and the last year 
reported to SOPHID indicated that the date of death in HARS was incorrect 
(probably incorrectly linked to an ONS death report).  
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Table 3.14. Results of record linkage ( = exact match, X = discordant or missing information, empty cells not considered). 
Match 
Score 
Sdex
1
 Dob
2
 Sex Clinic 
Local 
patient ID 
number  
Risk 
Group 
Eth
3
 
Date of HIV 
diagnosis
4
 
Duplicates identified 
in HARS 
Duplicates identified 
in SOPHID 
Individual links after 
deduplication 
         n Cumulative n Cumulative n Cumulative 
1         580 580 297 297 34,718 34,718 
2    one or other not matching    730 1,310 495 792 29,371 64,089 
3 X        305 1,615 366 1,158 919 65,008 
4  X       208 1,823 186 1,344 533 65,541 
5   X      31 1,854 12 1,356 64 65,605 
6   X     Year of diagnosis only 69 1,923 27 1,383 71 65,676 
1 
Soundex, 2 Date of birth, 3 Ethnicity, 4 Date of diagnosis in HARS, datepos in SOPHID 
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There were also 1,449 (2.2%) records where the individual was reported to 
SOPHID in an earlier year than they were reported as newly diagnosed to 
HARS. The largest percentage (45.5% [659]) of these records were only 
reported to SOPHID one calendar year before they were reported to HARS but 
the difference was greater than five years for 18.2% (264) and greater than ten 
years for 2.6% (38). Examination of a subset of these records indicated that 
these were reliable links. Where the difference was one year the date of 
diagnosis was reported late to HARS, possibly because the date of report was 
written on the form instead of the date of diagnosis. Where the difference was 
greater, the individual was likely to have attended different clinics over time and 
either the original diagnosis was not reported to HARS or the original diagnosis 
was reported but was not linked to the subsequent report to HARS. Of the 1,449 
links between HARS and SOPHID records, there were 42 where the year of last 
report to SOPHID was before the year of HIV diagnoses reported to HARS. 
These also appeared to be reliable links with the same causes as described 
above. However, a third (14) of these HARS records were reports of deaths 
compared to only 63 (4.3%) of these 1,449 links. 
The factors associated with record linkage were reassessed after this final 
process and compared to the previous assessment of record linkage between 
HARS and SOPHID carried out in 2003. As previously, the most significant 
factor was the period of HIV diagnosis, which was associated with a substantial 
increase in the proportion linked over time (Table 3.15). There was a similar 
pattern of record linkage to that in 2003 but with a higher proportion linked in 
1995 and 1996, due to inclusion of SOPHID records from those years, and a
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Table 3.15. Number and percentage of HARS records linked to SOPHID 
 
Number of 
linked HARS 
patients   
n    
(distribution, %) 
All newly 
diagnosed 
patients 
n    
(distribution, %) 
Percentage 
of newly 
diagnosed 
patients 
linked 
% 
Multivariable 
adjusted     
odds ratio    
(95% confidence 
interval) 
2003 
multivariable 
adjusted     
odds ratio    
(95% confidence 
interval) 
         
    Period of HIV diagnosis      
1979-1984 322  (0.5) 431  (0.6) 75 0.17  (0.12,  0.23) 0.18  (0.14,  0.24) 
1985-1989 3,163  (5) 6,146  (8) 51 0.15  (0.14,  0.17) 0.12  (0.11,  0.13) 
1990-1994 6,807  (10) 9,684  (13) 70 0.30  (0.27,  0.33) 0.24  (0.22,  0.27) 
1995-1999 11,361  (17) 12,731  (16) 89 0.62  (0.56,  0.68) 0.77  (0.71,  0.84) 
2000-2004 25,325  (39) 27,509  (36) 92 0.83  (0.77,  0.90) - 
2005-2007 18,698  (28) 20,711  (27) 90 - n/a 
      
   Age group      
15-24 7,994  (12) 9,663  (13) 83 1.16  (1.05,  1.27) 1.07  (0.98,  1.17) 
25-29 13,762  (21) 16,407  (21) 84 1.07  (0.99,  1.16) 1.04  (0.96,  1.12) 
30-34 15,494  (24) 18,052  (23) 86 - - 
35-39 12,214  (19) 14,112  (18) 87 1.00  (0.91,  1.08) 0.93  (0.85,  1.01) 
40-44 7,305  (11) 8,492  (11) 86 0.93  (0.84,  1.03) 0.88  (0.80,  0.98) 
45+ 8,907  (14) 10,486  (14) 85 0.73  (0.67,  0.80) 0.82  (0.74,  0.90) 
      
   Risk group      
Sex between men 28,641  (44) 33,369  (43) 86 - - 
Heterosexual sex (men) 12,312  (19) 14,184  (18) 87 0.59  (0.53,  0.64) 0.51  (0.47,  0.55) 
Heterosexual sex (women) 20,565  (31) 22,902  (30) 90 0.73  (0.67,  0.80) 0.58  (0.54,  0.63) 
Injecting drug use 2,176  (3) 3,108  (4) 70 0.56  (0.49,  0.63) 0.46  (0.41,  0.51) 
Blood/blood products 683  (1) 846  (1) 81 1.19  (0.93,  1.52) 1.91  (1.53,  2.40) 
Other/not known 1,299  (2) 2,803  (4) 46 0.36  (0.31,  0.40) 0.17  (0.15,  0.20) 
      
   Region of diagnosis      
London 34,953  (53) 41,755  (54) 84 - - 
Outside London 30,723  (47) 35,457  (46) 87 0.76  (0.72,  0.80) 1.16  (1.10,  1.23) 
      
   Ethnicity      
White  32,707  (50) 34,585  (45) 95 - - 
Black African 24,550  (37) 26,690  (35) 92 0.53  (0.48,  0.58) 0.71  (0.64,  0.79) 
Black Caribbean 2,158  (3) 2,318  (3) 93 0.60  (0.51,  0.72) 0.71  (0.57,  0.88) 
Black Other 874  (1) 937  (1) 93 0.64  (0.49,  0.83) 0.62  (0.42,  0.91) 
Indian\Pakistani\Bangladeshi 896  (1) 987  (1) 91 0.53  (0.42,  0.67) 0.57  (0.43,  0.76) 
Other/mixed 2,791  (4) 2,948  (4) 95 0.77  (0.65,  0.92) 0.63  (0.50,  0.78) 
Not known 1,700  (3) 8,747  (11) 19 0.02  (0.02,  0.02) 0.29  (0.27,  0.31) 
      
    Total 65,676  (100) 77,212  (100) 85 - - 
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Figure 3.8. Percentage of HARS records linked to SOPHID records by year of diagnosis (1985 to 2007). 
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generally higher proportion linked in earlier years (Figure 3.8). Individuals 
infected through blood/blood products were no longer significantly more likely to 
have records linked than individuals infected through sex between men 
(p=0.17) as record linkage improved little for this group. Record linkage in 2008 
was greater for individuals diagnosed in London than elsewhere, in contrast to 
2003. The effects of age group and ethnicity were similar to 2003. 
3.5.3.1 Discussion 
This final record linkage process was relatively non-labour-intensive and quick 
because the algorithm was restricted to matches that were considered very 
robust. Yet the yield was improved and a number of additional duplicates were 
identified in each of the datasets. Incorporation of validations to the matching 
prevented many incongruous links being made between individuals where one 
was reported to have died before the other was reported. There were some 
inconsistencies between dates reported to HARS and SOPHID but examination 
of individual records indicated that the links were valid and reliable. Reports to 
SOPHID before dates of HIV diagnosis in HARS were valid and therefore the 
earliest date seen for care should be used as the date of HIV diagnosis of the 
individual in the integrated dataset. However, links between records that 
included a report of death to HARS before the last report to SOPHID should not 
be used in the integrated dataset because the data indicated that either the date 
of death was wrong or the individual was inappropriately reported to SOPHID 
after their death. These could be used in future analyses but would require 
manual checking and amendment to ensure data validity. 
 144 
 
3.5.4 Summary of record linkage between HARS and SOPHID 
Overall, approximately 75-80% of potential matches between HARS and 
SOPHID were highly likely to be true links (excluding fuzzy matches). With just 
soundex, date of birth and sex, the algorithm linked 73% of the 1997-2002 
SOPHID records to HARS but 83% of the 1995 to 2007 SOPHID records to 
HARS. Fuzzy matching increased the percentage of the 1997-2002 records 
linked by 5% (to 78%) whereas matching with local patient ID number increased 
the percentage of the 1995-2007 records linked by 2% (to 85%). Overall, there 
were 28,680 records linked in data to the end of 2002, 36,143 to the end of 
2003 and 65,676 to the end of 2008. Investigation of inconsistent dates resulted 
in the exclusion of fuzzy soundex and date of birth matching in the final 
algorithm and exclusion of links where the year of death was inconsistent with 
other reported dates. After these exclusions, a final total of 65,309 records 
linked between HARS and SOPHID were accepted for the integrated dataset. 
This latest analysis supported the previous conclusion that the majority of 
individuals diagnosed before 1995 with HARS records that did not link to 
SOPHID records had probably died without their death being reported. This was 
consistent with the decreasing proportion linked before 1995 (from 86.4% in 
1995 to 46.6% in 1986) but also with the higher proportion matched in the early 
years after inclusion of SOPHID data from 1995 and 1996 (the last two years 
before HAART substantially reduced mortality). However, the decreasing 
proportion linked was also likely to reflect some emigration and name changes.  
Between 1995 and 2007, when SOPHID data have been collected, an annual 
mean of 9.1% of new HIV diagnoses were not linked to SOPHID. Previous 
analysis suggested that a quarter to a third of these reports could be fuzzy 
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matched but reliable linkage would require manual review. It is likely that a 
further substantial proportion of the non-linked reports between 1995 and 2007 
were related to the same individual but reported with identifiers too different to 
allow specific record linkage without extensive manual review. It is therefore 
likely that only a minority of individuals who have positive test results never 
return for results or subsequent care. 
There is a minimal cost associated with record linkage between HARS and 
SOPHID as the algorithms can be run quickly using existing data management 
resources. One-off exact matching for specific analyses would be the cheapest 
process as it requires only a simple, ad-hoc database query but it would only 
link 83% of historical records. Routine use of exact matching for record linkage 
at little extra cost could reduce costs of follow-up, improve data consistency and 
provide regularly updated linked datasets for analysis. The more complex 
record matching techniques developed and validated for this thesis can be run 
almost as quickly and simply as exact matching queries, provide some 
additional yield, and exclude probable false links to further improve data quality. 
Therefore, different record linkage methodologies are probably of comparable 
cost-effectiveness and the new algorithms developed may not have 
substantially reduced potential inclusion bias in subsequent analyses as yields 
are not greatly improved. However, the understanding of the data for future 
analyses should provide a long-term benefit for the improved use and 
interpretation of surveillance data.  In particular, it is useful to know the limits of 
record linkage and that non-linked records are not necessarily due to under-
reporting. Furthermore, cost-effectiveness of surveillance is likely to improve if 
routine processes are developed around a core system of record linkage. 
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3.6 Record linkage of SOPHID and CD4 records 
3.6.1 Use of local patient ID numbers in the 1997-2003 SOPHID 
dataset to link to CD4 records (2004) 
3.6.1.1 Data preparation 
The 1997-2003 SOPHID dataset was used (Section 3.5.2.1), which contained 
the local patient ID number requested for all individuals reported to the 2003 
survey. Records of patients reported in more than one year were linked on the 
basis of matching soundex code, date of birth and sex. Matching reports that 
were known to relate to more than one individual were not linked. There were 
158,459 records for the 49,197 individuals in the SOPHID 1997-2003 dataset. 
The CD4 Surveillance database archived in January 2004 contained 69,498 
records of individuals with CD4 counts aged older than 14 years. This dataset 
contained 17,597 records with no soundex code, 6,152 records with no date of 
birth (2,892 records with neither soundex nor date of birth) and 6,838 records 
with no sex. There were 36,027 records that had been linked to records in 
HARS. A subset of 4,491 records had no local patient ID number reported from 
the laboratory, of which 402 were reported with only a soundex but no date of 
birth and 27 were reported with only a date of birth but no soundex.  
3.6.1.2 Record linkage process 
A different strategy was used than that used for linking reports between the 
SOPHID and HARS databases in 2004 (Section 3.5.2.2). Linked records were 
not excluded from further matching because it was thought that duplicates could 
be identified as multiple links to the same record. However, it was necessary to 
ensure that links were mutually exclusive so that the same pair of records was 
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not counted more than once. Therefore, a record of all links was made where 
more than one SOPHID record linked to a CD4 record or vice versa. There 
were up to three links per record and these were defined as primary, secondary 
and tertiary links according to the amount of information that matched. Primary 
links had more matching information than tertiary links indicating that the 
records were more likely to relate to the same individual. Arbitrary allocation 
was made where more than one SOPHID record linked to a CD4 record with an 
equivalent degree of matching information or vice versa. Data that were missing 
in both datasets were not considered as a match. 
Fuzzy local patient ID numbers were where a five-digit/character element of the 
number was present in the matching local patient ID number. Because sites can 
use similar formats for their patient ID numbers, these were only used to link 
records if the dates of birth and location also matched. Fuzzy soundex and date 
of birth matches were not carried out because corroborating information on risk 
group and ethnicity was not available and the majority of fuzzy matches were 
expected to have been identified through local patient ID number and location 
matching. Because laboratories were the source of CD4 data whereas 
hospitals/clinics were the usual source of SOPHID data, an intermediary table 
was created to match comparable data sources. Laboratories, hospitals and 
clinics in similar geographical areas were grouped taking account of reported 
sources of CD4 counts and prior knowledge.  
Visual FoxPro 5.0 was used for the analysis.  
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3.6.1.3 Results 
There were 33,406 primary links made between the SOPHID and CD4 datasets 
(Table 3.16). These accounted for 68% (33,406/49,197) of the SOPHID records 
and 48% (33,406/69,498) of the CD4 Surveillance records. Of the primary 
records linked, 26,585 (80%) were exact soundex, date of birth and sex 
matches and a further 992 (3.0%) had the same soundex and date of birth but 
different sex. There were 17,312 (52% of the total) primary links made using 
local patient ID numbers of which 4,453 were fuzzy matches. Of the latter, 
3,081 (69%) also matched on soundex and date of birth compared to 8,402 
(65%) of the 12,859 exact local patient ID number matches. There were 1,234 
and 653 links where the soundex and date of birth respectively were discordant 
and 3,968 and 32 where the CD4 soundex and date of birth respectively were 
missing. Record linkage to SOPHID was achieved for 3,971 (23%) of the 
17,597 CD4 records with no soundex code but only 389 (5.7%) of the CD4 
records with no sex and only 32 (0.5%) of the 6,152 CD4 records with no date 
of birth. 
There were 959 secondary links and 15 tertiary links indicating that 944 CD4 
records linked to two SOPHID records and 15 CD4 records linked to three 
SOPHID records. In comparison, there were 1,080 SOPHID records linked to 
two CD4 records and 14 SOPHID records linked to three CD4 records (primary 
matching). This suggests that 2% (974/49,197) of SOPHID records and 1.6% 
(1,108/69,498) of CD4 records were potentially duplicates or that records from 
more than one individual were inappropriately deduplicated in each dataset. 
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Table 3.16. Results of record linkage between SOPHID and CD4 Surveillance   
( = exact match, X = discordant) 
Match 
Score 
Soundex 
code 
Date 
of 
birth 
Sex Loc
1
 
Local 
patient ID 
number 
Primary links 
Secondary 
links 
Tertiary 
links 
number cumulative (%)   
1      8,187 8,187 (25) 147 3 
2 missing     2,653 10,840 (32) 31  
3 X     904 11,744 (35) 304 8 
4  X    498 12,242 (37) 110 2 
5 X X   
 
>4 characters 
243 12,485 (37) 29  
6   
X             
or missing 
X  215 12,700 (38) 5  
7 
X             
or missing 
 
X             
or missing 
X  159 12,859 (38) 20  
8     
 
>4 characters 
3,026 15,885 (47) 24  
9   X  
 
>4 characters 
55 15,940 (48) 4  
10 
X             
or missing 
 
X             
or missing 
 
 
>4 characters 
1,372 17,312 (52) 131 2 
11     X 10,438 27,750 (83) 93  
12   X   X 485 28,235 (84) 18  
13    X X 4,934 33,169 (99) 43  
14   X  X X 237 33,406 (100) 0  
1 Location 
 
There were 33,471 (48%) records in CD4 Surveillance that had not previously 
been linked to records in HARS. Record linkage to SOPHID confirmed that 17% 
(5,791) of these records were derived from HIV-infected individuals. Many of 
these records were probably not previously linked to HARS because they were 
missing soundex codes (43% [2,472]). Overall, record linkage of CD4 
Surveillance records to SOPHID increased the proportion of records linked to 
either HARS or SOPHID from 52% to 60%. Very few records without a date of 
birth were linked to either HARS or SOPHID (<1%) although these records only 
accounted for 9% (6,152/69,498) of all CD4 Surveillance records. 
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3.6.1.4 Discussion 
A substantial number and proportion of CD4 Surveillance records were linked to 
SOPHID records. Soundex, date of birth and local patient ID number were all 
essential to maximise the number linked. However, a substantial number of 
records with missing soundex were linked indicating that many of these would 
now link to HARS. 
A considerable number of the linked records were not previously linked to 
HARS records therefore confirming that these individuals reported to CD4 
Surveillance were HIV-infected. However, 40% of CD4 records remained 
unlinked. It was likely that many of these were duplicate records or records that 
could not be linked because they lacked soundex and/or date of birth 
information. The substantial proportion of records with both soundex and date of 
birth that remained unlinked were possibly from individuals who were no longer 
in E,W&NI in the years of the SOPHID surveys due to either death or 
emigration. It is also likely that a number of these records were from individuals 
without HIV infection (Section 2.3.5).   
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3.6.2 Record linkage between CD4 Surveillance and SOPHID 
using multiple records for each individual: 2008 
As for record linkage between HARS and SOPHID, the datasets for record 
linkage between SOPHID and CD4 Surveillance were modified in 2008 
although the central methodology remained the same. The datasets included all 
reports to CD4 Surveillance and SOPHID (Report Tables), which permitted 
record linkage between multiple reports of an individual with all different 
combinations of the patient identifiers considered for matching. 
This process was carried out by a junior member of staff under my supervision. 
3.6.2.1 Data sources 
There were 1,306,513 records relating to 112,215 adults in the CD4 
Surveillance dataset to the end of 2007 and 562,130 records relating to 79,596 
adults (aged older than 14 years) in the SOPHID 1995-2007 dataset. Records 
were not excluded because of missing date of birth, soundex or sex as these 
records could still be linked despite missing information.  
3.6.2.2 Record linkage process 
Reports in the SOPHID and CD4 Surveillance databases were linked using a 
streamlined version of the previous record linkage algorithm (Table 3.17). At 
least two of soundex code, date of birth and local patient ID number were 
required to match. Matching dates of birth were accepted if at least five 
characters of the local patient ID number also matched (match score 5). 
Matching patient ID numbers from any sites were accepted if at least two of the 
day, month or year of birth also matched (match score 6). The location of the 
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clinic or laboratory was not considered as this had not been found to 
substantially improve the sensitivity or specificity of the algorithm. This algorithm 
also did not incorporate fuzzy soundex code and date of birth matching. 
Microsoft Access 2003 was used for the analysis.  
As previously, the record linkage algorithm was not mutually exclusive and 
records were not excluded from subsequent matching. Therefore, records could 
be linked a number of times between the datasets, identifying possible 
duplicates. Where possible duplicate records were found, the link with the 
lowest match score was retained or arbitrary allocation was made if there was 
an equivalent degree of matching information. 
3.6.2.3 Results 
At the end of the record linkage process, there were 59,814 links between the 
SOPHID and CD4 Surveillance datasets (Table 3.17). This was after 
deduplicating 9,888 records from the CD4 Surveillance dataset and 739 records 
from SOPHID. The algorithm linked 75% (59,813/79,596) of all SOPHID records 
and 63% (59,813/94,873) of all CD4 Surveillance records (denominators 
updated to account for deduplication). Of the records linked, 50,819 (85%) had 
the same soundex code and date of birth, 48,275 (81%) had the same local 
patient ID number and 41,284 (69%) had all three matching. There were 8,994 
(15%) links that had either a different, or missing, soundex code or date of birth. 
The majority of these (93% [8,346/8,994]) had discordant soundex codes. Only 
2,002 (3.3%) of the links were based on fuzzy local patient ID number (match 
score 5) or fuzzy date of birth (match score 6).  
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Table 3.17. Results of record linkage between SOPHID and CD4 Surveillance 
datasets   ( = exact match, empty cells not considered) 
 
3.6.2.4 Factors associated with record linkage 
The factors associated with record linkage between CD4 Surveillance and 
SOPHID were similar to those between HARS and SOPHID. An increasing 
proportion of SOPHID records were linked to CD4 Surveillance with increasing 
year that an individual was first reported to SOPHID (Table 3.18). However, a 
lower proportion of records were linked in 2006 and 2007 than between 2000 
and 2005. This may have been because a few laboratories were not able to 
report CD4 cell counts for 2006 and 2007 (Section 2.3.2). Individuals infected 
through sex between men were significantly more likely to have records linked 
than all other individuals and particularly more than for individuals without a 
reported risk group. Fewer records of black Africans or black Caribbeans linked 
than for other individuals except that markedly fewer records linked for 
individuals without a reported ethnicity. There was a substantially higher 
proportion of records linked for individuals who were first reported from London 
compared to elsewhere. 
Match 
Score 
Soundex 
code 
Date of birth Sex 
Local patient 
ID number 
Primary links 
number cumulative (%) 
1     41,284 41,284  (69) 
2 
discordant 
or missing 
   6,648 47,932 (80) 
3    
discordant         
or missing 
9,535 57,467  (96) 
4  one or other not matching  344 57,811  (97) 
5    
 
>4 characters 
1,699 59,510  (99) 
6  
 
two of day, 
month or year 
  303 59,813  (100) 
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Table 3.18. Number and percentage of SOPHID records linked to CD4  
 
Number of 
linked SOPHID 
patients   
n         
(distribution, %) 
All SOPHID 
patients 
n       
(distribution, %) 
Percentage 
of SOPHID 
patients 
linked 
% 
Multivariable 
adjusted        
odds ratio       
(95% confidence 
interval) 
        
    First year reported to SOPHID     
1995 10,070  (16) 13,467  (17) 75 0.89  (0.84,  0.95) 
1996-1997 5,330  (9) 7,736  (10) 69 0.69  (0.65,  0.74) 
1998-1999 5,256  (9) 7,112  (9) 74 0.87  (0.81,  0.93) 
2000-2001 6,958  (12) 8,911  (11) 78 1.22  (1.14,  1.30) 
2002-2003 10,472  (18) 13,598  (17) 77 1.34  (1.27,  1.42) 
2004-2005 11,701  (20) 14,464  (18) 81 1.72  (1.62,  1.82) 
2006-2007 10,026  (17) 14,308  (18) 70 - 
     
   Age group     
15-25 4,871  (8) 6,598  (8) 74 1.06  (0.99,  1.14) 
25-29 10,576  (18) 13,960  (18) 76 1.04  (0.98,  1.10) 
30-34 14,379  (24) 19,149  (24) 75 - 
35-39 12,672  (21) 16,560  (21) 77 1.07  (1.02,  1.13) 
40-44 7,689  (13) 10,227  (13) 75 1.01  (0.95,  1.07) 
45+ 9,626  (16) 13,102  (16) 73 0.97  (0.92,  1.03) 
     
    Risk group     
MSM 26,280  (44) 32,643  (41) 81 - 
Heterosexual men 11,023  (18) 14,909  (19) 74 0.75  (0.71,  0.79) 
Heterosexual women 18,222  (30) 24,185  (30) 75 0.80  (0.75,  0.85) 
IDU 1,845  (3) 2,624  (3) 70 0.66  (0.61,  0.73) 
Blood/blood products 713  (1) 1,129  (1) 63 0.60  (0.52,  0.68) 
Other/not known 1,730  (3) 4,106  (5) 42 0.18  (0.17,  0.20) 
     
   Region first reported from     
London 35,097  (59) 42,424  (53) 83 - 
Outside London 24,716  (41) 37,172  (47) 66 0.33  (0.32,  0.34) 
     
   Ethnicity     
White  30,715  (51) 39,615  (50) 78 - 
Black African 21,068  (35) 28,491  (36) 74 0.78  (0.74,  0.82) 
Black Caribbean 1,885  (3) 2,449  (3) 77 0.78  (0.71,  0.87) 
Black Other 1,108  (2) 1,366  (2) 81 0.98  (0.85,  1.13) 
Indian\Pakistani\Bangladeshi 785  (1) 1,009  (1) 78 1.09  (0.93,  1.28) 
Other/mixed 3,028  (5) 3,772  (5) 80 0.97  (0.89,  1.06) 
Not known 1,224  (2) 2,894  (4) 42 0.28  (0.26,  0.30) 
     
    Total 59,813  (100) 79,596  (100) 75 - 
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3.6.2.5 Discussion 
This record linkage process was more efficient than the previous one because it 
used strategies that I had developed over time. In particular, the algorithm was 
restricted to robust matches based on at least two of soundex code, date of 
birth and local patient ID number and all reported combinations of those patient 
identifiers were considered for record linkage. This latest algorithm was not 
based on soundex with fuzzy date of birth or local patient ID number due to 
redundancy in soundex codes (Section 3.4.1). Yet, it produced a yield 
substantially higher than that achieved with a more complicated algorithm in 
2004 (75% of SOPHID records linked versus 68% in the 2004 analysis). This 
may have been due in part, to improved reporting of local patient ID number to 
SOPHID from clinics outside London. A large number of duplicate CD4 
Surveillance records were found, which provides further evidence of under-
deduplication in that database due to incompleteness of patient identifiers 
(Chapter 2.3).  
3.7 Conclusion 
There was no gold standard to use for comparison of links between datasets. 
Although the majority of links had corroborating information and were thought to 
be true links it appeared that there was a substantial, but unknown, number of 
additional true links that could not be identified due to coding or other errors. 
The subset investigation of the non-exact matches showed that a small but 
significant proportion of true links were missed if only exact soundex, date of 
birth and local patient ID number were used. Fuzzy matching probably identified 
some of these true links but introduced errors by falsely linking individuals. Also, 
substantial numbers remained unlinked even after fuzzy matching. 
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Determination of which fuzzy matches were true links and identification of 
additional true links would require the allocation of considerable resources for 
follow-up. Therefore, links made with fuzzy matching were not used for record 
linkage in 2008 to create the final integrated dataset for subsequent analyses.  
There were some significant differences between record linkage of HARS and 
SOPHID compared to SOPHID and CD4 Surveillance. Whereas the percentage 
of HARS records linked to SOPHID (85%) was similar to the percentage of 
SOPHID records linked to HARS (83%), the percentage of SOPHID records 
linked to CD4 Surveillance (76%) was substantially greater than the percentage 
of CD4 Surveillance records linked to SOPHID (63%). This was because there 
were a similar number of records of individuals in the SOPHID and HARS 
datasets used for record linkage but many more records of individuals in the 
CD4 Surveillance dataset. This is likely to be due to two main reasons: i) a 
reduced ability to deduplicate the CD4 Surveillance dataset because of 
incomplete reporting of soundex codes and, to a lesser extent, dates of birth ii) 
the reporting of CD4 cell count data for individuals who did not have HIV 
infection from laboratories unable to distinguish patients by HIV status. Because 
of missing soundex codes and dates of birth in the CD4 Surveillance dataset, 
the final SOPHID-CD4 Surveillance record linkage was based relatively less on 
these patient identifiers (85%) and more on local patient ID numbers (81%) than 
SOPHID-HARS record linkage (98% and 55% respectively). This also resulted 
in a higher percentage of different, or missing, soundex codes, dates of birth or 
sex between SOPHID and CD4 Surveillance links (15% [8,995/59,814]) than 
between SOPHID and HARS links (2.4% [1,587/65,676]). 
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Record linkage in 2008 resulted in 65,676 links between HARS and SOPHID 
and 59,814 links between SOPHID and CD4 Surveillance. Record linkage 
between HARS and SOPHID shows that it can enable ethnicity information to 
be shared between these complementary national HIV surveillance systems. 
This would considerably reduce the need for follow-up and the amount of 
missing information used in further analyses of data, strengthening the 
conclusions made. Also, the numbers of records linked were large enough to 
allow analysis of combined data such as the date of diagnosis from HARS, 
treatment information from SOPHID and the CD4 cell count at HIV diagnosis 
from CD4 Surveillance. However, analyses that make use of integrated 
datasets need to take account of bias introduced by record linkage.  
Between both HARS and SOPHID and between SOPHID and CD4 
Surveillance, the proportion of linked records was substantially affected by the 
year of HIV diagnosis, the risk group and ethnicity as well as whether the 
individual was first reported from London or not. Significantly fewer records 
were linked between HARS and SOPHID for individuals diagnosed in the years 
before 1995, indicating that many of these individuals were likely to have died 
without being reported, emigrated or changed names (such that they did not 
appear in SOPHID records in 1995). The under-reporting of deaths was 
probably substantial prior to 1995 as the death rate was high and ONS reports 
of non-HIV-related deaths were not received until 1997. This is supported by the 
reduced record linkage for older individuals who were more likely to have died. 
The poor record linkage for individuals diagnosed during these early years 
disproportionally affected MSM, IDU and individuals infected through 
blood/blood products as a much higher proportion of heterosexuals were 
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diagnosed since the mid-1990s. Of those who were not reported to have died 
before 1995, 89.0% of heterosexuals were diagnosed after 1994 compared to 
58.3% of MSM, 48.8% of IDU and 19.5% of individuals infected through 
blood/blood products. Due to the commonality between risk group and ethnicity, 
similar differences were observed by ethnicity though these effects were 
reduced after accounting for changes over time. This may be due to the 
unfamiliarity of uncommon names. Additionally, the proportion linked differed 
between reporting sites but little of this variation was captured by either their 
size or location (London or not). It is likely that the completeness and quality of 
reporting was more a function of the staff and their local patient record systems.  
Record linkage between SOPHID and CD4 Surveillance was also affected by 
the same factors mentioned above. However, the proportion of records linked 
declined in the most recent years. This may be because not all of these recently 
diagnosed individuals had a CD4 cell count measurement by the end of 2007 or 
because some of their CD4 cell counts measurements had not yet been 
reported. As with record linkage between HARS and SOPHID, fewer records 
linked for heterosexuals and individuals of black African or black Caribbean 
ethnicity after adjusting for the year of first report to SOPHID (non significant 
difference for individuals of other non-white ethnicities). Record linkage was 
significantly greater for reports from London compared to those from outside 
London, which is likely to be due to the greater dependence on local patient ID 
number for matching and the longer inclusion of local patient ID number in the 
SOPHID data from London. 
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Record linkage has been used between reports of HIV/AIDS cases and deaths 
to quantify under-reporting or for identification of losses to follow-up. 
Probabilistic record linkage between known HIV/AIDS deaths and known non-
deaths with active follow-up was assessed in Australia and found to have a 
sensitivity* of 82% and a specificity of 92%229. The limited sensitivity was 
attributed to a lack of patient identifiers on the HIV/AIDS databases. Various 
deterministic record linkage strategies between an AIDS registry and a hospital 
discharge file in New York State achieved sensitivities of 32-85% and positive 
predictive values of 14%-99%230. Errors in patient identifiers were also found to 
be a key limiting factor in the effectiveness of the process. These reporting 
errors are important to consider if record linkage is used to estimate under-
reporting of HIV/AIDS cases because non-linked records cannot be considered 
to separate individuals if identifiers are not complete or reliable. This may have 
resulted in under-estimation of reporting completeness in Italy, France and 
E,W&NI155;172;213;231. Adjustments for under-reporting are no longer used in 
E,W&NI because results from this thesis have shown the frequent variability in 
reported patient identifiers for the same individual and the inability of 
deduplication within datasets and of record linkage between datasets to identify 
all records from the same individual. 
The development of the record linkage algorithms took a great deal of time over 
a number of years. At the most complex, this involved a 72-part algorithm to 
                                            
*
 Sensitivity measures the percentage of true positives that are correctly identified whereas 
specificity measures the percentage of true negatives that are correctly identified. For record 
linkage, sensitivity describes the percentage of records that should link between two datasets 
that are actually linked by a record linkage process. In contrast, specificity describes the 
percentage of records that should not link between two datasets that remain unlinked after the 
record linkage process. In this case, the true status of the patients had been confirmed through 
active follow-up against which record linkage strategies could be compared. 
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delineate all of the exact and fuzzy matches between HARS and SOPHID 
datasets, each of which required filters to be created on each of the datasets 
and joins made between them. Yet, amalgamation of accepted matches, which 
had previously been evaluated, resulted in much quicker processes. Exclusion 
of fuzzy matches, which were shown to increase the yield but with a need for 
manual record inspection, also increased the efficiency. The matching of 
multiple records per individual more than compensated for the exclusion of 
fuzzy matches without loss of specificity. Lessons learnt from previous record 
linkage resulted in the most efficient and productive process being implemented 
in 2008. However, ongoing manual checking of non-matching individual records 
and follow-up is recommended for continuing the integration of the surveillance 
systems and for future development of the record linkage algorithm. 
Record linkage of HIV case reports is increasingly being undertaken by the HIV 
surveillance team to reduce the follow-up needed for missing information, to 
account for under-reporting and to integrate data for new analyses. Reducing 
follow-up lightens the workload of data providers but redirects the workload of 
the HIV surveillance team into record linkage instead of follow-up. However, 
record linkage needs to be reliable if used to update patient records without 
increasing the misclassification bias of subsequent analyses. I concluded that at 
least two of soundex, date of birth and local patient ID number should match for 
record linkage to be accepted without further manual review. 
The supplementation of data from one surveillance system to another can result 
in increased accuracy through reductions in under-reporting or over-counting 
(due to duplicate records). If either of these effects is significant, published 
trends over time could be markedly affected. The inability to deduplicate all CD4 
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Surveillance records due to lack of patient identifiers and the potential reporting 
of non-HIV-infected patients means that non-linked reports should not be 
considered as under-reporting to HARS or SOPHID. Yet, record linkage raises 
the potential of supplementing HARS with SOPHID records and vice versa. 
Based on results in this chapter, HPA surveillance systems are changing to 
incorporate ongoing record linkage and validation of HIV case reports as they 
are received. Since 2008, providers of SOPHID data were being prompted to 
clarify whether reports of HIV diagnoses that had not been received by SOPHID 
(according to record linkage using soundex, date of birth and local patient ID 
number) should in fact be added to SOPHID. Of the 83,393 HIV diagnoses 
reported in 2007, 853 were followed-up in this way but only 56 were added to 
SOPHID (276 were already reported with different identifiers and 510 had never 
returned for their results [the remainder should not have been reported 
according to the SOPHID protocol]). This indicated that there was very little 
under-reporting to SOPHID of individuals who were reported to HARS. This 
process will be continued because it is largely automated within the general 
SOPHID validation process and therefore requires minimal additional workload. 
Similar follow-up could be incorporated into CD4 Surveillance processes to 
improve record linkage and into HARS processes to improve completeness. 
There were 6,993 SOPHID records for individuals first seen for HIV care 
between 2000 and 2007 that were not linked to HARS (Figure 3.9). Addition of 
these to HARS would increase the number of HIV diagnoses each year by a 
mean of 12.6% (874) during this period. The usual data entry process for 
addition of these records to HARS would be likely to find most of the non-linked 
fuzzy matches. The usual deduplication process would reduce the number of 
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records considered to be additional HIV diagnoses but it is likely that the result 
would still indicate significant under-reporting to HARS. 
Substantial under-reporting to HARS, however, is not indicated by the very 
similar trends in the number of HIV diagnoses reported to HARS and the 
number of individuals first seen for clinical care in SOPHID (Figure 3.10). 
Numbers were slightly higher for SOPHID reports than HARS, which may 
indicate better deduplication in HARS, deduplication to reports of HIV diagnoses 
prior to 1995 in HARS, or under-reporting to HARS. Yet, the records that were 
linked accounted for 88.4% of the HARS records and 86.0% of the SOPHID 
records. The very similar patterns may provide further evidence that the non-
linked records related to the same individuals and that these were reported to 
both systems but with different identifiers. It is unlikely that the effects of under-
reporting and deduplication in each system would match each other so closely. 
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Figure 3.9. Numbers of HIV diagnoses over time if SOPHID records for 
individuals first seen for care that did not link to HARS were considered to be 
under-reported and added to the number of HIV diagnoses reported to HARS 
 
 In conclusion, to prevent over-counting due to the duplication of reports with 
different identifiers, the addition of non-linked SOPHID records to HARS should 
not be undertaken without further follow-up with the data providers. It is likely 
that many of these records will have also been reported to HARS but with 
patient identifiers too different to allow reliable record linkage. Although some 
under-reporting would be accounted for, this would inflate the numbers newly 
diagnosed. Multiple reporting systems have the potential to increase the 
ascertainment of reports but a single integrated surveillance system with unified 
resources for follow-up is likely to be more efficient and contain fewer 
inconsistencies, particularly if these systems are known to be subject to coding 
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errors. Therefore, there is a need for care when adding reports from novel, 
parallel surveillance systems (such as surveillance of recent HIV infections) to 
HARS because of the potential for creation of additional duplicates. 
Figure 3.10. Numbers of HIV diagnoses reported to HARS and numbers first 
seen for clinical care reported to SOPHID 
 
Finally, there is potential to link HIV surveillance data to patient records in other 
national HIV databases (of ART resistance, seroconverters and HIV-infected 
pregnant women), in research databases (such as the Collaborative HIV 
Cohort232), in other infectious disease surveillance databases (for example: 
sexually transmitted infections [STIs], TB, hepatitis, pneumococcal infection), 
and in non-infectious disease databases (such as cancer registries). Some of 
these have already been undertaken (resistance, TB, pneumococcal, hepatitis), 
are being developed (HIV-infected pregnant women [data from the National 
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Study of HIV in Pregnancy and Childhood]) or are being considered 
(Collaborative HIV Cohort and HPA STI databases). The methodologies have 
all been deterministic but the hierarchical algorithms have varied according to 
the commonality of data variables. Record linkage allows new analysis without 
additional and reproduced data collection and is therefore likely to be 
increasingly used in both surveillance and research as computing power 
increases, data transfer becomes more user-friendly and data management 
skills become more prevalent. In particular, data collection from NHS providers 
is becoming increasingly rationalised by central bodies (NHS Information 
Centre) to reduce the repeated reporting of the similar information. This is 
creating a need for further record linkage to integrate reports to achieve the 
vision of a single, centrally-mandated electronic care record for patients 
(National Programme for Information Technology). Both locally in HIV 
surveillance, and externally, statistics generated from these processes will need 
to put measures in place to prevent over-counting through duplication and to 
account for inclusion bias resulting from differential record linkage. 
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Chapter 4. Creation of a single, robust integrated dataset 
4.1 Introduction 
The primary aim of the processes described in this chapter was to generate and 
describe a single, robust integrated dataset from the records in each of the 
three independent HIV surveillance systems based on the bilateral record 
linkage achieved in Chapter 3. This dataset would then be used for all 
subsequent analyses. Creation of the integrated dataset required a decision of 
whether to exclude records that did not link uniquely between all three systems 
and selection and rationalisation of a common set of data variables to create 
patient records containing a coherent sequence of events.  
The first part of this chapter focuses on the justification for the inclusion of 
records in the integrated dataset. The primary methodology was triangulation of 
records linked between SOPHID, HARS and CD4 Surveillance – my aim was to 
create unique and consistent links between all three datasets. This required 
consideration of links that did not form a coherent triangle, links that only formed 
two sides of the triangle, and multiple links to the same record. 
Full integration of the three independent, national HIV case reporting systems 
depended not only on record linkage of the datasets but on integration of data 
variables. Information relating to the same HIV-infected individual from the 
different systems needed to be assimilated and validated so that a complete 
and consistent description of the individual with a coherent timeline of events 
was available for analysis. Data were examined to determine which should be 
used in the integrated dataset according to whether any inconsistencies were 
thought to be due to coding errors, under-reporting or unreliable record linkage. 
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Information selected for the integrated patient record, such as the date of 
diagnosis, first CD4 cell count, date first seen for clinical care, date of starting 
ART, date of AIDS diagnosis and date of death were then validated for 
chronological consistency. This process led to further exclusion of a small 
number of records but resulted in a final, single, robust, integrated dataset. 
4.2 Aims 
a) To create unique and consistent links between the three independent HIV 
surveillance datasets to generate a single, robust integrated dataset. 
b) To integrate data variables from the three independent HIV surveillance 
datasets so that a complete and consistent description of the individual with 
a coherent timeline of events was available for analysis 
4.3 Triangulation of record linkage between HARS, SOPHID 
and CD4 Surveillance to create the integrated dataset 
4.3.1 Records linked between SOPHID, HARS and CD4 
Surveillance  
Triangulation of record linkage between HARS, SOPHID and CD4 Surveillance 
was carried out to create an integrated dataset. Links between SOPHID and 
HARS were considered as the basis for triangulation because the greater 
completeness of patient identifiers in these datasets conferred greater reliability 
to these links than those to CD4 Surveillance (Chapter 3). My ultimate aim was 
to obtain unique and consistent links between all three datasets (Figure 4.1a). 
However, in order to achieve this, it was necessary to find an approach that 
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could be used where the three links did not triangulate (Figure 4.1b), or where 
there were only two links (Figure 4.1c). Where the three links did not triangulate, 
the CD4 Surveillance records were considered duplicates and these records 
were merged. Where there were only two links, the records were compared to 
see whether the non-linked records were likely to have been reported from the 
same individual, in which case the triangle could be completed. However, it was 
possible that some of the CD4 Surveillance records would link onwards to 
SOPHID or HARS records that were different to those forming the base of the 
triangle (Figures 4.1b and 4.1c). For example, where there were no links 
between HARS and CD4 Surveillance but links between SOPHID and HARS 
and between SOPHID and CD4 Surveillance, the records from CD4 
Surveillance could link onwards to SOPHID, HARS or both SOPHID and HARS 
records (Figure 4.1d). Multiple SOPHID or HARS records linking to CD4 
Surveillance could identify further duplicates or be unreliable, due to unspecific 
deduplication of CD4 Surveillance records.  
There were 65,309 unique links between HARS and SOPHID after excluding 
367 records where the date of death reported to HARS was before the date last 
seen for care as reported to SOPHID (Section 3.5.2.4). Of these, there were 
49,071 unique links between HARS, SOPHID and CD4 Surveillance (Figure 
4.1a). There were 357 links between HARS and SOPHID that each linked to a 
CD4 Surveillance record but where these CD4 Surveillance records were 
different (Figure 4.1b). There were 53,605 links where SOPHID records linked 
both to HARS and CD4 Surveillance but for 1,988 of these, the HARS record 
did not uniquely link to CD4 Surveillance (Figure 4.1c(i)). Conversely, there 
were 49,696 links where HARS records linked both to SOPHID and CD4 
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Surveillance but for 1,665 of these, the SOPHID record did not uniquely link to 
CD4 Surveillance (Figure 4.1c(ii)). 
The 357 links shown in Figure 4.1b were considered to be due to duplicates in 
the CD4 Surveillance database because they linked separately to HARS and 
SOPHID. These were records of individuals that had information reported 
differently at the time of HIV diagnosis and during follow-up (most had been 
diagnosed prior to data collection by SOPHID) and with some information 
missing from reports to CD4 Surveillance (e.g. Figure 4.2) 
Figure 4.1. Schema showing combinations of linked records between HARS, 
SOPHID and CD4 Surveillance (number of records shown in bold) 
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Figure 4.2. Deduplication of CD4 Surveillance records through triangulation 
 
The links shown in Figure 4.1c(i) and 4.1c(ii) were made up of combinations of 
links shown in Figure 4.1d and 4.1e respectively. These links were considered 
in the order described above to see whether the records could be reliably 
triangulated, either through further deduplication of records (Figures 4.1b, 1d(ii), 
1d(iii) 1e(ii) and 1e(iii)), or through linkage of the third side of the triangle 
(Figures 4.1d(i), 1d(iii), 1e(i) and 1e(iii)). The 196 and 532 records with multiple 
links to both HARS and SOPHID (Figure 4.1d(iv) and Figure 4.1e(iv)) were 
excluded from further analysis as these were determined to include a high 
proportion of records that had been inappropriately deduplicated in the CD4 
Surveillance dataset. The 1,594 and 947 links in Figure 4.1d(i) and Figure 
4.1e(i) were found to be fuzzy matches with either missing or discordant 
information between HARS/SOPHID and CD4 Surveillance and it was therefore 
thought that the third side of the triangle could be linked with confidence. The 
173 and 158 links in Figure 4.1d(ii) and 4.1e(ii) were found to consist of a 
mixture of duplicates and non-duplicates and were therefore excluded from 
further analysis. The 25 and 28 links in Figure 4.1d(iii) and 4.1e(iii) were 
excluded as there was no evidence that the multiple SOPHID or HARS records 
were duplicates. 
 
HARS
Patient ID number = 12345
Soundex code = A123
Date of birth = 1/1/1960
Sex = M
SOPHID
Patient ID number = 67890
Soundex code = A123
Date of birth = 1/1/1960
Sex = M
CD4 Surveillance record Y
Patient ID number = 12345
Soundex code = not reported
Date of birth = 1/1/1960
Sex = M
CD4 Surveillance record X
Patient ID number = 67890
Soundex code = A123
Date of birth = 1/1/1960
Sex = not reported
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The triangulation process above resulted in a total of 51,969 unique links 
between all three datasets (Figures 4.1a + 1b + 1d(i) + 1e(i)). There were a total 
of 4,078 further records that linked but that were excluded from further analysis 
as they included multiple links between datasets, largely due to records that had 
been inappropriately deduplicated in the CD4 Surveillance dataset. There 
remained 9,262 records linked uniquely between HARS and SOPHID where 
neither was linked to CD4 Surveillance records. 
Finally, there were 6,467 SOPHID records that were linked to CD4 Surveillance 
records but not to HARS records (Figure 4.1g(i)) and 1,089 of these CD4 
Surveillance records were linked to HARS. Similarly, 4,723 HARS records were 
linked to CD4 Surveillance records but not to SOPHID records (Figure 4.1g(ii)), 
of which 2,864 linked via CD4 Surveillance to SOPHID. These links were not 
mutually exclusive and there were 734 common links between HARS, CD4 
Surveillance and SOPHID (Figure 4.1g(iii)). However, many of these links were 
not unique and linked further to multiple HARS or SOPHID records. These links 
were therefore not considered to be reliable enough for further analysis. 
4.3.2 Unique bilateral links and non-linked records 
A full understanding of the data and creation of an integrated dataset could only 
be achieved by consideration of unique bilateral links between two datasets and 
records that did not link at all. Particular questions that needed answering were: 
could SOPHID records linked to CD4 Surveillance but not HARS be included in 
the integrated dataset with the date of diagnosis defined from these data? 
Could HARS records linked to CD4 Surveillance but not SOPHID be included in 
the integrated dataset for analyses that did not require treatment information? 
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Record linkage provided the potential for any combination of the data to be 
used but for this thesis, questions of which subset of data to use could only be 
answered by considering the analyses that were going to be performed on the 
data and the public health benefits and research knowledge that could be 
achieved. The analyses planned were: 
1. An analysis of CD4 cell counts at the time of HIV diagnosis and the factors 
associated with late diagnosis (CD4 cell count less than 200 cells/mm3) and 
consequent mortality. 
2. Quantification of follow-up time for each individual by level of 
immunosuppression and use of these data to calculate the incidence of first 
clinical AIDS diagnoses and deaths. 
3. Development of algorithms to determine the time of starting ART in order to 
improve the completeness of these data for further analysis 
4. An analysis of the rate of change of CD4 cell counts after starting ART. 
Data requirements for the first two analyses were the date of diagnosis, place 
of diagnosis, demographics (including risk group and ethnicity), date of death 
and CD4 cell count (only at diagnosis for analysis 1 but all for analysis 2). 
Country of infection, country of birth and year of arrival were supplementary 
data required for the analysis of late diagnosis. Data requirements for the third 
analysis were the date of starting ART, the first date reported to be on ART, 
date of first clinical AIDS diagnosis and all CD4 cell counts. The last analysis 
required those for the third analysis and the date of diagnosis, demographics 
and the place of starting treatment. 
I decided that HARS data linked to SOPHID but not to CD4 Surveillance could 
not substantially contribute to the integrated dataset for this thesis as no dates 
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were associated with the CD4 cell counts collected in SOPHID. SOPHID data 
alone was also inadequate for the same reasons. HARS data alone could 
contribute to analysis 1 where CD4 counts were reported on clinician report 
forms (CHR) but none of the other analyses. CD4 Surveillance data were not 
all from confirmed HIV-infected individuals and did not include risk group or 
ethnicity and therefore could not be included in the integrated dataset without 
linkage to either HARS or SOPHID. However, these combinations of data could 
be used for other analyses not considered in this thesis. 
4.3.2.1 Could SOPHID records linked to CD4 Surveillance but not 
HARS be included in the integrated dataset with the date of 
diagnosis defined from these data? 
Data requested in SOPHID reports included the dates first seen (‘datepos’) and 
last seen for care. The date last seen for care in the earliest calendar year in 
which the individual was reported to SOPHID was derived from the combined 
dataset. Some records had evidence of previous care reported and many 
individuals first reported in 1995 were clearly diagnosed prior to that year.  
For SOPHID records uniquely linked to CD4 Surveillance but not to HARS, 
there was potential to use the first CD4 cell count or the date first reported to be 
seen for care as a proxy for the time of HIV diagnosis. SOPHID records that 
were not linked to HARS were most likely reported to HARS but with identifiers 
too different to allow record linkage. Therefore, SOPHID records uniquely linked 
to CD4 Surveillance but not to HARS could be used to supplement the number 
of newly diagnosed individuals included in analyses 1 and 2 and the number of 
individuals starting ART included in analyses 3 and 4. There were 5,204 of 
these records in total, of which 4,310 were first seen for care after 1995. 
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With regards analyses 1 and 2, neither SOPHID nor CD4 Surveillance include 
data on country of infection or country of birth and therefore these records 
would have to be excluded from analyses using this information. Secondly, this 
addition of 4,310 (5.6%) links was thought to be unlikely to markedly increase 
the proportion of individuals newly diagnosed who could be included in the 
integrated dataset (Figure 4.3). Finally, if HARS records that were not linked to 
SOPHID were also included in analyses then individuals could be counted more 
than once. Therefore, these data were not included in analyses 1 or 2. 
Figure 4.3. Overall numbers of HIV diagnoses reported to HARS, numbers 
linked to both SOPHID and CD4 Surveillance and numbers potentially 
represented by links between SOPHID and CD4 Surveillance 
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With regards analyses 3 and 4, linked SOPHID/CD4 Surveillance data already 
included all necessary variables for these analyses except for the date of first 
AIDS diagnosis. Additionally, these 4,310 (5.4%) links would not markedly 
supplement the numbers of individuals first seen for care who could be included 
in the integrated dataset (Figure 4.4). Therefore, I decided that these data 
would not be included in the integrated dataset. 
Figure 4.4. Overall numbers of individuals first seen for care reported to 
SOPHID: numbers linked to HARS and CD4 Surveillance and numbers not 
linked 
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4.3.2.2 Could HARS records linked to CD4 Surveillance but not 
SOPHID be included in the integrated dataset for analyses that 
did not require treatment information? 
HARS records linked to CD4 Surveillance but not SOPHID could be included in 
the analysis of CD4 cell counts at the time of HIV diagnosis and consequent 
mortality (analysis 1). However, the additional number (2,754 [3.6%]) of unique 
links between HARS and CD4 Surveillance that were not linked to SOPHID was 
relatively small (Figure 4.5). Therefore, these links were not included in the 
integrated dataset and a consistent dataset of triangulated links between all 
three datasets was used throughout the subsequent analyses in this thesis. 
Figure 4.5. Overall numbers of HIV diagnoses reported to HARS, numbers 
linked to HARS and CD4 Surveillance only and all other HIV diagnoses 
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4.4 Integrating data variables in the integrated dataset 
4.4.1 Sex, risk group, ethnicity and date of birth 
Risk group and ethnicity are reported to HARS and SOPHID whereas sex and 
date of birth are additionally reported to CD4 Surveillance. Risk group was 
preferentially assigned according to how it was reported to HARS as it is 
primarily determined by health advisors at the time of HIV diagnosis or through 
follow-up by the HPA research nurse. For the 874 (1.7%) individuals for whom 
this information was not recorded in HARS, 525 (60.0%) could be assigned 
from SOPHID reports. Sex was also assigned from HARS as risk group and sex 
are internally consistency-checked within each database to detect records of 
female MSM, which are then followed-up. Ethnicity was less often missing in 
SOPHID than in HARS as it is followed-up for SOPHID if missing or reported 
differently over time. Therefore, ethnicity information was assigned from 
SOPHID, unless missing, in which case it was assigned from HARS (498/975). 
As patients may give false dates of birth when taking an HIV test that may get 
reported to HARS, dates of birth were assigned from SOPHID as these dates, 
reported from the notes of continuing clinical HIV care, were assumed to be 
more reliable (1,687 [3.4%] were reported differently to HARS). 
4.4.2 Date of first UK diagnosis  
The date of HIV diagnosis in the UK is a vital piece of information in HIV 
surveillance systems and in the integrated dataset. Data about the date of HIV 
diagnosis in the UK are reported to HARS (the date of HIV diagnosis and date 
of first positive test), SOPHID (the date first seen for clinical care [earliest of the 
dates last seen for care in each survey period], date of first positive test, date of 
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AIDS diagnosis and date of starting ART), and CD4 Surveillance (the date of 
first CD4 cell count measurement). In HARS, the date of HIV diagnosis 
attributed to a patient is the first of any date reported except for the date of 
previous positive test because this may be abroad. In the integrated dataset, 
dates from other surveillance systems were used to investigate whether the 
date of previous positive test reported to HARS could be validated. Dates from 
SOPHID and CD4 Surveillance, which occurred before the date of HIV 
diagnosis in HARS, were also examined to see whether they were likely to have 
occurred in the UK. Validated dates were used to update the date of HIV 
diagnosis in the integrated dataset according to the principle of assigning the 
first date reported as employed in HARS. 
There were 427 records in the linked HARS dataset that had a previous positive 
test in the UK in a year before the date of HIV diagnosis. A further 908 had a 
reported previous positive test abroad in a year prior to diagnosis in the UK. 
Almost two-thirds, 63.9% (273) had a date first seen for clinical care in the same 
calendar year as the date of HIV diagnosis and 229 of these also had the first 
CD4 cell count in the same calendar year as the date of HIV diagnosis. 
Therefore, the majority of the links between HARS, SOPHID and CD4 
Surveillance did not validate the date of previous positive test as being in the 
UK. Therefore, this analysis supports the internal HARS protocol of not using 
earlier dates of first positive tests to update the date of HIV diagnosis.  
There were 2,172 individuals whose earliest date seen for care reported to 
SOPHID was before the date of HIV diagnosis reported to HARS: for 1,010 it 
was within 1 year, 535 within 2 years and 627 more than 2 years (Table 4.1). 
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 Table 4.1. Number of years between the date first seen for care reported to 
SOPHID and the date of HIV diagnosis reported to HARS where the date first 
seen for care was earlier than the date of HIV diagnosis (n=2,172) 
 
Where SOPHID recorded an earlier calendar year of diagnosis than HARS 
(n=1,162) and the first year seen for care was only one year earlier than the 
year of diagnosis (n=535), 54.6% of records had their first CD4 count in the year 
of diagnosis and 39.5% in earlier years. Where the first year seen for care was 
more than one year earlier than the year of diagnosis (n=627), 18.3% of records 
had their first CD4 count in the year of diagnosis and 79.0% in earlier years. 
This suggested that the date first seen reported to SOPHID was valid even if it 
was earlier than the date of HIV diagnosis reported to HARS and therefore it 
was used to update the date of HIV diagnosis in the integrated dataset. 
There were 4,978 individuals (9.6% of 51,969 records in the integrated dataset) 
who were reported to SOPHID as having had their first HIV diagnosis (datepos) 
in a calendar year before their date of diagnosis reported to HARS or the 
earliest date last seen as reported to SOPHID. Records for the majority of these 
individuals (71.3% [3,569]) had their first CD4 cell count in the same year as the 
date of diagnosis/earliest date last seen. This indicates that these first dates of 
HIV diagnosis as reported to SOPHID (datepos) should not be used to update 
Number of years 
between the date 
first seen for care 
and the date of HIV 
diagnosis 
0 1 2 3 4 5 6 7 8 9 10 11 12 
Number of 
individuals 
(%) 
1,010 535 156 108 86 62 53 41 37 30 24 15 15 
46.5 24.6 7.2 5.0 4.0 2.9 2.4 1.9 1.7 1.4 1.1 0.7 0.7 
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the date of HIV diagnosis in the integrated dataset because many of these 
dates are likely to be prior to arrival in UK. However, these dates could be used 
as probable evidence of prior diagnosis abroad and be used to exclude records 
from subsequent analyses. 
In contrast, there were 10,452 records where the SOPHID datepos was earlier 
in the same calendar year as the year of diagnosis/earliest year seen for care. 
Of these, 4,246 were not reported to be the 1st or 15th of the month, or the 30th 
June (likely to reflect retrospective approximations). These were considered 
reliable enough to update the date of HIV diagnosis in the integrated dataset.  
There were 1,052 individuals (2.0% of 51,969 linked between HARS and 
SOPHID) who were reported to have started ART in a calendar year before 
their date of diagnosis/earliest date last seen. Most (864 [82.1%]) of these 
individuals had their first CD4 cell count measured in the same year as the year 
of diagnosis/earliest year seen for care. However, almost all (1,036 [98.5%]) 
had a reported date of diagnosis reported to SOPHID (datepos) and most of 
these (719 [69.4%]) were earlier or the same as the reported date of starting 
ART. This suggests that many of the dates of starting ART were correct but that 
they were likely to be prior to arrival in the UK. Of the 1,052 individuals, there 
were 598 (56.8%) who had been reported by a clinician of whom 309 (51.7%) 
had a reported year of arrival in the UK. A large percentage of these individuals 
(74.4% [230]) were reported to have arrived in the UK after they started ART. 
These analyses indicate that the reported date of starting ART should not be 
used to update the date of HIV diagnosis in the integrated dataset. However, 
these dates could be used as probable evidence of prior diagnosis and 
treatment abroad and be used to exclude records from subsequent analyses. 
 182 
 
The majority of individuals in the integrated dataset (73.8% [38,345]) had their 
first CD4 cell count in the same year as their date of diagnosis/earliest date last 
seen (82.4% [34,629/42,007] between 1996 and 2007). Only a small 
percentage (1.8% [949]) had their first CD4 cell count before the year of their 
first HIV diagnosis/year first seen for care. Manual review of a subset of the 
latter showed that most were likely to be due to inappropriate deduplication in 
CD4 Surveillance and therefore, this small proportion of records was excluded 
from further analysis. However, the first CD4 cell count was in the same 
calendar year but earlier than the date of diagnosis/earliest date last seen for 
2,061 records. There was good evidence from manual review that these CD4 
cell counts were consistent for each individual and often reported from the same 
laboratory. Therefore, the earliest date of these CD4 cell count measurements 
was used to update the date of HIV diagnosis in the integrated dataset. 
In summary, in the integrated dataset, the date of HIV diagnosis in E,W&NI was 
assigned to be the earliest of the following: i) the earliest date of HIV/AIDS 
diagnosis or death as reported to HARS; ii) the earliest date last seen for care 
as reported to SOPHID; iii) the earliest date of HIV diagnosis (datepos) reported 
to SOPHID if it was in the same year as one of the above; iv) the date of the 
first CD4 cell count reported to CD4 Surveillance if it was in the same year as 
one of the above. The dates of first positive test from HARS and SOPHID (if 
prior to the year of diagnosis already defined) and the date of starting ART from 
SOPHID were not valid for updating the date of HIV diagnosis in the integrated 
dataset because of the likelihood that many of these dates occurred prior to 
arrival in the UK. This algorithm is consistent with the internal HARS protocol for 
processing multiple reports from the same individual that include earlier dates. 
 183 
 
4.4.3 Date of first AIDS diagnosis 
There were 9,782 records in the integrated dataset for individuals who had been 
reported to HARS as clinically diagnosed with AIDS. The earliest date of AIDS 
diagnosis reported to SOPHID was earlier than the date reported to HARS for 
1,205 individuals. Two-thirds (67.2% [810]) of these were in the same calendar 
year, a fifth (21.2% [255]) were in the previous calendar year and 2.1% (25) 
were in a calendar year more than six years previously. These dates reported to 
SOPHID were used to update the earliest date of AIDS diagnosis in the 
integrated dataset. There were only two records with a clinical stage of AIDS 
first reported earlier than both the dates of AIDS reported to HARS and 
SOPHID. These were also updated in the integrated dataset. 
There were 7,446 records in the integrated dataset without a date of AIDS 
reported to HARS but with AIDS reported to SOPHID. Almost all (99.4% 
[7,398]) of these had both a date of AIDS diagnosis and a clinical stage of AIDS 
reported to SOPHID. The date of AIDS diagnosis was the same as, or earlier 
than, the earliest date last seen with clinical stage of AIDS for almost all (99.8% 
[7,382]) of these records. There were 519 (7.0%) records with the earliest date 
of AIDS diagnosis reported to SOPHID earlier than the combined date of HIV 
diagnosis in the integrated dataset. Where the date of AIDS diagnosis reported 
to SOPHID was in the same calendar year as the combined date of HIV 
diagnosis (62.0% [322]), two-thirds (66.5% [214]) had the same month and 
three-quarters (77.6% [250]) had the AIDS diagnosis reported as the 1st or 15th 
of the month. For these records, the combined date of HIV diagnosis in the 
integrated dataset was not updated but the date of AIDS diagnosis was updated 
to be the same as the date of HIV diagnosis. Where the date reported to 
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SOPHID was in an earlier calendar year than the combined date of HIV 
diagnosis (38.0% [197]) and where year of arrival in the UK was reported to 
HARS (14.6% [76]), the majority (68.4% [52]) had AIDS prior to arrival in the 
UK. Therefore, these dates of AIDS diagnosis were used to update the date of 
AIDS diagnosis but not the date of HIV diagnosis in the integrated dataset and 
assumed to occur before arrival in the UK. There were 6,927 remaining records 
with a date of AIDS diagnosis reported to SOPHID but not to HARS. All of these 
dates were used to update the date of AIDS diagnosis in the integrated dataset. 
4.4.4 Date of last contact with services/date of death 
The last date of contact with HIV services was defined in the integrated dataset 
as the date of latest CD4 cell count, the date of the latest report to SOPHID or 
the date of the latest AIDS diagnoses prior to death. The majority (85.7% 
[44,579]) of these dates in the integrated dataset were in the same calendar 
year. There were 32,658 (62.8%) with the date last seen reported to SOPHID 
after the latest CD4 cell count measurement reported, 11,919 (22.9%) where 
these dates were the same, and 7,392 (14.2%) where the latest CD4 cell count 
was after the date last seen reported to SOPHID. Where the date last seen was 
after the latest CD4 cell count, 83.9% (27,388) were in the same year, 10.1% 
(3,313) in the following year, and 0.8% (277) more than five years later. Where 
the latest CD4 cell count was after the date last seen, 71.3% (5,272) were in the 
same year, 21.1% (1,559) in the following year, and 2.2% (159) more than five 
years later. There were only 22 records where the last date of contact with HIV 
services was updated with the first AIDS diagnosis because this was prior to 
death (indicating contact with services) but after the latest CD4 cell count and 
the latest report to SOPHID. 
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The date of death was defined primarily from HARS as this was the traditional 
basis of surveillance of deaths among HIV-infected individuals and includes 
record linkage between HARS and ONS (Office of National Statistics data) and 
follow-up (Section 2.2). Dates of death were first supplemented from SOPHID 
and then from CD4 Surveillance. There were 4,415, 382 and 38 records in the 
integrated dataset for individuals reported to have died with dates of death 
derived from HARS, SOPHID, and CD4 Surveillance respectively. However, 10 
(0.2%), 24 (6.3%) and 27 (71.1%) of these records were excluded from 
subsequent analysis as there were either reports of CD4 cell counts 
measurements or contact with HIV services after the date of death. These 
records could not be resolved without further follow-up because the discordant 
dates could arise from either coding errors in any of the dates reported, 
incorrect deduplication of records, or incorrect record linkage between any of 
the HIV surveillance databases and the ONS database of deaths. There were a 
final total of 4,774 deaths between 1995 and 2007 in the integrated dataset.  
4.4.5 Previous diagnosis before HIV diagnosis in the UK 
There were 1,304 records in the integrated dataset with a date of a previous 
positive HIV test reported to HARS in an earlier calendar year than the date of 
HIV diagnosis (earliest from all sources). Three-quarters (74.5% [971]) indicated 
that the previous HIV test occurred abroad. Most of these dates were 
approximations (e.g. 30/06/2001) and therefore only the calendar year was 
considered. Additionally, there were 936 records with a comment on a HARS 
form indicating a previous positive HIV test but no reported date. 
There were 4,844 records in the integrated dataset that had an HIV diagnosis 
(datepos) reported to SOPHID in a calendar year before the date of HIV 
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diagnosis. A fifth of these (19.0% [920]) also had evidence of a previous 
positive HIV test reported to HARS. A further 267 and 1,011 records had a date 
of an AIDS diagnosis and date of starting ART, respectively, reported to 
SOPHID in a calendar year before the date of HIV diagnosis in the integrated 
dataset, of which 89 and 191 had not been previously identified.  
In total, there were 6,444 (12.4%) records in the integrated dataset with 
evidence of a previous HIV diagnosis, of which 5,766 had a reported year of 
previous HIV diagnosis. The year of previous HIV diagnosis was one year 
earlier than the date of HIV diagnosis in the integrated dataset for a third of 
records (33.9% [1,955]) but more than five years earlier for a quarter of records 
(24.9% [1,438]) (Table 4.2). 
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Table 4.2. Number of calendar years between HIV diagnosis in the integrated 
dataset and the reported year of previous HIV diagnosis (where reported) 
 
By year of HIV diagnosis in the UK in the integrated dataset, there was an 
increasing trend in the number of records with a previous diagnosis (Figure 4.6). 
However, since 1987, this number accounted for a fairly stable percentage of all 
HIV diagnoses in the integrated dataset, with an annual mean of 11.5%. 
Figure 4.6. Number of records with a previous HIV diagnosis and the annual 
total of HIV diagnoses as a percentage of all HIV diagnoses  
Number of years 
between 
diagnosis in the 
integrated dataset 
and previous HIV 
diagnosis 
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Number of 
individuals 
1,955 937 584 483 369 299 237 200 139 143 399 21 
(%) 33.9 16.3 10.1 8.4 6.4 5.2 4.1 3.5 2.4 2.5 6.9 0.4 
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4.4.6 Pregnancy and recent infection status at HIV diagnosis 
There were 3,657 women from E,W&NI who were identified in HARS as 
pregnant at HIV diagnosis with an HIV-related event within 91 days of their date 
of HIV diagnosis reported to HARS. These records were either reported from an 
antenatal clinic with pregnancy marked on the form or with pregnancy or 
antenatal testing marked as the reason for test. The integrated dataset included 
records for 2,487 (68.0%) of these pregnant women but only 2,429 (97.7%) 
were updated as being pregnant at HIV diagnosis because the event date 
reported on the HARS form at the time of pregnancy was within nine months of 
their date of HIV diagnosis in the integrated dataset (earliest from all sources). 
Pregnancy at the time of HIV diagnosis has only been collected in HARS since 
2000 on the CHR (Figure 4.7). These reports accounted for an annual mean of 
17.2% of all women diagnosed with HIV infection in the integrated dataset 
between 2000 and 2007 but an annual mean of 21.8% of all women reported on 
a CHR between 2000 and 2007. HIV diagnoses among women reported from 
laboratories without a CHR cannot be classified by pregnancy status. 
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Figure 4.7. Number of HIV diagnoses in the integrated dataset by sex, showing 
whether women were reported on a CHR and pregnant at the time of diagnosis. 
 
There were 2,998 records in the integrated dataset with some evidence of 
recent infection reported to HARS. The variables used were symptoms of 
seroconversion indicated on the CHR, or in the comment field on any form, or a 
negative HIV test within a year of the date of HIV diagnosis. The majority 
(60.6% [1,817]) were identified by a previous negative HIV test, with 31.1% 
(932) identified by symptoms of seroconversion and/or 28.4% (851) identified by 
a comment (Figure 4.8). The introduction of the CHR and increases in HIV 
testing (identification of previous negative HIV tests) increased the percentage 
of all HIV diagnoses in the integrated dataset with evidence of recent infection 
from 2% or less before 2000 (except 1998) to over 10% in 2005 and 2006. 
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Figure 4.8. Number of HIV diagnoses with evidence of recent infection in the 
integrated dataset according to how this evidence was reported. 
 
Figure 4.9. Percentage of all HIV diagnoses in the integrated dataset with 
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4.4.7 CD4 cell counts 
CD4 cell counts were available from CD4 Surveillance, HARS and SOPHID. If 
reporting were complete: CD4 Surveillance would include all CD4 cell counts for 
an individual over time; HARS would include CD4 cell counts at the time of first 
presentation in the UK for the two-thirds of presentations that were reported by 
clinicians since 2000; and SOPHID would include the last CD4 cell count during 
the survey period for all individuals since 2000 (Chapter 2). As the date of CD4 
cell count was required for subsequent analyses but not collected in SOPHID, 
only CD4 cell counts at the time of first presentation from HARS were used to 
supplement CD4 Surveillance. 
4.4.7.1 Identification and deletion of duplicate CD4 cell counts 
There were 1,242,903 CD4 cell counts in the CD4 Surveillance dataset and 
28,263 CD4 cell counts in the HARS dataset to the end of 2007. A total of 
902,838 (72.6%) and 21,100 (74.7%) of these CD4 cell counts were from the 
50,953 individuals in the integrated dataset. Integration led to the creation of 
12,397 duplicate CD4 count measurements on the same date. As expected, 
there was a high correlation (r=0.97) between the duplicate measurements but 
1,926 (0.21% of all measurements) CD4 cell counts were not the same (Figure 
10). Possible explanations are that some samples were analysed twice on the 
same day for quality control, results were rounded to the nearest ten before 
being reported or that clerical errors occurred. To maintain maximum 
consistency of the CD4 cell counts in the integrated dataset, these duplicate 
measurements reported to HARS were deleted. A further 6,187 of the remaining 
CD4 cell counts reported to HARS were deleted because the preceding or 
following CD4 cell count reported to CD4 Surveillance was the same. Finally, 
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2,145 CD4 cell counts from HARS were deleted because of the following: they 
were measured within 14 days of a CD4 cell count reported to CD4 
Surveillance; they were not the first CD4 cell count reported; they were earlier 
than the date of HIV diagnosis in the integrated dataset and appeared to be 
mostly spurious dates; they had CD4 cell counts of zero that did not appear to 
match subsequent CD4 cell counts; they were multiples of ten of subsequent 
CD4 cell counts. There were 3,203 CD4 cell counts from HARS remaining in the 
integrated dataset.  
Figure 4.10. Correlation between duplicate CD4 cell count measurements 
reported both to CD4 Surveillance and HARS. 
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Duplicate measurements were also identified within CD4 Surveillance records. 
There were 16,605 records with identical CD4 cell counts reported within 14 
days of a previous measurement. Three quarters (75.7% [12,907]) were from 
the same laboratory and the majority (85.0% [10,759]) of these were from two 
large London laboratories with multiple clinics on different sites. For one 
laboratory, 96.4% (8,329) of these duplicates occurred in 2004 and 2005 with 
93.3% (7,821) within 2 days of each other. In the other laboratory, 82.4% 
(1,795) occurred in 2006 with 91.3% (1,651) within 1 day of each other. These 
duplicates were therefore deleted along with a further 404 repeated 
measurements at other laboratories identified in this manner. The majority of 
repeat measurements from different laboratories (96.0% [3,569/3,718]) were 
from four laboratories. These tended to occur within two days of the previous 
measurement and in specific years and therefore 3,471 CD4 cell counts were 
also deleted as probable duplicates. 
4.4.7.2 Identification and deletion of invalid CD4 cell counts 
Potentially incorrect measurements are often validated in clinical practice by 
testing a second sample shortly afterwards233;234. There were 35,189 (4.0%) 
CD4 counts in the integrated dataset that were followed by a repeat 
measurement within 14 days for 17,067 individuals. For 5,268 (30.9%) 
individuals, their first CD4 cell count was repeated within 14 days with a median 
change in CD4 cell counts of 1 (inter-quartile range [IQR] -22, 40; range -1,240, 
1,165) cells/mm3. Without knowing which of these was the most accurate 
reflection of the true CD4 cell count, the measurement bias was minimised by 
averaging the values, using the first date and deleting the 5,268 repeat 
measurements. 
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There were 12,782 individuals with 27,518 CD4 cell counts followed by a repeat 
measurement within 14 days and also preceded by a measurement within 182 
days. CD4 cell counts that were likely to be incorrect were identified as being 
either substantially higher, or lower, than both the preceding and repeat 
measurements to exclude expected variation. The median change in CD4 cell 
counts prior to the suspect measurement was 42 (IQR 21, 80; range -1,655, 
1,995) cells/mm3 and the median change to the repeat measurement was 3 
(IQR -30, 54; range -1,900, 1,690) cells/mm3. There were 2,807 (22.0%) 
individuals with 3,374 (12.2%) CD4 cell counts that were more than 100 
cells/mm3 (arbitrarily chosen) higher or lower than both the preceding and 
repeat measurements. Manual examination of the longitudinal CD4 cell counts 
for a number of these individuals showed that there was a mixture of erroneous 
single measurements and whole histories of highly variable measurements. The 
single erroneous measurements should be excluded from the former, whereas 
the latter should be further investigated to ensure that the CD4 cell counts and 
dates reliably represented the measurements for a single individual. However, it 
was not possible to distinguish between the two situations without either manual 
review or much more complicated statistical analysis, which was not appropriate 
at this stage. Substantial bias could be introduced by including or excluding all 
records for individuals who had highly variable CD4 cell counts depending on 
whether these records incorrectly represented more than one individual due to 
unspecific deduplication or not. Conversely, bias could be slightly reduced by 
excluding single erroneous CD4 cell counts that were likely to be due to 
recording errors and the removal of a single CD4 cell count from individuals 
who had highly variable CD4 cell counts was unlikely to create significant bias. 
On consideration of these potential impacts on the dataset, and the difficulty in 
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identifying whether the repeat CD4 cell count or the measurement before it 
were erroneous, I averaged the potentially erroneous and repeat CD4 cell 
counts, used the first measurement date and deleted the 3,374 repeat 
measurements. 
There were a total of 881,415 CD4 cell counts for the 50,953 individuals in the 
final integrated dataset. 
4.5 Conclusion 
This chapter shows how a single integrated dataset with coherent patient 
records was created by the triangulation of records and the justifiable selection 
and rationalisation of their constituent variables. The process also reduced 
missing information in each dataset. Numbers remaining for analysis were still 
equivalent to multinational cohort collaborations (such as EUROSIDA235) while 
having the benefits of national representativeness, good ethnicity information 
and complete patient follow-up from first diagnosis in the UK. 
This was the first time that an integrated dataset had been created from these 
three national HIV surveillance systems to create a single coherent sequence of 
events for each individual (Figure 4.11). Patients in this dataset can now be 
followed from the first known diagnosis of HIV infection or first presentation for 
HIV care in the UK, through first development of AIDS defining illness and 
initiation of ART to death. Their CD4 cell counts in relation to this process can 
be monitored. The effects of patient factors such as risk group, ethnicity, 
pregnancy status, geographical region and age can be analysed with the latter 
three specific to time periods along the process (Figure 4.11). 
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Triangulation supported and validated record linkage as well as enabling record 
linkage between two datasets via the third dataset. It revealed further 
inappropriate deduplication within CD4 Surveillance as previously identified 
through record linkage. Records were excluded because of multiple links or 
inconsistent information. These validations reduced the number of records in 
the integrated dataset but increased confidence in the reliability of the data. 
Resources may need to be redirected away from follow-up for missing 
information to follow-up to resolve inconsistent information. A reasonable and 
useful assumption made was that record linkage between HARS and SOPHID 
could provide a solid basis for analysis and further record linkage. Other record 
linkage that did not result in reliable triangulation was not included in the 
integrated dataset largely because certain information was missing or because 
it would prevent a robust analysis of bias. 
 
 197 
 
 
Figure 4.11. Timeline of monitored events for a single individual with diagnosed HIV infection. 
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infection
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Symptoms of HIV infection
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clinical AIDS 
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Date of 
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diagnosis or care
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Last date 
known not to 
be on ART
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Integration from multiple sources also provided insight about data quality that 
could not be determined or quantified from single surveillance systems. For 
example, there was evidence of substantial and fairly stable proportions 
previously diagnosed before first presentation in the UK as reported to HARS 
(around one individual among every eight newly diagnosed). These data for 
Africans could be compared to the results of Project Nasah, which showed that 
just over a fifth of African respondents living in the UK were probably first 
diagnosed with HIV prior to their residence in the UK236. Similar findings have 
also been reported from the United States of America when surveillance data 
were compared to an interview survey237. Previous diagnosis may be important 
to consider in subsequent analyses and may indicate some under-reporting or 
an inability to link records within HARS.  There was also a clear indication of 
under-reporting of AIDS to HARS or an inability to link these records in HARS. 
Integrated data about AIDS diagnoses was crucial for the reliable quantification 
of AIDS incidence (Chapter 7). In summary, integration allowed sufficient 
resolution of this information for further analysis but raised questions for further 
investigation. 
The process of integration also provided insights to data from HARS as a single 
source. There was an annual mean of 17.2% of all women diagnosed with HIV 
infection who were pregnant between 2000 and 2007 compared to 21.8% of 
women reported on a CHR. This suggests that a substantial number of women 
were being diagnosed through antenatal screening but may not be recorded as 
such if a CHR is not received. This provides further justification for the need to 
investigate data from surveillance (including linking to other datasets such as 
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that of the National Study of HIV in Pregnancy and Childhood) and to adjust it 
for missing information or for known biases in data collection but also suggests 
that further improvements in surveillance systems could prevent these 
discrepancies. This is particularly important because of the high public health 
policy impact of surveillance data238. Furthermore, these investigations also 
indicated that detection of seroconversion at the time of HIV diagnosis may be 
increasing. This is an interesting finding with significant public health 
ramifications because it may provide further evidence of increased HIV testing 
rates in E,W&NI239;240. Earlier diagnoses suggest some success of HIV testing 
policies and/or increased health seeking behaviour111;241. 
Integration did reveal limitations of the surveillance datasets other than under-
reporting. In particular, records from CD4 Surveillance that had been 
inappropriately deduplicated had to be excluded and it is possible that some of 
these were not identified and remain in the dataset. However, it would be 
difficult to identify these without substantial manual review and follow-up with 
clinics. Furthermore, the resulting misclassification bias was likely to result in 
non-detection of differences rather than spurious results and the effect was 
likely to be limited by the large number of records available for analysis. 
Additionally, duplicate and repeat CD4 cell count measurements were identified 
in CD4 Surveillance. Such issues are expected in observational cohort data 
because of laboratory logistics (tests contracted out may be recorded in two 
places), open access to GUM services (testing at diagnosis and retesting 
elsewhere on entry to care)3, and the natural and measurement variability of 
CD4 cell counts31;43;242-244. These were accounted for by averaging repeat CD4 
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cell counts and deleting duplicate CD4 cell counts but this was unlikely to fully 
eradicate measurement bias and it is likely that not all duplicate and repeat CD4 
cell counts were identified. This measurement bias must be considered in 
subsequent analyses. 
The issues of data quality raised above may affect surveillance data more than 
research data due to the integration of surveillance data from a larger number 
and variety of sources and the potential for more intensive and expensive 
efforts to clean smaller research datasets. However, as cohorts expand, more 
research on the algorithms for data validation and processing may be required. 
In conclusion, record linkage and triangulation can be used to validate data but 
also indicate that variables are duplicated in different surveillance systems. 
Integration of data at national level has the potential to reduce and rationalise 
data collection and the burden on data providers but record linkage must be 
high to achieve completeness. However, if these data are all captured routinely 
at the service delivery level, and not specifically for surveillance needs, then 
improvements will not reduce data collection at that level (may apply to CD4 
Surveillance and SOPHID where electronic data exist locally, but not to the 
completion of paper-based HARS forms). At the national level, some resources 
are likely to need redirection from follow-up of individual records to data 
validation and confirmation of record linkages. This may be achieved most 
effectively if record linkage and validation are ongoing as reports are received. 
These would be steps towards full integration of these surveillance systems.  
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Chapter 5. Potential for bias in analyses of the integrated dataset 
5.1  Introduction 
This chapter scrutinises expected sources of potential bias to facilitate the clear 
interpretation of subsequent analyses of the integrated dataset as 
recommended for observational studies245. Differences in the integrated dataset 
not solely related to the outcome under analysis could otherwise cause spurious 
conclusions to be drawn. The key types of bias investigated in this chapter were 
unequal inclusion of records in the integrated dataset, differential CD4 cell count 
monitoring, disparate loss to follow-up (LTFU) and unequal inclusion of events 
due to the varied proximity of CD4 cell counts. Inclusion bias was addressed in 
detail because it can substantially affect all epidemiological studies but 
differential monitoring and LTFU were addressed specifically as these types of 
bias often affect cohort  analyses246. Observational cohorts based on clinic 
populations may be particularly sensitive to bias introduced through left, right 
and interval censoring because patient attendance may be related to their 
clinical status247-249. Analyses of incidence (Chapter 7) and of rates of change in 
CD4 cell counts (Chapter 9) were statistically approached as cohort analyses. 
Bilateral record linkage has been shown to find matches differentially between 
groups of individuals (Section 3.5.1.6). Creation of the integrated dataset also 
involved further exclusion of records such that those included had different 
characteristics to those excluded. A statistical analysis of the factors associated 
with inclusion in the final integrated dataset was therefore undertaken to 
characterise the potential inclusion bias. Over-representation of certain groups 
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of individuals in the integrated dataset and differences in outcomes between 
groups could lead to biased results. While characterisation of the potential bias 
would not prevent error being introduced to subsequent analyses, 
understanding of the likely error could prevent false conclusions being drawn. 
Once the bias of inclusion in the integrated dataset had been characterised, 
categories with small numbers or categories of missing information were 
considered for exclusion because results for these groups could not be 
meaningfully interpreted. Results for individuals without reported ethnicity or risk 
group would be difficult to interpret meaningfully but before exclusion it was 
expedient to determine whether this would introduce additional bias arising from 
the disproportionate exclusion of deaths. Inability to collect information on 
ethnicity or risk group was hypothesised to be due to incapacity on admission to 
HIV-related clinical care and subsequent death.  
Differential CD4 cell count monitoring and LTFU were considered because 
these could directly bias subsequent results247-254. In addition, they may be 
associated with health and confounded with other effects such as adherence, 
psychosexual health, mental health and co-morbidities. Individuals with fewer 
CD4 cell counts, infrequent CD4 monitoring and more LTFU would be under-
represented in the dataset.  Studies have demonstrated how this can result in 
fewer observed events, loss of power and significant differences between 
predicted and observed outcomes255-257. Therefore, a statistical analysis of the 
factors associated with having only one CD4 cell count was undertaken along 
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with descriptive analysis of the number and frequency of CD4 cell counts for 
each individual and statistical analysis of temporary and permanent LTFU. 
Finally, the proximity of CD4 cell count measurements to HIV diagnosis, AIDS 
diagnosis and death and factors associated with having a CD4 cell count within 
a defined period of these events were statistically characterised to help 
understand the effects of informative censoring. The delay from HIV diagnosis 
to first CD4 count could introduce bias in analyses of incidence due to left-
censoring if follow-up time was considered to start at the first CD4 count and 
events before this time were excluded. The period between the last CD4 cell 
count and AIDS or death could introduce bias due to right-censoring of follow-
up time and events. The results of these analyses were used in the analysis 
and interpretation of CD4 cell counts at the time of HIV diagnosis (chapter 6) 
and the incidence of AIDS and death (chapter 7). 
These analyses provided interesting results about CD4 cell count monitoring 
and follow-up as well as a deeper understanding of the integrated dataset.   
5.2  Aims 
The following investigations were carried out to consider how the inclusion of 
records, the inclusion of events, the number and frequency of CD4 cell count 
monitoring and LTFU may bias the results of subsequent analyses. 
a) To determine factors associated with the inclusion of records in the 
integrated dataset. 
 204 
 
b) To determine whether individuals in the integrated dataset who had died 
were less likely to have ethnicity or risk group reported. 
c) To describe the frequency and regularity of CD4 monitoring and to 
determine factors associated with: 
a. Having only one CD4 count; 
b. Having infrequent CD4 counts (a long median time between counts). 
d) To determine factors that were independently associated with the incidence 
of permanent and temporary LTFU. 
e) To describe the time between CD4 count measurements and HIV diagnosis, 
first AIDS diagnoses and deaths and to determine factors associated with 
having a CD4 cell count measured within a defined time from these events. 
 
5.3  Methods 
5.3.1 Factors associated with inclusion in the integrated dataset 
A dataset was created containing single records with data from 87,521 
individuals reported to HARS as diagnosed with HIV infection in England, Wales 
and Northern Ireland (E,W&NI) before 1st January 2008 and reported by the end 
of June 2008 (excluding 377 with no date of birth reported). These records were 
flagged if included in the integrated dataset and multivariable logistic regression 
was used to consider factors associated with inclusion. The factors considered 
were the period of HIV diagnosis, age group at HIV diagnosis, region of HIV 
diagnosis, risk group and ethnicity. Additionally, the Mantel-Haenszel estimate 
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of the odds ratio was used to determine whether death or a reported AIDS 
diagnosis were associated with inclusion in the integrated dataset. This analysis 
was stratified by the period of diagnosis for two reasons: 1) individuals 
diagnosed prior to 1995 must have survived to access care in 1995 to be 
included in SOPHID; 2) unreported deaths were likely to disproportionally 
reduce the proportion of records linked for individuals diagnosed prior to 1995.  
5.3.2 Frequency of CD4 cell count monitoring 
The integrated dataset consisted of separate records for each CD4 cell count 
measured between the time of HIV diagnosis and the end of 2007. Multivariable 
logistic regression was used to determine the factors associated with having 
only one CD4 count. The Mantel-Haenszel estimate of the odds ratio was used 
to determine whether death or a reported AIDS diagnosis were associated with 
having only one CD4 count. For individuals with more than one CD4 count, the 
Kaplan-Meier estimate was used to describe the overall time between 
consecutive CD4 counts. Descriptive analysis of the time between CD4 counts 
and descriptive analysis of the total number and frequency of CD4 counts was 
used to illustrate how CD4 count monitoring differed according to determining 
factors. A scatter plot overlaid with a linear regression plot of time between the 
first and last CD4 counts against the total number of CD4 counts was used to 
investigate the number of individuals with either a few CD4 counts over a long 
period of time or many CD4 counts over a short period of time. 
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5.3.3 Poisson regression analysis of loss to follow-up 
The period over which each individual was followed in the cohort was defined 
by separate CD4 counts in the integrated dataset (taking account of incomplete 
record linkage, LTFU, emigration and unreported deaths). Patient follow-up was 
split into distinct periods based on available CD4 cell counts (Figure 5.1).  
In the analysis of temporary LTFU, each period of follow-up was assumed to 
start on the date of the CD4 cell count and end at the earliest of a) the next CD4 
cell count, b) death, c) 31st December 2007, d) 91 days following the date of 
each CD4 count if the CD4 count was followed by another but not within 365 
days. Follow-up was censored immediately after the last CD4 count if it was 
before the 1st January 2007 or if it was more than 365 days before the date of 
death. CD4 counts measured in 2007 were excluded from this analysis because 
of insufficient follow-up. Because individuals often have CD4 counts monitored 
quarterly258;259, time at risk was expected to be continuous for most individuals 
although split into periods. However, follow-up censored because the 
subsequent CD4 count was measured after more than 365 days was defined as 
temporary LTFU (threshold informed by the Kaplan-Meier estimate of time 
between consecutive CD4 counts). If a patient was temporarily lost to follow-up 
365 days after any particular CD4 count, they were allowed to re-enter the risk 
set if and when they had a further CD4 measurement. 
Each period of follow-up, and losses to follow-up, were then allocated to a CD4 
count category, age group and location (London or outside London) depending 
on the value of the CD4 count, the age at the time of the CD4 count and where 
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it was measured. This allowed these determining factors to change over time for 
each individual, but considered them to be constant during each period of 
follow-up. This ensured that person years of follow-up (PYFU) were included in 
the analysis with the appropriate determining factors. Finally, PYFU were 
allocated to calendar years in which they occurred. In the analysis of permanent 
LTFU, periods of follow-up were determined as above, but a last CD4 cell count 
before 1st January 2007 or no death reported within 365 days of the last CD4 
cell count was considered as permanent LTFU.  
Figure 5.1. Hypothetical calculation of periods of follow-up 
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Poisson regression was used for the analysis of incidence rates. This method 
assumes that rates are constant within time periods and estimates rate ratios 
between groups. The approach of allowing a patient’s status to change permits 
the inclusion of variables that change over time. All PYFU are considered 
together where all determining variables are equal. This method is suited to 
analysis of trends as PYFU within the same calendar year are aggregated. 
The main effects model included the following: 
1. time-updated categorical variables: CD4 cell count categories, age groups, 
grouped calendar years 
2. time-updated binary variables: previous AIDS diagnosis, region 
3. fixed categorical variables: ethnicity; risk group (heterosexuals split by sex – 
numbers were not sufficient to split IDUs by sex). 
5.3.4 Proximity of CD4 cell count measurements to events 
Multivariable logistic regression was used to determine factors associated with 
having a CD4 cell count measured within a defined time from HIV diagnosis, to 
first AIDS diagnosis and to death. The defined time used to investigate these 
associations was informed by the Kaplan-Meier estimate of the time between a) 
each individual’s date of HIV diagnosis and first CD4 cell count measurement; 
b) an individual’s last CD4 cell count measurement and the date of death for 
individuals known to have died; c) an individual’s last CD4 cell count 
measurement before their first AIDS diagnosis and the date of first AIDS 
diagnosis for individuals reported to have been diagnosed with AIDS. 
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5.4  Results 
5.4.1 Factors of inclusion in the integrated dataset 
The 50,953 individual records in the integrated dataset accounted for 58.2% of 
the total 87,521 HARS records (Table 5.1). Excluding those who were known to 
have died before 1995 who could not have been reported to SOPHID, this 
percentage increased to 67.3% of 77,212. The lower rate of inclusion in the 
integrated dataset in 2005-2007 compared with 2000-2004 may have been 
because a few laboratories were not able to report CD4 cell counts for 2007 
(Section 2.3.2). Records from outside London were less likely to be included 
(adjusted odds ratio [AOR] 0.59; 95% CI 0.57, 0.61).  
MSM were more likely to be included in the integrated dataset than other 
individuals, except recipients of blood/blood products (AOR 1.00; 95% CI 0.88, 
1.14) and heterosexual women diagnosed antenatally (AOR 1.02; 0.93,  1.12), 
after accounting for other factors. Recipients of blood/blood products were 
poorly represented in the integrated dataset because most of these individuals 
were diagnosed before 1990 and less likely to survive to be included in 
SOPHID. There was also a higher proportion of younger individuals (AOR for 
those aged 15-25 years 1.41; 95% CI 1.33, 1.49 compared to those aged 30-34 
years) and white individuals (AOR for black Africans 0.73; 95% CI 0.69, 0.76 in 
comparison) included in the integrated dataset. 
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Table 5.1. Number and percentage of HARS records in the integrated dataset 
 
Number of HARS 
patients included   
n             
(distribution, %) 
All newly 
diagnosed patients   
n              
(distribution, %) 
Percentage of  
newly diagnosed 
patients included 
% 
Multivariable 
adjusted odds ratio       
(95% confidence 
interval) 
    Period of HIV diagnosis     
1979-1984 248  (0.5) 1,258  (1.6) 20 0.10  (0.08,  0.12) 
1985-1989 2,504  (5) 11,243  (15) 22 0.14  (0.13,  0.15) 
1990-1994 5,230  (10) 12,196  (16) 43 0.40  (0.38,  0.42) 
1995-1999 8,851  (17) 13,004  (17) 68 0.97  (0.92,  1.02) 
2000-2004 20,352  (40) 28,376  (37) 72 1.26  (1.21,  1.32) 
2005-2007 13,768  (27) 21,444  (28) 64 - 
        Age group at HIV diagnosis     
15-25 6,382  (13) 10,800  (14) 59 1.41  (1.33,  1.49) 
25-29 10,662  (21) 18,161  (24) 59 1.14  (1.09,  1.20) 
30-34 11,889  (23) 20,233  (26) 59 - 
35-39 9,457  (19) 16,027  (21) 59 0.98  (0.94,  1.03) 
40-44 5,673  (11) 9,910  (13) 57 0.94  (0.89,  1.00) 
45-49 3,158  (6) 5,624  (7) 56 0.91  (0.85,  0.97) 
50-54 1,846  (4) 3,206  (4) 58 0.97  (0.89,  1.05) 
>54 1,886  (4) 3,560  (5) 53 0.77  (0.71,  0.83) 
        Region of diagnosis     
Outside London 21,878  (43) 39,393  (51) 56 0.59  (0.57,  0.61) 
London 29,075  (57) 48,128  (62) 60 - 
        Risk group     
MSM 22,984  (45) 40,186  (52) 57 - 
Heterosexual men 9,221  (18) 15,046  (19) 61 0.86  (0.81,  0.90) 
Heterosexual women 13,355  (26) 20,616  (27) 65 0.93  (0.88,  0.98) 
Heterosexual women 
(diagnosed antenatally) 
2,403  (5) 3,320  (4) 72 1.02  (0.93,  1.12) 
IDU 1,621  (3) 3,533  (5) 46 0.85  (0.78,  0.92) 
Recipients of blood products 487  (1) 1,715  (2) 28 1.00  (0.88,  1.14) 
Children infected vertically 29  (0.1) 43  (0.1) 67 0.67  (0.35,  1.29) 
Not reported 853  (2) 3,062  (4) 28 0.51  (0.46,  0.56) 
        Ethnicity     
White  25,870  (51) 41,693  (54) 62 - 
Black African 18,594  (36) 27,936  (36) 67 0.73  (0.69,  0.76) 
Black Caribbean 1,700  (3) 2,439  (3) 70 0.81  (0.73,  0.89) 
Black Other 680  (1) 1,079  (1) 63 0.73  (0.64,  0.84) 
Indian\Pakistani\Bangladeshi 722  (1) 1,154  (1) 63 0.83  (0.73,  0.95) 
Other Asian 89  (0.2) 113  (0.1) 79 1.27  (0.80,  2.00) 
Other/mixed 2,137  (4) 3,063  (4) 70 0.88  (0.81,  0.96) 
Not reported 1,161  (2) 10,044  (13) 12 0.10  (0.09,  0.11) 
    Total 50,953  (100) 87,521  (100) 58 - 
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Stratification of included records by the period of HIV diagnosis indicated that 
the percentage of patients who were reported to have died decreased over time 
(Table 5.2). A lower proportion of records for individuals who died were included 
in the integrated dataset than for individuals who were not known to have died 
(26.8% [4,405/16,443] versus 65.5% [46,548/71,078]; p<0.01), irrespective of 
the period of HIV diagnosis. However, the univariable odds of being included in 
the integrated dataset increased after the earliest period of diagnosis. There 
was low inclusion of HARS patients who were diagnosed between 1985 and 
1994 and who were not reported to have died. 
Table 5.2. Percentage and number of HARS records that were included in the 
integrated dataset according to whether individuals had died or not. 
    Period of HIV     
           Diagnosis 
Percentage of 
HARS patients 
who had died 
%    (n) 
Percentage of HARS 
patients who had died 
that were included  
%    (N) 
Percentage of HARS 
patients who had not 
died that were 
included  
%    (N) 
Univariable odds 
ratio for each 
period 
(95% confidence 
interval) 
        
1979-1984 76.6  (964) 11.8  (964) 45.6  (294) 0.16  (0.12,  0.22) 
1985-1989 57.0  (6,408) 14.0  (6,408) 33.2  (4,835) 0.33  (0.30,  0.36) 
1990-1994 39.9  (4,867) 29.4  (4,867) 51.8  (7,329) 0.39  (0.36,  0.42) 
1995-1999 14.4  (1,871) 50.6  (1,871) 71.0  (11,133) 0.42  (0.38,  0.46) 
2000-2004 5.7  (1,614) 46.2  (1,614) 73.3  (26,762) 0.31  (0.28,  0.35) 
2005-2007 3.4  (719) 37.4  (719) 65.1  (20,725) 0.32  (0.27,  0.37) 
     
Overall 18.8  (16,443) 26.8  (16,443) 65.5  (71,078) 0.19  (0.19,  0.20) 
 
Categorisation of individuals who had died according to whether they had died 
within 31 days of their HIV diagnosis or not indicated that overall, 14.1% of 
individuals who died, did so shortly after HIV diagnosis (Table 5.3). These 
individuals accounted for a relatively small proportion of individuals who had 
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died, who were diagnosed before 1995, and who were not included in the 
integrated dataset. However, deaths shortly after HIV diagnosis accounted for 
an increasing percentage of all individuals who had died and who were not 
included in the integrated dataset (62.4% for individuals diagnosed between 
2005 and 2007). 
Overall, 9.8% (15.7% of those diagnosed after 1994) of patients who had died 
within 31 days of diagnosis were included in the integrated dataset compared to 
29.0% (68.6% of those diagnosed after 1994) of patients who had died more 
than 31 days after diagnosis (Table 5.3). None of the individuals who were 
diagnosed before 1995 and who had died within 31 days of diagnosis were 
included in the integrated dataset because they could not have been linked to 
SOPHID records.  
Table 5.3. Percentage and number of HARS patients who were included in the 
integrated dataset according to whether they had died within 31 days of HIV 
diagnosis or not. 
    Period of HIV     
           diagnosis 
Percentage of HARS 
patients who died and 
were not included 
who died within 31 
days of diagnosis 
%  (N) 
Percentage of HARS 
patients who died 
within 31 days of 
diagnosis that were 
included  
%  (N) 
Percentage of HARS 
patients who died more 
than 31 days after 
diagnosis that were 
included  
%  (N) 
Univariable odds 
ratio for inclusion in 
the dataset by time 
from diagnosis 
(95% confidence 
interval) 
        
1979-1984 3.8  (850) 0  (32) 12.2  (932) - 
1985-1989 5.2  (5,511) 0  (285) 14.6  (6,123) - 
1990-1994 11.4  (3,435) 0  (390) 32.0  (4,477) - 
1995-1999 31.4  (924) 9.4  (320) 59.1  (1,551) 0.07  (0.05,  0.11) 
2000-2004 48.4  (868) 18.0  (512) 59.3  (1,102) 0.15  (0.11,  0.20) 
2005-2007 62.4  (450) 18.3  (344) 54.9  (375) 0.18  (0.13,  0.27) 
     
Overall 14.1  (12,038) 9.8  (1,883) 29.0  (14,560) 0.27  (0.23,  0.31) 
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A decreasing percentage of patients had ever had AIDS (Table 5.4). Patients 
with AIDS were less likely than those without AIDS to be included in the 
integrated dataset if they were diagnosed before 1995. In contrast, a reported 
AIDS diagnosis was not associated with inclusion in the integrated dataset for 
patients diagnosed after 1994. 
Table 5.4. Percentage and number of HARS records that were included in the 
integrated dataset according to whether individuals had a reported AIDS 
diagnosis or not. 
    Period of HIV     
           diagnosis 
Percentage of 
HARS patients 
who had AIDS 
% 
Percentage of HARS 
patients who had AIDS 
that were included  
%    (N) 
Percentage of HARS 
patients who had not 
AIDS that were 
included 
%    (N) 
Univariable odds 
ratio for each 
period            
(95% confidence 
interval) 
        
1979-1984 75.5  (950) 14.4  (950) 36.0  (308) 0.30  (0.22,  0.41) 
1985-1989 58.1  (6,528) 19.7  (6,528) 25.9  (4,715) 0.70  (0.64,  0.77) 
1990-1994 46.8  (5,703) 38.6  (5,703) 46.6  (6,493) 0.72  (0.67,  0.77) 
1995-1999 24.8  (3,220) 68.2  (3,220) 68.0  (9,784) 1.01  (0.93,  1.10) 
2000-2004 12.7  (3,608) 71.2  (3,608) 71.8  (24,768) 0.97  (0.90,  1.05) 
2005-2007 8.4  (1,798) 63.5  (1,798) 64.3  (19,646) 0.97  (0.87,  1.07) 
     
Overall 24.9  (21,807) 43.7  (21,807) 63.0  (65,714) 0.46  (0.44,  0.47) 
 
5.4.2 Further exclusions from the integrated dataset 
The small number of records of children infected vertically (29 [0.1%]; 250 CD4 
cell count measurements) were excluded from all further analyses. This group 
was unlikely to provide statistically significant comparisons with other groups 
and were potentially too different to be merged with other groups of individuals. 
Records without a reported ethnicity and records without a reported risk group 
accounted for 0.9% (464) and 0.7% (342) of the individuals in the integrated 
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dataset. These relatively small numbers were excluded from further analyses 
because results could not be interpreted but it was unlikely to add much bias. 
5.4.3 Differential CD4 cell count monitoring and loss to follow-up 
There were 50,167 individuals with 875,237 CD4 cell counts in the final 
integrated dataset after exclusions; a median of 13 (IQR 5, 24) per patient. 
There were 3,442 (6.7%) individuals who had only one CD4 cell count and one 
individual had a maximum of 154 CD4 counts. The number of CD4 counts 
measured increased each year, from 20 in 1986 to 115,577 in 2007.  
5.4.3.1 Individuals with only one CD4 cell count  
A third (33.1% [1,138]) of the 3,442 individuals with only one CD4 cell count had 
it measured in 2007 and a further 9.0% (309) in 2006. Many of these individuals 
would be expected to have further CD4 counts reported. A quarter (26.0% 
[600]) of the individuals with single counts before 2007 were known to have died 
and 80.3% (482) of these were known to have died in the same or subsequent 
year (decreasing from 53.2% in 1995 to 8.7% in 2006). 
A first CD4 cell count of 350 cells/mm3 or more was independently associated 
with having only one CD4 cell count in the integrated dataset compared to 
counts of 200-249 cells/mm3 (AOR at 350-499 cells/mm3 1.53; 95% CI 1.29, 
1.81) (Table 5.5): Younger age at the time of HIV diagnosis was also associated 
with having only one CD4 cell count (AOR at 15-24 years 1.41; 95% CI 1.23, 
1.62 compared to age group 35-39 years). Individuals diagnosed between 1995 
and 1998 or after 2004 were more likely to have only one CD4 cell count and 
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particularly those diagnosed in 2007. Individuals diagnosed before 1995 were 
likely to have subsequent measurements as they also had to have been 
reported to SOPHID since 1995. Individuals diagnosed outside of London, MSM 
and heterosexual women diagnosed antenatally, and individuals of white 
ethnicity were less likely to have only one CD4 cell count.  
Table 5.5. Percentage of all individuals who had only one CD4 count and who 
were not known to have died in the same or subsequent year. 
 
Number of  
individuals 
with/without only 
one CD4 count 
Percentage with only 
one CD4 count  
(not died in the same or 
subsequent year)  
(%) 
Multivariable 
adjusted          
odds ratio                
(95% confidence 
interval) 
    Calendar year of  
                        HIV diagnosis 
   
<1991 94 / 3,338 2.7 0.73 (0.56, 0.95) 
1991/1992 38 / 1,944 1.9 0.51 (0.36, 0.74) 
1993/1994 59 / 2,352 2.4 0.69 (0.51, 0.93) 
1995/1996 162 / 3,116 4.9 1.43 (1.15, 1.78) 
1997/1998 168 / 3,487 4.6 1.28 (1.03, 1.60) 
1999/2000 176 / 4,516 3.8 - 
2001/2002 269 / 7,359 3.5 0.90 (0.74, 1.09) 
2003/2004 421 / 9,507 4.2 1.08 (0.90, 1.30) 
2005/2006 575 / 8,853 6.1 1.62 (1.36, 1.93) 
2007 975 / 2,758 26.1 9.21 (7.78, 10.92) 
   Age group at  
                      HIV diagnosis 
   
15-24 467 / 6,146 7.1 1.41 (1.23, 1.62) 
25-29 646 / 9,998 6.1 1.18 (1.04, 1.34) 
30-34 607 / 11,069 5.2 1.01 (0.89, 1.14) 
35-39 509 / 8,649 5.6 - 
40-44 320 / 5,135 5.9 1.00 (0.86, 1.16) 
45-49 176 / 2,881 5.8 0.98 (0.81, 1.18) 
50-54 101 / 1,667 5.7 1.08 (0.86, 1.36) 
>54 111 / 1,685 6.2 1.14 (0.91, 1.43) 
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   First CD4 cell count  
                              category 
   
<50 247 / 5,449 4.3 0.86 (0.70, 1.05) 
50-99  169 / 3,473 4.6 0.96 (0.77, 1.19) 
100-149 157 / 3,283 4.6 0.92 (0.73, 1.15) 
150-199 171 / 3,421 4.8 0.93 (0.75, 1.16) 
200-249 195 / 3,742 5.0 - 
250-299 203 / 3,697 5.2 1.02 (0.83, 1.26) 
300-349 226 / 3,771 5.7 1.18 (0.96, 1.45) 
350-499 710 / 9,182 7.2 1.53 (1.29, 1.81) 
>499 859 / 11,212 7.1 1.61 (1.36, 1.91) 
    
   AIDS at HIV diagnosis    
No 2,607 / 39,518 6.2 - 
Yes 330 / 7,712 4.1 0.92 (0.80, 1.06) 
   Region of diagnosis    
Outside London 1,247 / 20,430 5.8 0.89 (0.82, 0.97) 
London 1,690 / 26,800 5.9 - 
    
   Risk group    
MSM 1,042 / 21,783 4.6 - 
Heterosexual men 695 / 8,645 7.4 1.56 (1.37, 1.78) 
Heterosexual women 909 / 12,584 6.7 1.29 (1.13, 1.47) 
Heterosexual women 
(diagnosed antenatally)  
130 / 2,271 5.4 0.81 (0.65, 1.01) 
IDU 128 / 1,478 8.0 2.36 (1.93, 2.88) 
Recipients of blood products 33 / 469 6.6 2.17 (1.48, 3.18) 
    
   Ethnicity    
White  1,239 / 24,886 4.7 - 
Black-African  1,266 / 17,011 6.9 1.42 (1.25, 1.61) 
Black Caribbean  123 / 1,528 7.5 1.39 (1.13, 1.72) 
Black – other/unspecified  76 / 835 8.3 1.48 (1.13, 1.92) 
Indian/Pakistani/Bangladeshi  43 / 609 6.6 1.18 (0.84, 1.65) 
Other Asian 44 / 625 6.6 1.12 (0.81, 1.56) 
Other/mixed  146 / 1,736 7.8 1.47 (1.21, 1.78) 
    
    Total 2,937 / 47,230 5.9 - 
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5.4.3.2 Frequency of CD4 cell count monitoring  
There were 46,725 individuals who had more than one CD4 cell count. The 
median for all individuals of the mean times between each individual’s 
consecutive CD4 counts was 98 days (IQR 77, 131). The median standard 
deviation of time between CD4 counts for these individuals was 52 (IQR 34, 94) 
(Figure 5.2). Only few individuals had CD4 cell counts measured very regularly 
(low standard deviation in times between CD4 counts) and usually at one month 
or three month intervals 
Figure 5.2. Plot of mean against standard deviation for time between CD4 
counts (of each individual with more than two CD4 counts; excluding results 
with a mean or standard deviation above the 95th percentile). 
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The median time between any one CD4 count and the next was 85 days (IQR 
53, 115). The Kaplan-Meier estimate showed that 41.5% (95% CI 41.4%, 
41.6%), 9.0% (95% CI 8.9%, 9.0%) and 2.3% (95% CI 2.3%, 2.3%) of CD4 cell 
counts were followed by a subsequent measurement within 3 months, 6 months 
and a year (Figure 5.3). 
Figure 5.3. Kaplan-Meier estimate of time between consecutive CD4 cell counts 
(for individuals with more than one CD4 cell count) 
 
The median time between CD4 counts varied particularly by the CD4 count and 
also by whether the individual had a previous AIDS diagnosis (Table 5.6). The 
latter appeared to be a temporary effect as individuals appeared to have had 
shorter median times between consecutive counts (58 days [IQR 31, 92]) in the 
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CD4 counts appeared to have been measured increasingly less frequently since 
the mid-1990s. Both the median follow-up between first and last CD4 cell 
counts and the overall number of CD4 cell counts fell over time since the first 
CD4 cell count due to censoring. However, there were relatively few CD4 cell 
counts measured for individuals whose first CD4 cell count was prior to 1995. 
In descriptive analysis, risk group appeared to have relatively little association 
with the time between consecutive CD4 counts but substantial association with 
follow-up due to the timing of diagnosis of different groups. However, IDUs (91 
days between consecutive CD4 counts [IQR 55, 133]) were monitored least 
frequently and MSM (84 days [IQR 50, 113]) most frequently.  
Ethnicity had relatively little association with the frequency or length of follow-
up. However, black Caribbean individuals (91 days between consecutive CD4 
counts [IQR 57, 123]) were monitored slightly less frequently than individuals of 
other ethnicity (85 days [IQR 52, 115]). Individuals of white ethnicity had the 
longest follow-up (4.8 years [IQR 2.1, 9.2]) but also the most CD4 cell counts 
(17 [IQR 8, 32]). There was no substantial effect of age. 
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Table 5.6. Median times between consecutive CD4 counts and between first 
and last CD4 count (only individuals with more than one CD4 count). 
 
Median times between 
consecutive CD4 counts  
(IQR) /days 
Median times between  
first and last CD4 counts  
(IQR) /years 
Median overall number 
of CD4 counts  
(IQR) 
    
    Year of CD4 cell count (of each CD4 count) (of first CD4 count) (of first CD4 count) 
<1991 101  (70, 175) 16.8  (7.6, 17.5) 46  (25, 67) 
1991/1992 84  (43, 124) 15.0  (5.4, 15.8) 41  (19, 60) 
1993/1994 82  (42, 127) 12.8  (3.0, 13.7) 31  (10, 49) 
1995/1996 70  (35, 124) 11.1  (6.1, 11.8) 34  (16, 46) 
1997/1998 77  (43, 117) 9.4  (8.0, 10.2) 31  (18, 40) 
1999/2000 82  (49, 111) 7.4  (6.5, 8.0) 24  (14, 31) 
2001/2002 84  (51, 111) 5.3  (4.6, 6.0) 19  (11, 24) 
2003/2004 88  (56, 113) 3.4  (2.8, 4.1) 13  (8, 17) 
2005/2006 91  (61, 119) 1.6  (1.1, 2.2) 7  (5, 10) 
2007 89  (56, 112) 0.4  (0.2, 0.6) 3  (2, 4) 
       Age group (at each CD4 count) (at first CD4 count) (at first CD4 count) 
15-24 87  (49, 125) 3.6  (1.5, 6.9) 12  (5, 23) 
25-29 86  (49, 122) 4.1  (1.7, 7.9) 14  (6, 26) 
30-34 85  (50, 119) 4.2  (1.9, 7.7) 15  (7, 27) 
35-39 86  (53, 115) 4.0  (1.8, 7.0) 14  (7, 25) 
40-44 86  (55, 113) 3.6  (1.5, 6.6) 14  (6, 25) 
45-49 85  (54, 112) 3.4  (1.4, 6.6) 14  (6, 25) 
50-54 85  (56, 111) 3.9  (1.7, 7.0) 15  (7, 27) 
>54 85  (56, 108) 3.4  (1.3, 6.2) 13  (6, 25) 
       CD4 cell count category (at each CD4 count) (at first CD4 count) (at first CD4 count) 
<50 50  (28, 90) 3.5  (1.4, 6.4) 15  (7, 26) 
50-99  56  (30, 91) 3.8  (1.7, 6.9) 15  (7, 27) 
100-149 63  (35, 96) 3.8  (1.7, 6.8) 15  (7, 26) 
150-199 67  (36, 98) 3.6  (1.6, 6.7) 14  (7, 25) 
200-249 75  (42, 102) 3.9  (1.8, 7.2) 15  (7, 26) 
250-299 83  (49, 106) 3.8  (1.6, 6.9) 14  (6, 25) 
300-349 87  (56, 113) 4.0 (1.7, 7.5) 14  (7, 26) 
350-499 91  (63, 119) 3.9  (1.7, 7.6) 13  (6, 26) 
>499 96  (75, 127) 4.2  (1.8, 8.0) 12  (5, 24) 
    
   Previous AIDS diagnosis (before each CD4 count) (before first CD4 count) (before first CD4 count) 
No 89  (56, 119) 3.8  (1.7, 7.2) 13  (6, 25) 
Yes 84  (49, 107) 4.3  (1.8, 7.5) 17  (8, 29) 
    
   Region of CD4 cell count (each CD4 count) (first CD4 count) (first CD4 count) 
Outside London 85  (56, 112) 3.3  (1.5, 5.9) 12  (6, 22) 
London 86  (51, 119) 4.5  (1.9, 8.2) 15  (6, 28) 
 
 221 
 
    
   Risk group    
MSM 84  (50, 113) 4.8  (2.1, 9.4) 17  (8, 33) 
Heterosexual men 89  (56, 116) 3.2  (1.3, 5.7) 11  (5, 20) 
Heterosexual women 89  (56, 115) 3.3  (1.5, 5.7) 12  (6, 21) 
Heterosexual women 
(diagnosed antenatally)  
88  (49, 119) 2.8  (1.2, 4.6) 9  (5, 16) 
IDU 91  (55, 133) 4.4  (1.7, 8.9) 12.5  (5, 25) 
Recipients of blood products 85  (55, 114) 7.0  (2.7, 13.2) 22  (9, 44) 
    
   Ethnicity    
White 85  (51, 114) 4.8  (2.1, 9.2) 17  (8, 32) 
Black-African 88  (56, 115) 3.1  (1.3, 5.2) 11  (5, 19) 
Black Caribbean 91  (57, 123) 3.4  (1.4, 6.0) 11  (5, 20) 
Black – other/unspecified 88  (52, 122) 3.6  (1.3, 6.8) 11  (5, 22) 
Indian/Pakistani/Bangladeshi 89  (56, 117) 3.6  (1.5, 7.2) 13.5  (6, 26) 
Other Asian  85  (56, 113) 3.1  (1.2, 5.9) 12  (6, 22) 
Other/mixed 85  (52, 119) 3.6  (1.4, 7.4) 13  (5, 26) 
    
    Total 85  (53, 115) 3.9  (1.7, 7.3) 14  (6, 26) 
 
Table 5.7. Median times between consecutive CD4 counts in the five years 
before and after a first AIDS diagnosis 
Years before and after first 
                        AIDS diagnosis 
Number of CD4 
cell counts 
Median (IQR) /days 
-5 4,873 89  (51, 135) 
-4 6,864 85  (49, 128) 
-3 9,493 86  (49, 128) 
-2 13,285 84  (48, 122) 
-1 18,264 78  (42, 118) 
0 46,818 58  (31, 92) 
1 46,695 76  (42, 102) 
2 37,669 84  (50, 107) 
3 32,374 84  (55, 111) 
4 27,952 84  (53, 112) 
5 22,979 85  (56, 112) 
 
For those individuals with a reported date of starting ART (startART), there was 
also a temporarily increased frequency of CD4 cell count monitoring (56 days 
[IQR 31, 91] between counts) in the year of startART (Table 5.8). 
 222 
 
Table 5.8. Median times between consecutive CD4 counts in the five years 
before and after starting ART 
Years before and 
             after startART 
Number of CD4 
cell counts 
Median (IQR) /days 
-5      7,067  98  (63, 154) 
-4     10,201  95  (63, 146) 
-3     14,349  93  (63, 140) 
-2     20,560  91  (61, 135) 
-1     32,942  84  (49, 119) 
0   100,145  56  (31, 91) 
1     82,608  84  (55, 105) 
2     65,454  90  (61, 112) 
3     54,854  90  (61, 113) 
4     45,196  90  (61, 114) 
5     37,185  90  (61, 114) 
 
There was also evidence that the first CD4 count measurement was followed 
relatively quickly by another CD4 count while subsequent CD4 counts were 
measured less frequently (Figure 5.4). Further analysis showed that this 
frequent monitoring of CD4 counts at the initiation of care was carried out 
irrespective of the level of first CD4 count (Figure 5.5). Individuals with very low 
first CD4 counts (CD4 <100 cells/mm3) continued to be monitored frequently but 
gradually less so over time.  
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Figure 5.4. Median (IQR) times between consecutive CD4 counts according to 
their chronological order (for up to the first 30 CD4 counts of an individual) 
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Figure 5.5. Median times between consecutive CD4 counts by CD4 cell count 
category (for up to the first 30 CD4 counts of an individual) 
 
There were only a very small number of records in the integrated dataset for 
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Figure 5.6. Scatter plot and linear regression plot of time between the first and 
last CD4 cell counts against the total number of CD4 cell counts (of each 
individual with more than one CD4 cell count). 
 
5.4.3.3 Temporary LTFU during care 
Temporary LTFU, defined as subsequent CD4 cell counts measured after 365 
days or more, occurred after 17,079 (2.1%) CD4 counts and for 12,246 (26.2%) 
individuals. The median CD4 cell count just prior to a period of temporary LTFU 
was 390 (IQR 240, 561) cells/mm3. The rate of temporary LTFU decreased 
markedly over time (AOR in 1991/1992 2.07 and AOR in 2005/2006 0.47 
compared to 2001/2002) (Table 5.9). Temporary LTFU also decreased with age 
0
5
0
1
0
0
1
5
0
N
u
m
b
e
r 
o
f 
C
D
4
 c
e
ll 
c
o
u
n
t 
m
e
a
s
u
re
m
e
n
ts
0 5 10 15 20
Time between first and last CD4 cell count (for each individual) / years
 226 
 
(AOR at 15-24 years 1.36 and AOR at >54 years 0.65 compared to 35-39 
years). Patients who had previously been diagnosed with AIDS were less likely 
to be temporarily LTFU (AOR 0.68). Rates of temporary LTFU were higher at 
low CD4 cell counts (AOR at less than 50 cells/mm3 1.30) and high CD4 cell 
counts (AOR at greater than 499 cells/mm3 1.27) compared to CD4 cell counts 
of 200-249 cells/mm3. MSM had a lower rate of temporary LTFU than 
heterosexuals (AOR for heterosexual men 1.40 and AOR for heterosexual 
women 1.09) and IDUs (AOR 1.91), but a higher rate than recipients of 
blood/blood products (AOR 0.78). Black individuals had a higher rate of 
temporary LTFU than white individuals after adjusting for other factors (AOR for 
black Africans 1.26 and AOR for black Caribbeans 1.49).  
Table 5.9. Factors associated with the rate of temporary LTFU (CD4 count 
followed by more than 365 days before the next CD4 cell count).   
 
Number of CD4 
counts with >365 
days to next CD4 
count / PYFU 
Rate of temporary   
LTFU 
(>365 days to next  
CD4 cell count) / % 
Multivariable    
rate ratio                
(95% confidence 
interval) 
    Year of CD4 cell count    
<1991 271 / 856 31.6 2.57 (2.27, 2.93) 
1991/1992 665 / 3,335 19.9 1.71 (1.57, 1.86) 
1993/1994 1,193 / 6,988 17.1 1.53 (1.43, 1.64) 
1995/1996 1,725 / 10,186 16.9 1.62 (1.52, 1.72) 
1997/1998 1,926 / 15,082 12.8 1.28 (1.21, 1.35) 
1999/2000 2,452 / 21,342 11.5 1.15 (1.09, 1.21) 
2001/2002 2,998 / 28,716 10.4 - 
2003/2004 3,188 / 43,691 7.3 0.67 (0.63, 0.70) 
2005/2006 2,661 / 55,568 4.8 0.44 (0.41, 0.46) 
 
 227 
 
   Age group at CD4 count    
15-24 1,317 / 7,392 17.8 1.71 (1.60, 1.82) 
25-29 3,066 / 21,258 14.4 1.38 (1.32, 1.45) 
30-34 4,289 / 38,104 11.3 1.16 (1.11, 1.22) 
35-39 3,743 / 43,508 8.6 - 
40-44 2,298 / 32,519 7.1 0.91 (0.86, 0.96) 
45-49 1,162 / 19,411 6.0 0.80 (0.74, 0.85) 
50-54 645 / 11,278 5.7 0.78 (0.72, 0.85) 
>54 559 / 12,296 4.5 0.66 (0.60, 0.72) 
    
   CD4 cell count category    
<50 726 / 6,479 11.2 1.26 (1.15, 1.38) 
50-99  662 / 6,556 10.1 1.16 (1.06, 1.28) 
100-149 891 / 9,136 9.8 1.15 (1.05, 1.25) 
150-199 990 / 11,546 8.6 1.04 (0.95, 1.13) 
200-249 1,194 / 14,637 8.2 - 
250-299 1,316 / 16,643 7.9 0.98 (0.91, 1.06) 
300-349 1,555 / 17,759 8.8 1.10 (1.02, 1.18) 
350-499 4,077 / 46,337 8.8 1.12 (1.05, 1.20) 
>499 5,668 / 56,672 10.0 1.32 (1.24, 1.41) 
    
   Previous AIDS diagnosis    
No 13,635 / 125,028 10.9 - 
Yes  3,444 / 60,739 5.7 0.59 (0.56, 0.61) 
    
   Region of CD4 cell count    
Outside London 5,758 / 65,824 8.7 0.99 (0.96, 1.02) 
London 11,321 / 119,943 9.4 - 
 
   Risk group    
MSM 8,798 / 105,686 8.3 - 
Heterosexual men 2,615 / 26,264 10.0 1.40 (1.32, 1.47) 
Heterosexual women 3,672 / 39,529 9.3 1.09 (1.03, 1.15) 
Heterosexual women 
(diagnosed antenatally)  
668 / 5,013 13.3 1.44 (1.32, 1.58) 
IDU 1,047 / 6,139 17.1 1.91 (1.79, 2.04) 
Recipients of blood products 279 / 3,135 8.9 0.78 (0.69, 0.88) 
   Ethnicity    
White 10,382 / 119,006 8.7 - 
Black-African 4,809 / 48,021 10.0 1.26 (1.20, 1.33) 
Black Caribbean 583 / 4,801 12.1 1.49 (1.36, 1.62) 
Black – other/unspecified 304 / 2,932 10.4 1.17 (1.04, 1.31) 
Indian/Pakistani/Bangladeshi 202 / 2,252 9.0 1.10 (0.95, 1.27) 
Other Asian 159 / 1,999 8.0 1.08 (0.92, 1.26) 
Other/mixed 640 / 6,754 9.5 1.09 (1.01, 1.18) 
    Total 17,079 / 185,768 9.2 - 
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5.4.3.4 Permanent LTFU during care 
There were 45,678 individuals who had 759,660 CD4 cell counts measured 
before 2007 and 10,365 (22.7%) of these individuals were permanently lost to 
follow-up. The median CD4 cell count just prior to permanent LTFU was 369 
(IQR 220, 540) cells/mm3. Multivariable analysis indicated that the rate of 
permanent LTFU increased significantly over time and was particularly high in 
2005/6 (AOR 2.01 compared to 2001/2) (Table 5.10). This may be partly 
artificial due to insufficient follow-up from 2005/6 to distinguish permanent LTFU 
from temporary LTFU. There was a relatively high rate of permanent LTFU in 
1995/6 (AOR 1.23). Permanent LTFU was relatively high for younger patients 
(AOR at ages 15-24 years 1.98 and AOR at ages 25-29 years 1.61 compared to 
age group 35-39 years). Individuals with CD4 cell counts less than 200 
cells/mm3 had higher rates of LTFU and these rates were particularly high at 
CD4 cell counts less than 50 cells/mm3 (AOR 2.66). Individuals who had been 
previously diagnosed with AIDS were less likely to be lost to follow-up (AOR 
0.57). Individuals with CD4 cell counts measured outside London were more 
likely to be lost to follow-up (AOR 1.41). IDUs were more than twice as likely as 
MSM to be lost to follow-up (AOR 2.35). Heterosexuals and non-white 
individuals were also significantly more likely than MSM and white individuals to 
be lost to follow-up. 
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Table 5.10. Factors associated with the rate of permanent LTFU (last CD4 cell 
count before the end of 2006 and not known to have died within 365 days)  
 
Number of CD4 
counts with last CD4 
count / PYFU 
Rate of permanent   
LTFU (including 
>365 days to death) 
% 
Multivariable    
rate ratio                
(95% confidence 
interval) 
    Year of CD4 cell count    
<1991 8 / 856 0.9 0.20 (0.10, 0.41) 
1991/1992 82 / 3,335 2.5 0.61 (0.49, 0.77) 
1993/1994 255 / 6,988 3.6 0.85 (0.74, 0.98) 
1995/1996 537 / 10,186 5.3 1.23 (1.11, 1.36) 
1997/1998 507 / 15,082 3.4 0.89 (0.80, 0.99) 
1999/2000 779 / 21,342 3.7 0.99 (0.91, 1.09) 
2001/2002 1,148 / 28,716 4.0 - 
2003/2004 2,074 / 43,691 4.7 1.08 (1.00, 1.16) 
2005/2006 4,975 / 55,568 9.0 2.01 (1.88, 2.14) 
 
 
   Age group at CD4 count    
15-24 853 / 7,392 11.5 1.98 (1.82, 2.14) 
25-29 1,876 / 21,258 8.8 1.61 (1.52, 1.72) 
30-34 2,341 / 38,104 6.1 1.19 (1.12, 1.26) 
35-39 2,181 / 43,508 5.0 - 
40-44 1,437 / 32,519 4.4 0.91 (0.85, 0.97) 
45-49 733 / 19,411 3.8 0.83 (0.77, 0.91) 
50-54 410 / 11,278 3.6 0.85 (0.77, 0.95) 
>54 534 / 12,296 4.3 1.03 (0.94, 1.14) 
   CD4 cell count category    
<50 656 / 6,479 10.1 2.66 (2.39, 2.96) 
50-99  449 / 6,556 6.8 1.63 (1.45, 1.84) 
100-149 518 / 9,136 5.7 1.23 (1.10, 1.37) 
150-199 622 / 11,546 5.4 1.10 (0.99, 1.22) 
200-249 761 / 14,637 5.2 - 
250-299 877 / 16,643 5.3 0.97 (0.88, 1.07) 
300-349 944 / 17,759 5.3 0.96 (0.87, 1.05) 
350-499 2,444 / 46,337 5.3 0.96 (0.89, 1.04) 
>499 3,094 / 56,672 5.5 1.05 (0.97, 1.14) 
    
   Previous AIDS diagnosis    
No 8,106 / 125,028 6.5 - 
Yes  2,259 / 60,739 3.7 0.57 (0.54, 0.59) 
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5.4.4 Proximity of CD4 cell count measurements to events 
5.4.4.1 HIV diagnosis and time to first CD4 cell count 
The median time to first CD4 cell count after HIV diagnosis was 15 (IQR 4, 69) 
days. This was substantially higher for individuals diagnosed before 1990 
because few CD4 cell counts were reported before this time (Figure 5.7). 
Percentages of individuals diagnosed since 2000 who had not had a CD4 cell 
count within three months, six months and a year were 10.1%, 6.1% and 3.1% 
respectively (Table 5.11). A substantial proportion of individuals diagnosed 
since 1995 had not had a CD4 cell count measurement by one month. 
However, after two months there was only a gradual increase in the proportion 
of individuals with a CD4 cell count measurement (Figure 5.8). 
   Region of CD4 cell count    
Outside London 4,780 / 65,824 7.3 1.41 (1.35, 1.47) 
London 5,585 / 119,943 4.7 - 
    
   Risk group    
MSM 3,492 / 105,686 3.3 - 
Heterosexual men 2,372 / 26,264 9.0 1.66 (1.55, 1.77) 
Heterosexual women 3,250 / 39,529 8.2 1.26 (1.18, 1.35) 
Heterosexual women 
(diagnosed antenatally)  
640 / 5,013 12.8 1.38 (1.25, 1.53) 
IDU 486 / 6,139 7.9 2.35 (2.14, 2.59) 
Recipients of blood products 125 / 3,135 4.0 1.06 (0.88, 1.27) 
    
   Ethnicity    
White 4,284 / 119,006 3.6 - 
Black-African 4,830 / 48,021 10.1 1.90 (1.78, 2.03) 
Black Caribbean 349 / 4,801 7.3 1.60 (1.43, 1.79) 
Black – other/unspecified 205 / 2,932 7.0 1.60 (1.39, 1.85) 
Indian/Pakistani/Bangladeshi 147 / 2,252 6.5 1.53 (1.30, 1.81) 
Other Asian 115 / 1,999 5.8 1.26 (1.04, 1.52) 
Other/mixed 435 / 6,754 6.4 1.69 (1.53, 1.87) 
    
    Total 10,365 / 185,768 5.6 - 
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Figure 5.7. Kaplan-Meier estimate of time from HIV diagnosis to first CD4 cell 
count measurement (first five years and first six months shown separately) 
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Table 5.11. Median time from HIV diagnosis to first CD4 count measurement 
and Kaplan-Meier estimate of proportion without a CD4 cell count after three, 
six and twelve months after HIV diagnosis, by period of HIV diagnosis 
Period of HIV 
     diagnosis 
Median (IQR) /days 
Kaplan-Meier estimate of proportion (95% CI) without a 
CD4 cell count within x months after HIV diagnosis / % 
x = 3 x = 6 x = 12 
<1990 2,078  (1,318, 2,955) 97.6 (96.9, 98.1) 96.9 (96.1, 97.5) 94.9 (94, 95.7) 
1990-1994 140  (13, 963) 53.5 (52.1, 54.8) 47.9 (46.6, 49.3) 40.6 (39.3, 42) 
1995-1999 21  (5, 140) 29.8 (28.9, 30.8) 22.1 (21.2, 22.9) 15.9 (15.2, 16.7) 
2000-2004 12  (3, 32) 12.1 (11.6, 12.5) 7.6 (7.2, 8.0) 4.2 (4.0, 4.5) 
2005-2007 9  (2, 24) 7.0 (6.6, 7.5) 3.8 (3.5, 4.2) 1.3 (1.2, 1.6) 
 
Of individuals diagnosed since 1995, there were 85.7% (36,295/42,342) who 
had a CD4 cell count within 91 days of their HIV diagnosis (Table 5.12). The 
percentage of individuals with a CD4 cell count within 91 days of diagnosis 
increased substantially over time (from 32.4% in 1995/6 to 97.1% in 2007; AOR 
for 2007 12.69 compared to 1997/8). However, this was likely to be, in part, an 
artefact of censoring the data at the end of 2007. Age younger than 35 years at 
HIV diagnosis was independently associated with lower odds of having had a 
prompt CD4 cell count (AOR for ages 15-25 years 0.68 and AOR for ages 30-
34 years 0.91 compared to ages 35-39 years). Individuals with AIDS at the time 
of HIV diagnosis were more likely to have had a prompt CD4 cell count (AOR 
1.39) as were heterosexual women diagnosed antenatally when compared to 
MSM (AOR 1.83). Other heterosexuals (AOR for men 0.81 and AOR for women 
0.87) and IDU (AOR 0.76) were less likely to have a prompt CD4 cell count than 
MSM. Individuals of black African (AOR 0.91) or black Caribbean (AOR 0.85) 
ethnicity were less likely to have prompt CD4 cell counts than white individuals. 
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Table 5.12. Factors associated with having a CD4 cell count measurement 
within 91 days of HIV diagnosis (individuals diagnosed since 1995) 
 
Number of 
individuals 
with/without a CD4 
cell count within 91 
days of HIV 
diagnosis 
Percentage with a 
CD4 cell count  
within 91 days of 
HIV diagnosis   
 (%) 
Multivariable    
odds ratio                
(95% confidence 
interval) 
       Year of CD4 cell count    
1995/1996 2,047 / 1,231 62.4 0.62 (0.56, 0.68) 
1997/1998 2,663 / 992 72.9 - 
1999/2000 3,841 / 851 81.9 1.69 (1.52, 1.87) 
2001/2002 6,522 / 1,106 85.5 2.28 (2.06, 2.52) 
2003/2004 8,987 / 941 90.5 3.73 (3.36, 4.13) 
2005/2006 8,611 / 817 91.3 4.08 (3.68, 4.54) 
2007 3,624 / 109 97.1 12.69 (10.34, 15.58) 
       Age group at HIV diagnosis    
15-24 4,120 / 839 83.1 0.68 (0.61, 0.75) 
25-29 7,076 / 1,408 83.4 0.76 (0.69, 0.83) 
30-34 8,493 / 1,443 85.5 0.91 (0.83, 0.99) 
35-39 7,103 / 1,039 87.2 - 
40-44 4,246 / 595 87.7 0.96 (0.86, 1.08) 
45-49 2,382 / 338 87.6 0.96 (0.83, 1.10) 
50-54 1,386 / 198 87.5 1.03 (0.87, 1.22) 
>54 1,489 / 187 88.8 1.14 (0.96, 1.35) 
       AIDS at HIV diagnosis    
No 30,591 / 5,238 85.4  
Yes  5,704 / 809 87.6 1.39 (1.28, 1.51) 
       Region of HIV diagnosis    
Outside London 16,508 / 2,499 86.9 0.96 (0.91, 1.02) 
London 19,787 / 3,548 84.8  
      Risk group    
MSM 14,818 / 2,549 85.3  
Heterosexual men 7,459 / 1,260 85.5 0.81 (0.74, 0.90) 
Heterosexual women 10,764 / 1,823 85.5 0.87 (0.79, 0.96) 
Heterosexual women   
(diagnosed antenatally)  
2,219 / 166 93.0 1.83 (1.53, 2.20) 
IDU 858 / 217 79.8 0.76 (0.65, 0.90) 
Recipients of blood products 177 / 32 84.7 0.86 (0.58, 1.28) 
      Ethnicity    
White 16,781 / 3,018 84.8  
Black-African 15,041 / 2,368 86.4 0.91 (0.83, 1.00) 
Black Caribbean 1,294 / 230 84.9 0.85 (0.73, 1.00) 
Black – other/unspecified 716 / 98 88.0 1.15 (0.92, 1.45) 
Indian/Pakistani/Bangladeshi 503 / 78 86.6 1.05 (0.81, 1.35) 
Other Asian 566 / 62 90.1 1.24 (0.94, 1.63) 
Other/mixed 1,394 / 193 87.8 1.23 (1.04, 1.45) 
        Total 36,295 / 6,047 85.7 - 
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There were some significant differences in the effects of the factors on the odds 
of having had a CD4 cell count measurement within 30, 91 and 182 days of HIV 
diagnosis (Table 5.13). It became clear that much of the association between 
diagnosis in 2007 and having had a CD4 cell count within the different time 
frames was artificial and due to censoring at the end of 2007. Heterosexual 
women diagnosed antenatally were less likely than MSM to have had a CD4 
cell count within 30 days of HIV diagnosis (AOR 0.87) but more likely than MSM 
to have had a CD4 cell count within 91 or 182 days (AOR 1.99) of HIV 
diagnosis. Individuals older than 55 years were about a third more likely to have 
had a CD4 cell count measurement within 182 days than individuals aged 35-39 
years (AOR 1.32) but this effect was not significant within a time frame of 30 or 
91 days. Similarly, diagnosis outside London was associated with lower odds of 
having had a CD4 cell count within 182 days (AOR 0.89) but this association 
was not significant for the other time frames. Also, the association of black 
African and black Caribbean ethnicity were not associated with odds of having 
had a CD4 cell count within 182 days. 
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Table 5.13. Factors associated with having a CD4 cell count measurement 
within 30, 91 and 182 days of HIV diagnosis (individuals diagnosed since 1995) 
 
Multivariable odds ratio of having a CD4 cell count within x 
days of HIV diagnosis (95% confidence interval) 
 x = 30 x = 91 x = 182 
    Year of CD4 cell count    
1995/1996 0.72 (0.66, 0.80) 0.62 (0.56, 0.68) 0.59 (0.53, 0.66) 
1997/1998 - - - 
1999/2000 1.47 (1.34, 1.61) 1.69 (1.52, 1.87) 1.70 (1.51, 1.92) 
2001/2002 2.02 (1.86, 2.20) 2.28 (2.06, 2.52) 2.36 (2.11, 2.65) 
2003/2004 2.35 (2.17, 2.56) 3.73 (3.36, 4.13) 4.58 (4.05, 5.19) 
2005/2006 2.68 (2.47, 2.92) 4.08 (3.68, 4.54) 4.78 (4.22, 5.43) 
2007 4.57 (4.07, 5.13) 12.69 (10.34, 15.58) 38.87 (25.78, 58.59) 
       Age group at HIV diagnosis    
15-24 0.76 (0.70, 0.82) 0.68 (0.61, 0.75) 0.68 (0.60, 0.77) 
25-29 0.84 (0.78, 0.90) 0.76 (0.69, 0.83) 0.76 (0.68, 0.84) 
30-34 0.95 (0.89, 1.02) 0.91 (0.83, 0.99) 0.96 (0.87, 1.07) 
35-39 - - - 
40-44 1.00 (0.92, 1.08) 0.96 (0.86, 1.08) 1.04 (0.91, 1.19) 
45-49 0.94 (0.85, 1.04) 0.96 (0.83, 1.10) 1.00 (0.85, 1.17) 
50-54 1.03 (0.91, 1.17) 1.03 (0.87, 1.22) 1.07 (0.87, 1.31) 
>54 1.02 (0.90, 1.15) 1.14 (0.96, 1.35) 1.32 (1.06, 1.64) 
       AIDS at HIV diagnosis    
No - - - 
Yes  1.27 (1.19, 1.35) 1.39 (1.28, 1.51) 1.50 (1.36, 1.66) 
       Region of HIV diagnosis    
Outside London 0.96 (0.92, 1.00) 0.96 (0.91, 1.02) 0.89 (0.83, 0.95) 
London - - - 
       Risk group    
MSM - - - 
Heterosexual men 0.83 (0.77, 0.89) 0.81 (0.74, 0.90) 0.78 (0.70, 0.88) 
Heterosexual women 0.86 (0.80, 0.93) 0.87 (0.79, 0.96) 0.87 (0.78, 0.98) 
Heterosexual women 
(diagnosed antenatally)  
0.87 (0.78, 0.98) 1.83 (1.53, 2.20) 1.99 (1.57, 2.51) 
IDU 0.67 (0.59, 0.77) 0.76 (0.65, 0.90) 0.73 (0.61, 0.88) 
Recipients of blood products 0.85 (0.62, 1.15) 0.86 (0.58, 1.28) 0.92 (0.57, 1.50) 
    Ethnicity    
White - - - 
Black-African 0.86 (0.80, 0.92) 0.91 (0.83, 1.00) 0.91 (0.82, 1.02) 
Black Caribbean 0.77 (0.68, 0.87) 0.85 (0.73, 1.00) 0.94 (0.78, 1.14) 
Black – other/unspecified 0.87 (0.74, 1.02) 1.15 (0.92, 1.45) 1.07 (0.82, 1.40) 
Indian/Pakistani/Bangladeshi 1.00 (0.82, 1.22) 1.05 (0.81, 1.35) 1.08 (0.80, 1.47) 
Other Asian 1.21 (0.99, 1.48) 1.24 (0.94, 1.63) 1.06 (0.77, 1.46) 
                           Other/mixed 1.12 (0.99, 1.27) 1.23 (1.04, 1.45) 1.25 (1.02, 1.52) 
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5.4.4.2 Death and time from last CD4 cell count 
There were 4,564 individuals with a reported date of death in the integrated 
dataset. All of these deaths occurred since 1995 as all individuals in the 
integrated dataset had been reported to SOPHID. Therefore, individuals whose 
last CD4 cell count before death was prior to 1995 were excluded from the 
remainder of this analysis. For the remaining 4,179 deaths, the median time 
between the last CD4 cell count measurement and the date of death was 68 
days (IQR 28, 164). This time between last CD4 cell count and death decreased 
with increasing period of last CD4 cell count (Figure 5.9). This was not simply 
due to decreasing follow-up to the end of 2007 because the Kaplan-Meier 
estimates changed little when only deaths within two years of the last CD4 cell 
count measurement were considered. Overall estimates of the percentages of 
individuals with more than three months, six months and a year between their 
last CD4 cell count and death were 42.2%, 23.3% and 10.1% respectively 
(excluding individuals with their last CD4 cell count in 2007 because they could 
not have had more than 365 days to their date of death). 
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Figure 5.9. Kaplan-Meier estimate of time from last CD4 count measurement to 
death (individuals with a last CD4 count measurement in 1995 or later) 
 
Of individuals with their last measurement between 1995 and 2006, 90.0% 
(3,582/3,982) had a CD4 cell count within 365 days of death (Table 5.14). The 
median of the last CD4 cell count within 365 days of death was 55 (IQR 13, 
190) cells/mm3 compared to 100 (IQR 21, 300) cells/mm3 where the last 
measurement was more than 365 days before death.  In multivariable analysis, 
individuals with a CD4 cell count less than 50 cells/mm3 (AOR 1.74) and 
individuals with a previous AIDS diagnosis (AOR 2.39) were more likely to have 
had a CD4 cell count within 365 days of death. Individuals aged older than 54 
years also had increased odds of having had a CD4 cell count within 365 days 
of death (AOR 2.04). IDU (AOR 0.69) and individuals aged 25-29 years (AOR 
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0.64) were less likely to have had a CD4 cell count within 365 days of death. 
Individuals with their last CD4 cell count in 1995 or 1996 (AOR 0.34) were 
substantially less likely to have had a CD4 cell count within 365 days of death 
than those who had their last CD4 cell count measurement in 2001 or 2002, 
who in turn, were substantially less likely to have had a CD4 cell count within 
365 days of death than those who had their last CD4 cell count measurement in 
2005 or 2006 (AOR 2.75). IDU were less likely to have a CD4 cell count within 
365 days of death than MSM (AOR 0.69). There was no evidence of an 
association between ethnicity and having had a CD4 cell count within 365 days 
of death.  
Table 5.14. Factors associated with having a CD4 count measurement within 
365 days of death (individuals’ last measurement between 1995 and 2006) 
 
Number of 
individuals 
with/without a CD4 
cell count within 365 
days of death 
Percentage with    
a CD4 cell count  
within 365 days    
of death   
 (%) 
Multivariable    
odds ratio                
(95% confidence 
interval) 
    Year of last CD4 cell count    
1995/1996 1,025 / 186 84.6 0.34 (0.23, 0.51) 
1997/1998 522 / 54 90.6 0.78 (0.50, 1.23) 
1999/2000 491 / 60 89.1 0.73 (0.47, 1.13) 
2001/2002 437 / 39 91.8 - 
2003/2004 537 / 39 93.2 1.40 (0.87, 2.26) 
2005/2006 570 / 22 96.3 2.75 (1.58, 4.77) 
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   Age group    
15-24 53 / 8 86.9 1.24 (0.54, 2.86) 
25-29 274 / 61 81.8 0.64 (0.44, 0.94) 
30-34 630 / 86 88.0 0.96 (0.69, 1.34) 
35-39 736 / 87 89.4 - 
40-44 641 / 59 91.6 1.21 (0.85, 1.74) 
45-49 513 / 56 90.2 0.98 (0.68, 1.42) 
50-54 299 / 20 93.7 1.54 (0.92, 2.60) 
>54 436 / 23 95.0 2.04 (1.24, 3.35) 
    
   CD4 cell count category    
<50 1,679 / 139 92.4 1.74 (1.02, 2.96) 
50-99  470 / 57 89.2 1.02 (0.58, 1.80) 
100-149 336 / 31 91.6 1.25 (0.68, 2.33) 
150-199 223 / 30 88.1 0.89 (0.47, 1.68) 
200-249 166 / 20 89.2 - 
250-299 143 / 22 86.7 0.73 (0.37, 1.43) 
300-349 112 / 18 86.2 0.69 (0.34, 1.41) 
350-499 224 / 40 84.8 0.58 (0.32, 1.06) 
>499 229 / 43 84.2 0.61 (0.34, 1.11) 
    
   Previous AIDS diagnosis    
No 927 / 194 82.7 - 
Yes  2,655 / 206 92.8 2.39 (1.88, 3.04) 
    
   Region of CD4 cell count    
Outside London 1,466 / 162 90.0 0.88 (0.70, 1.11) 
London 2,116 / 238 89.9 - 
    
   Risk group    
MSM 2,076 / 222 90.3 - 
Heterosexual men 577 / 57 91.0 0.82 (0.55, 1.23) 
Heterosexual women 514 / 54 90.5 0.95 (0.61, 1.46) 
Heterosexual women   
(diagnosed antenatally)  
20 / 4 83.3 0.42 (0.13, 1.41) 
IDU 302 / 54 84.8 0.69 (0.49, 0.98) 
Recipients of blood products 93 / 9 91.2 1.16 (0.56, 2.41) 
    
   Ethnicity    
White 2,565 / 294 89.7 - 
Black-African 704 / 76 90.3 0.86 (0.57, 1.32) 
Black Caribbean 75 / 11 87.2 0.64 (0.31, 1.31) 
Black – other/unspecified 40 / 3 93.0 1.54 (0.45, 5.29) 
Indian/Pakistani/Bangladeshi 53 / 6 89.8 0.82 (0.33, 2.03) 
Other Asian 28 / 2 93.3 1.01 (0.22, 4.54) 
Other/mixed 117 / 8 93.6 1.47 (0.69, 3.12) 
    
    Total 3,582 / 400 90.0 - 
 240 
 
5.4.4.3 First AIDS diagnosis and time from previous CD4 cell count 
There were 16,616 individuals with a reported AIDS diagnosis in the integrated 
dataset. A substantial proportion of these diagnoses occurred at the time of HIV 
diagnosis and before a CD4 cell count had been measured such that there were 
only 10,266 (61.8%) AIDS diagnoses with a prior CD4 cell count measurement. 
Only 18.0% (873/1,797) of the AIDS diagnoses before 1995 had an earlier CD4 
cell count measurement, compared to 63.1% (9,393/14,819) since 1995, and 
therefore individuals whose last CD4 cell count before AIDS was prior to 1995 
were excluded from the remainder of this analysis. There were 9,087 AIDS 
diagnoses with a prior CD4 cell count measurement, which was in 1995 or later. 
Whereas 89.1% (7,236/8,118) of individuals with AIDS diagnoses more than 
three months after HIV diagnosis had a previous CD4 cell count measurement, 
this was only the case for 29.7% (1,851/6,222) of individuals with AIDS 
diagnoses within three months of their HIV diagnosis (Figure 5.10). 
The median time between the last CD4 cell count measurement before AIDS 
and the date of AIDS diagnosis was 21 days (IQR 3, 66). This interval was 
shorter for individuals with AIDS within three months of their HIV diagnosis 
(median 1 day [IQR 0, 12]) than for individuals with AIDS more than three 
months after HIV diagnosis (median 33 days [IQR 9, 87]). For individuals with 
AIDS more than three months after HIV diagnosis, the time between the CD4 
cell count and AIDS diagnosis decreased with increasing year of CD4 cell count 
(Figure 5.11), as for time to death, and this was not simply due to decreasing 
follow-up to the end of 2007. Overall percentages of individuals with more than 
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three months, six months and a year between their CD4 cell count and AIDS 
diagnosis were 23.5%, 11.8% and 5.9% respectively (excluding individuals with 
their CD4 cell count measurement in 2007 because they could not have had 
more than 365 days to their date of AIDS diagnosis). 
Figure 5.10. Numbers of AIDS diagnoses categorised by time from HIV 
diagnosis and the previous CD4 cell count measurement 
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Figure 5.11. Kaplan-Meier estimate of time from CD4 count measurement to 
AIDS diagnosis (individuals with a last CD4 count in 1995 or later) 
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For individuals with their last CD4 cell count measurement between 1995 and 
2006 and without AIDS at HIV diagnosis, there were a number of factors 
associated with the odds of having a CD4 cell count measurement within 365 
days prior to a first AIDS diagnosis (Table 5.15). The odds of having a CD4 cell 
count measurement within 365 days prior to a first AIDS diagnosis was 
particularly high for individuals whose last CD4 cell count before AIDS was 
measured since 2003 when compared to 2001/2002 (AOR for 2003/4 1.63 and 
AOR for 2005/6 3.31), whereas these odds were low if the last CD4 cell count 
before AIDS was measured in 1995/6 (AOR 0.52) or 1999/2000 (AOR 0.70). 
There appeared to be an increasing likelihood of having a CD4 cell count 
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measurement within 365 days prior to a first AIDS diagnosis with increasing age 
(AOR for ages 15-24 years 0.56 and AOR for ages older than 54 years 2.38 
compared to ages 35-39 years). Multivariable analysis indicated that the odds of 
having a CD4 cell count measurement within 365 days prior to a first AIDS 
diagnosis decreased with increasing CD4 cell count (AOR for CD4 cell count 
less than 50 cells/mm3 2.01 and AOR for CD4 cell count greater than 499 
cells/mm3 0.49 compared to CD4 category 200-249 cells/mm3). Individuals 
whose last CD4 cell count before AIDS was measured outside London were 
significantly less likely to have a CD4 cell count measurement within 365 days 
prior to a first AIDS diagnosis (AOR 0.60). There was no significant effect of 
ethnicity and little effect of risk group, although IDU were significantly less likely 
to have a CD4 cell count within 365 days prior to a first AIDS diagnosis (AOR 
0.61). 
Table 5.15. Factors associated with having a CD4 cell count measurement 
within 365 days of a first AIDS diagnosis (individuals with their last 
measurement between 1995 and 2006 and without AIDS at HIV diagnosis) 
 
Number of 
individuals 
with/without a CD4 
cell count within 365 
days of AIDS 
Percentage with    
a CD4 cell count  
within 365 days    
of AIDS   
 (%) 
Multivariable    
odds ratio                
(95% confidence 
interval) 
    Year of last CD4 cell count    
1995/1996 1,314 / 141 90.3 0.52 (0.37, 0.71) 
1997/1998 985 / 57 94.5 1.14 (0.78, 1.66) 
1999/2000 795 / 77 91.2 0.70 (0.49, 0.99) 
2001/2002 937 / 68 93.2 - 
2003/2004 1,202 / 58 95.4 1.63 (1.13, 2.35) 
2005/2006 1,151 / 28 97.6 3.31 (2.10, 5.20) 
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   Age group    
15-24 230 / 29 88.8 0.56 (0.35, 0.89) 
25-29 840 / 85 90.8 0.70 (0.51, 0.95) 
30-34 1,460 / 117 92.6 0.84 (0.63, 1.13) 
35-39 1,494 / 94 94.1 - 
40-44 1,063 / 54 95.2 1.26 (0.89, 1.78) 
45-49 605 / 24 96.2 1.59 (1.00, 2.54) 
50-54 331 / 16 95.4 1.43 (0.82, 2.49) 
>54 361 / 10 97.3 2.38 (1.21, 4.66) 
    
   CD4 cell count category    
<50 1,063 / 45 95.9 2.01 (1.29, 3.12) 
50-99  760 / 32 96.0 1.90 (1.17, 3.06) 
100-149 693 / 28 96.1 1.85 (1.12, 3.04) 
150-199 643 / 39 94.3 1.13 (0.71, 1.78) 
200-249 633 / 42 93.8 - 
250-299 526 / 39 93.1 0.83 (0.53, 1.32) 
300-349 450 / 38 92.2 0.74 (0.46, 1.18) 
350-499 882 / 84 91.3 0.63 (0.42, 0.93) 
>499 734 / 82 90.0 0.49 (0.33, 0.72) 
    
   Region of CD4 cell count    
Outside London 2,183 / 187 92.1 0.60 (0.49, 0.74) 
London 4,201 / 242 94.6 - 
    
   Risk group    
MSM 3,325 / 219 93.8 - 
Heterosexual men 1,068 / 59 94.8 0.87 (0.59, 1.28) 
Heterosexual women 1,449 / 99 93.6 0.83 (0.57, 1.20) 
Heterosexual women   
(diagnosed antenatally)  
143 / 10 93.5 0.90 (0.43, 1.89) 
IDU 307 / 36 89.5 0.61 (0.41, 0.89) 
Recipients of blood products 92 / 6 93.9 1.08 (0.46, 2.54) 
    
   Ethnicity    
White 3,741 / 268 93.3 - 
Black-African 2,001 / 122 94.3 0.94 (0.65, 1.37) 
Black Caribbean 172 / 10 94.5 0.87 (0.44, 1.73) 
Black – other/unspecified 98 / 7 93.3 0.84 (0.37, 1.90) 
Indian/Pakistani/Bangladeshi 90 / 7 92.8 0.68 (0.30, 1.55) 
Other Asian 66 / 5 93.0 0.71 (0.28, 1.85) 
Other/mixed 216 / 10 95.6 1.33 (0.68, 2.59) 
    
    Total 6,384 / 429 93.7 - 
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5.5  Discussion 
There was significant potential for bias due to differential inclusion, CD4 cell 
count monitoring, temporary and permanent LTFU, which may in turn bias the 
subsequent analyses. 
5.5.1 Potential inclusion bias  
A key determinant of bias, created by the formation of the integrated dataset, 
was the disproportionate exclusion of records for individuals diagnosed before 
1995 that were not linked to SOPHID reports. This was primarily due to deaths 
before 1995, when there was a high mortality rate, including deaths that were 
not reported. Individuals included had to have survived long enough and 
remained in E,W&NI long enough to be reported to SOPHID247. This bias was 
likely to be the main cause of the following observations: a) permanent LFTU 
was low before 1993; b) individuals diagnosed before 1995 were less likely to 
only have one CD4 cell count; c) the proportion of patients with AIDS included 
in the integrated dataset was low. Even after 1995, individuals who had died 
were less likely to be included in the integrated dataset than those who had not 
and particularly individuals who died shortly after diagnosis. Their short survival 
was likely to have reduced their likelihood of being reported to SOPHID. An 
AIDS diagnosis was associated with non-inclusion before 1995 but not 
afterwards, probably due to the high risk of death due to AIDS before 1995, and 
the relatively good survival afterwards with effective treatment. 
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The overall effect of differential inclusion in the integrated dataset on 
subsequent analyses would likely be the significant over-estimation of positive 
outcomes and under-estimation of negative outcomes. This is primarily because 
individuals who had died were less likely to be included than others, 
underestimating late diagnosis and consequent mortality (many of those who 
died shortly after diagnosis without a CD4 cell count were probably severely 
immunocompromised), underestimating the incidence of AIDS and death, and 
overestimating rates of CD4 increases after initiation of ART. The differential 
inclusion of population groups probably had a similar effect on overall outcomes  
because the adjusted odds ratios were marked, indicating that certain groups 
were substantially under-represented. As the under-represented groups were 
those also likely to have poorer outcomes, due to either socioeconomic status 
(e.g. non-white ethnicities and heterosexuals) or biological mechanisms (e.g. 
older aged individuals subject to faster progression of infection). 
Greater representation in the integrated dataset may be due to a combination of 
longer follow-up and less emigration, and therefore increasing information and 
opportunity to link records. Coding errors of less common surnames may also 
be a contributing factor among individuals of non-white ethnicities. Bias towards 
these groups and towards London may also be due to higher completeness and 
consistency of reporting from large urban clinics with electronic databases and 
data managers and the earlier, and therefore more complete, collection of local 
patient ID numbers from London. The greater record linkage of records since 
2000 was probably due to the greater completion of local patient ID numbers on 
reports of new HIV diagnoses by clinicians. 
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The formation of the integrated dataset also resulted in the exclusion of records 
for the majority of patients without ethnicity or risk group reported. These 
individuals were likely to have poorer outcomes causing subsequent population 
summary outcomes to be over/under-estimated but relatively little in magnitude 
due to the relatively small numbers in these groups. The additional exclusion of 
the few remaining individuals with no reported risk group or ethnicity 
disproportionately excluded deaths but this created probably only a marginal 
additional bias. Similarly, there was probably little effect of excluding the small 
number of children infected vertically from subsequent analyses. 
There was also evidence of inclusion bias arising from record linkage due to the 
delay in measuring CD4 cell counts. Individuals diagnosed between 2005 and 
2007 were less likely to be included in the integrated dataset than individuals 
diagnosed between 2000 and 2004. This is likely to be largely due to individuals 
diagnosed in 2007 who had their first CD4 cell count in 2008 or later. 
The inclusion bias introduced due to formation of an integrated dataset is likely 
to be a particular issue for analyses based on linked electronic patient records 
collected through complementary surveillance systems but may similarly affect 
cohort studies based on the integration of data from various sources249;260-262. 
This could be addressed analytically by sampling or weighting to adjust for 
greater representativeness. For example, inverse probability weighting is a 
relatively simple method to proportionally account for missing observations 
according to the number of records missing from each category when the 
population from which the sample comes from, and its breakdown by category, 
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are known. HIV surveillance data may not capture the whole HIV-diagnosed 
population, but are very comprehensive and nationally representative, and 
therefore provide a good opportunity to identify, quantify and account for bias. 
However, complex bootstrapping techniques are required subsequent to the 
inverse probability weighting to calculate confidence intervals. Furthermore, 
inverse probability weighting assumes that individuals are missing at random 
and therefore that individuals included in the analysis have the same 
risks/outcomes as those not included with the same characteristics. A neater 
solution for prospective data would be to minimise the source of this bias by 
integration to create a single HIV surveillance system or extensive follow-up to 
ensure near-complete record linkage. It is important to note that results of 
subsequent analyses may be easier to interpret in light of the systematic 
inclusion bias described above (where set algorithms determine the record 
linkage) than if the records had been linked manually and subjectively. 
5.5.2 Potential bias due to data being right-censored 
These results showed that potential bias due to data being censored had to be 
considered in subsequent analyses. There was evidence of overrepresentation 
of individuals with CD4 cell counts within 91 days of HIV diagnosis, which was 
even more marked with a cut-off of 182 days. This was partly due to the 
formation of the integrated dataset, requiring record linkage to CD4 
Surveillance, which resulted in all individuals included who were diagnosed in 
2007 having CD4 cell counts by the end of 2007.  
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AIDS diagnoses and deaths were more likely to be preceded by a CD4 cell 
count within 365 days if the last CD4 cell count before the event occurred in 
2005 or 2006. Because data were censored at the end of 2007, the proportion 
of individuals with CD4 counts within the previous 365 days of AIDS or death 
was probably overestimated for these years. Furthermore, all individuals who 
had CD4 counts in 2007 and who had died or been diagnosed with AIDS were 
excluded from analyses of time from previous CD4 cell count because these 
events cannot have occurred more than 365 days after the CD4 cell count. This 
would be expected to bias the analysis of the incidence of AIDS and death 
(chapter 7)247. This was also evident in the high rate of permanent LTFU in 
2005 and 2006, which was likely to be an artefact of incomplete follow-up: 
almost 5,000 individuals had their last CD4 cell count in 2005 or 2006 and were 
not known to have died within 365 days but individuals with subsequent CD4 
cell counts reported after the end of 2007 would have been misclassified.  
5.5.3 Potential bias due to early mortality (left-censoring) 
Deaths shortly after HIV diagnosis accounted for a substantial proportion of all 
deaths among those who were not included in the integrated dataset, 
particularly among those diagnosed since 1995. Additionally, individuals who 
died shortly after HIV diagnosis were less likely to be included in the integrated 
dataset than individuals who died more than a month after HIV diagnosis. This 
was probably due to a combination of lack of opportunity to measure CD4 cell 
counts before death and under-reporting of inpatient care to SOPHID. This 
measure of bias is very difficult to ascertain in cohort studies and very difficult to 
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correct for because these individuals are not included in the dataset247. 
Surveillance data provides the advantage of quantifying the inclusion bias and 
demonstrates the importance of maximising the completeness of mortality data 
from national death statistics257;263. 
The low inclusion of records for individuals who had died was likely to result in 
an under-estimation of the incidence of death, particularly because individuals 
who died shortly after HIV diagnosis would contribute little follow-up time. 
However, this was less likely to affect the pattern of incidence between groups. 
5.5.4 Potential bias due to differential loss to follow-up  
5.5.4.1 Permanent LTFU (emigration, under-reported deaths or inability to 
link records) 
Younger individuals were more likely to be permanently LTFU than older 
individuals and also more likely to have only one CD4 cell count. This was also 
the case for Black Africans, in particular, but also other non-white individuals 
compared to white individuals. This may reflect temporary migration to the UK 
of foreign students, business people and unsuccessful asylum seekers264;265. 
Young people are also likely to be more mobile, and more likely to marry, 
resulting in higher apparent LTFU due to the reporting of different patient 
identifiers. Permanent LTFU may also reflect avoidance of healthcare systems 
by migrants (including unsuccessful asylum seekers and undocumented 
migrants) who fear being forcibly relocated, detained or deported265-269. 
Individuals choosing not to remain where they are forcibly relocated and 
subsequent avoidance of healthcare systems may partly explain the higher 
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permanent LTFU among individuals from outside London. Youth256;270-278 and 
race265;272;277;279-281 have been widely found to be associated with LTFU with the 
latter a likely proxy for foreigner/migrant status273;275;276 or eligibility for care274. 
Rates of permanent LTFU were lower for MSM than for heterosexuals and 
particularly high for IDU after controlling for ethnicity and similar differences 
were seen for the odds of having only one CD4 cell count. This may also reflect 
the higher emigration of individuals who were not born in the UK, who may be 
more prevalent among heterosexuals and IDU than among MSM. Many HIV-
infected IDU in the UK were born and infected in southern Europe, many HIV-
infected white heterosexuals were born and infected in Africa whereas many 
HIV-infected white MSM were born and infected in the UK265;282. However, there 
may also be different emigration rates for individuals who were born in the UK 
because MSM may be more likely to stay in the UK due to criminalisation of 
homosexuality in some other countries283. Additionally, the complex lifestyles 
and marginalisation of IDU, due to the illegality of drug use, are also likely to 
account for a substantial degree of permanent LTFU284. MSM may be more 
likely to be reported with consistent identifiers as they may be less mobile, due 
to the attraction of living in areas with a high density of other gay men and the 
concentrated location of these areas, and less likely to change names due to 
marriage than other individuals285. High rates of LTFU among IDU have been 
well documented270;273;276;281;286. However, other studies did not find higher rates 
among heterosexuals than MSM, which may be due to inclusion and adjustment 
for migrant status in those studies273;276. 
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Rates of permanent LTFU were greater for individuals with low CD4 cell counts 
and particularly substantial for those with CD4 cell counts less than 100 
cells/mm3. This may have been due to a combination of under-reported deaths 
and the repatriation of people born outside the UK who didn’t expect to live very 
long. The under-reporting of deaths was also indicated by the relatively high 
rate of permanent LTFU in 1995/6 at a time when the number of deaths among 
HIV-infected individuals in E,W&NI was at a maximum. In contrast, there were 
lower odds of permanent LTFU after an AIDS diagnosis, which may indicate 
that people who had been ill were less likely to emigrate and that there was 
more complete reporting of deaths after an AIDS diagnosis than other deaths 
(reflecting the under-reporting of non-AIDS deaths). Similar results were found 
in other studies of permanent LTFU, which noted the limitations of under-
reported deaths and the potential for the transfer of care to other clinics within 
or outside the country250;256;265;270;273;276. However, the median CD4 cell counts 
prior to permanent LTFU were greater than those prior to temporary LTFU, 
indicating that it was unlikely that permanent LTFU was mostly due to death. 
These findings may indicate bias in the overall estimates of short-term mortality, 
incidence rates of AIDS and death, and rates of change of CD4 cell counts after 
starting ART due to the under-representation of events. If individuals with 
greater permanent LTFU were also more likely to die, develop AIDS or have 
faster CD4 cell count responses to ART, then the overall results of subsequent 
analyses would be under-estimated. Additionally, differential LTFU between 
groups may bias their comparative event rates in subsequent analyses 
particularly due to fewer events rather than reduced follow-up time.  
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The overall incidence rate of permanent LTFU in the integrated dataset was 5.6 
(10,365/185,768) per 100 PYFU and was 4.1 (4,508/108,832) per 100 PYFU 
between 1997 and 2004. This was very similar to the incidence of 3.7 per 100 
PYFU found in a multi-centre study of combined clinical cohort data of 12,304 
patients from mostly European countries and 4.3 per 100 PYFU found in a 
multi-centre study of combined clinical cohort data of 1,756 patients from a 
region in France270;276. These rates were similar, which suggested that the 
limitations of record linkage between national HIV surveillance data were offset 
by the benefits of national coverage to account for transfers between clinics. 
However, the bias introduced by each of these reasons for LTFU may be 
different and there is some evidence that individuals who transfer their care may 
be seeking expert care and therefore over-represented in centres of excellence 
that are often used for cohort studies287. Rates were lower (3 per 100 PYFU) in 
an American cohort study but this was an interval cohort study of enrolled 
patients and therefore these patients were more likely to be attendees most 
engaged with their clinical care249;288;289. Rates were substantially higher (17.2 
per 100 PYFU) in less developed countries despite the similar determining 
factors275;290. Many studies could not provide rates for comparison because 
rates were not measured. Furthermore, factors associated with LTFU were 
often not determined because numbers were relatively small. 
It is important to note that rates of LTFU from clinical cohorts may be much 
higher than in the integrated dataset due to undocumented transfers to care 
elsewhere. In a collaborative study with a large HIV clinic in south-east London, 
we showed that almost two-fifths of patients were permanently LTFU from the 
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clinic but that almost half of these subsequently received care at another clinic 
in the UK (through record linkage to the national SOPHID dataset)265.    
5.5.4.2 Temporary LTFU (non-attendance, under-reporting or inability to link 
records) 
Rates of temporary LTFU decreased with age, which may reflect knowledge of 
the lower risk of progression among young people, as shown by other studies 
275;279;280;291. Temporary LTFU was higher for MSM than for recipients of 
blood/blood products, but lower than for other groups, and particularly high for 
IDU. Similar factors were found to be associated with temporary LTFU in the 
literature279;281;292. Recipients of blood/blood products were likely to be closely 
associated with healthcare as many were haemophiliacs. MSM were likely to 
have high awareness of the need for regular monitoring of their infection 
whereas heterosexual women diagnosed antenatally were likely to have 
frequent check-ups during pregnancy and be associated with healthcare 
through care of their children293. IDU were least likely to prioritise their health 
and have complex lifestyles resulting in irregular attendance with services284. 
Rates of temporary LTFU were high for black individuals and were particularly 
high for black Caribbeans compared to white individuals. This was probably due 
to complex housing, employment, immigration and financial needs, associated 
with deprivation, which often have to be prioritised above long-term healthcare 
needs267;294-297. Stigma and discrimination of HIV infection are also substantial 
among black communities, which can discourage disclosure and complicate 
access to healthcare294;295;297. These factors all form personal/cultural, 
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structural, and financial barriers to care298. Higher rates of LTFU among minority 
ethnic groups have been reported in the literature279-281;286;291;298. 
Rates of temporary LTFU were high at both low and high CD4 cell counts. 
Temporary LTFU at high CD4 counts has been reported previously and may be 
due to the lower risk and less need for regular monitoring275. Other studies that 
did not find an association between CD4 cell counts and temporary LTFU only 
had the power to compare high and low CD4 counts291;298. CD4 cell counts were 
monitored more frequently after low CD4 counts and there were lower rates of 
temporary LTFU after an AIDS diagnosis indicating the close monitoring of 
infections at times of high risk of mortality, consistent with the literature279;291. 
The high rates of temporary LTFU at low CD4 cell counts do not seem to fit with 
these results unless these patients were admitted to hospital for inpatient care 
and the CD4 counts during this time were reported with different patient 
identifiers and therefore not linked to previous records. 
Temporary LTFU was likely to bias overall results from subsequent analyses 
towards over-estimation in contrast to permanent LTFU. This was due to the 
under-estimation of follow-up time but had minimal impact on the number of 
events. This was because deaths could not have occurred during the period of 
temporary LTFU and AIDS diagnoses were unlikely to be missed, unless due to 
non-reporting, because individuals with AIDS were likely to present for 
healthcare and be cared for by an HIV specialist.  
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Comparisons of the overall incidence of temporary LTFU were difficult to make 
with studies reported in the literature. Many studies that considered missed 
appointments or retention in studies compared proportions and did not formally 
calculate PYFU or incidence rates. A study of a prospective cohort, which 
divided the number interviewed in the last 12 months by the number enrolled, 
found retention rates of 79 to 95% in different sites280. However, as other 
studies279;281, this did not separate temporary and permanent LTFU. A study 
that interviewed women about their health service use found that 92% had 
visited an outpatient or emergency department in the last six months286. 
5.5.4.3 Summary of LTFU analyses 
Formation of the integrated dataset from national surveillance data and national 
mortality statistics was believed to have minimised the under-reporting of 
deaths, particularly those that occur at home or in a hospice, which is a 
significant factor for clinic cohorts. However, relatively high rates of permanent 
LTFU after low CD4 cell counts, among IDUs and in 1995/1996 suggest that not 
all HIV surveillance records were linked to their appropriate death reports. 
National follow-up through linkage of records from almost all 
immunology/haematology laboratories minimised the over-estimation of LTFU 
due to transfer between clinics within E,W&NI. However, the inherent 
disadvantage of analysis of LTFU from the integrated dataset was the potential 
for over-estimating rates due to the inability to link patient records over time. 
Yet, there was no plausible reason for changed patient identifiers to be 
associated with CD4 cell counts or a previous AIDS diagnosis, or so closely 
aligned with results from other studies with regard age, risk and ethnicity. 
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Therefore, the differential LTFU found in the integrated dataset, except for 
changes over time, was likely to reflect true LTFU and needed to be considered 
as a source of potential bias in subsequent analyses.  
5.5.5 Potential bias due to the differential inclusion of events: 
differential event rate in Poisson analysis 
5.5.5.1 Time from HIV diagnosis to first CD4 cell count  
The proportion of individuals with a CD4 cell count within 91 days of their HIV 
diagnosis increased significantly over time suggesting that the CD4 Surveillance 
data became more complete, record linkage improved, or that there was a true 
reduction in the time between diagnosis and measurement of CD4 cell counts 
(the particularly high proportion with CD4 cell counts within 91 days of diagnosis 
in 2007 was probably an artefact created by censoring the data at the end of 
2007 (Section 5.4.4.1)). A lower proportion of younger people had a CD4 count 
within 91 days of HIV diagnosis than older people, which may reflect knowledge 
of the greater risk of progression for older people or greater concerns about 
health among older people124;299. MSM were less likely to have CD4 counts 
within 91 days of HIV diagnosis compared to women diagnosed antenally but 
more likely than other heterosexuals and IDU. IDU were least likely to have 
timely CD4 counts reflecting their complex lifestyles resulting in irregular 
attendance with services284. Interestingly, heterosexual women diagnosed 
antenally were less likely than MSM to have CD4 cell counts within 30 days of 
diagnosis suggesting that the greater return for follow-up care within 91 days 
may be partly determined by the antenatal care schedule. The earlier CD4 
counts for MSM than for other heterosexuals may be due to greater knowledge 
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of HIV among MSM and less difficulty in accepting a diagnosis. White 
individuals were more likely to have a CD4 count within 91 days of HIV 
diagnosis compared to black African and black Caribbean individuals, which 
may also relate to awareness of, and stigma associated with, HIV infection as 
well as lower prioritisation of health needs due to other economic 
concerns267;294-297. AIDS at the time of HIV diagnosis was associated with more 
immediate measurement of CD4 cell counts, reflecting the urgent need for 
information to help manage the infection due to the high risk of death124;299. 
Many of these results were consistent with those of other studies. Previous 
publications reported delayed initiation of care associated with calendar time300-
302, age300;303;304, IDU risk167;301;305;306, non-white ethnicity169;304;305;307, and a lack 
of AIDS symptoms or high CD4 cell count308;309. The difference between MSM 
and heterosexuals was not found in the literature but this may be due to lack of 
power. However, studies did find that individuals who were not aware of their 
HIV risk before testing or who had no previous HIV test experienced delayed 
initiation of care167;306. Additionally, qualitative studies found that women’s 
psychological responses to learning of their diagnosis were most strongly 
associated with delayed care seeking, while for MSM, this reflected a strong 
reluctance to begin ART310;311. Interestingly, women diagnosed antenatally were 
reported to have long delays before entry into care in two studies in contrast to 
results from the integrated dataset, which may reflect different pathways into, 
and eligibility for, care between the Americas and the UK312;313. One London 
study found similar proportions of black African and white individuals received 
HIV care within one month of HIV diagnosis but did not control for other 
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factors171. In addition to the factors investigated from the integrated dataset, 
socioeconomic factors, such as unemployment306 and lack of health 
insurance169;302;309, and healthcare factors, such as lack of personal post-test 
discussion or counselling167;170;306, anonymous and first-time testing314 and 
diagnosis at an unfamiliar testing site169;170;305 were associated with delayed 
access to care. 
Overall comparisons with time to first CD4 cell count or initiation of HIV care 
were hampered by the variety of definitions used, the study characteristics and 
changes over calendar time. Delayed entry to HIV care was reported for 17-
58% of individuals between 1993 and 2003 and largely from the United States, 
where pathways into, and eligibility for, care may differ significantly from the 
UK167;169;302;303;305;306;313;314. However, these studies suggest that the evidence of 
delays between HIV diagnosis and first CD4 cell count demonstrated from 
analysis of the integrated dataset were true delays of entry into HIV care rather 
than artefacts of linked HIV surveillance data. 
Analysis of time from HIV diagnosis to first CD4 cell count quantified the extent 
to which the subsequent analysis of late diagnosis was biased by exclusion of 
records that did not have a CD4 count within a defined time. Over one in seven 
individuals diagnosed since 1995 did not have a CD4 count within the following 
91 days, and this would have resulted in inclusion bias if the CD4 counts at the 
time of HIV diagnosis were different for these individuals than those included in 
the analysis. Extending the cut-off time from HIV diagnosis would increase the 
proportion with CD4 counts included in the analysis but CD4 counts further from 
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the date of HIV diagnosis would be less representative of the true CD4 cell 
count at the time of HIV diagnosis and potentially subject to treatment or other 
effects. The overall estimate of late diagnosis would be affected by the 
differential inclusion of groups of individuals due to the different proportions with 
CD4 cell counts within the cut-off period from HIV diagnosis. For example, 
individuals with AIDS at HIV diagnosis would be over-represented and if their 
CD4 counts at the time of HIV diagnosis were lower than for other individuals, 
the overall estimate of late diagnosis would be over-estimated. Additionally, 
differential inclusion could result in biased comparisons between groups if those 
included were not representative of all individuals in the group.  
5.5.5.2 Time from CD4 cell counts to AIDS and death 
The proportion of individuals who had their last CD4 cell count measurement 
within 365 days of death was higher for those with CD4 counts less than 50 
cells/mm3 and for those with a previous AIDS diagnosis. This was likely to 
reflect the increased risk of death at these low CD4 counts and after AIDS124;299 
but also may reflect the increased frequency of CD4 count monitoring at low 
CD4 cell counts and after AIDS (Section 5.4.3.2). A similar effect was observed 
for CD4 cell counts within 365 days of AIDS for those with CD4 counts less than 
150 cells/mm3 for similar reasons. There was some evidence of a lower 
proportion with CD4 count within 365 days of death among younger people and 
strong evidence with time to first AIDS diagnosis, which also was likely to be 
due to slower progression of infection among younger individuals124;299. Only 
IDU were less likely than MSM to have a CD4 cell count within 365 days of 
AIDS or death, which probably reflects their less frequent attendance for health 
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services because IDU have higher rates of AIDS and death124;299. Individuals 
last CD4 cell counts were less likely to be within 365 days of death if they were 
measured in 1995/6. If this was due to no CD4 count being measured during 
that time (rather than unreported or unlinked data), this may reflect less benefit 
derived from monitoring levels of immunosuppression in the pre-HAART era 
when fewer treatment options were available to patients with low CD4 counts. 
There was no significant effect of ethnicity on the odds of having a CD4 count 
within 365 days of AIDS or death despite some ethnic groups having CD4 
counts monitored less frequently and higher rates of temporary and permanent 
LTFU than others. 
It is important to note that less than a third of individuals with AIDS diagnoses 
within three months of HIV diagnosis had a previous CD4 cell count compared 
to nine-tenths where AIDS was diagnosed more than three months after HIV 
diagnosis. Exclusion of follow-up time before the first CD4 cell count in analysis 
of incidence estimates was therefore a likely source of bias. 
Analysis of the time between CD4 cell counts and AIDS and death, together 
with the analyses of temporary and permanent LTFU, provided some measure 
of the extent to which the analysis of incidence rates of AIDS and death were 
biased. One in ten deaths and almost one in six first AIDS diagnoses occurred 
more than 365 days after the last CD4 count and were therefore considered to 
have occurred during a period of LTFU. These events and time could be 
included in the analysis by extending the cut-off but the CD4 cell count, and 
other time-updated variables, would be increasingly less representative of the 
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true level of immunosuppression at the time of death. Therefore right-censored 
follow-up time was necessary to limit misclassification bias247. However, 
excluding these periods of LTFU was likely to bias the incidence of events 
towards under-estimation because LTFU was probably due to death in some 
cases and was higher at low CD4 cell counts and after an AIDS diagnosis.  
Further work could provide greater insight to the relationships between CD4 cell 
count monitoring and deaths by investigating causes of death in the HARS data 
but would have to consider the particular biases in death reports (Section 2.2.8). 
5.5.6 Potential bias due to the differential monitoring CD4 cell 
counts: differential contribution to analysis of rates of 
change of CD4 cell counts after starting ART 
CD4 cell counts were monitored more frequently at lower CD4 cell counts and 
in individuals with a previous AIDS diagnosis, particularly at the time of the 
AIDS diagnosis. Individuals with a low first CD4 cell count were also more likely 
to have more than one measurement. These results reflect the need for 
information about the level of immunosuppression, which is required to manage 
HIV infection at times when there is a high risk of death124;299;315. For individuals 
with a reported date of starting ART, there was also an increased frequency of 
CD4 cell count measurements at the time of starting ART as recommended by 
guidelines123. More intensive monitoring is recommended to confirm the need to 
start ART and to determine the immunological response233. In particular, 
national guidelines recommend CD4 measurement by GUM/HIV specialists, 
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and not necessarily at the time of HIV diagnosis, which may lead to a variety of 
practice and delays for some individuals who need prompt ART105;316. 
There were differences in the frequency, number and duration of monitoring of 
CD4 counts between groups and over time but it is likely that some of these 
effects were confounded and would not demonstrate statistical significance in 
multivariable analysis. A key potential confounder of these effects is calendar 
time, because CD4 counts were measured less frequently since the mid-1990s. 
This may reflect real trends in monitoring due to the reduced risk of progression 
with effective ART but would affect the risk groups and ethnic groups differently. 
Differences in the frequency and number of CD4 counts may introduce bias to 
analyses of rates of change of CD4 counts after starting ART248.  
There were few patients with only a few CD4 cell counts over a long period of 
time and few with many measurements over a short period. The former may be 
due to inability to link all CD4 counts for an individual (Chapters 3 and 4), under-
reporting of CD4 counts (Section 2.3.2), right censoring (Section 5.5.2), or long-
term LTFU (Section 5.5.4). Right-censoring is particularly likely to explain the 
high proportion of patients with only one CD4 count that were diagnosed 
between 2005 and 2007 because an increasing proportion of these individuals 
had limited time to return for subsequent CD4 measurements. Death in the 
same or subsequent year as the CD4 count was taken into account in the 
analysis but other deaths and unreported deaths were not. Long-term LTFU 
(either a loss to clinical follow-up or a limited ability to link records over time) 
was likely to account for the majority of the remaining patients with only one 
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CD4 count because this was associated with younger age, residence in 
London, heterosexual risk, non-white ethnicity and CD4 counts greater than 350 
cells per mm3. These factors in turn, are often associated with mobility, 
particularly international migrancy and dissociation from healthcare services 
due to uncertain legal migration status. These characteristics are important to 
identify because subsequent analyses may be biased by their under-
representation. For example, a CD4 count close to diagnosis is required for 
analysis of late diagnosis, CD4  counts are used as the basis for analysis time 
to determine the incidence of AIDS and death, and individuals with single CD4 
counts will contribute little to the analysis of CD4 count changes after initiation 
of ART. 
Patients with many CD4 measurements over a short period may be due to 
inappropriate deduplication of CD4 Surveillance records or particular 
needs/demands for frequent CD4 count monitoring (such as virological failure or 
adherence monitoring). Although these reasons could not be differentiated in 
these analyses, the numbers were small enough to indicate that these records 
were unlikely to substantially bias the results of subsequent analyses. 
Measurement of CD4 cell counts was more frequent in the period shortly after 
HIV diagnosis, irrespective of the CD4 cell count category, which probably 
reflects uncertainty in a single measurement and the clinical need for 
confirmation with a second sample243;317. This effect was likely have an impact 
on determination of baseline CD4 cell counts at the time of HIV diagnosis and 
was therefore taken into account in their definition (Section 6.3.1). 
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Guidelines before 2008 did not state how often CD4 cell counts should be 
monitored or how often patients should attend as there was little evidence for 
the historical practice of three-monthly follow-up258. Modelling suggests that 
monitoring should vary according to the status of infection, which may reflect 
actual practice although local policies vary318. These results could be used to 
inform guidelines for best practice after validation for cost-effectiveness. 
Association between groups of individuals or time-updated characteristics with 
an increased frequency or number of CD4 cell counts could result in over-
representation in analyses of rates of change of CD4 counts after starting ART. 
If these groups or characteristics were also associated with rates of change of 
CD4 counts after starting ART then this would bias those results. These 
associations were therefore considered in more detail in chapter 9 once dates 
of starting treatment had been considered. 
5.6 Conclusion 
Surveillance data for public health action may not be as accurate as clinical 
data or data collected and validated for research studies. The greater number of 
individuals included limits the manual consistency checking of integrated data at 
the individual level that is possible for smaller datasets, and therefore increases 
the risk of errors. These errors potentially cause outliers in analyses such as 
very short or long times between CD4 cell counts and large fluctuations 
between CD4 cell counts. The collection of data via multiple sources and the 
need for subsequent centralised record linkage, require centralised resources 
and limit the completeness of integrated datasets. However, this approach 
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minimises the resources required at local level and some errors can be 
removed with little concern for reducing the high power of statistical analyses 
due to the large numbers involved. Furthermore, triangulation allows direct 
quantification of inclusion bias as the disaggregate characteristics of the 
denominator are known. Surveillance that collates data already collected at a 
local level is therefore cost-effective319, has full national coverage and therefore 
large numbers (allowing monitoring of rare events and minority groups), and is 
not time-limited (therefore timely, continually updated, and relevant for public 
health action). Bias is minimised because UK HIV surveillance data are 
collected prospectively and therefore cannot be biased by knowledge of 
outcomes. However, it is important to note that many statistical tests are 
performed on these data, both within this thesis and within wider surveillance 
work, and therefore, some significant associations that are found could be due 
to chance. 
Drawbacks of the integrated dataset were that the limited dataset may not have 
included other confounding factors and that changes in risk factors over time 
were not recorded. However, risk factors analysed for outcomes such as late 
diagnosis, the incidence of AIDS and death and rates of change of CD4 cell 
counts after starting ART could also be considered as proxy measures for other 
factors, such as socioeconomic status, HIV awareness, and adherence to 
therapy. However, the risk factors of risk group and ethnicity are of practical use 
for targeting more qualitative research about underlying reasons and for 
targeting prevention efforts. Misclassification bias due to errors in the 
measurement of risk factors, and particularly CD4 cell count measurements, 
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would be expected to reduce differences in the results and may have affected 
these analyses of surveillance data to a greater extent than clinical cohorts 
because of unspecific record linkage. 
The analyses of temporary and permanent LTFU show that surveillance data 
can be used to create a pseudo-cohort with very large numbers of patients 
(almost 46,000) and PYFU (over 220,000). The use of CD4 cell counts to define 
person-years ensures that patients were under follow-up, which may otherwise 
be a limitation of using surveillance data. The CD4 Surveillance procedures 
require annual attempts to link together all CD4 counts for the same patient and 
account for transfers between clinics even if the CD4 cell counts were reported 
from different laboratories. However, imperfect record linkage within and 
between surveillance systems due to changed patient identifiers can result in 
gaps in follow-up. While considerable effort is made to minimise the linkage of 
records from different people and the inaccurate recording of information, 
surveillance data cannot be quality assessed to the same extent as data from 
local cohort studies. However, local cohort studies need to censor follow-up 
when transfers are made to other clinics or estimates of LTFU may substantially 
reflect transfer rates. This would be difficult in the UK due to the open access 
policy of HIV services. Therefore estimates of LTFU from national surveillance 
may be less biased by transfers than local cohort studies but more subject to 
bias from incomplete record linkage. Permanent LTFU from the entire UK 
cohort could only be explained by emigration, unreported death or death 
reported with different identifiers, continued care in the UK that was not reported 
or reported with different identifiers or complete dissociation from HIV care. 
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Unreported deaths were believed to be minimal due to record linkage to death 
notifications and under-reported continued care in the UK was also believed to 
be minimal due to the near complete coverage of surveillance systems. 
Substantial effort was made to maximise reliable record linkage and permanent 
dissociation from HIV care in the UK is unlikely for long periods of time because 
of the free availability of treatment, the open access to anonymous and 
confidential care, and the progressive nature of HIV infection. In contrast, the 
large proportion of individuals diagnosed with HIV infection in the UK who were 
born abroad supports the conclusion that the majority of permanent LTFU was 
due to emigration. 
These analyses have shown that subsequent analyses must consider left and 
right censoring. Follow-up should start from the time of HIV diagnosis rather 
than at the time of the first CD4 cell count to maximise the inclusion of the 
numerous events that occur soon after diagnosis. However, analyses of the 
integrated dataset could not include individuals, follow-up time or events where 
LTFU occurred before a CD4 cell count was measured or where no CD4 cell 
counts for an individual were reported. Consideration of right censoring at the 
end of the study period and during periods of LTFU was important because 
LTFU did not occur randomly. LTFU was associated with factors that were 
independently associated with progression and therefore censoring was 
informative. Methodological strategies could therefore bias follow-up time and 
event rates. In particular, individuals diagnosed in 2007 should be excluded 
from subsequent cohort analyses due to insufficient follow-up time before 
censoring at the end of December 2007. 
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The results of these analyses indicate that 91 days between HIV diagnosis and 
first CD4 cell count could be an appropriate cut-off for the definition of CD4 cell 
counts at the time of HIV diagnosis. Additionally, a cut-off of 365 days could be 
appropriate to capture most variation in follow-up and therefore to minimise bias 
due to excluding AIDS or death events more than 365 days after a CD4 cell 
count measurement. These values were therefore used in subsequent analyses 
with sensitivity analyses to determine the influence of varying the methodology. 
The understanding of the data gained through these exploratory investigations 
would be invaluable for the interpretation of subsequent analyses. 
 270 
 
Chapter 6. Late HIV diagnosis and consequent short-term mortality 
6.1 Introduction 
The estimated prevalence of HIV infection and numbers of new HIV diagnoses 
in the UK increased between 1998 and 2007 but a substantial number and 
proportion of HIV-infected individuals remained undiagnosed223;282 and many 
individuals were diagnosed at a late stage of infection80;300;320-326. Prior to 
diagnosis, individuals cannot receive appropriate care, inform their sexual 
partners or be guided in safer sexual behaviour in knowledge of their status327-
329. Individuals who remain unaware of their HIV status for a long time and are 
diagnosed late lose the opportunity to start ART appropriately. Late initiation of 
ART has been shown to be associated with increased morbidity and 
mortality124;125;330. Delays in diagnosis also reflect lost opportunities to reduce: i) 
HIV transmission, ii) the risk of death between diagnosis and initiation of 
HAART, and iii) costs of care331;332. This represented a continuing challenge for 
HIV testing promotion and policy-making as highlighted in the 2004 annual 
report of the Chief Medical Officer for England in the section “No time to wait: 
The importance of early diagnosis of HIV” 333. The primary aim of this chapter 
was to use the integrated dataset to investigate late diagnosis and consequent 
mortality. Largely due to the work contributing to this thesis, late diagnosis has 
since been used as a measure of the effect of the Department of Health’s 
National Strategy for Sexual Health and HIV for England, which aimed to 
reduce the number of undiagnosed HIV infections in the population and to 
reduce HIV transmission by prioritising HIV testing111;241.  
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CD4 cell counts at the time of HIV diagnosis provide an indication of time from 
infection and of the risk of progression unaffected by ART32;124;299;334. The time 
taken from infection to diagnosis has implications for HIV prevention efforts and 
HIV testing strategies, and the individual and population risks of AIDS and 
death are crucial for clinical decision-making. 
Numerous definitions have been used to define late HIV diagnosis in the 
literature and have generally been based either on CD4 cell counts or a clinical 
diagnosis of AIDS at the time of HIV diagnosis335-342. Low CD4 counts or AIDS 
generally reflect a long time from infection due to the slow rate of progression of 
HIV-related immunosuppression (Section 1.3.1). An uncommon exception is 
that individuals can experience substantial immunosuppression and also AIDS-
defining illnesses shortly after infection340;343.  
Studies that have considered first AIDS diagnoses at the time of HIV diagnosis, 
as a proportion of all first AIDS diagnoses, do provide an indication of late HIV 
diagnosis because this proportion would be low if all infections were diagnosed 
promptly, when there is a low risk of AIDS336;344-349. These studies have been 
facilitated by the availability of surveillance data on AIDS diagnoses185;347-349. 
However, the denominator is also dependent on the availability of effective ART 
and prophylaxis for opportunistic infections. Effective prevention of AIDS among 
previously diagnosed individuals will decrease the denominator and increase 
the proportion of AIDS diagnosed at the time of HIV diagnosis irrespective of 
the time between infection and HIV diagnosis. This limits the implications that 
can be drawn from comparisons between countries and over time. 
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Additionally, studies that have considered AIDS diagnoses that occur around 
the time of an HIV diagnosis, as a proportion of all HIV diagnoses, also provide 
an indication of late HIV diagnosis168;350-354. Results from these studies are not 
affected by treatment or prophylaxis. However, the numerator is unlikely to be 
comparable between countries and over time because the background rates of 
AIDS-defining illnesses can vary between populations and over time and can 
occur at different levels of immunosuppression355-359. 
In contrast, low CD4 cell counts at the time of HIV diagnosis are not affected by 
treatment or prophylaxis and are not affected by varying AIDS incidence. The 
risk of AIDS or death at various CD4 counts is of high importance to the patient 
and physician and largely determines the clinical management of infection. 
Since the widespread availability of combination ART in 1996, CD4 cell counts 
have been used as the most reliable predictor of the short-term risk of AIDS or 
death to determine the need for ART (based on results from cohort studies) 
124;125;299;360. Studies have shown that there is a low short-term risk of 
progression to AIDS for untreated individuals with CD4 counts above 200 
cells/mm3 although viral load and age independently increase that risk299. 
Patients with CD4 counts below 200 cells/mm3 when starting HAART have a 
substantially higher risk of progression to AIDS and death124;361. Therefore, 
British treatment guidelines between 1997 and 2007 have recommended that all 
individuals initiate HAART before CD4 counts fall below 200 cells/mm3 but that 
treatment is deferred for most until counts are below 350 cells/mm3 129-135;362.  
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The ART Cohort Collaboration, which includes 13 cohort studies from Europe 
and North America, showed that after starting HAART the rate of progression to 
AIDS or death fell markedly, with most of the reduction in the first six months of 
therapy124. It is important, therefore, that individuals have the optimal chance of 
surviving the first six months of HAART.  
Short-term mortality quantifies the implications of late diagnosis by considering 
it as a risk factor for death within a year of diagnosis. It is possible that late 
diagnosis has a long-lasting effect on survival but short-term survival requires 
shorter follow-up and is therefore timelier and less biased by loss to follow-up. 
Time of infection cannot be reliably estimated at the individual level from CD4 
cell counts at the time of HIV diagnosis due to the wide variability in rates of 
progression but can provide an indication of the duration of infection at the 
population level363.  
Studies have shown that in the UK, heterosexuals have generally been 
diagnosed later than MSM, and that black Africans have been diagnosed later 
than white individuals164;320. However, these factors have not been considered 
independently. There has been no published evidence of earlier diagnosis 
among HIV infected individuals in the UK over time. Short-term mortality post-
HIV diagnosis had not been previously reported. 
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6.2 Aims 
a) To use the integrated dataset to explore national trends in the proportions of 
adults diagnosed late with HIV infection between 1995 and 2007 and factors 
associated with being diagnosed late using an appropriate and generalisable 
definition. 
b) To use the integrated dataset to determine national trends in the short-term 
mortality (death within the year after HIV diagnosis) of adults newly 
diagnosed with HIV infection between 1995 and 2007, and to determine the 
impact of late diagnosis and other risk factors on short-term mortality. 
c) To use the integrated dataset to quantify late diagnosis and consequent 
short-term mortality among individuals heterosexually infected with HIV and 
diagnosed between 2000 and 2007. To identify risk factors for late diagnosis 
and short-term mortality among these heterosexuals including additional HIV 
surveillance information, such as country of birth, which was collected and 
followed-up for heterosexuals diagnosed in England, Wales and Northern 
Ireland (Section 2.2.9) since 2000.   
d) To use the integrated dataset to estimate the short-term mortality that could 
be prevented if all adults, except those recently arrived in the UK with low 
CD4 cell counts, were diagnosed promptly. 
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6.3 Methods 
6.3.1 Data preparation for analysis of late HIV diagnosis 
The main study population comprised all adults (aged 15 years or older) 
reported as newly diagnosed with HIV infection in England, Wales and Northern 
Ireland in the integrated dataset between January 1995 and December 2007. 
Late diagnosis was defined by CD4 cell counts and the analysis was based 
upon the subset of the population who had a reported CD4 cell count 
measurement in the 91 days following the date of HIV diagnosis, subject to 
sensitivity analysis. This cut-off was chosen, based on previous analyses 
(Sections 5.4.4.1 and 5.5.5.1), to provide the least-biased estimates of late 
diagnosis by maximising the number of patients included in the analysis and 
minimising the possibility that HAART had affected the CD4 cell counts 
analysed124;364. The CD4 cell count closest to the date of HIV diagnosis was 
used in the analysis. Sensitivity analysis also considered definitions using the 
first two CD4 cell counts to match recommendations to account for 
measurement variation233. Individuals with CD4 cell counts less than 200 
cells/mm3 within 91 days of the date of HIV diagnosis were considered late 
diagnosed.  
Firstly, CD4 cell counts at the time of HIV diagnosis for individuals reported to 
have previously received care were compared to those of individuals who had 
no evidence of previous care at the time of HIV diagnosis. Based on these 
results, these records were excluded from further analysis. 
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Secondly, analyses were carried out to determine whether a significant 
proportion of individuals with CD4 cell counts less than 200 cells/mm3 could be 
misclassified as diagnosed late due to seroconversion343. Seroconverters were 
considered to be individuals diagnosed with seroconversion illness or evidence 
of a negative HIV test within the year prior to HIV diagnosis. Seroconverters 
with low CD4 counts who were fast progressors could be considered to be 
diagnosed late in terms of their risk of mortality but not in terms of preventative 
mortality. Furthermore, fast progressors could not be reliably distinguished from 
individuals who experienced temporary immunosuppression at seroconversion. 
Therefore seroconverters (Section 6.4.1) were excluded from further analysis. 
Risk factors considered in the analysis of late diagnosis included the calendar 
year of HIV diagnosis in the UK (grouped into two-year periods except for 2007, 
which was considered separately because these data may have been 
significantly affected by inclusion bias – Sections 5.4.1 and 5.5.1), age group, 
geographic region of HIV diagnosis, risk group and ethnic group.  
Sensitivity analysis involved: a) increasing the CD4 cell count cut-off for the 
definition of late diagnosis to 350 cells/mm3; b) defining late diagnosis by either 
AIDS within three months of an HIV diagnosis or CD4 cell counts less than 200 
cells/mm3 within 91 days; c) defining late diagnosis as either both, the mean of, 
or either of, the first two CD4 cell count measurements (first within 91 days of 
HIV diagnosis and second within 91 days of the first) being less than 200 
cells/mm3; d) using CD4 cell counts within either 30 days, 60 days or 182 days 
of the HIV diagnosis. 
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The sub-analysis of late diagnosis among HIV-infected heterosexuals analysed 
the first CD4 count within 91 days of HIV diagnosis between January 2000 and 
December 2007. The additional factor considered as a possible determinant of 
late diagnosis was a combined factor including more detailed information about 
the risk group collected through follow-up. This information was hierarchically 
combined as follows: probable infection from a high-risk partner (MSM, IDU or 
recipient of blood/blood products), probable infection abroad (by world region of 
infection), and, for those probably infected in the UK, probable transmission 
from someone infected inside or outside the UK (Appendix A.5).  
6.3.2 Data preparation for analysis of short-term and preventable 
mortality 
Short-term mortality was defined as death from any cause within a year of the 
date of HIV diagnosis. In this analysis, the year of HIV diagnosis was replaced 
by the period of HIV diagnosis, which was categorised according to the 
availability of ART and its effectiveness at reducing mortality 365. The pre-
HAART era was considered to be 1995 only, the introduction of protease 
inhibitors and availability of effective combination therapy defined the early-
HAART era as 1996 and 1997, the availability of non-nucleoside reverse 
transcriptase inhibitors (NNRTIs) and improved use of combination therapy 
defined the mid-HAART era as 1998 to 2002 inclusive, whereas the introduction 
of other drug classes and wider choices for combination therapy defined the 
late-HAART era as 2003-2007. Sensitivity analyses were carried out by defining 
short-term mortality using different cut-off times from HIV diagnosis to death: 
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three months; six months and 24 months. Sensitivity analyses were also carried 
out using multiple categorisations of CD4 counts, the logarithm of CD4 counts, 
late diagnosis defined by CD4 counts less than 350 cells/mm3, and late 
diagnosis defined by CD4 counts less than 200 cells/mm3 or AIDS at diagnosis. 
Preventable mortality was estimated by building simple scenario models based 
on proportions recently arrived in the UK, proportions diagnosed late, and the 
fraction of observed deaths within a year of diagnosis. Preventable deaths were 
assumed to be those that occurred among individuals diagnosed late who had 
the opportunity for earlier diagnosis as they had not recently arrived in the UK. It 
was assumed that individuals with a CD4 cell count measurement within 91 
days of HIV diagnosis were representative of all individuals diagnosed. It was 
also assumed that the mortality rate could be reduced to that among individuals 
diagnosed promptly. The analysis was repeated assuming that heterosexuals 
without a reported country of birth or year of arrival were in the UK at least two 
years prior to HIV diagnosis. 
6.3.3 Statistical analysis 
The definition of a binary outcome permitted the use of multivariable logistic 
regression to determine adjusted odds ratios (AOR) and 95% confidence 
intervals (CI). 
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6.4 Results 
6.4.1 CD4 cell counts for all adults newly diagnosed with HIV 
There were 42,342 individuals newly diagnosed with HIV infection between 
1995 and 2007 of whom 36,295 (85.7%) had CD4 cell counts measured within 
91 days of their HIV diagnosis. The proportion of the latter diagnosed with CD4 
cell counts less than 200 cells/mm3 was 33.9% (12,291/36,295). 
Just over one in nine individuals (12.0% [5,083/42,342]) had evidence of 
previous care of whom 22.6% (1,150) were reported to have started ART before 
their date of new HIV diagnosis. Most individuals (85.5% [4,344]) with evidence 
of previous care had CD4 cell counts within 91 days of their new HIV diagnosis 
date, of which 25.8% (1,120/4,344) were less than 200 cells/mm3 compared to 
35.0% (11,171/31,951) for those without evidence of previous care.  
There were 2,567 individuals with evidence of recent infection (excluding those 
with previous care) of whom 87.9% (2,256) had CD4 counts measured within 91 
days of their HIV diagnosis. Fewer (8.6% [195/2,256]) of these individuals had 
first CD4 cell counts less than 200 cells/mm3 than individuals without evidence 
of recent infection or previous care (37.0% [10,976/29,695]) (p<0.01).  
6.4.2 Late diagnosis of adults newly diagnosed with HIV without 
evidence of recent infection or previous care 
There were 34,692 adults in the integrated dataset without evidence of recent 
infection or previous care who were diagnosed between 1995 and 2007. 
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Overall, 85.6% (29,695) of individuals had CD4 cell counts within 91 days of 
their HIV diagnosis, increasing from 61.7% (810) in 1995 to 97% (2,878) in 
2007. CD4 cell counts reported to CD4 Surveillance were distributed similarly to 
those reported to HARS (Figure 6.1). The overall proportion diagnosed late, 
with CD4 counts less than 200 cells/mm3 was 37.0% (10,976). The median CD4 
count of those diagnosed late was 76 cells/mm3 (IQR 27, 135) compared to 410 
cells/mm3 (IQR 300, 566) for those not diagnosed late. The associations 
between late diagnosis and date of HIV diagnosis and between late diagnosis 
and age at HIV diagnosis were not linear and not easily reflected by simple 
transformations (Figures 6.2, 6.3). Therefore date of HIV diagnosis and age 
were categorised for subsequent analyses.  
Figure 6.1. Distribution of CD4 cell counts within 91 days of HIV diagnosis 
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Figure 6.2. Percentage of individuals diagnosed late by year of HIV diagnosis 
 
Figure 6.3. Percentage of individuals diagnosed late by age at HIV diagnosis 
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The overall percentage diagnosed with CD4 cell counts less than 200 cells/mm3 
(within 91 days of HIV diagnosis) declined from 40.3% (1,292/3,203) in 
1999/2000 to 32.6% (938/2,878) in 2007 (Table 6.1). This decline was 
statistically significant and continued throughout 1995/6 to 2007. The proportion 
of individuals who were diagnosed late increased with increasing age, from 
17.6% (593/3,362; AOR 0.32, 95% CI 0.28, 0.35) among individuals aged 15-25 
years to 54.5% (675/1,239; AOR 1.87, 95% CI 1.65, 2.13) among individuals 
aged older than 54 years (compared to individuals aged 34-39 years). 
Individuals diagnosed outside London were marginally more likely to be 
diagnosed late (37.4% [5,177/13,827] compared to 36.5% [5,799/15,868]; AOR 
1.07, 95% CI 1.02, 1.13). In comparison to MSM (28.0% [3,121/11,142]), all 
groups were more likely to be diagnosed late except heterosexual women 
diagnosed antenatally (22.0% [447/2,034]; AOR 0.80, 95% CI 0.70, 0.91). A 
particularly high proportion of recipients of blood/blood products were 
diagnosed late (59.1% [81/137]; AOR 2.54, 95% CI 1.78, 3.63 in comparison to 
MSM). All other ethnic groups were more likely to be diagnosed late than white 
individuals (although the AOR for Indian/Pakistani/Bangladeshi individuals was 
only marginally significant statistically). 
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 Table 6.1. Proportion diagnosed late and odds ratios for late diagnosis – adults 
in the integrated dataset with CD4 counts within 91 days of their HIV diagnosis 
 
Number of patients   
with CD4 cell counts    
at HIV diagnosis   
n    (% of all) 
Percentage of 
patients diagnosed 
late (CD4<200 cells    
per mm
3
) 
%   (n) 
Multivariable adjusted 
odds ratio for late 
diagnosis        
(95% confidence interval) 
       
    Period of HIV diagnosis    
1995-1996 1,701  (6) 38.2  (650) 1.14 (1.01, 1.30) 
1997-1998 2,213  (7) 40.0  (886) 1.08 (0.97, 1.22) 
1999-2000 3,203  (11) 40.3  (1,292) - 
2001-2002 5,466  (18) 37.9  (2,073) 0.82 (0.75, 0.90) 
2003-2004 7,505  (25) 35.7  (2,683) 0.72 (0.66, 0.79) 
2005-2006 6,729  (23) 36.5  (2,454) 0.74 (0.67, 0.81) 
2007 2,878  (10) 32.6  (938) 0.65 (0.58, 0.72) 
    
   Age group at HIV diagnosis    
15-25 3,362  (11) 17.6  (593) 0.32 (0.28, 0.35) 
25-29 5,798  (20) 27.5  (1,594) 0.53 (0.49, 0.57) 
30-34 6,959  (23) 36.8  (2,559) 0.81 (0.75, 0.87) 
35-39 5,780  (19) 41.4  (2,392) - 
40-44 3,435  (12) 46.1  (1,583) 1.25 (1.15, 1.37) 
45-49 1,975  (7) 50.3  (994) 1.51 (1.36, 1.68) 
50-54 1,147  (4) 51.1  (586) 1.60 (1.40, 1.82) 
>54 1,239  (4) 54.5  (675) 1.87 (1.65, 2.13) 
    
   Region of diagnosis    
Outside London 13,827  (47) 37.4  (5,177) 1.07 (1.02, 1.13) 
London 15,868  (53) 36.5  (5,799) - 
    
   Risk group    
MSM 11,142  (38) 28.0  (3,121) - 
Heterosexual men 6,487  (22) 48.9  (3,174) 1.77 (1.62, 1.92) 
Heterosexual women 9,333  (31) 42.3  (3,952) 1.57 (1.44, 1.71) 
Heterosexual women 
(diagnosed antenatally) 
2,034  (7) 22.0  (447) 0.80 (0.70, 0.91) 
IDU 562  (2) 35.8  (201) 1.48 (1.23, 1.77) 
Recipients of blood products 137  (0.5) 59.1  (81) 2.54 (1.78, 3.63) 
    
   Ethnicity    
White  12,734  (43) 30.2  (3,847) - 
Black African 13,319  (45) 43.4  (5,787) 1.63 (1.50, 1.77) 
Black Caribbean 1,115  (4) 36.1  (402) 1.23 (1.07, 1.41) 
Black Other 614  (2) 39.7  (244) 1.55 (1.30, 1.86) 
Indian\Pakistani\Bangladeshi 431  (1) 38.5  (166) 1.23 (0.99, 1.51) 
Other Asian 462  (2) 43.1  (199) 2.06 (1.69, 2.51) 
Other/mixed 1,020  (3) 32.5  (331) 1.22 (1.05, 1.41) 
    
    Total 29,695  (100) 37.0  (10,976) - 
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6.4.3 Sensitivity analyses for late diagnosis 
6.4.3.1 Analysis of various definitions of late diagnosis 
Increasing the CD4 count cut-off for the definition of late diagnosis to 350 
cells/mm3 increased the proportion considered to be diagnosed late to 60.0% 
(17,819/26,695) (Table 6.2). However, there was little change in the adjusted 
odds ratios for late diagnosis between groups in comparison to the previous 
analysis. The only marked difference between the analyses was that 
heterosexual women diagnosed antenatally were not significantly less likely to 
be diagnosed late than MSM using the cut-off of 350 cells/mm3.  
Defining late diagnosis as either AIDS within three months of an HIV diagnosis 
or CD4 counts less than 200 cells/mm3 within 91 days increased the proportion 
considered to be diagnosed late to 39.5% (11,715/26,695) (Table 6.2). There 
were 737 individuals diagnosed with AIDS at CD4 counts greater than 199 
cells/mm3, with a median CD4 count of 300 (IQR 234, 418) cells/mm3. There 
were no marked differences between the adjusted odds ratios between groups 
in this analysis compared to that without the inclusion of AIDS diagnoses. 
Fewer than two-thirds (63.4% [18,835/29,695]) of individuals with their first CD4 
cell counts within 91 days of HIV diagnosis had a second measurement within 
91 days of the first (Table 6.3). The percentage of individuals considered to be 
diagnosed late increased from 32.9% (6,206), to 39.0% (7,338) and to 45.2% 
(8,521) as the definition was changed from both, the mean of, or either of, these 
measurements being less than 200 cells/mm3. Although the percentage 
diagnosed late varied as the definition changed, the adjusted odds ratios of the 
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determining factors varied relatively little. However, definition of late diagnosis 
as both or the mean of the first two CD4 cell count less than 200 cells/mm3 
reduced the effects of the region and Indian\Pakistani\Bangladeshi ethnicity 
such that they were no longer statistically significant (Table 6.3). 
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 Table 6.2. Proportion diagnosed late and odds ratios for late diagnosis using 
different definitions of late HIV diagnosis – individuals with CD4 cell counts 
within 91 days of their HIV diagnosis 
 
Late diagnosis defined as  CD4 
less than 350 cells/mm
3
 
Late diagnosis defined as  CD4 
less than 200 cells/mm
3
  or AIDS 
diagnosis 
Percentage of 
patients 
diagnosed late 
(CD4<200 cells    
per mm
3
) 
%   (n) 
Multivariable 
adjusted odds 
ratio for late 
diagnosis        
(95% confidence 
interval) 
Percentage of 
patients 
diagnosed late 
(CD4<200 cells    
per mm
3
) 
%   (n) 
Multivariable 
adjusted odds 
ratio for late 
diagnosis        
(95% confidence 
interval) 
        
    Period of HIV diagnosis     
1995-1996 59.1  (1,006) 1.13 (1.00, 1.28) 41.2  (701) 1.17 (1.03, 1.33) 
1997-1998 60.5  (1,339) 1.06 (0.94, 1.19) 43.2  (956) 1.11 (0.99, 1.25) 
1999-2000 61.9  (1,983) - 43  (1,377) - 
2001-2002 61.1  (3,341) 0.86 (0.78, 0.94) 40.8  (2,231) 0.83 (0.75, 0.91) 
2003-2004 60  (4,505) 0.79 (0.72, 0.86) 38.2  (2,869) 0.71 (0.65, 0.78) 
2005-2006 60.1  (4,046) 0.79 (0.72, 0.87) 38.5  (2,592) 0.71 (0.65, 0.78) 
2007 55.6  (1,599) 0.71 (0.64, 0.79) 34.4  (989) 0.62 (0.56, 0.70) 
        Age group at HIV diagnosis     
15-25 42.4  (1,426) 0.43 (0.39, 0.47) 19.3  (649) 0.32 (0.29, 0.36) 
25-29 52.4  (3,040) 0.61 (0.56, 0.65) 29.7  (1,723) 0.54 (0.50, 0.58) 
30-34 61.2  (4,260) 0.88 (0.82, 0.95) 39.3  (2,734) 0.82 (0.76, 0.88) 
35-39 63.4  (3,664) - 43.8  (2,529) - 
40-44 67  (2,302) 1.23 (1.13, 1.35) 49.2  (1,689) 1.30 (1.19, 1.41) 
45-49 71.6  (1,414) 1.58 (1.41, 1.77) 53.4  (1,055) 1.56 (1.41, 1.74) 
50-54 69.6  (798) 1.49 (1.29, 1.71) 54  (619) 1.64 (1.44, 1.87) 
>54 73.8  (915) 1.90 (1.65, 2.19) 57.9  (717) 1.98 (1.74, 2.25) 
        Region of diagnosis     
Outside London 60.7  (8,392) 1.07 (1.02, 1.13) 39.9  (5,516) 1.07 (1.02, 1.13) 
London 59.4  (9,427) - 39.1  (6,199) - 
        Risk group     
MSM 48.9  (5,444) - 29.9  (3,332) - 
Heterosexual men 71.2  (4,621) 1.58 (1.46, 1.72) 52.1  (3,379) 1.77 (1.63, 1.92) 
Heterosexual women 66.8  (6,238) 1.42 (1.31, 1.54) 45.5  (4,242) 1.57 (1.44, 1.71) 
Heterosexual women 
(diagnosed antenatally) 
53  (1,078) 0.98 (0.88, 1.11) 22.7  (461) 0.73 (0.64, 0.83) 
IDU 58.7  (330) 1.51 (1.27, 1.80) 38.1  (214) 1.49 (1.25, 1.78) 
Recipients of blood products 78.8  (108) 2.34 (1.53, 3.57) 63.5  (87) 2.71 (1.88, 3.90) 
        Ethnicity     
White  50.5  (6,434) - 32.1  (4,086) - 
Black African 69.5  (9,255) 2.09 (1.93, 2.26) 46.7  (6,215) 1.74 (1.61, 1.89) 
Black Caribbean 57.3  (639) 1.27 (1.11, 1.45) 37.8  (421) 1.22 (1.06, 1.41) 
Black Other 62.9  (386) 1.70 (1.42, 2.03) 41  (252) 1.52 (1.28, 1.82) 
Indian\Pakistani\Bangladeshi 59.6  (257) 1.29 (1.05, 1.59) 41.5  (179) 1.29 (1.05, 1.59) 
Other Asian 67.1  (310) 2.27 (1.85, 2.79) 45.2  (209) 2.10 (1.72, 2.56) 
Other/mixed 52.7  (538) 1.19 (1.04, 1.36) 34.6  (353) 1.24 (1.08, 1.43) 
     
    Total 60.0  (17,819) - 39.5  (11,715) - 
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 Table 6.3. Proportion diagnosed late and odds ratios for late diagnosis 
considering two CD4 cell counts in the definition of late HIV diagnosis – first 
within 91 days of their HIV diagnosis and second within 91 days of the first 
 
Percentage      
of individuals 
with CD4 within 
91 days of HIV 
diagnosis 
included in this 
analysis 
%   (n) 
Multivariable adjusted odds ratio for late diagnosis        
(95% confidence interval) 
Late diagnosis 
defined as both 
first two CD4 
counts less than 
200 cells/mm
3
 
Late diagnosis 
defined as mean 
of first two CD4 
counts less than 
200 cells/mm
3
 
Late diagnosis 
defined as either 
of first two CD4 
counts less than 
200 cells/mm
3
 
    Period of HIV diagnosis     
1995-1996 54.6 1.31 (1.11, 1.55) 1.23 (1.05, 1.45) 1.25 (1.06, 1.47) 
1997-1998 57.7 1.11 (0.95, 1.29) 1.10 (0.95, 1.28) 1.12 (0.97, 1.30) 
1999-2000 65.4 - - - 
2001-2002 61.8 0.84 (0.75, 0.95) 0.83 (0.74, 0.93) 0.85 (0.76, 0.96) 
2003-2004 66.3 0.77 (0.68, 0.86) 0.77 (0.69, 0.86) 0.76 (0.69, 0.85) 
2005-2006 65.7 0.78 (0.69, 0.87) 0.80 (0.71, 0.89) 0.83 (0.74, 0.93) 
2007 61.1 0.69 (0.59, 0.79) 0.73 (0.64, 0.84) 0.74 (0.64, 0.84) 
   Age group at HIV diagnosis      
15-25 57.5 0.39 (0.34, 0.45) 0.36 (0.31, 0.41) 0.37 (0.32, 0.42) 
25-29 61.0 0.62 (0.56, 0.69) 0.58 (0.53, 0.65) 0.57 (0.51, 0.63) 
30-34 63.6 0.87 (0.79, 0.96) 0.84 (0.77, 0.92) 0.83 (0.76, 0.91) 
35-39 65.3 - - - 
40-44 66.2 1.23 (1.10, 1.38) 1.21 (1.09, 1.35) 1.27 (1.14, 1.41) 
45-49 66.5 1.32 (1.16, 1.50) 1.41 (1.24, 1.60) 1.46 (1.28, 1.66) 
50-54 66.2 1.59 (1.35, 1.87) 1.60 (1.36, 1.88) 1.56 (1.33, 1.84) 
>54 65.9 1.57 (1.34, 1.84) 1.62 (1.39, 1.90) 1.73 (1.48, 2.03) 
   Region of diagnosis      
Outside London 63.3 1.02 (0.95, 1.08) 1.06 (1.00, 1.13) 1.18 (1.11, 1.26) 
London 63.5 - - - 
   Risk group      
MSM 64.8 - - - 
Heterosexual men 61.8   1.84 (1.65, 2.05) 1.88 (1.69, 2.08) 1.84 (1.65, 2.04) 
Heterosexual women 62.1 1.55 (1.39, 1.73) 1.61 (1.45, 1.79) 1.62 (1.46, 1.79) 
Heterosexual women 
(diagnosed antenatally) 
70.4 0.55 (0.46, 0.66) 0.57 (0.49, 0.68) 0.64 (0.55, 0.75) 
IDU 50.0 1.59 (1.23, 2.05) 1.61 (1.26, 2.07) 1.69 (1.33, 2.16) 
Recipients of blood products 65.7 2.40 (1.56, 3.69) 2.53 (1.63, 3.93) 2.42 (1.54, 3.81) 
   Ethnicity      
White  64.3 - - - 
Black African 63.0 1.63 (1.47, 1.81) 1.59 (1.44, 1.76) 1.65 (1.49, 1.82) 
Black Caribbean 58.2 1.42 (1.18, 1.70) 1.31 (1.09, 1.57) 1.25 (1.05, 1.49) 
Black Other 61.6 1.66 (1.32, 2.09) 1.61 (1.28, 2.01) 1.61 (1.29, 2.02) 
Indian\Pakistani\Bangladeshi 61.3 1.12 (0.85, 1.48) 1.30 (1.00, 1.69) 1.42 (1.09, 1.85) 
Other Asian 68.2 2.29 (1.80, 2.91) 1.99 (1.56, 2.52) 2.04 (1.61, 2.59) 
Other/mixed 63.8 1.27 (1.06, 1.53) 1.23 (1.03, 1.47) 1.30 (1.10, 1.55) 
      
    Total 63.4 - - - 
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6.4.3.2  Analysis of various definitions of late diagnosis using 
different cut-off times from HIV diagnosis to first CD4 cell count 
Increasing the time between HIV diagnosis and first CD4 cell count used for the 
definition of late diagnosis increased the percentage and number of individuals 
that were included in the analysis (Section 5.4.4.1). For cut-offs of 30 days, 60 
days and 182 days between first CD4 cell count and HIV diagnosis, the 
percentages and numbers included were 71.7% (24,869), 81.9% (28,405) and 
90.5% (31,390) of all 34,692 individuals in the integrated dataset who were 
diagnosed between 1995 and 2007 (Table 6.4). However, the different cut-offs 
had little effect on the adjusted odds ratios for late diagnosis. 
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Table 6.4. Proportion diagnosed late and odds ratios for late diagnosis defined 
by CD4 counts less than 200 cells/mm3 within 30 days, 60 days and 182  
 days of their HIV diagnosis 
 
Multivariable adjusted odds ratio for late diagnosis        
(95% confidence interval) 
Late diagnosis 
defined as CD4 <  
200 cells/mm
3
 within 
30 days of HIV 
diagnosis 
Late diagnosis 
defined as CD4 <  
200 cells/mm
3
 within 
60 days of HIV 
diagnosis 
Late diagnosis 
defined as CD4 <  
200 cells/mm
3
 within 
182 days of HIV 
diagnosis 
       
    Percentage (number) of all 
individuals in the analysis 
71.7%  (24,869) 81.9%  (28,405) 90.5%  (31,390) 
    
    Period of HIV diagnosis    
1995-1996 1.07 (0.93, 1.23) 1.11 (0.97, 1.26) 1.15 (1.02, 1.29) 
1997-1998 1.03 (0.90, 1.17) 1.06 (0.94, 1.20) 1.09 (0.97, 1.21) 
1999-2000 - - - 
2001-2002 0.83 (0.75, 0.92) 0.82 (0.74, 0.90) 0.83 (0.76, 0.91) 
2003-2004 0.74 (0.67, 0.81) 0.73 (0.66, 0.80) 0.73 (0.67, 0.80) 
2005-2006 0.76 (0.69, 0.84) 0.73 (0.66, 0.80) 0.74 (0.68, 0.81) 
2007 0.66 (0.58, 0.74) 0.65 (0.58, 0.72) 0.65 (0.58, 0.72) 
   Age group at HIV diagnosis    
15-25 0.31 (0.28, 0.35) 0.31 (0.28, 0.35) 0.33 (0.29, 0.36) 
25-29 0.53 (0.48, 0.58) 0.53 (0.49, 0.58) 0.54 (0.50, 0.58) 
30-34 0.82 (0.76, 0.89) 0.82 (0.76, 0.88) 0.82 (0.76, 0.88) 
35-39 - - - 
40-44 1.26 (1.15, 1.39) 1.25 (1.15, 1.37) 1.26 (1.15, 1.37) 
45-49 1.50 (1.34, 1.68) 1.51 (1.36, 1.69) 1.50 (1.36, 1.67) 
50-54 1.57 (1.36, 1.80) 1.58 (1.38, 1.80) 1.62 (1.43, 1.84) 
>54 1.90 (1.65, 2.18) 1.89 (1.66, 2.15) 1.88 (1.66, 2.13) 
   Region of diagnosis    
Outside London 1.06 (1.00, 1.12) 1.07 (1.01, 1.13) 1.08 (1.03, 1.14) 
London - - - 
   Risk group    
MSM - - - 
Heterosexual men 1.74 (1.58, 1.90) 1.76 (1.62, 1.92) 1.80 (1.66, 1.95) 
Heterosexual women 1.58 (1.44, 1.73) 1.58 (1.45, 1.73) 1.58 (1.45, 1.72) 
Heterosexual women 
(diagnosed antenatally) 
0.82 (0.71, 0.96) 0.81 (0.71, 0.93) 0.82 (0.72, 0.94) 
IDU 1.56 (1.27, 1.91) 1.52 (1.26, 1.84) 1.49 (1.25, 1.77) 
Recipients of blood products 2.32 (1.56, 3.44) 2.41 (1.68, 3.47) 2.80 (1.98, 3.97) 
   Ethnicity    
White  - - - 
Black African 1.61 (1.47, 1.76) 1.62 (1.49, 1.76) 1.62 (1.50, 1.76) 
Black Caribbean 1.20 (1.03, 1.40) 1.24 (1.07, 1.43) 1.23 (1.07, 1.40) 
Black Other 1.46 (1.20, 1.78) 1.51 (1.26, 1.81) 1.53 (1.28, 1.82) 
Indian\Pakistani\Bangladeshi 1.16 (0.92, 1.46) 1.23 (1.00, 1.53) 1.19 (0.96, 1.46) 
Other Asian 2.04 (1.65, 2.53) 2.05 (1.68, 2.51) 2.02 (1.66, 2.46) 
Other/mixed 1.15 (0.99, 1.35) 1.21 (1.04, 1.40) 1.22 (1.06, 1.41) 
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6.4.4 Short-term mortality 
Estimated short-term mortality accounted for 17.9% (744/4,183) of all deaths 
occurring among this population between 1995 and 2007. Although short-term 
mortality declined when HAART became available, it accounted for an 
increasing percentage of all deaths between 1995 and 2001 (7.9% (47/597) in 
1995 to 28.5% (68/239) in 2001) before stabilising at an average of 26.4% 
between 2001 and 2007. Short-term mortality between 2000 and 2007 was 
1.9% (505) of all 27,201 newly diagnosed individuals and 2.0% (483/24,444) of 
those with CD4 cell counts within 91 days of HIV diagnosis.  
The number of deaths among all individuals was particularly high during the first 
three months after HIV diagnosis and then declined gradually but remained 
elevated for the first two years after HIV diagnosis in comparison to the low rate 
thereafter (Figure 6.4). Overall short-term mortality among all individuals 
diagnosed between 1995 and 2007 was 2.08% (721/34,692) (Table 6.5). The 
mortality percentages within one, three, six, 12 and 24 months of diagnosis 
among all individuals diagnosed between 1995 and 2007 were 0.35% (123), 
1.01% (350), 1.46% (505), 2.08% (721) and 2.93% (1,018) respectively.  
The factors associated with short-term mortality were similar to those for late 
diagnosis. Short-term mortality declined over time from 3.6% (98/2,697) in 
1995/6 to 1.1% (34/2,968) in 2007 (AOR 0.25, 95% CI 0.16, 0.37) with 
significant drops between 1995/6 and 1997/8 (AOR 0.61, 95% CI 0.45, 0.83) 
and between 2005/6 and 2007 (AOR 0.62, 95% CI 0.42, 0.90). The percentage 
of deaths 
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Figure 6.4. Number of deaths among all individuals who were known to have 
died by the time from HIV diagnosis to death (deaths within five years of HIV 
diagnosis and 12 months of a CD4 cell count) 
 
within a year of HIV diagnosis increased markedly from 0.5% (20/4,037) among 
those aged 15-25 years to 6.9% (97/1,399) among those aged older than 54 
years (AOR 13.35, 95% CI 8.17, 21.81). Short-term mortality was higher among 
individuals diagnosed outside London than in London (AOR 1.24, 95% CI 1.06, 
1.45). Heterosexual men (AOR 1.38, 95% CI 1.09, 1.74) and IDU (AOR 2.30, 
95% CI 1.53, 3.46) were more likely to die within a year of HIV diagnosis than 
MSM but heterosexual women diagnosed antenatally were least likely to do so 
(AOR 0.17, 95% CI 0.06, 0.47). Short-term mortality was more likely for Black 
African (AOR 1.27, 95% CI 1.019, 1.61) and Indian/Pakistani/Bangladeshi (AOR 
1.71, 95% CI 1.04, 2.80) individuals. 
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Table 6.5. Short-term mortality and odds ratios for short-term mortality among 
all individuals diagnosed between 1995 and 2007 
 
Short-term mortality     
among all patients 
 (total number diagnosed ) 
%   (n) 
Multivariable adjusted odds 
ratio for late diagnosis        
(95% confidence interval) 
      
    Period of HIV diagnosis   
1995-1996 3.6  (98 / 2,697) 1.57 (1.18, 2.09) 
1997-1998 2.5  (77 / 3,062) 0.95 (0.71, 1.29) 
1999-2000 2.6  (103 / 3,923) - 
2001-2002 1.9  (121 / 6,418) 0.70 (0.53, 0.91) 
2003-2004 1.9  (156 / 8,280) 0.69 (0.53, 0.89) 
2005-2006 1.8  (132 / 7,344) 0.62 (0.48, 0.81) 
2007 1.1  (34 / 2,968) 0.38 (0.26, 0.57) 
   
   Age group at HIV diagnosis   
15-25 0.5  (20 / 4,037) 0.26 (0.16, 0.42) 
25-29 1.0  (70 / 6,983) 0.50 (0.37, 0.66) 
30-34 1.6  (130 / 8,137) 0.76 (0.60, 0.97) 
35-39 2.1  (139 / 6,630) - 
40-44 2.8  (109 / 3,933) 1.35 (1.05, 1.74) 
45-49 4.0  (91 / 2,255) 1.99 (1.52, 2.60) 
50-54 4.9  (65 / 1,318) 2.40 (1.77, 3.26) 
>54 6.9  (97 / 1,399) 3.50 (2.67, 4.60) 
   
   Region of diagnosis   
Outside London 2.3  (360 / 15,935) 1.24 (1.06, 1.45) 
London 1.9  (361 / 18,757) - 
   
   Risk group   
MSM 1.9  (248 / 13,124) - 
Heterosexual men 3.1  (233 / 7,584) 1.38 (1.09, 1.74) 
Heterosexual women 1.8  (202 / 10,920) 1.05 (0.81, 1.36) 
Heterosexual women 
(diagnosed antenatally) 
0.2  (4 / 2,187) 0.17 (0.06, 0.47) 
IDU 3.8  (27 / 713) 2.30 (1.53, 3.46) 
Recipients of blood products 4.3  (7 / 164) 1.49 (0.68, 3.30) 
   
   Ethnicity   
White  2.2  (331 / 15,092) - 
Black African 2.0  (308 / 15,423) 1.27 (1.01, 1.61) 
Black Caribbean 1.8  (23 / 1,312) 0.97 (0.62, 1.51) 
Black Other 2.0  (14 / 693) 1.37 (0.78, 2.40) 
Indian\Pakistani\Bangladeshi 3.8  (19 / 499) 1.71 (1.04, 2.80) 
Other Asian 2.2  (11 / 506) 1.49 (0.80, 2.78) 
Other/mixed 1.3  (15 / 1,167) 0.80 (0.47, 1.36) 
   
    Total 2.1  (721 / 34,692) - 
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The majority (86.0% [590/686]) of those who died within a year of diagnosis 
were diagnosed late. The number of deaths among individuals diagnosed late 
was particularly high during the first three months after HIV diagnosis but 
remained elevated for the first two years after HIV diagnosis in comparison to 
deaths among those diagnosed with higher CD4 cell counts (Figure 6.5). 
Among individuals diagnosed late, the percentage who had died increased from 
1.06% (116) within one month of diagnosis to 7.07 (776) within two years of 
diagnosis. In contrast, these percentages were 0.04% (7) and 0.88% (165) 
among individuals diagnosed with higher CD4 cell counts (Table 6.6). 
Figure 6.5. Number of deaths among those diagnosed late and those diagnosed 
earlier by time from HIV diagnosis to death (deaths within three years of HIV 
diagnosis) 
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Table 6.6. Percentage of deaths among those diagnosed late and those 
diagnosed earlier by time from HIV diagnosis to death 
 Percentage of deaths among individuals newly diagnosed 
Time from HIV diagnosis 
                                 (months) 
Diagnosed with CD4 < 200 
cells/mm
3
  
Diagnosed with CD4 ≥ 200 
cells/mm
3
 
1 1.06  (116) 0.04  (7) 
3 2.92  (320) 0.16  (30) 
6 4.05  (444) 0.27  (51) 
12 5.38  (590) 0.51  (96) 
24 7.07  (776) 0.88  (165) 
 
Short-term mortality (i.e. deaths within the first year) decreased with increasing 
CD4 cell counts at the time of HIV diagnosis for those individuals with 
measurements within 91 days of their HIV diagnosis (Figure 6.6). Short-term 
mortality was relatively high for individuals diagnosed with CD4 counts between 
0 and 239 cells/mm3 but decreased from 10.7% at CD4 counts between 0 and 
19 cells/mm3 to 1.7% at CD4 counts between 220 and 239 cells/mm3.  
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Figure 6.6. Short-term mortality and numbers diagnosed by CD4 cell count 
categories at HIV diagnosis (CD4 cell counts grouped from 0-19 cells/mm3, 20-
39 cells/mm3 etc.) 
 
Individuals diagnosed late were eleven times more likely to die from any cause 
within a year of HIV diagnosis than individuals diagnosed more promptly (5.4% 
[590/10,976] vs 0.5% [96/18,719]) (Table 6.7). This difference was marked 
among all groups. The independent effect of late diagnosis on short-term 
mortality, after controlling for other factors, remained strong (AOR 8.71, 95% CI 
6.97, 10.87). Period and region of HIV diagnosis and age group were 
significantly associated with short-term mortality in multivariable analysis. 
Heterosexual men did not have significantly higher odds of short-term mortality 
than MSM although there was a weak residual association (AOR 1.26, 95% CI 
0.99, 1.61). Heterosexual women were less likely to die within a year of HIV 
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diagnosis than MSM (OR 0.21, 95% CI 0.08, 0.59) but IDU had slightly higher 
odds of short-term mortality compared to MSM even after controlling for late 
diagnosis (AOR 2.39, 95% CI 1.56, 3.67). There were no statistically significant 
differences in the odds of short-term mortality between white individuals and 
individuals in other ethnic groups suggesting that differences in short-term 
mortality were explained by different proportions diagnosed late. 
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Table 6.7. Short-term mortality and factors associated with short-term mortality 
among individuals with CD4 cell counts within 91 days of their HIV diagnosis 
 
Short-term mortality among patients with 
CD4 cell counts at HIV diagnosis Multivariable adjusted odds 
 ratio for short-term mortality 
(95% confidence interval) 
 
CD4 < 200 
%   (n) 
CD4 ≥ 200 
%   (n) 
       
   Late HIV diagnosis status    
CD4 < 200 5.4  (590) - 8.71 (6.97, 10.87) 
CD4 ≥ 200 - 0.5  (96) - 
    
    Period of HIV diagnosis    
1995-1996 12.6  (82) 1.0  (10) 2.13 (1.56, 2.90) 
1997-1998 7.7  (68) 0.4  (5) 1.12 (0.81, 1.55) 
1999-2000 5.7  (73) 1.0  (19) - 
2001-2002 5.0  (104) 0.4  (14) 0.78 (0.59, 1.04) 
2003-2004 4.5  (121) 0.6  (28) 0.76 (0.58, 1.00) 
2005-2006 4.6  (113) 0.4  (15) 0.69 (0.52, 0.91) 
2007 3.1  (29) 0.3  (5) 0.44 (0.29, 0.66) 
    
   Age group at HIV diagnosis    
15-25 2.5  (15) 0.1  (4) 0.49 (0.30, 0.80) 
25-29 3.4  (54) 0.3  (12) 0.71 (0.52, 0.96) 
30-34 3.9  (100) 0.5  (22) 0.85 (0.66, 1.09) 
35-39 4.5  (108) 0.7  (23) - 
40-44 5.9  (93) 0.6  (11) 1.25 (0.96, 1.63) 
45-49 7.9  (79) 1.0  (10) 1.76 (1.33, 2.33) 
50-54 9.2  (54) 1.2  (7) 2.01 (1.46, 2.78) 
>54 12.9  (87) 1.2  (7) 2.85 (2.14, 3.80) 
    
   Region of diagnosis    
Outside London 5.8  (298) 0.5  (45) 1.18 (1.00, 1.38) 
London 5.0  (292) 0.5  (51) - 
    
   Risk group    
MSM 6.2  (194) 0.5  (38) - 
Heterosexual men 6.2  (198) 0.8  (27) 1.26 (0.99, 1.61) 
Heterosexual women 4.3  (170) 0.4  (22) 0.99 (0.75, 1.29) 
Heterosexual women 
(diagnosed antenatally) 
0.4  (2) 0.1  (2) 0.21 (0.08, 0.59) 
IDU 10.4  (21) 1.7  (6) 2.39 (1.56, 3.67) 
Recipients of blood products 6.2  (5) 1.8  (1) 1.01 (0.42, 2.39) 
    
   Ethnicity    
White  6.9  (266) 0.6  (49) - 
Black African 4.4  (256) 0.5  (39) 1.00 (0.78, 1.28) 
Black Caribbean 4.7  (19) 0  (0) 0.73 (0.45, 1.19) 
Black Other 4.1  (10) 0.8  (3) 1.04 (0.58, 1.88) 
Indian\Pakistani\Bangladeshi 10.8  (18) 0.4  (1) 1.57 (0.94, 2.63) 
Other Asian 4.5  (9) 0.8  (2) 1.13 (0.60, 2.13) 
Other/mixed 3.6  (12) 0.3  (2) 0.67 (0.39, 1.18) 
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6.4.5 Sensitivity analyses for short-term mortality 
6.4.5.1 Analysis of various definitions of short-term mortality using 
different cut-off times from HIV diagnosis to death 
Varying the cut-off time between HIV diagnosis and death for the definition of 
short-term mortality significantly changed some of the comparative effects of the 
associated factors (Table 6.8). Increasing the time between diagnosis and 
death from three months to 24 months resulted in a decrease in the adjusted 
odds ratio for late diagnosis from 15.41 (95% CI 10.52, 22.56) to 6.99 (95% CI 
5.87, 8.33). In contrast, the effects of period of HIV diagnosis, age group and 
risk group became more significant as the cut-off increased. Compared to 
1999/2000, there was no significant difference in the odds of death within three 
months of diagnosis for any period of HIV diagnosis except 1995/6, when death 
was more likely (AOR 1.72; 95% CI 1.07, 2.74). For deaths within six months of 
diagnosis, diagnosis in 2007 was associated with significantly lower odds of 
death than diagnosis in 1999/2000 (AOR 0.55; 95% CI 0.35, 0.86). For deaths 
within 24 months of diagnosis, there were also significant differences for 
diagnoses in 1997/8 and 2005/6 compared to 1999/2000 and the odds ratios for 
diagnoses 1995/6 and 2007 were greater. Being aged 45 years or older was 
associated with significantly higher odds of death after diagnosis irrespective of 
the cut-off used. However, the odds of death when diagnosed aged 40-44 years 
compared to those when aged 35-39 years became significantly different as the 
cut-off increased from three months to six months and there was evidence of 
significantly lower odds of death among younger individuals as the cut-off 
increased to more than six months. Interestingly, mortality within three months 
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of diagnosis was not significantly different for MSM than for any other risk 
group. Consideration of deaths within 24 months of diagnosis indicated that 
heterosexual men had significantly higher odds of mortality than MSM (AOR 
1.24; 95% CI 1.00, 1.54). Diagnosis outside London was consistently 
associated with higher mortality whereas there were consistently no significant 
differences in mortality between white individuals and other ethnic groups. 
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Table 6.8. Factors associated with short-term mortality among individuals with 
CD4 cell counts within 91 days of their HIV diagnosis: considering different cut-
offs of time from HIV diagnosis to death 
 
Multivariable adjusted odds ratio for  short-term mortality 
(95% confidence interval) 
 
Deaths within three 
months of diagnosis  
Deaths within six 
months of diagnosis 
Deaths within 24 
months of diagnosis 
       
   Late HIV diagnosis status    
CD4 < 200 15.41 (10.52, 22.56) 12.63 (9.39, 16.99) 6.99 (5.87, 8.33) 
CD4 ≥ 200 - - - 
    
    Period of HIV diagnosis    
1995-1996 1.72 (1.07, 2.74) 1.59 (1.09, 2.32) 3.24 (2.50, 4.21) 
1997-1998 1.39 (0.89, 2.17) 1.13 (0.78, 1.64) 1.40 (1.07, 1.85) 
1999-2000 - - - 
2001-2002 0.79 (0.52, 1.20) 0.77 (0.55, 1.08) 0.84 (0.65, 1.08) 
2003-2004 0.97 (0.66, 1.42) 0.81 (0.59, 1.11) 0.81 (0.64, 1.04) 
2005-2006 0.98 (0.66, 1.44) 0.72 (0.52, 1.00) 0.68 (0.53, 0.88) 
2007 0.64 (0.37, 1.10) 0.55 (0.35, 0.86) 0.34 (0.23, 0.51) 
    
   Age group at HIV diagnosis    
15-25 0.74 (0.39, 1.39) 0.72 (0.42, 1.22) 0.51 (0.34, 0.77) 
25-29 0.87 (0.57, 1.33) 0.89 (0.63, 1.27) 0.82 (0.64, 1.06) 
30-34 0.90 (0.63, 1.30) 0.89 (0.65, 1.21) 0.90 (0.72, 1.12) 
35-39 - - - 
40-44 1.26 (0.86, 1.84) 1.37 (1.00, 1.88) 1.32 (1.05, 1.67) 
45-49 2.11 (1.44, 3.09) 1.92 (1.38, 2.68) 1.92 (1.50, 2.46) 
50-54 1.92 (1.21, 3.05) 1.96 (1.33, 2.89) 2.04 (1.54, 2.72) 
>54 3.55 (2.42, 5.20) 3.29 (2.36, 4.57) 3.02 (2.34, 3.90) 
    
   Region of diagnosis    
Outside London 1.38 (1.11, 1.72) 1.24 (1.03, 1.50) 1.17 (1.02, 1.34) 
London - - - 
    
   Risk group    
MSM - - - 
Heterosexual men 1.06 (0.76, 1.49) 1.25 (0.95, 1.66) 1.24 (1.00, 1.54) 
Heterosexual women 0.87 (0.60, 1.26) 0.98 (0.71, 1.33) 0.98 (0.77, 1.23) 
Heterosexual women 
(diagnosed antenatally) 
0.37 (0.13, 1.06) 0.29 (0.11, 0.82) 0.31 (0.15, 0.65) 
IDU 1.76 (0.93, 3.33) 2.29 (1.39, 3.77) 2.82 (1.99, 4.00) 
Recipients of blood products 0.79 (0.24, 2.60) 1.13 (0.44, 2.91) 0.73 (0.31, 1.74) 
    
   Ethnicity    
White  - - - 
Black African 1.04 (0.74, 1.45) 0.91 (0.68, 1.20) 0.98 (0.79, 1.21) 
Black Caribbean 0.87 (0.45, 1.66) 0.71 (0.40, 1.26) 0.76 (0.50, 1.15) 
Black Other 0.49 (0.15, 1.58) 1.06 (0.54, 2.07) 0.98 (0.59, 1.65) 
Indian\Pakistani\Bangladeshi 1.65 (0.83, 3.29) 1.50 (0.83, 2.70) 1.56 (0.99, 2.46) 
Other Asian 1.17 (0.50, 2.74) 1.17 (0.58, 2.36) 0.97 (0.54, 1.75) 
Other/mixed 0.82 (0.39, 1.71) 0.73 (0.39, 1.36) 0.71 (0.45, 1.12) 
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6.4.5.2 Different categorisation of CD4 cell counts 
Determination of the association between CD4 cell counts and short-term 
mortality by analysis of the effect of CD4 count categories showed that there 
was a non-linear decrease in the odds of death within a year of diagnosis with 
increasing CD4 count category (Table 6.9).  
Neither the square root transformation or the base ten logarithm transformation 
of the CD4 cell count fully reflected the high short-term mortality at very low 
CD4 cell counts, the lower short-term mortality at CD4 counts over 100 
cells/mm3, and the continuing all-cause mortality at high CD4 counts (Figures 
6.7 and 6.8). However, the log transformation more closely reflected the 
association with short-term mortality. Analysis showed that an increase of one 
log in CD4 counts at the time of HIV diagnosis was associated with a five-fold 
decrease in the odds of death within a year of HIV diagnosis. 
Consideration of the effect of late diagnosis, as defined by CD4 counts less 
than 350 cells/mm3, on short-term mortality indicated slightly higher odds than 
with the definition of CD4 counts less than 200 cells/mm3 (AOR 9.65, 95% CI 
6.90, 13.50 compared to AOR 8.71, 95% CI 6.97, 10.87). The odds ratio for 
short-term mortality was even greater when AIDS diagnoses were included in 
the definition of late diagnosis along with CD4 counts less than 200 cells/mm3 
(AOR 13.93, 95% CI 10.58, 18.33). 
The different categorisation of CD4 cell counts or late diagnosis in the various 
multivariable models had little effect on the odds ratios for the other factors. 
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Individuals diagnosed outside London had marginally higher odds of short-term 
mortality than individuals diagnosed in London but this was only statistically 
significant when late diagnosis was included in the model defined by CD4 
counts less than 350 cells/mm3. A similar pattern was observed for the odds of 
short-term mortality for heterosexual men. 
Table 6.9. Effect of CD4 cell counts and late diagnosis on short-term mortality 
among individuals with CD4 cell counts within 91 days of their HIV diagnosis 
  
 
 
Multivariable adjusted odds ratio for short-term  mortality        
(95% confidence interval) 
 
CD4 cell count 
categories        
Log CD4 at 
diagnosis 
Late diagnosis 
defined by CD4 
less than 350 
 cells/mm
3
        
Late diagnosis 
defined by CD4 
less than 200 
 cells/mm
3
 or AIDS 
at diagnosis       
        
   CD4 category at diagnosis     
<50 5.37 (3.79, 7.62)    
50-99  2.63 (1.79, 3.85)    
100-149 1.89 (1.25, 2.84)    
150-199 0.90 (0.56, 1.46)    
200-249 -    
250-299 0.36 (0.19, 0.70)    
300-349 0.34 (0.17, 0.67)    
350-499 0.26 (0.15, 0.45)    
>499 0.19 (0.11, 0.34)    
     
   Log CD4 at diagnosis  0.22 (0.20, 0.24)   
     
   CD4 < 350 cells/mm
3
  
                          at diagnosis 
    
CD4 < 350   9.65 (6.90, 13.50)  
CD4 ≥ 350   -  
     
   CD4 < 200 cells/mm
3
  
               or AIDS at diagnosis 
    
CD4 < 200 or AIDS    13.93 (10.58, 18.33) 
CD4 ≥ 200 and no AIDS    - 
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    Period of HIV diagnosis     
1995-1996 2.05 (1.50, 2.80) 2.11 (1.54, 2.90) 2.08 (1.53, 2.82) 2.08 (1.53, 2.84) 
1997-1998 1.06 (0.76, 1.46) 1.04 (0.75, 1.44) 1.13 (0.82, 1.55) 1.09 (0.79, 1.51) 
1999-2000 - - - - 
2001-2002 0.79 (0.59, 1.05) 0.80 (0.60, 1.07) 0.76 (0.57, 1.01) 0.78 (0.59, 1.04) 
2003-2004 0.78 (0.59, 1.03) 0.75 (0.56, 0.99) 0.72 (0.55, 0.94) 0.77 (0.59, 1.02) 
2005-2006 0.69 (0.52, 0.92) 0.64 (0.48, 0.85) 0.65 (0.49, 0.86) 0.70 (0.53, 0.93) 
2007 0.45 (0.30, 0.68) 0.42 (0.28, 0.63) 0.41 (0.27, 0.61) 0.45 (0.30, 0.68) 
     
   Age group at HIV diagnosis     
15-25 0.54 (0.33, 0.89) 0.48 (0.29, 0.78) 0.40 (0.24, 0.65) 0.52 (0.32, 0.85) 
25-29 0.75 (0.55, 1.01) 0.69 (0.51, 0.95) 0.63 (0.47, 0.85) 0.72 (0.53, 0.98) 
30-34 0.86 (0.67, 1.11) 0.83 (0.64, 1.07) 0.81 (0.63, 1.04) 0.85 (0.66, 1.10) 
35-39 - - - - 
40-44 1.26 (0.96, 1.64) 1.31 (1.00, 1.71) 1.30 (1.00, 1.69) 1.23 (0.94, 1.60) 
45-49 1.75 (1.32, 2.33) 1.89 (1.42, 2.51) 1.81 (1.37, 2.40) 1.72 (1.30, 2.28) 
50-54 1.97 (1.42, 2.72) 2.12 (1.53, 2.94) 2.17 (1.58, 2.98) 1.98 (1.44, 2.73) 
>54 2.97 (2.23, 3.97) 3.28 (2.45, 4.39) 3.04 (2.29, 4.03) 2.75 (2.07, 3.66) 
     
   Region of diagnosis     
Outside London 1.16 (0.99, 1.36) 1.16 (0.99, 1.37) 1.20 (1.02, 1.41) 1.17 (1.00, 1.37) 
London - - - - 
     
   Risk group     
MSM - - - - 
Heterosexual men 1.16 (0.91, 1.48) 1.17 (0.91, 1.50) 1.38 (1.08, 1.76) 1.24 (0.97, 1.59) 
Heterosexual women 0.92 (0.70, 1.21) 0.91 (0.69, 1.20) 1.04 (0.80, 1.37) 0.98 (0.75, 1.28) 
Heterosexual women 
(diagnosed antenatally) 
0.26 (0.09, 0.72) 0.25 (0.09, 0.70) 0.19 (0.07, 0.51) 0.23 (0.08, 0.63) 
IDU 2.29 (1.48, 3.53) 2.26 (1.46, 3.51) 2.39 (1.57, 3.63) 2.37 (1.55, 3.64) 
Recipients of blood products 0.96 (0.40, 2.27) 1.00 (0.42, 2.42) 1.11 (0.47, 2.64) 0.95 (0.40, 2.26) 
     
   Ethnicity     
White  - - - - 
Black African 1.06 (0.83, 1.36) 1.06 (0.82, 1.36) 0.99 (0.78, 1.27) 0.96 (0.75, 1.22) 
Black Caribbean 0.70 (0.43, 1.15) 0.71 (0.43, 1.16) 0.75 (0.46, 1.22) 0.73 (0.44, 1.19) 
Black Other 1.00 (0.55, 1.80) 1.01 (0.56, 1.84) 1.07 (0.59, 1.92) 1.04 (0.58, 1.87) 
Indian\Pakistani\Bangladeshi 1.61 (0.96, 2.71) 1.69 (1.00, 2.86) 1.57 (0.95, 2.61) 1.51 (0.90, 2.53) 
Other Asian 0.99 (0.52, 1.87) 1.01 (0.53, 1.93) 1.19 (0.63, 2.23) 1.10 (0.58, 2.07) 
Other/mixed 0.67 (0.38, 1.18) 0.71 (0.40, 1.24) 0.70 (0.40, 1.22) 0.66 (0.38, 1.15) 
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Figure 6.7. Short-term mortality and numbers diagnosed by logarithm (base 10) 
of the CD4 cell count at HIV diagnosis (log CD4 less or equal to three) 
 
Figure 6.8. Short-term mortality and numbers diagnosed by square root of the 
CD4 cell count at HIV diagnosis (square root of CD4 less or equal to 31)  
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6.4.6 Late diagnosis and consequent mortality among 
heterosexuals with CD4 cell counts measured at diagnosis 
In the integrated dataset, 19,882 heterosexuals were newly diagnosed with HIV 
infection between January 2000 and December 2007 and 17,843 (89.7%) of 
these individuals had a CD4 cell count measured within 91 days of their HIV 
diagnosis. Records were excluded from the analysis if they had evidence of 
previous diagnosis or evidence of recent seroconversion (9.7% [1,726] and 
2.9% [524] respectively, of those with CD4 cell counts at diagnosis). 
6.4.6.1 Patient characteristics 
The majority (64.4%, 10,049 of 15,593) of newly diagnosed heterosexuals were 
female of which 19.5% (1,964/10,049) were diagnosed antenatally (Table 6.10).  
The median age at diagnosis of women diagnosed antenatally (28 years) was 
lower than that of other women (33 years) and men (36 years). Almost three 
quarters (74.6%) of heterosexuals were black African, 13.3% were white and 
4.4% were black Caribbean. Half (49.2%) of white individuals were women 
compared to 43% of Indian/Pakistani/Bangladeshi individuals and 56.9% of 
black Caribbean individuals and two-thirds of all other ethnic groups. However, 
similar proportions of women were diagnosed through antenatal testing across 
ethnic groups. The median age at diagnosis was similar across ethnic groups 
when split by how infection was acquired except that white men were older than 
other men. 
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Where information on how infection was acquired was known, almost all (93.7% 
[10,422/11,126]) black Africans were probably infected in Africa (40% [4,170] of 
these in Zimbabwe) and 99.1% (8,632) of these were born in Africa (of the 
8,714 individuals with a country of birth reported). Of these black Africans born 
and infected in Africa, 30.9% (2.666) had been in the UK less than two years 
prior to diagnosis, 20.0% (1,728) two or three years, 20.7% (1,785) four or more 
years and 28.4% (2,453) had no year of arrival reported. In contrast, two thirds 
(66.1% [466/705]) of white individuals infected outside the UK and with a 
reported country of birth were born in the UK (82.0% [382] of whom were men 
and 34.3% [160] of whom were white men infected in Thailand). Where 
information on how infection was acquired was known, almost half (45.1% 
[309/626]) of black Caribbeans were infected in the Caribbean (73.8% [228] of 
whom in Jamaica) and 24.2% were infected in the UK by a partner infected 
outside Europe. Half of black Caribbeans infected in the Caribbean were male 
(46.6% [144/309]) whereas 68.1% [113/166] of those infected in the UK by a 
partner infected outside Europe were male. Of black Caribbeans with a reported 
country of birth, 69.5% [232/334] of those infected outside the UK were born in 
the Caribbean whereas 46.8% [73/156] of those infected in the UK were born in 
the Caribbean. 
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Table 6.10. Characteristics of heterosexuals at HIV diagnosis by ethnicity and sex/reason for test 
  Ethnicity 
Total 
  
Black 
African 
White 
Black 
Caribbean 
Black 
Other 
Indian\ 
Pakistani\ 
Bangladeshi 
Other 
Asian 
Other/mixed 
Number 
diagnosed 
(percentage) 
Male 3,754  (67.7) 1,052  (19.0) 295  (5.3) 121  (2.2) 118  (2.1) 69  (1.2) 135  (2.4) 5,544  (100) 
Female  
(not diagnosed 
antenatally) 
6,312  (78.1) 837  (10.4) 315  (3.9) 213  (2.6) 70  (0.9) 133  (1.6) 205  (2.5) 8,085  (100) 
Female 
(diagnosed 
antenatally) 
1,567  (79.8) 181  (9.2) 75  (3.8) 42  (2.1) 19  (1.0) 40  (2.0) 40  (2.0) 1,964  (100) 
Median age 
at diagnosis 
(IQR) 
Male 36  (31, 41) 41  (34, 51) 36  (30, 44) 35  (30, 38) 38  (32, 47) 34  (30, 40) 35  (30, 41) 36  (31, 43) 
Female  
(not diagnosed 
antenatally) 
33  (28, 38) 33  (25, 42) 33  (28, 42) 31  (26, 39) 35  (29, 45) 29  (26, 34) 31  (26, 38) 33  (27, 39) 
Female 
(diagnosed 
antenatally) 
28  (25, 32) 26  (22, 31) 28  (24, 31) 29  (23, 32) 25  (22, 28) 28  (25, 31) 29  (25, 33) 28  (24, 32) 
Percentage 
infected 
abroad 
where 
known 
(%) 
Male 92 58 64 70 79 77 81 83 
Female 
(not diagnosed 
antenatally) 
90 28 57 58 49 80 78 80 
Female 
(diagnosed 
antenatally) 
91 23 68 69 26 88 70 82 
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6.4.6.2 Late diagnosis 
Two-fifths (41.8% 6,515 of 15,593) of heterosexuals were diagnosed late 
between 2000 and 2007 (Table 6.11). There were no significant differences in 
the proportions diagnosed late among individuals infected abroad. However, 
heterosexuals infected from a high-risk partner (30.0% diagnosed late; AOR 
0.70; 95% CI 0.52, 0.95) and heterosexuals infected in the UK by partners 
infected outside Europe (23.3% diagnosed late; AOR 0.44; 95% CI 0.38, 0.51) 
were less likely to be diagnosed late than heterosexuals infected in Africa 
(44.4% diagnosed late). Women diagnosed antenatally (22.1% diagnosed late; 
AOR 0.49; 95% CI 0.44, 0.55) were less likely to be diagnosed late than other 
women (42.1% diagnosed late), who were less likely to be diagnosed late than 
men (48.3% diagnosed late; AOR 1.10; 95% CI 1.02, 1.19). Fewer individuals 
were diagnosed late in 2003/4 (40.5% [2,054/5,071]; AOR 0.83; 95% CI 0.72, 
0.95) in comparison to 2000 (46.3% [493/1,064]) but there was no further 
decline to 2005/6 or 2007 (41.6% [1,854/4,459] and 40.8% [610/1,495] 
respectively). The percentage diagnosed late increased with age from 20.1% 
among those aged 15-25 years to 54.2% among those aged older than 54 
years (AOR 0.33, 95% CI 0.29, 0.38 and AOR 1.38, 95% CI 1.15, 1.67 
respectively compared to individuals aged 35-39 years). Individuals diagnosed 
outside London were less likely to be diagnosed late than those diagnosed in 
London (AOR 0.84; 95% CI 0.78, 0.90). A lower percentage of white (34.5% 
[714/2,070]; AOR 0.72; 95% CI 0.63, 0.83) and black Caribbean (35.3% 
[242/685]; AOR 0.72; 95% CI 0.63, 0.83) heterosexuals were diagnosed late 
than black Africans (44% [5,015/11,633]).  
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Among black African heterosexuals born and infected in Africa (those with 
clinician reports only) the length of stay in the UK prior to diagnosis was 
associated with late diagnosis: 42.5% (2,091/4,926) of those who had been in 
the UK less than five years prior to diagnosis were diagnosed late in contrast to 
53.2% (667/1,253) of those who had been in the UK for five or more years prior 
to diagnosis (p<0.01); 44.0% (1,080/2,453) of those with no year of arrival 
reported were diagnosed late. 
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Table 6.11. Late diagnosis and factors associated with late diagnosis among 
heterosexuals with CD4 cell counts within 91 days of their HIV diagnosis 
 
Percentage of patients 
diagnosed late  
(CD4<200 cells/mm
3
) 
%   (n) 
Multivariable adjusted odds 
ratio for late diagnosis 
(95% confidence 
 interval) 
   How infection was acquired   
Heterosexual sex with a high-risk partner 30.0  (73) 0.70 (0.52, 0.95) 
Heterosexual sex abroad:   
In Africa 44.4  (5,017) - 
In Latin America/Caribbean 40.0  (179) 0.96 (0.75, 1.23) 
An Asia 45.9  (272) 0.90 (0.72, 1.12) 
In other region abroad 37.5  (125) 0.90 (0.70, 1.16) 
Heterosexual sex in the UK:   
With a partner infected outside Europe 23.3  (310) 0.44 (0.38, 0.51) 
With a partner infected within Europe 42.5  (113) 1.08 (0.82, 1.42) 
With a partner infected in an unknown location 34.3  (60) 0.74 (0.53, 1.04) 
Heterosexual sex: no further information 40.9  (366) 0.79 (0.67, 0.92) 
      Sex/reason for test   
Male 48.3  (2,675) 1.10 (1.02, 1.19) 
Female (not diagnosed antenatally) 42.1  (3,405) - 
Female (diagnosed antenatally) 22.1  (435) 0.49 (0.44, 0.55) 
   
    Period of HIV diagnosis   
2000 46.3  (493) - 
2001-2002 42.9  (1,504) 0.89 (0.77, 1.03) 
2003-2004 40.5  (2,054) 0.83 (0.72, 0.95) 
2005-2006 41.6  (1,854) 0.87 (0.75, 1.00) 
2007 40.8  (610) 0.84 (0.70, 0.99) 
   Age group at HIV diagnosis   
15-25 20.1  (373) 0.33 (0.29, 0.38) 
25-29 32.0  (1,040) 0.56 (0.50, 0.62) 
30-34 42.5  (1,575) 0.83 (0.75, 0.91) 
35-39 48.3  (1,421) - 
40-44 54.6  (947) 1.29 (1.14, 1.45) 
45-49 55.2  (550) 1.36 (1.17, 1.57) 
50-54 55.3  (301) 1.42 (1.17, 1.71) 
>54 54.2  (308) 1.38 (1.15, 1.67) 
   Region of diagnosis   
Outside London 39.6  (3,229) 0.84 (0.78, 0.90) 
London 44.2  (3,286) - 
   Ethnicity   
Black African 43.1  (5,015) - 
White  34.5  (714) 0.72 (0.63, 0.83) 
Black Caribbean 35.3  (242) 0.76 (0.61, 0.94) 
Black Other 42.8  (161) 1.09 (0.87, 1.36) 
Indian\Pakistani\Bangladeshi 44.4  (92) 1.02 (0.75, 1.40) 
Other Asian 49.2  (119) 1.70 (1.24, 2.31) 
Other/mixed 45.3  (172) 1.17 (0.94, 1.46) 
      Total 41.8  (6,515) - 
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6.4.6.3 Short-term mortality 
The overall short-term mortality of heterosexuals with CD4 cell counts within 91 
days of diagnosis was 2.1% (329/15,593) (Table 6.12). The majority (87.2% 
[287/329]) of those who died within a year of diagnosis were diagnosed late. 
Hence, the short-term mortality was 4.4% (287/6,515) among those diagnosed 
late and 0.5% (42/9,078) among others (AOR 7.66, 95% CI 5.51, 10.67).  
Independently of late diagnosis, short-term mortality was higher for 
heterosexuals infected in the UK by partners infected within Europe (AOR 2.25; 
95% CI 1.14, 4.44) than for heterosexuals infected in Africa. Women diagnosed 
antenatally (0.2% [4/1,964] died within a year of diagnosis; AOR 0.21; 95% CI 
0.08, 0.56) were less likely to experience short-term mortality than other women 
(1.9% [151/8,085] died within a year of diagnosis), who were less likely to 
experience short-term mortality than men (3.1% [174/5,544] died within a year 
of diagnosis; AOR 1.35; 95% CI 1.07, 1.70). Older age was associated with 
short-term mortality (AOR 2.67; 95% CI 1.72, 4.15 for those aged older than 54 
years at diagnosis compared to those aged 35-39 years). Individuals of ‘black-
other’ ethnicity were the only ethnic group to be less likely to die within a year of 
diagnosis than black Africans after controlling for other factors (AOR 0.33; 95% 
CI 0.13, 0.84). There was no significant regional effect (AOR 1.01; 95% CI 0.80, 
1.28). 
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Table 6.12. Short-term mortality and factors associated with short-term mortality 
among heterosexuals with CD4 cell counts within 91 days of their HIV diagnosis 
 
Short-term mortality among 
heterosexuals with CD4 cell  
counts at HIV diagnosis 
Multivariable adjusted 
odds ratio for  short-
term mortality 
(95% confidence interval)  
CD4 < 200 
%   (n) 
CD4 ≥ 200 
%   (n) 
       
   Late HIV diagnosis status    
CD4 < 200 4.4  (287) - 7.66 (5.51, 10.67) 
CD4 ≥ 200 - 0.5  (42) - 
    
   How infection was acquired    
Heterosexual sex with a high-risk partner 4.1  (3) 0  (0) 0.69 (0.21, 2.34) 
Heterosexual sex abroad:    
In Africa 4.3  (214) 0.6  (37) - 
In Latin America/Caribbean 5.6  (10) 0.4  (1) 1.95 (0.90, 4.21) 
An Asia 4.4  (12) 0.3  (1) 0.71 (0.34, 1.45) 
In other region abroad 7.2  (9) 0.5  (1) 1.27 (0.61, 2.66) 
Heterosexual sex in the UK:    
With a partner infected outside Europe 3.5  (11) 0.1  (1) 0.67 (0.36, 1.25) 
With a partner infected within Europe 11.5  (13) 0.7  (1) 2.25 (1.14, 4.44) 
With a partner infected in an unknown location 8.3  (5) 0  (0) 1.27 (0.47, 3.42) 
Heterosexual sex: no further information 2.7  (10) 0  (0) 0.51 (0.26, 0.99) 
    
   Sex (reason for test)    
Male 5.6  (150) 0.8  (24) 1.35 (1.07, 1.70) 
Female (not diagnosed antenatally) 4.0  (135) 0.3  (16) - 
Female (diagnosed antenatally) 0.5  (2) 0.1  (2) 0.21 (0.08, 0.56) 
    
    Period of HIV diagnosis    
2000 4.5  (22) 1.9  (11) - 
2001-2002 4.7  (71) 0.4  (8) 0.80 (0.52, 1.22) 
2003-2004 4.2  (87) 0.4  (13) 0.76 (0.50, 1.15) 
2005-2006 4.5  (84) 0.3  (9) 0.77 (0.51, 1.18) 
2007 3.8  (23) 0.1  (1) 0.61 (0.35, 1.07) 
    
   Age group at HIV diagnosis    
15-25 1.9  (7) 0.1  (2) 0.49 (0.24, 1.00) 
25-29 3.2  (33) 0.3  (6) 0.86 (0.57, 1.30) 
30-34 3.0  (48) 0.5  (11) 0.85 (0.59, 1.22) 
35-39 3.7  (53) 0.8  (12) - 
40-44 4.9  (46) 0.5  (4) 1.16 (0.79, 1.69) 
45-49 7.5  (41) 1.1  (5) 1.94 (1.31, 2.88) 
50-54 7.6  (23) 0.8  (2) 1.85 (1.14, 3.01) 
>54 11.7  (36) 0  (0) 2.67 (1.72, 4.15) 
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6.4.7 Crude estimation of preventable short-term mortality 
There were 10,787 MSM diagnosed between 2000 and 2007 with no evidence 
of previous diagnosis. Among the 9,742 with CD4 cell counts within 91 days of 
diagnosis, 22.3% were diagnosed late. Short-term mortality among those 
diagnosed late was 4.8% compared to 0.4% among those diagnosed with 
higher CD4 cell counts. Assuming that those with CD4 cell counts at diagnosis 
were representative of all MSM diagnosed between 2000 and 2007, an 
estimated 149 MSM would have died within a year of HIV diagnosis with 115 
(77.5%) of them being diagnosed late. Assuming that earlier diagnosis and 
treatment could have reduced the mortality rate among MSM diagnosed late to 
that among MSM diagnosed promptly, only 43 deaths would have been 
observed within a year of HIV diagnosis with 10 (22.3%) of them among those 
that would have been diagnosed late. The estimated 105 preventable deaths 
accounted for 71.0% of all estimated deaths within a year of diagnosis and 
11.1% (115/952) of all deaths that occurred among MSM between 2000 and 
2007. 
    
   Region of diagnosis    
Outside London 4.5  (146) 0.5  (23) 1.01 (0.80, 1.28) 
London 4.3  (141) 0.5  (19) - 
    
   Ethnicity    
Black African 4.1  (208) 0.5  (33) - 
White  7.3  (52) 0.4  (6) 1.05 (0.67, 1.64) 
Black Caribbean 2.9  (7) 0  (0) 0.33 (0.13, 0.84) 
Black Other 3.7  (6) 0.9  (2) 1.05 (0.50, 2.21) 
Indian\Pakistani\Bangladeshi 4.3  (4) 0  (0) 0.77 (0.26, 2.26) 
Other Asian 4.2  (5) 0.8  (1) 1.54 (0.58, 4.05) 
Other/mixed 2.9  (5) 0  (0) 0.54 (0.21, 1.37) 
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There were 13,316 black African heterosexuals, 2,475 white heterosexuals and 
827 black Caribbean heterosexuals diagnosed between 2000 and 2007 with no 
evidence of previous diagnosis or seroconversion (Table 6.13). Assuming that 
late diagnosis and consequent short-term mortality was not preventable among 
recent arrivals in the UK, there would have been an estimated 96 deaths within 
a year of HIV diagnosis among black Africans recently arrived in the UK and 
diagnosed late. No deaths would have been expected among white individuals 
recently arrived and diagnosed late and only four would have been expected 
among black Caribbeans recently arrived and diagnosed late. Assuming that 
short-term mortality among other individuals could be reduced to that of 
individuals who were not diagnosed late by preventing late diagnoses, 55, ten 
and zero deaths within a year of diagnosis would have been expected among 
these three ethnic groups. The combined number of deaths expected within a 
year of diagnosis was 60% (151/252) of that observed for black African 
heterosexuals, 50% (4/8) for black Caribbean heterosexuals and only 17% 
(10/60) for white heterosexuals. The potentially preventable deaths accounted 
for 18% (101/560), 13% (4/30) and 23% (50/217) of all deaths observed 
between 2000 and 2007 for black African, black Caribbean and white 
heterosexuals respectively. 
Numbers were large enough to analyse preventable short-term mortality among 
black African heterosexuals by sex/reason for test. An estimated 78 deaths 
within a year of diagnosis would have been expected among men, of which 48 
(61%) would have been among recent arrivals diagnosed late and 30 (39%) 
would have been among other individuals. Prevention of late diagnosis among 
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non-recent arrivals could have reduced the observed number of deaths within a 
year of diagnosis among men by 35% (from 120) and the number of all deaths 
by 16% (from 255 to 213) during the period. A similar effect would have been 
expected among women: an estimated 77 deaths within a year of diagnosis 
would have been expected – a 41% decrease in short-term mortality and an 
18% decrease in all mortality during the period. Mortality was so low for women 
diagnosed antenatally that the estimated number of deaths within a year of 
diagnosis was actually greater than the number observed indicating that there 
was no demonstrable preventable short-term mortality among this group. 
Estimated preventable short-term mortality increased slightly but did not change 
markedly if heterosexuals without a reported country of birth or year of arrival 
were assumed to have been in the UK at least two years prior to HIV diagnosis 
(although numbers were small for black Caribbean heterosexuals). 
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Table 6.13. Estimation of preventable short-term mortality among heterosexuals. 
    
Number of 
individuals 
newly 
diagnosed 
Proportion 
of recent 
arrivals 
Proportion  
of recent 
arrivals 
diagnosed 
late 
Estimated 
short-term 
mortality 
among recent 
arrivals 
diagnosed 
late 
Estimated 
short-term 
mortality 
among other 
individuals if 
not diagnosed 
late 
Potential short-
term mortality 
as fraction of 
observed 
short-term 
mortality 
Potentially 
preventable 
short-term 
mortality 
Potentially 
preventable 
short-term 
mortality as a 
percentage of all 
deaths 
           
Assuming heterosexuals with a reported country of birth and year of arrival were representative of all heterosexuals  
    All black African heterosexuals  13,316 41%  (5,460) 42%  (2,285) 4.2%  (96) 0.5%  (55) 151 / 252  (60%) 40%  (117) 18%  (117 / 560) 
    All white heterosexuals  2,475 4%  (97) 33%  (32) 0%  (0) 0.4%  (10) 10 / 60  (17%) 83%  (50) 23%  (50 / 217) 
    All black Caribbean heterosexuals 827 26%  (215) 37%  (80) 4.6%  (4) 0%  (0) 4 / 8  (50%) 50%  (4) 13%  (4 / 30) 
           
    Black African heterosexual men 4,289 40%  (1,733) 52%  (901) 5.3%  (48) 0.9%  (30) 78 / 120  (65%) 35%  (42) 16%  (42 / 255) 
    Black African heterosexual women 
                  (not diagnosed antenatally) 
7,310 44%  (3,221) 42%  (1,353) 3.9%  (53) 0.4%  (23) 77 / 130  (59%) 41%  (53) 18%  (53 / 287) 
    Black African heterosexual women 
                         (diagnosed antenatally) 
1,717 38%  (655) 21%  (134) 1.2%  (2) 0.1%  (1) 3 / 2  (150%) - - 
          
Assuming heterosexuals without a reported country of birth or year of arrival were in the UK at least two years prior to HIV diagnosis 
    All black African heterosexuals  13,316 29%  (3,879) 42%  (1,624) 4.2%  (68) 0.5%  (58) 127 / 252  (40%) 50%  (125) 22%  (125 / 560) 
    All white heterosexuals  2,475 5%  (117) 33%  (38) 0%  (0) 0.4%  (10) 10 / 60  (17%) 83%  (50) 23%  (50 / 217) 
    All black Caribbean heterosexuals 827 11%  (91) 37%  (34) 4.6%  (2) 0%  (0) 2 / 8  (25%) 75%  (6) 20%  (6 / 30) 
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6.5 Discussion 
6.5.1 Overview 
This analysis estimated the proportion of individuals diagnosed late and 
subsequent short-term mortality. It also identified groups that were more likely 
to be diagnosed late with HIV infection and more likely to die before treatment 
could improve or stabilise their condition. Between 1995 and 2007, almost two-
fifths of all individuals were diagnosed late and one in fifty of all individuals died 
within a year of their HIV diagnosis. Overall, late diagnosis decreased over time, 
increased with age and was significantly lower for MSM, heterosexual women 
diagnosed antenatally, individuals of white ethnicity and individuals diagnosed 
in London than for other groups. Among heterosexuals diagnosed since 2000, 
there was evidence that individuals with a high-risk partner and individuals 
infected in the UK by a partner from outside Europe were less likely to be 
diagnosed late. Most importantly, the results show that although short-term 
mortality decreased over time independently of CD4 counts at diagnosis, and 
presumably due to HAART, those diagnosed late were still approximately ten 
times more likely to die within a year of diagnosis than comparable individuals 
who were not diagnosed late (5.4% versus 0.5%). The results indicate that 
substantial mortality could be avoided by reducing late diagnoses. 
The decline in the proportion of HIV-infected individuals diagnosed late between 
1995 and 2007 suggests that increases in HIV testing366 have resulted in earlier 
diagnosis of HIV-infected individuals (there was no evidence from these 
analyses that the availability of HAART in 1996 resulted in a marked increase in 
earlier patient-initiated HIV testing). This means that each year a higher 
 318 
 
proportion of those diagnosed with HIV could be offered therapy early and 
therefore expect a longer and healthier life124;330;367;368. However, the increase in 
numbers of diagnoses of black African heterosexuals (excluding women 
diagnosed antenatally) who were more likely to be diagnosed with low CD4 cell 
counts resulted in about a third of individuals still being diagnosed late since 
2003 and substantial effort is still required to counter this situation. In addition to 
lives lost, there are financial implications of late diagnosis because direct care 
costs in the year following diagnosis are more than 200% higher for patients 
diagnosed late331. However, a much higher proportion of non-white 
heterosexuals were infected abroad369, and therefore, late diagnoses among 
heterosexuals also reflects a lack of opportunities to diagnose earlier.  
Older age, in particular, was associated with both late diagnosis and short-term 
mortality and therefore diagnosis earlier in the course of infection, and at a 
younger age, would synergistically reduce short-term mortality. This was 
evident in that the adjusted odds ratio for short-term mortality among women 
diagnosed antenatally was approximately one fifth of that among other women 
even after controlling for age and late diagnosis. Interestingly, the lower 
proportion of MSM diagnosed late at a similar age to heterosexual men and 
women (not diagnosed antenatally) suggests that they may have been infected 
later in life, which implies that prevention of transmission among heterosexuals 
may need to target heterosexuals at a younger age than MSM. This warrants 
further investigation before changing any public health interventions as this 
observation could also be a result of faster progression or lower pre-infection 
CD4 cell counts among heterosexuals. 
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Women and white individuals may have been infected longer than men and 
other ethnicities diagnosed with similar CD4 counts due to higher CD4 counts 
prior to diagnosis – if these differences persist over time (Section 1.3.2). 
However, proportions diagnosed late across sex and ethnic groups are 
comparable for risks of progression because time since infection, sex and 
ethnic group have little clinical significance on progression of infection after 
adjusting for CD4 cell count and other biomarkers/clinical information49;79;81;82;370 
(hence treatment guidelines do not recommend initiation of antiretroviral 
treatment at different CD4 counts according to sex and ethnicity). 
Although late diagnosis was less common among MSM than other HIV-infected 
individuals371;372, around a fifth were diagnosed late in 2007, which supports 
findings of a continued high proportion of late diagnoses among MSM300;320. 
This is likely to be due to men not presenting for or declining HIV testing 
because it is likely that most actively homosexual men in the UK are aware of 
the risk of HIV infection373. As most MSM newly diagnosed in the UK were 
infected in the UK and have been exposed to years of health promotion, this 
should strengthen calls for targeted messages to highlight the benefits of early 
testing and for HIV testing policy to target this issue. 
Earlier diagnosis of MSM since 1995 may be due in part to increased 
awareness of the benefits of early testing due to HIV testing promotion 
efforts374;375. However, increasing incidence in MSM376, increasing age at 
infection, and a decreasing contribution to new diagnoses of long-term 
undiagnosed MSM who were infected during the peaks in incidence of HIV in 
1983 and in 1989/1990377 could also account for part of this trend. Yet, 
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encouragingly, MSM coming forward earlier for testing were likely to have 
contributed to increases in the numbers of new HIV diagnoses since 2000369. 
The results suggest that groups at high risk of late diagnosis (including 
individuals born in the UK who were exposed to HIV in high prevalence 
countries) should be targeted for appropriate public health action.  Such action 
might include health promotion, opportunistic screening, and removal of any 
barriers to testing. Although the proportion of MSM and sub-Saharan-born 
genitourinary medicine (GUM) clinic attendees who accepted HIV testing 
increased to 86% and 85% respectively in 2007, 35% of MSM and 30% of sub-
Saharan-born individuals whose HIV infection could have been diagnosed 
during their GUM clinic attendance left undiagnosed378;379. Perceptions of risk, 
accessibility of healthcare, fear of deportation, fear of criminalisation and 
community stigma171;297;353;380-385 may all reduce the success of testing policies. 
In particular, there has been concern that the exclusion of ‘irregular’ migrants, 
including failed asylum seekers and visa-overstayers, from eligibility to free HIV 
treatment from the NHS created a barrier to HIV testing, and may have 
hindered efforts to reduce transmission386;387. This may have been compounded 
by social and economic insecurity among ‘irregular’ migrants whose life 
circumstances may consequently place them at greater risk of HIV infection. 
Even if some undiagnosed HIV-infected individuals are encouraged to seek a 
diagnosis through targeted HIV testing promotion campaigns, opportunistic 
screening in a variety of healthcare settings should be considered and among 
groups other than MSM, pregnant women and GUM clinic attendees106-
109;342;388-392. This could be cost-effective even without considering the benefits 
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of prevented transmission393. The intensification of antenatal HIV screening, 
move towards opt-out HIV testing in GUM clinics and change from pre-test 
counseling to pre-test discussion have been very successful115;394;395. Data are 
now available to support the geographical targeting of increased HIV testing396 
but robust evaluation of HIV testing in a variety of settings in the locality of 
communities at high risk of HIV infection is now required. In particular, new 
patient checks in primary care may provide the earliest opportunity to diagnose 
infection among new entrants to the UK107;297;385. However, seeking an HIV test 
may not be the highest priority for these individuals who may also face financial, 
housing, immigration, relationship and discrimination problems in the UK236. 
Short-term mortality may also be reduced by increasing awareness of the risks 
associated with late diagnosis among professionals carrying out health 
assessments for asylum seekers from Africa and the Caribbean (these 
professionals are already recommended to consider HIV397;398). This is 
suggested given the markedly increased numbers of applications for asylum 
from Zimbabweans and Jamaicans between 1999 and 2002399;400 and the large 
number of HIV-infected heterosexuals with insecure immigration or asylum 
seeker status401;402. 
Late diagnosis also varied by region of diagnosis, which may be due to factors 
that could not be considered, such as differences between populations (for 
example awareness of the benefits of HIV testing) or differences in testing 
policy and practice (for example contact tracing and partner notification). It was 
likely to be due to a combination of community and provider characteristics as 
MSM were diagnosed earlier than heterosexuals and because HIV testing 
uptake is known to vary between GUM and antenatal clinics115. 
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6.5.2 Preventable mortality 
Estimated short-term mortality accounted for over a quarter of all deaths 
between 2001 and 2007 and was ten times higher among newly diagnosed 
individuals who were diagnosed late than among those diagnosed promptly. 
The scope for reducing late diagnoses and the consequent short-term mortality 
of recent arrivals to the UK may be limited, as they may already have low CD4 
counts before arrival in the UK. There were marked differences in the proportion 
of recent arrivals between ethnic groups with nine-tenths of black Africans being 
infected abroad in particular. Therefore, less short-term mortality could have 
been prevented by earlier diagnosis in the UK among black African and black 
Caribbean heterosexuals (short-term mortality could have been reduced by 
40% and 50% respectively) than was possible among MSM and white 
heterosexuals (short-term mortality could have been reduced by about four-
fifths). Yet, the absolute number of preventable deaths among black African 
heterosexuals over the period and the potential reduction in overall mortality 
may have been larger than that among MSM because estimated short-term 
mortality accounted for a higher proportion of all deaths (45% (252/560) of all 
deaths among black African heterosexuals occurring between 2000 and 2007 
versus 16% (149/952) of all deaths among MSM and 28% (60/217) of all deaths 
among white heterosexuals). This analysis suggests that reductions in short-
term mortality resulting from prompt diagnosis of all individuals could have given 
a 11% (105/952), 18% (101/560) and 23% (50/217) reduction in the number of 
all deaths among MSM, black African heterosexuals and white heterosexuals, 
respectively, between 2000 and 2007 (deaths among black Caribbeans were 
too few to calculate robust estimates). Numbers of deaths among black Africans 
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were large enough to suggest that less short-term mortality may have been 
preventable among men (35%) than women who were not diagnosed 
antenatally (41%). Given that many individuals diagnosed late had been in the 
UK for two or more years prior to diagnosis, the potential for reducing short-term 
mortality by earlier diagnosis is substantial. It is even possible that significant 
reductions in mortality could be achieved among recent arrivals by earlier 
diagnosis even if these CD4 cell counts were not greater than 200 cells/mm3. 
Pre-treatment deaths and deaths that occur shortly after starting HAART could 
be prevented if diagnosis was made earlier in the course of infection. 
6.5.3 Comparisons 
6.5.3.1 Late diagnosis 
The percentage of HIV-infected individuals diagnosed late in other developed 
countries varied substantially168;339;372;391;403-411 and trends over time also 
varied405-407;409;410;412. However, the factors associated with late diagnosis 
indicate that comparisons between countries should consider the stage of the 
HIV epidemic and trends in diagnoses among different risk groups410. 
Other studies have reported associations between population factors and the 
late diagnosis of HIV infection similar to those found in this analysis: 
age271;301;405;407-410;413;414; sex301;408-410;413;414; risk group301;372;405;407;408; 
ethnicity/race271;410;413;415; time301;406;408;415; migration301;391;409. Some studies 
have identified factors associated with late diagnosis that were not available in 
the integrated dataset. These include being unemployed, in a couple or having 
children408, a lack of earlier/routine testing405;410 and diagnosis at health care 
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settings405;410 (the latter is an effect of, rather than a possible determinant of, 
late diagnosis and so would not help identify groups at increased risk). 
Finally, comparisons between reports of late diagnosis should consider the 
setting in which the studies were conducted because results and changes over 
time may be locally specific416. This may explain why data from a subset of 
larger UK clinics showed that 26.8% of individuals were diagnosed late338. 
6.5.3.2 Consequent mortality 
The ART Cohort Collaboration showed that the probability of death in the first 
year of treatment was lower for individuals who started HAART with a CD4 
count greater than 199 cells/mm3 than for those who started HAART late124. 
The higher mortality in the era of HAART availability among individuals who 
were diagnosed late in my analyses (4.1% of non-IDU individuals aged younger 
than 50 years died within a year and 10.6% of non-IDU individuals aged 50 
years or older) may be due to a high number and proportion of deaths occurring 
in those diagnosed late between diagnosis and treatment initiation. I aimed to 
investigate the consequences of late diagnosis rather than the consequences of 
late initiation of ART and suggest that there are many deaths that could be 
prevented by earlier diagnosis. Similar results have subsequently been found 
elsewhere412;417. Reviews of deaths418 and hospitalisations419 among HIV-
infected individuals in the UK found that 24% and 17% were due to late 
diagnosis and that this was the major preventable cause of death418. Late 
diagnosis and consequent mortality can be prevented with repeated HIV testing 
and effective linkage to, and retention in, care 168;271;413;414;420-422. 
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6.5.3.3 Late diagnosis of heterosexuals 
Other studies in London have found that black-Africans tend to present later 
than white individuals80;321;324;326. However, these have not controlled for 
differences between risk groups or how/where infection was acquired, which 
explained differences in the proportion diagnosed late between ethnicities in this 
analysis. Increasing age and male sex were consistently associated with late 
diagnosis in studies from other countries but these did not consider 
heterosexuals separately and did not show a difference between heterosexuals 
and homosexual men168;331;423. However, two of these studies also considered 
HIV testing history and aspects of sexual behaviour, which were likely to be 
associated with sexual orientation. 
Evidence of earlier diagnosis among individuals with a high-risk partner and 
individuals infected in the UK by a partner from outside Europe suggests that 
awareness of risk among these groups resulted in them seeking healthcare and 
requesting HIV tests. Earlier diagnosis among women diagnosed antenatally 
supports evidence that provider-initiated offer of HIV testing is effective. 
6.5.4 Limitations 
There are limitations to these analyses. The lack of information about viral loads 
at HIV diagnosis may limit the determination of odds ratios of short-term 
mortality because viral load has been shown to be predictive of progression of 
infection independently of CD4 counts and age for treatment naïve individuals 
299;424. However, in patients starting HAART, CD4 cell counts are the dominant 
prognostic factor and viral load levels have relatively little effect on subsequent 
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disease progression124;361. The effect of adherence could not be addressed as 
surveillance does not collect this information. 
The dataset contains some missing data, in particular, of where/how infection 
was acquired and year of arrival. How/where infections were acquired was a 
significant factor associated with late diagnosis but was not available in the 
majority of reports of diagnoses among MSM requiring this information to be 
analysed separately. Lack of information on year of arrival for the majority of 
MSM precluded the consideration of this factor in estimation of preventable 
mortality in this group. Furthermore, women diagnosed antenatally may not all 
have been identified through reports, which may have contributed to the lower 
proportion of other women diagnosed late compared to men.  
Despite the large overall number of records analysed, small numbers for all 
groups except black-African heterosexuals born and infected in Africa limited 
comparisons when stratified by other factors and the conclusions that could be 
drawn from these data. 
Further reports were expected of deaths within a year of diagnosis and 
individuals diagnosed towards the end of 2007 with CD4 cell counts within 91 
days of diagnosis may not have been included because those measurements 
occurred in 2008. These biases due to censoring of the data were particularly 
likely to affect the results of individuals who were diagnosed in 2007 but were 
unlikely to change the overall results.  
For the generalisation of these results to all new diagnoses in E,W&NI the 
immunological status of individuals with known CD4 counts should be 
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representative of comparable individuals without known CD4 counts. There was 
therefore significant potential for bias from not including those without CD4 cell 
counts reported to either surveillance system and those with CD4 cell counts 
more than 91 days after diagnosis. 
There were significant differences between groups in the proportions included in 
the integrated dataset (Sections 5.4.1 and 5.5.1). Heterosexuals, IDU, non-
white individuals, older people and individuals diagnosed outside London were 
under-represented in the integrated dataset and, as all of these groups were 
associated with late diagnosis, it was likely that the overall percentage 
diagnosed late, and therefore consequent mortality, were under-estimated. 
Consequent mortality was also likely to be substantially under-estimated 
because individuals who died were less likely to be included in the integrated 
dataset and because individuals who died within a month of HIV diagnosis were 
less likely to be included than other individuals who died (Sections 5.4.1 and 
5.5.1). As those who died and were not included in the integrated dataset were 
likely to have low CD4 cell counts, the adjusted odds ratios and statistical 
significance for late diagnosis were also likely to be underestimated. Therefore, 
heterosexuals (not diagnosed antenatally), IDU, non-white individuals, older 
people and individuals diagnosed outside London were even more likely to have 
been diagnosed late than the results indicate. Groups least likely to be included 
in the integrated dataset (such as individuals aged 55 years or older, IDU, black 
Africans and black – other individuals, and individuals diagnosed outside 
London) would be more likely to have truly higher odds of late diagnosis. 
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The analysis does not reflect late entry to clinical care because only individuals 
with CD4 cell counts within 91 days of diagnosis were included. Furthermore, 
about a tenth of records included in the integrated dataset were excluded due to 
evidence of previous diagnosis. Some of these individuals will only have had a 
previous positive HIV test result and not previously entered clinical care. 
Records with evidence of recent infection were also excluded. However, some 
of the 8.6% individuals observed with CD4 cell counts less than 200 cells/mm3 
would not have experienced spontaneous immune reconstitution after 
seroconversion. These individuals could be considered as diagnosed late with 
regards their prognosis but probably could not have been diagnosed 
significantly earlier to change their prognosis or reduce transmission343. 
Varying the definition of late diagnosis had little effect on the associations with 
the determining factors. Increasing the CD4 cell count cut-off to 350 cells/mm3 
(to reflect treatment guidelines published in 2008123) and including AIDS in the 
definition of late diagnosis increased the proportions diagnosed late but similarly 
in most groups. The use of AIDS-defining illnesses to define late diagnoses 
would be likely to introduce bias in this study. This is because only individuals 
reported by clinicians can be identified as having AIDS and clinicians may be 
likely to report if an individual has AIDS at HIV diagnosis. Additionally, the 
prevalence of AIDS defining illnesses is likely to vary among populations and 
the CD4 cell counts at which these occur varies355;356;425, which means that 
proportions diagnosed late defined by AIDS diagnoses may not be comparable 
between studies, countries or over time. Requiring two CD4 cell counts to 
define late diagnosis increased or decreased the proportion diagnosed late 
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depending upon the methodology but again, this had relatively little impact on 
the results. 
Late diagnosis and its impact on short-term mortality may have been 
underestimated if HAART had significantly increased CD4 counts between 
diagnosis and the first CD4 count. However, almost a quarter of individuals 
involved in this analysis had CD4 counts within a day of the date of HIV 
diagnosis, and a large majority within a month. HAART is unlikely to be started 
before blood is taken for determination of the CD4 cell count and the delay 
between diagnosis and first CD4 cell count is likely to be accounted for by 
confirmation of infection (there are no national guidelines for how this process 
should be managed). There were significant differences between groups with 
regard the proportions with CD4 cell counts within 91 days of HIV diagnosis. 
Sensitivity analyses, which considered different cut-offs of the time between 
diagnosis and first CD4 cell count in the definition of late diagnosis, showed that 
some of these differences were artificial. The cut-off of 91 days was judged to 
be the best balance between maximising inclusion of records and minimising 
inclusion of CD4 cell counts that may have changed since diagnosis (for optimal 
representativeness). However, there was an association between having AIDS 
at diagnosis and having CD4 cell counts at diagnosis, which may, in particular, 
indicate confounding and suggest that late diagnosis was over-estimated overall 
and that odds ratios were over-estimated for groups that were more likely to be 
diagnosed with AIDS. The greater proportion of CD4 cell counts among 
individuals with AIDS at HIV diagnosis may reflect prioritisation of measuring 
CD4 cell counts among people diagnosed with AIDS. However, around three-
fifths of all individuals diagnosed in E,W&NI between 1995 and 2007 were 
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represented in this analysis and bias should be minimised because deaths and 
CD4 cell counts are independently collected and matched to reports of new HIV 
diagnoses. Information missing due to inability to link records may be more 
likely to be missing at random than if solely collected through clinician reports. 
Additionally, the similar distributions of CD4 cell counts reported to CD4 
Surveillance, and CD4 cell counts reported by clinicians to HARS that were not 
available from CD4 Surveillance, supported the hypothesis that missing CD4 
cell counts were not markedly different from those analysed. 
Varying the definition of short-term mortality by using different cut-off times from 
HIV diagnosis and death significantly changed some of the comparative odds 
ratios. In particular, increased cut-off time between diagnosis and death was 
reflected in a decreased magnitude of the effect of late diagnosis on short-term 
mortality and a corresponding increase in the effects of period of HIV diagnosis, 
age group and risk group. This indicates that the effect of late diagnosis on 
mortality diminishes over time as is clear from trends in the number of deaths by 
time from HIV diagnosis. Increasing the cut-off time to death in the analysis 
increasingly took into account factors that were associated with death post-HIV 
diagnosis, explaining the increase in the adjusted odds ratio for IDU. However, 
limiting the definition of short-term mortality to deaths within three months of 
diagnosis would not capture deaths due to late diagnosis that occurred later in 
the year and therefore would have underestimated the effect of late diagnosis. 
Consideration of the association of CD4 cell count categories at the time of HIV 
diagnosis with short-term mortality indicated that there was not a clear 
difference between diagnosis with CD4 cell counts slightly less than 200 
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cells/mm3 or slightly more. There were marked declines in short-term mortality 
as CD4 cell counts increased to 250-299 cells/mm3 but then little further decline 
thereafter. Short-term mortality was lower among individuals diagnosed with 
CD4 cell counts between 150-199 cells/mm3 than at 200-249 cells/mm3 
although this was not statistically significant. This may reflect selection by 
indication426, in that individuals diagnosed with CD4 cell counts less than 200 
cells/mm3 were more promptly started on ART according to guidelines135 with 
consequently lower short-term mortality than those with CD4 cell counts 
between 200-249 cells/mm3. This analysis suggests that individuals would be 
particularly more likely to survive the first year after diagnosis if they were 
diagnosed before their CD4 cell counts fell below 250 cells/mm3. Guidelines 
released in 2008 recommend that individuals start ART as soon as they are 
ready after CD4 cell counts fall below 350 cells/mm3 123, supported by evidence 
from the SMART clinical trial and previous cohort studies427-429. This is more 
conservative than my conclusion but none of these results can specifically 
support the cost-effectiveness of the guideline threshold as the risk of 
progression appears to fall with increasing CD4 cell counts. However, this has 
brought UK guidelines into conformity with European362 and American 
guidelines430 and has raised calls for harmonisation of a definition of late 
diagnosis as CD4 cell counts less than 350 cells/mm3 337-339;342. 
6.5.5 Further work not presented in this thesis 
Further work was carried out in the development of these analyses that is not 
presented in this thesis239. Inverse probability weighting was used to account for 
missing observations: the CD4 cell counts that were not available at the time of 
HIV diagnosis. This enabled the estimation of numbers diagnosed late and the 
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number of deaths within a year of diagnosis assuming that those with CD4 cell 
counts at the time of HIV diagnosis were representative, in these regards, of all 
individuals newly diagnosed. The estimates produced were in close agreement 
with observed short-term mortality for all individuals newly diagnosed. This 
methodology could be particularly useful for analysing surveillance data, which 
may be incomplete due to under-reporting or due to limitations of matching 
datasets, but where the characteristics of the total population, including which 
individuals are included in ‘nested’ analyses, are known431.  
6.6 Conclusion 
Low CD4 cell counts at diagnosis reflect in general a long time from infection 
and are often indicative of a low awareness of individual risk of infection, a low 
personal drive to know one’s own status and/or a lack of encouragement from 
health services to be tested. Low CD4 counts also indicate that individuals have 
been unaware for a long time that they might infect their partner/s and unaware 
that they could reduce this risk through behavioural change32;334;363;432;433. 
Health promotion efforts can aim to improve awareness of risks, knowledge of 
access to health services, understanding of the benefits of knowing one’s HIV 
status and the acceptability of having an HIV test. HIV testing strategies can 
aim to improve the accessibility of HIV tests by offering and encouraging testing 
at a variety of health services in a culturally sensitive and acceptable fashion.  
In addition to the benefits to patients of an early diagnosis, there are substantial 
public health benefits associated with reducing the prevalence of undiagnosed 
HIV infection and reducing transmission. Almost 30% of HIV-infected individuals 
were estimated to be living with undiagnosed infection in 2007 (over two-fifths of 
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HIV-infected non-African men394). The Department of Health’s National Strategy 
for Sexual Health and HIV for England434 in 2001 aimed to reduce the 
prevalence of undiagnosed infection. While estimates suggest that it may have 
fallen among heterosexuals from 42% in 2001 to 30% in 2007, more needs to 
be done, particularly as the undiagnosed fraction remained stable about 25% 
among MSM over the same period394;435. Large numbers remain undiagnosed 
for a long time, and particularly those who are diagnosed late with high viral 
loads, may be a major source of new infections436. As well as not benefiting 
from therapy they form a reservoir for potential unwitting transmission and 
cannot take measures to reduce the risk of transmission to their partners by 
using HAART or changing their behaviour432;433;437;438. Both the National 
Strategy for Sexual Health and HIV for England434 and the Chief Medical Officer 
for England’s 2004 annual report333, prioritised the uptake of HIV testing in a 
variety of healthcare settings as a core HIV prevention intervention. This has 
also been a recommendation in other countries since 2003439. This strategy 
aims to reduce the number of missed diagnoses423;440-444 and numbers 
diagnosed as hospital inpatients236;297;419;444;445, thus reducing costs331. 
Development of HIV testing services in general medical practices, including for 
individuals from high prevalence countries388;446;447, may reduce late diagnosis 
for HIV-infected heterosexuals who also may be less likely to access other 
health care services171;323. In addition to testing, further resources may also 
need to be committed to contact tracing and partner notification to identify 
infected individuals early and reduce onward transmission, particularly in low 
prevalence areas. Clinicians should be particularly aware of the likely need for 
prompt initiation of HAART among men, older individuals, individuals from 
ethnic minorities or infected abroad and individuals diagnosed outside London. 
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Chapter 7. National incidence rates of death and first AIDS diagnoses 
7.1 Introduction 
Surveillance data are used to monitor trends in the numbers of AIDS diagnoses 
and deaths but the public health utility of this information can be increased by 
considering the number of people and characteristics of people at risk of these 
events with the integrated dataset. HARS data show that numbers of AIDS 
cases diagnosed and deaths were fairly stable between 1997 and 2007 
whereas SOPHID shows that the number of people living with diagnosed HIV 
infection increased during this same time period. Crude comparisons would 
indicate that the cumulative incidence of both AIDS and death continued to 
decline following the widespread availability of HAART since 1996. However, 
this cannot take account of changes in the population at risk or changes in the 
levels of risk due to the effect of HAART. Descriptive analysis is unable to show 
the extent to which changes in the frequency of events, such as AIDS 
diagnoses or deaths, are due to: 
a) changes in CD4 cell counts; 
b) changes in other risk factors for progression to AIDS or death due to 
changing characteristics of the population; 
c) an actual reduction in the risk of AIDS or death independent of CD4 cell 
counts and other population characteristics. 
The independent effects of CD4 cell counts and population characteristics were 
therefore investigated using multivariable Poisson regression analysis of the 
integrated dataset to compare incidence rates while adjusting for changes in 
other factors. The integrated dataset was therefore used to describe the 
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progression of infection among individuals to either AIDS or death as if they 
were being monitored as a prospective cohort. Such a ‘pseudo-cohort’ required 
definition of an individual’s person-years of follow-up (PYFU) – the time during 
which reports of that individual were being received by surveillance systems 
indicating that events, such as AIDS or death, would be reported if they were to 
occur. This was a natural extension of the Poisson regression analysis of loss to 
follow-up (LTFU) to investigate potential bias in chapter 5. For this analysis, it 
was also important to be able to monitor each patient’s changing level of risk 
over time to be able to determine the incidence rate of occurrence of each event 
per person per unit of time at each level of risk. This is because AIDS and death 
are highly associated with CD4 cell counts, which were used in this analysis as 
proxy markers of risk. 
7.2  Aims 
a) To use the integrated dataset to describe trends in the distribution of time 
spent in CD4 cell count categories by adults living with HIV in E,W&NI. 
b) To use the integrated dataset to determine national trends in the incidence 
of first AIDS diagnoses and death, independent of other factors. 
c) To use the integrated dataset to identify factors that were independently 
associated with the incidence of events and determine their relative effect. 
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7.3  Methods 
7.3.1 Data preparation 
The methodology used to determine patient follow-up was similar to that 
described earlier in the analysis of LTFU (Section 5.3.3).  CD4 cell counts in the 
integrated dataset were used to define the time over which each individual was 
followed in the cohort (to account for loss to follow-up, emigration and 
unreported deaths). Patient follow-up was split into distinct periods based on 
CD4 cell counts in the integrated dataset between 1995 and 2007 (Figure 7.1). 
Each period of follow-up was assumed to start on the date of the CD4 cell count 
and end at the earliest of a) the next CD4 cell count, b) a clinical event, c) 31st 
December 2007, d) 91 days following the date of each CD4 cell count if the 
CD4 cell count was followed by another but not within 365 days (temporary 
LTFU). Follow-up was censored immediately after the last CD4 cell count if it 
was before the 1st January 2007 or if it was more than 365 days before the date 
of death (permanent LTFU). Periods of follow-up defined by CD4 cell counts 
within 91 days of HIV diagnosis were considered to start at the date of 
diagnosis to account for the potential bias that could have been introduced by 
excluding follow-up and AIDS diagnoses during this period (Sections 5.4.4.3 
and 5.5.5.2). Each period of follow-up, and any events that occurred in that 
period, were then allocated to a category of risk depending on the value of the 
CD4 count448. This allowed each individual’s level of risk to change over time, 
but considered the level of risk to be constant (based on their CD4 count 
values) during each period of follow-up. Periods of follow-up were censored at a 
maximum of 91 days following the date of each CD4 cell count (subject to 
sensitivity analysis) during temporary LTFU because data gathered from 
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surveillance systems are likely to be incomplete and because imperfect record 
linkage within and between surveillance systems can lead to gaps in follow-up. 
Yet the patient can be considered to be under follow-up for part of this time, 
reflected in the 91 days, as most patients are only seen for clinical 
appointments three of four times a year. In contrast, periods of follow-up were 
censored immediately following the date of each CD4 cell count during 
permanent LTFU. If patient follow-up was censored by temporary LTFU, then 
they were allowed to re-enter the risk set if and when they had a further CD4 
measurement. This ensured that PYFU were included in the analysis at the 
appropriate level of risk and that an event that occurred a long time after the last 
CD4 cell count was measured was not considered to occur at that level of risk. 
Therefore, only events that occurred within the defined PYFU were considered 
in the analysis. Because many individuals have three or four CD4 cell counts 
each year, time at risk was expected to be continuous for most individuals 
(Sections 5.4.3.2 and 5.4.3.3) although split into periods with time-updated 
values of exposures. In the analysis of the incidence of first AIDS diagnoses, 
any CD4 cell counts that occurred after the event were excluded from the 
analysis. Also, because only the month of AIDS is reported to HARS, PYFU 
were considered to end in AIDS when AIDS was reported in the same or 
following twelve months (subject to sensitivity analysis). PYFU were terminated 
halfway between the CD4 cell count and the end of the month if the CD4 count 
was measured in the same month as the AIDS event, and on the 15th of the 
month in which AIDS was diagnosed when AIDS was reported in one of the 
following twelve months. 
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Figure 7.1. Hypothetical calculation of periods of follow-up 
 
 
PYFU and events were subdivided and allocated to calendar years in which 
they occurred. PYFU and events were also subdivided into those that occurred 
within the first six months after HIV diagnosis (subject to sensitivity analysis) 
and those that occurred subsequently. This allowed consideration of whether 
the risk of AIDS or death was higher in the first six months after HIV diagnosis 
than that which would have been expected based on the individuals’ CD4 cell 
counts at the time. This was hypothesised to reflect induction into treatment and 
care and to contribute to the peak in deaths within the first six months after HIV 
diagnosis (Section 6.4.4). 
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As CD4 counts were not linearly associated with AIDS or death, CD4 categories 
were used to assign levels of risk for descriptive analyses but the square root 
transformation of the CD4 cell count was used for multivariable analysis (as 
recommended by the literature [Section 1.3.1] and shown by closer fitting to the 
trend in incidence than when using the logarithm of the CD4 cell count [Figure 
7.4]). Age was included in the analysis as a continuous linear variable based on 
visual assessment of the plot of incidence by age (Figure 7.3) but was also 
presented in groups to simplify description of the data (Table 7.1). 
7.3.2 Statistical analysis 
Poisson regression was used for the analysis of incidence rates as described 
previously (Section 5.3.3).  
The main effects model included the following: 
1. time-updated continuous variables: square root of CD4 cell count; age 
2. time-updated binary variables: previous AIDS diagnosis; region; PYFU 
within the first six months after HIV diagnosis 
3. fixed categorical variables: calendar year of diagnosis; ethnicity; risk group. 
To investigate the possibility of different trends in incidence within the first six 
months after HIV diagnosis and incidence during subsequent follow-up, the 
analysis was repeated including an interaction between calendar year and 
whether PYFU were within the first six months after HIV diagnosis. 
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7.3.3 Sensitivity analyses 
Sensitivity analyses were carried out on the model for the incidence of death to 
determine the impact of varying the way in which PYFU were defined. Firstly, 
the analysis was repeated using the logarithm of the CD4 cell counts and 
categorisation of the CD4 cell counts. The analysis was also repeated, 
censoring the periods of follow-up as follows: 1) immediately or after 365 days 
during periods of temporary LTFU (deaths were still considered if within 365 
days of the last CD4 cell count); 2) at a maximum of six months (182 days) 
following the date of each CD4 count (deaths were only considered if within 182 
days of the last CD4 cell count) or only at the end of 2007 only – i.e. with no 
maximum; 3) at the end of continuous follow-up per individual – i.e. individuals 
were not allowed to re-enter the risk set and only the first continuous phase of 
follow-up was considered. The analysis was also repeated with: 4) termination 
of all follow-up at age 59 – to exclude the possibility of bias due to under-
identification of deaths through record linkage to ONS death files (limited to 
individuals over 59 years of age); 5) Subdividing follow-up one year after HIV 
diagnosis instead of six months after HIV diagnosis. The following sensitivity 
analyses were carried out on the model for AIDS incidence: 1) consideration of 
only AIDS diagnoses reported to HARS; 2) termination of all follow-up at the 
end of 1999 – to exclude the period during which AIDS reporting may have 
significantly dropped; 3) exclusion of time between HIV diagnosis and first CD4 
cell count for individuals with first CD4 cell count within 91 days of diagnosis.  
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7.4 Results: incidence of death (PYFU censored at 365 days) 
7.4.1 Deaths 
In the integrated dataset, there were 3,779 deaths with CD4 cell counts in the 
preceding year, increasing from 360 in 1995 to 555 in 1996, after which the 
numbers remained low (variation from 202 to 317). Deaths within the first six 
months of HIV diagnosis accounted for 14.0% (528/3,779) of these deaths 
increasing from 5.3% (19/360) in 1995 to 22.8% (72/316) in 2005 before falling 
to 17.6% (42/239) in 2007. 
7.4.2 Person-years of follow-up (PYFU) 
There were 830,904 CD4 cell counts from 49,677 individuals that defined PYFU 
in the risk set between 1995 and 2007 (Table 7.1). There was a median 3.67 
years between the start and end of follow-up (IQR 1.36, 7.00, range 1 day to 
13.1 years). A quarter (24.7% [12,278/49,677]) of individuals had gaps in their 
follow-up (summing up to a median 1.55 PYFU [IQR 0.93, 2.71] and adding five 
or more PYFU for 865 [1.7%] patients) so that, overall, individuals contributed a 
median 3.16 PYFU (IQR 1.15, 6.17, range 1 day to 13.1 years). There were a 
total of 204,233 PYFU, increasing from 3,929 in 1995 to 33,058 in 2007.  
By calendar year, an increasing proportion of the total PYFU were spent with 
high CD4 cell counts (Figure 7.2a). PYFU with CD4 cell counts below 100 
cells/mm3 accounted for 26.0%, 11.0%, 6.1% and 2.7% of the total PYFU in 
1995, 1998, 2001 and 2007 respectively. The equivalent trend for PYFU with 
CD4 cell counts of 350 cells/mm3 or above was 33%, 43%, 55% and 68%. 
Absolute PYFU with CD4 counts below 100 cells/mm3 remained substantial 
after 1995; 894, 784 and 892 years in 1998, 2001 and 2007 (Figure 7.2b). 
 342 
 
Figure 7.2a. Proportional distribution of PYFU by CD4 count category over time 
 
Figure 7.2b. Absolute distribution of PYFU by CD4 count category over time 
0
5,000
10,000
15,000
20,000
25,000
30,000
35,000
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Calendar year of follow-up
A
b
s
o
lu
te
 d
is
tr
ib
u
ti
o
n
 o
f 
P
Y
F
U
500+
350-499
200-349
250-299
200-249
150-199
100-149
50-99
<50
0%
20%
40%
60%
80%
100%
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Calendar year of follow-up
P
ro
p
o
rt
io
n
a
l 
d
is
tr
ib
u
ti
o
n
 o
f 
P
Y
F
U
500+
350-499
200-349
250-299
200-249
150-199
100-149
50-99
<50
 343 
 
PYFU within six months of HIV diagnosis accounted for 8.0% (16,415/204,233) 
of all PYFU and this proportion was fairly stable over time. PYFU within six 
months of HIV diagnosis accounted for an increasing proportion of all PYFU at 
CD4 cell counts less than 100 cells/mm3 (increasing from 17.1% in 1995 to 
61.7% in 2005 before falling to 50.6% in 2007) and a decreasing proportion of 
all PYFU at CD4 cell counts or 349 cells/mm3 or more (decreasing from 26.8% 
in 1995 to 8.9% in 2007). 
7.4.3 Incidence of death 
There was an overall incidence of death of 18.5 (95% CI 17.9, 19.1) per 1,000 
PYFU (Table 7.1). The incidence of death among MSM (19.4 [18.6, 20.2]) and 
heterosexual males (20.2 [18.7, 21.9]) was higher than that among 
heterosexual females (12.1 [11.1, 13.2]) and women diagnosed antenatally (3.3 
[2.0, 5.0]) but lower than that among recipients of blood/blood products (36.1 
[29.2, 44.2]) and IDUs (50.9 [45.4, 56.8]). Incidence among white (21.4 [20.6, 
22.3]) and Indian/Pakistani/Bangladeshi individuals (21.5 [16.2, 28.1]) was 
higher than among other groups (varying from 13.2 [12.3, 14.2] among black 
Africans to 15.6 [12.9, 18.7] among individuals of other/mixed ethnicity). The 
incidence rate increased linearly with age (Figure 7.3). The incidence of death 
within the first six months after HIV diagnosis was 32.2 (29.5, 35.0) per 1,000 
PYFU compared to 17.3 (16.7, 17.9) per 1,000 PYFU for those followed six 
months or more after HIV diagnosis. Incidence rates by CD4 cell count category 
were not linearly associated with death. The association between the square 
root of CD4 cell counts and incidence rates more closely approximated the 
incidence rates in each CD4 count category than the association with the 
logarithm of the CD4 count (Figure 7.4). 
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Figure 7.3. Incidence rates of death by age 
 
Figure 7.4. Modelled incidence rates of death by transformed CD4 cell counts 
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7.4.4 Trends in the incidence of death 
The incidence of death increased from 91.6 (82.4, 101.6) per 1,000 PYFU in 
1995 to 104.8 (96.3, 113.9) per 1,000 PYFU in 1996 before falling to 21.9 (19.3, 
24.8) per 1,000 PYFU in 2000 and to 7.2 (6.3, 8.2) per 1,000 PYFU in 2007 
(Table 7.1 and Figure 7.5). This overall trend over time was reflected in each 
CD4 cell count category (Figure 7.5). Trends in the incidence of death over time 
within the first six months after HIV diagnosis were less marked than those seen 
among deaths occurring more than six months after HIV diagnosis: 69.2 (47.6, 
97.2) per 1,000 PYFU in 1996 to 43.9 (31.5, 59.6) in 2000 and to 22.2 (16.0, 
30.0) in 2007 (Figure 7.6).  
 
Figure 7.5. Trends in the incidence of death stratified by CD4 count category 
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Figure 7.6. Trends in the incidence of death stratified according to follow-up 
within or more than six months after HIV diagnosis 
 
 
 
 
 
 
 
 
 
 
Table 7.1. Number of CD4 cell counts, PYFU and incidence of death stratified 
by demographic and other factors. 
 
Number of  
CD4 cell 
counts 
n (%) 
Person-years 
 of follow-up 
(%) 
Number of 
deaths 
n (%) 
Incidence rate 
(per 1,000 
PYFU) 
    Calendar year     
1995 19,682  (2) 3,929  (2) 360  (10) 91.6 
1996 23,375  (3) 5,294  (3) 555  (15) 104.8 
1997 29,719  (4) 6,820  (3) 317  (8) 46.5 
1998 33,699  (4) 8,103  (4) 252  (7) 31.1 
1999 41,874  (5) 9,618  (5) 252  (7) 26.2 
2000 49,813  (6) 11,444  (6) 251  (7) 21.9 
2001 56,035  (7) 12,957  (6) 244  (6) 18.8 
2002 64,730  (8) 15,167  (7) 202  (5) 13.3 
2003 82,711  (10) 19,541  (10) 282  (7) 14.4 
2004 95,137  (11) 23,153  (11) 251  (7) 10.8 
2005 109,482  (13) 26,599  (13) 316  (8) 11.9 
2006 109,078  (13) 28,540  (14) 258  (7) 9.0 
2007 115,569  (14) 33,058  (16) 239  (6) 7.2 
     
   PYFU within first six months 
                          after HIV diagnosis 
    
No 729,565  (88) 187,816  (92) 3251  (86) 17.3 
Yes 101,339  (12) 16,417  (8) 528  (14) 32.2 
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   CD4 cell count category     
<50 32,819  (4) 6,109  (3) 1,741  (46) 285.0 
50-99  34,159  (4) 6,431  (3) 490  (13) 76.2 
100-149 46,000  (6) 9,258  (5) 356  (9) 38.5 
150-199 58,308  (7) 11,950  (6) 241  (6) 20.2 
200-249 71,261  (9) 15,531  (8) 177  (5) 11.4 
250-299 78,296  (9) 18,070  (9) 159  (4) 8.8 
300-349 79,208  (10) 19,536  (10) 122  (3) 6.2 
350-499 198,378  (24) 52,054  (25) 247  (7) 4.7 
>499 232,475  (28) 65,290  (32) 246  (7) 3.8 
     
   Previous AIDS diagnosis     
No  538,971  (65) 136,429  (67) 1,001  (26) 7.3 
Yes 291,933  (35) 67,804  (33) 2,778  (74) 41.0 
     
   Region     
Outside London 307,729  (37) 73,835  (36) 1,538  (41) 20.8 
London  523,175  (63) 130,398  (64) 2,241  (59) 17.2 
     
   Age group     
15-25 30,520  (4) 7,716  (4) 56  (1) 7.3 
25-29 86,629  (10) 21,746  (11) 282  (7) 13.0 
30-34 160,769  (19) 39,954  (20) 647  (17) 16.2 
35-39 193,279  (23) 47,638  (23) 766  (20) 16.1 
40-44 152,151  (18) 37,350  (18) 678  (18) 18.2 
45-49 92,998  (11) 22,414  (11) 548  (15) 24.4 
50-54 53,981  (6) 12,958  (6) 323  (9) 24.9 
>54 60,577  (7) 14,454  (7) 479  (13) 33.1 
     
   Risk group     
MSM 457,677  (55) 111,436  (55) 2,159  (57) 19.4 
Heterosexual men 124,548  (15) 30,969  (15) 626  (17) 20.2 
Heterosexual women 188,618  (23) 46,603  (23) 565  (15) 12.1 
Heterosexual women 
(not diagnosed antenatally) 
25,805  (3) 6,450  (3) 21  (1) 3.3 
IDU 23,527  (3) 6,172  (3) 314  (8) 50.9 
Recipients of blood/blood products 10,729  (1) 2,601  (1) 94  (2) 36.1 
     
   Ethnicity     
White  512,215  (62) 125,016  (61) 2,682  (71) 21.5 
Black-African  234,175  (28) 57,792  (28) 764  (20) 13.2 
Black Caribbean  21,555  (3) 5,658  (3) 82  (2) 14.5 
Black – Other  12,906  (2) 3,322  (2) 47  (1) 14.1 
Indian/Pakistani/Bangladeshi  10,015  (1) 2,507  (1) 54  (1) 21.5 
Other Asian  9,681  (1) 2,374  (1) 32  (1) 13.5 
Other/mixed 30,357  (4) 7,561  (4) 118  (3) 15.6 
     
    Total 830,904  (100) 204,233  (100) 3,779  (100) 18.5 
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7.4.5 Poisson Regression 
Given the large number of deaths observed, there were significant variations in 
the incidence of death in univariable analyses for each factor considered (Table 
7.2). In particular, the incidence rate decreased by a fifth for every unit increase 
in the square root of the CD4 cell count (IRR 0.79; 95% CI 0.79, 0.80). The 
incidence rate was more than five times higher for individuals with PYFU who 
had a previous AIDS diagnosis (IRR 5.58; 95% CI 5.19, 6.00).  In addition, the 
incidence rate among individuals followed in the first six months after HIV 
diagnosis was substantially higher than that among individuals followed more 
than six months after HIV diagnosis (IRR 1.86; 95% CI 1.69, 2.04). The 
incidence rate among individuals under follow-up in 2007 was less than a tenth 
of that among individuals with follow-up in 1996 (IRR 0.07; 95% CI 0.06, 0.08). 
Adjustment for the CD4 cell count substantially decreased the decline in 
incidence observed between 1995 and 2007, particularly between 1995 and 
1998 (bivariable analysis – Figure 7.7). Adjustment for factors other than the 
CD4 cell count in a multivariable analysis generally attenuated the incidence 
rate ratios for most factors studied except for age, PYFU within first six months 
after HIV diagnosis and IDU risk (Table 7.2). However, there was little 
difference between the bivariable analysis and multivariable analysis in the 
decline observed between 1995 and 2007. Adjustment for other factors except 
for CD4 cell count made no appreciable difference to the trend over time in 
comparison to the univariable model. 
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Table 7.2. Results from univariable and multivariable Poisson regression 
analysis of the association between each factor and the incidence of death 
 
Univariable  
incidence rate ratio  
(95% confidence interval) 
Multivariable  
incidence rate ratio  
(95% confidence interval) 
    Calendar year   
1995 4.18 (3.56, 4.91) 1.65 (1.40, 1.95) 
1996 4.78 (4.12, 5.55) 1.91 (1.64, 2.22) 
1997 2.12 (1.80, 2.5) 1.18 (1.00, 1.39) 
1998 1.42 (1.19, 1.69) 1.07 (0.89, 1.27) 
1999 1.19 (1.00, 1.42) 1.03 (0.86, 1.23) 
2000 - - 
 
2001 0.86 (0.72, 1.02) 0.99 (0.83, 1.18) 
2002 0.61 (0.50, 0.73) 0.73 (0.61, 0.88) 
2003 0.66 (0.56, 0.78) 0.87 (0.73, 1.03) 
2004 0.49 (0.41, 0.59) 0.73 (0.61, 0.87) 
2005 0.54 (0.46, 0.64) 0.87 (0.74, 1.03) 
2006 0.41 (0.35, 0.49) 0.70 (0.59, 0.84) 
2007 0.33 (0.28, 0.39) 0.64 (0.54, 0.77) 
   
    Square root of CD4 cell count 0.79 (0.79, 0.80) 0.82 (0.82, 0.83) 
   
   PYFU within first six months 
                          after HIV diagnosis 
  
No - - 
Yes 1.86 (1.69, 2.04) 1.35 (1.22, 1.49) 
   
    Previous AIDS diagnosis   
Yes 5.58 (5.19, 6.00) 2.34 (2.16, 2.53) 
No - - 
   
    Region   
Outside London 1.21 (1.14, 1.29) 1.17 (1.10, 1.26) 
London - - 
   
    Age, per additional 10 years 1.33 (1.29, 1.38) 1.37 (1.33, 1.42) 
   
   Risk group   
MSM - - 
Heterosexual men 1.04 (0.95, 1.14) 0.87 (0.78, 0.97) 
Heterosexual women 0.63 (0.57, 0.69) 0.83 (0.73, 0.94) 
Heterosexual women 
 (diagnosed antenatally) 
0.17 (0.11, 0.26) 0.64 (0.41, 0.99) 
IDU 2.63 (2.33, 2.96) 2.06 (1.82, 2.32) 
Recipients of blood products 1.87 (1.52, 2.29) 1.13 (0.92, 1.40) 
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   Ethnicity   
White  - - 
Black African 0.62 (0.57, 0.67) 0.91 (0.81, 1.02) 
Black Caribbean 0.68 (0.54, 0.84) 0.90 (0.72, 1.12) 
Black Other 0.66 (0.49, 0.88) 0.87 (0.65, 1.17) 
Indian\Pakistani\Bangladeshi 1.00 (0.77, 1.31) 0.97 (0.73, 1.27) 
Other Asian 0.63 (0.44, 0.89) 0.83 (0.59, 1.18) 
Other/mixed 0.73 (0.60, 0.87) 0.89 (0.74, 1.07) 
 
 
Figure 7.7. Incidence rate ratio of death by calendar year of follow-up: 
comparison of different models 
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7.4.6 Interaction between calendar year and follow-up within six 
months of HIV diagnosis 
The model including an interaction between calendar year and whether follow-
up was within six months of HIV diagnosis or not indicated that incidence of 
death during follow-up within six months after HIV diagnosis did not decline over 
time (Table 7.3). In contrast, the rate ratio for follow-up more than six months 
after HIV diagnosis fell significantly between 1996 and 1997 (IRR 0.61, 95% CI 
0.53, 0.70), but then decreased more gradually to 2007 (Table 7.3). The rate 
ratios for risk groups were attenuated (except that heterosexual men had a 
lower rate of death than MSM in this model) and the effects of ethnic groups 
became non-significant. The rate ratios for CD4 cell counts, age, previous AIDS 
diagnosis and region did not change significantly.  
Table 7.3. Results from multivariable Poisson regression of the association 
between each factor and the incidence of death including an interaction 
between calendar year and PYFU within first six months after HIV diagnosis 
 
Multivariable  
incidence rate ratio  
(95% confidence interval) 
Multivariable  
incidence rate ratio: 
interaction between calendar 
year and PYFU within six 
months after HIV diagnosis  
(95% confidence interval) 
    Square root of CD4 cell count 0.82 (0.82, 0.83) 0.82 (0.82, 0.83) 
   
    PYFU within first six months 
                          after HIV diagnosis 
  
No - - 
Yes 1.35 (1.22, 1.49) 1.54 (1.10, 2.15) 
   
    Previous AIDS diagnosis   
No - - 
Yes 2.34 (2.16, 2.53) 2.35 (2.18, 2.54) 
   
    Age, per additional 10 years 1.37 (1.33, 1.42) 1.37 (1.33, 1.42) 
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    Calendar year all PYFU 
PYFU more than six months 
after HIV diagnosis 
1995 4.18 (3.56, 4.91) 1.77 (1.48, 2.11) 
1996 4.78 (4.12, 5.55) 2.01 (1.71, 2.36) 
1997 2.12 (1.80, 2.50) 1.22 (1.02, 1.46) 
1998 1.42 (1.19, 1.69) 1.10 (0.91, 1.33) 
1999 1.19 (1.00, 1.42) 1.08 (0.89, 1.30) 
2000 - - 
2001 0.86 (0.72, 1.02) 0.97 (0.79, 1.17) 
2002 0.61 (0.50, 0.73) 0.75 (0.61, 0.92) 
2003 0.66 (0.56, 0.78) 0.88 (0.73, 1.06) 
2004 0.49 (0.41, 0.59) 0.71 (0.58, 0.86) 
2005 0.54 (0.46, 0.64) 0.84 (0.69, 1.01) 
2006 0.41 (0.35, 0.49) 0.74 (0.61, 0.89) 
2007 0.33 (0.28, 0.39) 0.63 (0.51, 0.76) 
  
PYFU within six months after 
HIV diagnosis 
1995  0.50 (0.28, 0.89) 
1996  0.62 (0.38, 1.01) 
1997  0.76 (0.46, 1.27) 
1998  0.81 (0.48, 1.35) 
1999  0.73 (0.43, 1.22) 
2000  - 
2001  1.09 (0.69, 1.71) 
2002  0.86 (0.53, 1.40) 
2003  0.90 (0.57, 1.40) 
2004  1.10 (0.70, 1.72) 
2005  1.20 (0.78, 1.84) 
2006  0.72 (0.44, 1.18) 
2007  1.16 (0.72, 1.86) 
   
    Region   
Outside London 1.21 (1.14, 1.29) 1.17 (1.10, 1.25) 
London - - 
   
   Risk group   
MSM - - 
Heterosexual men 1.04 (0.95, 1.14) 0.87 (0.78, 0.97) 
Heterosexual women 0.63 (0.57, 0.69) 0.83 (0.73, 0.94) 
Heterosexual women 
 (diagnosed antenatally) 
0.17 (0.11, 0.26) 0.63 (0.41, 0.98) 
IDU 2.63 (2.33, 2.96) 2.07 (1.83, 2.33) 
Recipients of blood products 1.87 (1.52, 2.29) 1.13 (0.91, 1.39) 
   
   Ethnicity   
White  - - 
Black African 0.62 (0.57, 0.67) 0.90 (0.80, 1.02) 
Black Caribbean 0.68 (0.54, 0.84) 0.90 (0.72, 1.13) 
Black Other 0.66 (0.49, 0.88) 0.88 (0.65, 1.17) 
Indian\Pakistani\Bangladeshi 1.00 (0.77, 1.31) 0.97 (0.73, 1.27) 
Other Asian 0.63 (0.44, 0.89) 0.82 (0.58, 1.17) 
Other/mixed 0.73 (0.60, 0.87) 0.88 (0.73, 1.06) 
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7.4.7 Sensitivity analysis 
7.4.7.1 Transformation/categorisation of CD4 cell counts 
Replacement of the square root of the CD4 cell count in the multivariable 
analysis with CD4 categories had little effect on the incidence rate ratios or the 
trends observed (Figure 7.8). Use of the logarithm of the CD4 cell count 
increased the rate ratios before 2000 and reduced them afterwards such that 
there was a slightly more marked trend over time.  
Figure 7.8. Incidence rate ratio of death by calendar year of follow-up: 
multivariable models using CD4 count categories and transformations of the 
CD4 count compared to univariable analysis 
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7.4.7.2 Changing the strategy for censoring PYFU during 
temporary follow-up 
The number of PYFU increased to 215,449 and incidence decreased to 17.5 
(95% CI 17.0, 18.1) per 1,000 PYFU when the analysis was repeated with 
inclusion of all 365 days of follow-up time during periods of temporary LTFU. 
When follow-up was censored immediately during temporary LTFU, the number 
of PYFU decreased to 200,550 and incidence increased to 18.8 (95% CI 18.3, 
19.5) per 1,000 PYFU. The multivariable incidence rate ratios and estimates of 
incidence between 1995 and 2007 were almost exactly the same between the 
three models except that incidence estimates were reduced in 1995 and 1996 
with less follow-up included (Figure 7.9). There were no major differences 
between the models in the rate ratios for the other determining factors. 
Figure 7.9. Incidence rates and rate ratios of death by calendar year of follow-
up – comparison of multivariable models using different censoring strategies 
with temporary LTFU defined as no subsequent measurement within 365 days 
of a CD4 cell count. 
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7.4.7.3 Changing the definition of temporary LTFU 
When the definition of temporary LTFU was changed from 365 days, with 
follow-up time and deaths included for up to 365 days after a CD4 cell count 
measurement, to 182 days, with follow-up time and deaths included for up to 
182 days, overall estimates of incidence increased marginally from 17.5 (95% 
CI 17.0, 18.1) to 17.9 (95% CI 17.3, 18.6) (total PYFU decreased from 215,449 
to 180,821 years) (Figure 7.9). Without any temporary LTFU (follow-up after a 
CD4 cell count measurement considered to continue until 31 December 2007 or 
death), overall estimates of incidence declined to 15.6 (95% CI 15.1, 16.1) (total 
PYFU increased to 268,076 years). The number of deaths and PYFU included 
in the analysis increased with the maximum period of follow-up used for the 
definition of temporary LTFU and the number of individuals with gaps in their 
overall follow-up of more than five years declined from 1,472 to 865 to zero. 
When temporary LTFU was defined by more than 182 days with no subsequent 
CD4 cell count, estimates of incidence were lower between 1995 and 1998 but 
there was little difference between the estimates for 1999 to 2007 (Figure 7.10). 
Rate ratios were also slightly lower in 1996 and 1997. With follow-up continued 
until 31 December 2007 or death, estimates of incidence were lower throughout 
than with temporary LTFU defined by more than 365 days with no subsequent 
CD4 cell count, but particularly in 1995 and 1996. Rate ratios were relatively 
high before 2000 and low after 2000 (Figure 7.10). However, overall trends for 
both incidence and the rate ratios were similar between the three models with 
different definitions of temporary LTFU. Differences in the rate ratios for the 
other factors were negligible between the models with defined temporary LTFU 
but slightly more marked for the model without temporary LTFU. 
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Figure 7.10. Incidence rates and rate ratios of death by calendar year of follow-
up – comparison of multivariable models using different definitions of temporary 
LTFU. 
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7.4.7.5 Excluding follow-up after 59 years of age 
Exclusion of follow-up after 59 years of age reduced the overall PYFU to 
197,116 and the number of deaths to 3,533 resulting in an overall incidence of 
17.9 (95% CI 17.3, 18.5) per 1,000 PYFU. There were no substantial changes 
in incidence rate ratios in the model when compared to the original model 
including individuals of all ages. 
7.4.7.6 Follow-up split one year after HIV diagnosis instead of six 
months after HIV diagnosis 
When PYFU and events were subdivided into those that occurred within the first 
year after HIV diagnosis and those that occurred subsequently, the total number 
of PYFU and deaths included in the analysis did not change. The adjusted  
incidence rate ratio for follow-up within the first year after HIV diagnosis 
compared to later follow-up was 1.21 (95% CI 1.11, 1.32). This was slightly 
lower than in the original analysis (IRR 1.35; 95% CI 1.22, 1.49) and in the other 
sensitivity analyses. The rate ratios for the other factors did not differ 
substantially in this model compared to the original. 
7.5 Results: incidence of AIDS (PYFU censored at 365 days) 
7.5.1 AIDS 
Over a quarter of individuals in the integrated dataset (31.5% [14,647/46,527]) 
were reported to have had AIDS. Nine in ten (93.4% [13,675]) of these AIDS 
diagnoses followed a CD4 cell count in 1994 or later and 97.4% (13,323) of 
those were less than 12 months after a CD4 cell count and were considered in 
this analysis. Half (50.7% [6,760]) of these AIDS diagnoses were reported to 
HARS (may also have been reported to SOPHID) and half were reported to 
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SOPHID but not HARS (49.3% [6,563]). There was a high number of AIDS 
diagnoses within the first three months after HIV diagnosis after which numbers 
of AIDS diagnoses were low but remained slightly elevated during the first year 
(Figure 7.11). 
Figure 7.11. Number of AIDS diagnoses among all individuals who were known 
to have AIDS by the time from HIV diagnosis to AIDS (AIDS diagnoses within 
five years of HIV diagnosis and 12 months of a CD4 cell count) 
 
The number of AIDS diagnoses per calendar year varied from 910 to 1,089 
between 1995 and 1997 then fell to 698 in 1998. After 1998, AIDS diagnoses 
increased to 1,336 in 2003 then declined to 931 in 2007. AIDS within the first six 
months of HIV diagnosis occurred much more frequently than death within the 
first six months of HIV diagnosis. AIDS within the first six months of HIV 
diagnosis accounted for half (52.7% [7,015/13,323]) of the total number of AIDS 
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diagnoses. This percentage increased from 26.8% (239/891) in 1995 to 65.4% 
(753/1,152) in 2002 before declining to 51.9% (483/931) in 2007. 
The percentage of AIDS diagnoses that were reported to HARS declined from 
83.8% (747/891) in 1995 to 36.1% (336/931) in 2007, primarily due to a marked 
decline in HARS reports of AIDS diagnosed more than six months after HIV 
diagnosis (Figure 7.12). Therefore, the trend in the percentage of AIDS 
diagnoses that were reported to HARS was more marked for AIDS diagnoses 
that occurred more than six months after an HIV diagnosis (Figure 7.13). 
Figure 7.12. Numbers of AIDS diagnoses reported to HARS and SOPHID by 
whether AIDS was within the first six months after an HIV diagnosis or not 
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Figure 7.13. Percentage of AIDS diagnoses reported from HARS by whether 
AIDS was diagnosed within the first six months after an HIV diagnosis or not 
 
7.5.2 Person-years of follow-up  
There were 547,848 CD4 cell counts from 45,176 individuals that defined PYFU 
in the risk set between 1995 and 2007 (Table 7.6). Follow-up (median 2.0 PYFU 
[IQR 0.5, 4.6, range 1 day to 13.1 years] and the median number of CD4 cell 
counts during follow-up (8 [IQR 3, 18, range 1 to 124]) were slightly less per 
individual than for the analysis of incidence of death because PYFU between 
AIDS and death was excluded. There were a total of 136,648 PYFU, increasing 
from 3,436 in 1995 to 23,060 in 2007.  
The distribution of PYFU by CD4 cell count was very similar but lower than that 
in the analysis of death incidence. PYFU with CD4 cell counts below 100 
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1995, 1998, 2001 and 2007 respectively. The equivalent trend for PYFU with 
CD4 cell counts of 350 cells/mm3 or above was 43.9%, 54.3%, 61.5% and 
69.8%. Absolute PYFU with CD4 cell counts below 100 cells/mm3 declined from 
441.9 in 1995 to 264.6 in 1998 then increased to 402.2 in 2003 and then 
remained stable at a mean of 394.0 PYFU between 2003 and 2007. 
7.5.3 Incidence of AIDS 
There was an overall incidence of AIDS of 93.0 (95% CI 91.4, 94.6) per 1,000 
PYFU (Table 7.4). The incidence of AIDS within the first six months after HIV 
diagnosis was 469.0 (458.2, 479.9) per 1,000 PYFU compared to 44.9 (43.7, 
46.1) per 1,000 PYFU for those followed six months or more after HIV 
diagnosis. The incidence of AIDS was highest among heterosexual men (152.5 
[147.0, 158.2]), then in order of decreasing incidence, IDU (119.4 [108.7, 
130.8]), heterosexual women (112.6 [108.9, 116.4]), recipients of blood/blood 
products (83.9 [71.0, 98.5]), MSM (73.1 [71.2, 75.1]) and finally, women 
diagnosed antenatally (35.2 [30.5, 40.4]). Incidence was highest among 
Indian/Pakistani/Bangladeshi individuals (145.0 [126.2, 165.9]), similar among 
other Asians (134.4 [116.3, 154.5]) and black Africans (127.0 [123.4, 130.6]) 
and lowest among white individuals (76.5 [74.6, 78.4]). The increase in the 
incidence rate was approximately linear with age (Figure 7.14).  
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Table 7.4. Number of CD4 cell counts, PYFU and incidence of AIDS stratified 
by demographic and other factors. 
 
Number of  
CD4 cell 
counts 
n (%) 
Person-years 
 of follow-up 
(%) 
Number of AIDS 
diagnoses 
n (%) 
Incidence rate 
(per 1,000 
PYFU) 
    Calendar year     
1995 14,014  (3) 3,435  (3) 978  (8) 284.6 
1996 14,974  (3) 3,589  (3) 819  (6) 228.2 
1997 18,280  (3) 4,425  (3) 973  (8) 219.9 
1998 20,172  (4) 5,018  (4) 647  (5) 128.9 
1999 24,850  (5) 5,933  (4) 734  (6) 123.7 
2000 30,079  (5) 7,089  (5) 851  (7) 120.0 
2001 34,953  (6) 8,178  (6) 934  (7) 114.2 
2002 41,723  (8) 9,776  (7) 1093  (9) 111.8 
2003 54,647  (10) 12,910  (9) 1,282  (10) 99.3 
2004 63,850  (12) 15,531  (11) 1,224  (10) 78.8 
2005 74,556  (14) 18,145  (13) 1,211  (10) 66.7 
2006 74,705  (14) 19,554  (14) 1,075  (8) 55.0 
2007 81,045  (15) 23,059  (17) 885  (7) 38.4 
     
   PYFU within first six months 
                          after HIV diagnosis 
    
No 460,388  (84) 121,152  (89) 5,439  (43) 44.9 
Yes 87,460  (16) 15,495  (11) 7,267  (57) 469.0 
     
   CD4 cell count category     
<50 12,845  (2) 1,884  (1) 3,894  (31) 2066.4 
50-99  15,328  (3) 2,695  (2) 1,981  (16) 734.9 
100-149 23,653  (4) 4,610  (3) 1,369  (11) 296.9 
150-199 33,401  (6) 6,618  (5) 1,050  (8) 158.7 
200-249 45,068  (8) 9,651  (7) 959  (8) 99.4 
250-299 52,814  (10) 12,094  (9) 723  (6) 59.8 
300-349 55,378  (10) 13,716  (10) 618  (5) 45.1 
350-499 142,139  (26) 37,687  (28) 1,155  (9) 30.6 
>499 167,222  (31) 47,688  (35) 957  (8) 20.1 
     
   Region     
Outside London 209,412  (38) 50,992  (37) 5,072  (40) 99.5 
London  338,436  (62) 85,655  (63) 7,634  (60) 89.1 
     
   Age group     
15-25 27,086  (5) 6,898  (5) 504  (4) 73.1 
25-29 70,199  (13) 17,804  (13) 1,620  (13) 91.0 
30-34 116,316  (21) 29,357  (21) 2,861  (23) 97.5 
35-39 126,719  (23) 31,754  (23) 2,843  (22) 89.5 
40-44 92,416  (17) 22,963  (17) 2,065  (16) 89.9 
45-49 53,219  (10) 12,947  (9) 1,248  (10) 96.4 
50-54 29,707  (5) 7,179  (5) 725  (6) 101.0 
>54 32,186  (6) 7,741  (6) 840  (7) 108.5 
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Figure 7.14. Incidence rates of AIDS by age 
   Risk group     
MSM 300,490  (55) 74,949  (55) 5,478  (43) 73.1 
Heterosexual men 75,578  (14) 18,832  (14) 2,872  (23) 152.5 
Heterosexual women 126,874  (23) 31,430  (23) 3,540  (28) 112.6 
Heterosexual women 
(not diagnosed antenatally) 
23,251  (4) 5,769  (4) 203  (2) 35.2 
IDU 14,633  (3) 3,878  (3) 463  (4) 119.4 
Recipients of blood/blood products 7,022  (1) 1,787  (1) 150  (1) 83.9 
     
   Ethnicity     
White  336,200  (61) 84,016  (61) 6,428  (51) 76.5 
Black-African  155,617  (28) 38,249  (28) 4,857  (38) 127.0 
Black Caribbean  15,077  (3) 3,975  (3) 389  (3) 97.8 
Black – Other  8,780  (2) 2,302  (2) 212  (2) 92.1 
Indian/Pakistani/Bangladeshi  5,768  (1) 1,461  (1) 212  (2) 145.0 
Other Asian  6,025  (1) 1,466  (1) 197  (2) 134.4 
Other/mixed 20,381  (4) 5,175  (4) 411  (3) 79.4 
     
    Total 547,848  (100) 136,647  (100) 12,706  (100) 93.0 
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7.5.4 Trends in the incidence of AIDS 
The incidence of AIDS decreased from 284.6 (267.1, 303.1) per 1,000 PYFU in 
1995 to 38.4 (35.9, 41.0) per 1,000 PYFU in 2007 Table 7.4). There were 
marked declines between 1995 and 1998 and a gradual decline between 1998 
and 2007. The decline in the incidence of AIDS within the first six months after 
HIV diagnosis was less marked than that seen for AIDS occurring more than six 
months after HIV diagnosis (Figure 7.15). 
Figure 7.15. Trends in the incidence of AIDS stratified according to follow-up 
within, or more than, six months after HIV diagnosis 
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7.5.5 Poisson Regression 
There were significant variations in the incidence rate ratios for AIDS in 
univariable analyses for each factor considered, similar to that observed for 
deaths (Table 7.5). The relationship between AIDS incidence and square root of 
the CD4 cell count was very similar to that for the incidence of death (IRR 0.79; 
95% CI 0.78, 0.79). The incidence rate ratio for PYFU within the first six months 
after HIV diagnosis was greater than that for the incidence of death (IRR 10.45; 
95% CI 10.09, 10.82). The incidence rate among individuals under follow-up in 
2007 was about a eighth of that in 1995 (IRR 0.13; 95% CI 0.12, 0.15). 
Adjustment for the CD4 cell count markedly decreased the decline in incidence 
observed between 1995 and 1998 and explained much of the change in the 
incidence of AIDS between 1995 and 2000 (bivariable analysis – Figure 7.16). 
However, the trend after 2000 was similar to that in the univariable model. 
Adjustment for factors other than the CD4 cell count made the trend over time 
slightly more marked in comparison to the univariable model. Adjustment for all 
factors in a multivariable analysis resulted in a decline that was more marked 
than the univariable analysis but less marked than the bivariable analysis. 
Multivariable analysis attenuated the incidence rate ratios for all factors studied 
except for age (IRR 1.16; 95% CI 1.14, 1.18 compared to IRR 1.05; 95% CI 
1.03, 1.07 previously) (Table 7.5).  
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Figure 7.16. Incidence rate ratio of AIDS by calendar year at risk: comparison of 
different models 
 
 Table 7.5. Results from univariable and multivariable Poisson regression 
analysis of the association between each factor and the incidence of AIDS 
 
Univariable  
incidence rate ratio  
(95% confidence interval) 
Multivariable  
incidence rate ratio  
(95% confidence interval) 
    Calendar year   
1995 2.37 (2.16, 2.60) 1.46 (1.33, 1.61) 
1996 1.90 (1.73, 2.09) 1.25 (1.13, 1.37) 
1997 1.83 (1.67, 2.01) 1.38 (1.26, 1.51) 
1998 1.07 (0.97, 1.19) 0.95 (0.85, 1.05) 
1999 1.03 (0.93, 1.14) 0.98 (0.89, 1.08) 
2000 - - 
2001 0.95 (0.87, 1.04) 0.89 (0.81, 0.98) 
2002 0.93 (0.85, 1.02) 0.85 (0.78, 0.93) 
2003 0.83 (0.76, 0.90) 0.79 (0.72, 0.86) 
2004 0.66 (0.60, 0.72) 0.70 (0.64, 0.76) 
2005 0.56 (0.51, 0.61) 0.64 (0.59, 0.70) 
2006 0.46 (0.42, 0.50) 0.61 (0.56, 0.67) 
2007 0.32 (0.29, 0.35) 0.48 (0.44, 0.53) 
   
    Square root of CD4 cell count 0.79 (0.78, 0.79) 0.82 (0.82, 0.83) 
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    PYFU within first six months 
                          after HIV diagnosis 
  
No - - 
Yes 10.45 (10.09, 10.82) 5.79 (5.58, 6.02) 
   
    Region   
Outside London 1.12 (1.08, 1.16) 1.09 (1.05, 1.13) 
London - - 
   
    Age, per additional 10 years 1.05 (1.03, 1.07) 1.16 (1.14, 1.18) 
   
   Risk group   
MSM - - 
Heterosexual men 2.09 (1.99, 2.18) 0.99 (0.93, 1.05) 
Heterosexual women 1.54 (1.48, 1.61) 0.96 (0.91, 1.02) 
Heterosexual women 
 (diagnosed antenatally) 
0.48 (0.42, 0.55) 0.49 (0.42, 0.57) 
IDU 1.63 (1.49, 1.80) 0.99 (0.90, 1.09) 
Recipients of blood products 1.15 (0.98, 1.35) 0.61 (0.51, 0.71) 
   
   Ethnicity   
White  - - 
Black African 1.66 (1.60, 1.72) 1.11 (1.05, 1.18) 
Black Caribbean 1.28 (1.15, 1.42) 0.97 (0.87, 1.08) 
Black Other 1.20 (1.05, 1.38) 0.89 (0.77, 1.02) 
Indian\Pakistani\Bangladeshi 1.90 (1.65, 2.17) 1.44 (1.25, 1.66) 
Other Asian 1.76 (1.52, 2.02) 1.42 (1.23, 1.64) 
Other/mixed 1.04 (0.94, 1.15) 0.96 (0.87, 1.07) 
   
 
 
7.5.6 Interaction between calendar year and follow-up within six 
months of HIV diagnosis 
The analysis was repeated including an interaction between calendar year and 
whether follow-up was within six months of HIV diagnosis or not. The model 
indicated that the incidence of AIDS during follow-up within six months after HIV 
diagnosis increased between 1995 and 2000 (IRR 0.37; 95% CI 0.31, 0.45 in 
1995 compared to 2000) but then remained largely stable to 2007 (IRR 0.97; 
95% CI 0.80, 1.18 in 2007 compared to 2000) (Table 7.6). In contrast, the rate 
ratios for follow-up more than six months after HIV diagnosis followed a similar 
trend as in the overall multivariable analysis. Rate ratios compared to 2000 
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decreased markedly between 1995 (IRR 2.29; 95% CI 2.00, 2.63) and 1998 
(IRR 1.17; 95% CI 1.00, 1.38) and then continued to decrease more gradually 
until 2007 (IRR 0.50; 95% CI 0.43, 0.58).  Rate ratios for other factors did not 
appreciably change. 
Table 7.6. Results from multivariable Poisson analysis of the association 
between each factor and the incidence of AIDS including an interaction between 
calendar year and PYFU within first six months after HIV diagnosis 
 
Multivariable  
incidence rate ratio  
(95% confidence interval) 
Multivariable  
incidence rate ratio: 
interaction between calendar 
year and PYFU within six 
months after HIV diagnosis  
(95% confidence interval) 
    Square root of CD4 cell count 0.82 (0.82, 0.83) 
 
0.83 (0.83, 0.83) 
 
   
    PYFU within first six months 
                          after HIV diagnosis 
  
No - - 
Yes 5.79 (5.58, 6.02) 
 
7.53 (6.54, 8.67) 
    
    Region   
Outside London 1.09 (1.05, 1.13) 
 
1.08 (1.04, 1.12) 
 
London - - 
   
    Age, per additional 10 years 1.16 (1.14, 1.18) 
 
1.17 (1.14, 1.19) 
 
   
   Risk group   
MSM - - 
Heterosexual men 2.09 (1.99, 2.18) 0.99 (0.93, 1.05) 
Heterosexual women 1.54 (1.48, 1.61) 0.97 (0.91, 1.03) 
Heterosexual women 
 (diagnosed antenatally) 
0.48 (0.42, 0.55) 0.48 (0.42, 0.56) 
IDU 1.63 (1.49, 1.80) 1.01 (0.92, 1.11) 
Recipients of blood products 1.15 (0.98, 1.35) 0.57 (0.49, 0.68) 
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    Calendar year all PYFU 
PYFU more than six months 
after HIV diagnosis 
1995 1.46 (1.33, 1.61) 2.29 (2.00, 2.63) 
1996 1.25 (1.13, 1.37) 1.71 (1.48, 1.98) 
1997 1.38 (1.26, 1.51) 2.12 (1.85, 2.44) 
1998 0.95 (0.85, 1.05) 1.17 (1.00, 1.38) 
1999 0.98 (0.89, 1.08) 1.11 (0.95, 1.30) 
2000 - - 
2001 0.89 (0.81, 0.98) 0.94 (0.80, 1.10) 
2002 0.85 (0.78, 0.93) 0.83 (0.71, 0.97) 
2003 0.79 (0.72, 0.86) 0.90 (0.78, 1.04) 
2004 0.70 (0.64, 0.76) 0.71 (0.61, 0.83) 
2005 0.64 (0.59, 0.70) 0.66 (0.57, 0.77) 
2006 0.61 (0.56, 0.67) 0.61 (0.53, 0.70) 
2007 0.48 (0.44, 0.53) 0.50 (0.43, 0.58) 
  
PYFU within six months 
after HIV diagnosis 
1995  0.37 (0.31, 0.45) 
1996  0.55 (0.45, 0.67) 
1997  0.43 (0.36, 0.53) 
1998  0.70 (0.56, 0.86) 
1999  0.81 (0.67, 1.00) 
2000  - 
2001  0.91 (0.75, 1.11) 
2002  1.03 (0.85, 1.24) 
2003  0.81 (0.67, 0.97) 
2004  0.97 (0.80, 1.16) 
2005  0.95 (0.79, 1.14) 
2006  1.04 (0.87, 1.26) 
2007  0.97 (0.80, 1.18) 
   
   Ethnicity   
White  - - 
Black African 1.66 (1.60, 1.72) 1.10 (1.03, 1.17) 
Black Caribbean 1.28 (1.15, 1.42) 0.97 (0.87, 1.08) 
Black Other 1.20 (1.05, 1.38) 0.88 (0.76, 1.01) 
Indian\Pakistani\Bangladeshi 1.90 (1.65, 2.17) 1.44 (1.25, 1.65) 
Other Asian 1.76 (1.52, 2.02) 1.39 (1.21, 1.61) 
Other/mixed 1.04 (0.94, 1.15) 0.96 (0.87, 1.06) 
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7.5.7 Sensitivity analyses 
7.5.7.1 Consideration of only AIDS diagnoses reported to HARS 
Estimates of incidence decreased substantially when the analysis was repeated 
with consideration of only AIDS diagnoses reported to HARS. Although the 
shape of the trend over time was similar (Figure 7.17) there was a much more 
marked decline in the multivariable incidence rate ratios (from 2.62; 95% CI 
2.34, 2.93 in 1995 to 0.33; 95% CI 0.28, 0.38 in 2007 when compared to 2000) 
(Table 7.7). 
In addition to change in trend over time, there was a much higher rate ratio for 
individuals followed within the first six months after HIV diagnosis than for those 
followed subsequently (IRR 11.31; 95% CI 10.68, 11.97) than in the original 
model (Table 7.7). There were also changes in the rate ratios for other factors: 
in this model IDU were significantly less likely than MSM (IRR 0.77; 95% CI 
0.67, 0.88), and black Caribbeans were significantly less likely than white 
individuals (IRR 0.83; 95% CI 0.71, 0.98), to be diagnosed with AIDS. However, 
black Africans were no longer significantly more likely to be diagnosed with 
AIDS than white individuals (IRR 1.05; 95% CI 0.97, 1.14). Individuals receiving 
care outside London were even more likely to be diagnosed with AIDS than 
those cared for in London in comparison to the original model (IRR 1.31; 95% 
CI 1.24, 1.37). 
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Figure 7.17. Incidence rates and rate ratios of AIDS by calendar year of follow-
up – results from sensitivity analyses. 
 
 
 
 
 
 
 
 
 
 
 Table 7.7. Results of sensitivity analyses from multivariable Poisson regression 
analysis of the association between each factor and the incidence of AIDS 
 
Multivariable  
incidence rate ratio  
(95% confidence interval) 
 Original model 
Only considering 
AIDS from HARS 
Excluding PYFU 
before first CD4 cell 
count  
    Calendar year    
1995 1.46 (1.33, 1.61) 2.62 (2.34, 2.93) 1.51 (1.37, 1.67) 
1996 1.25 (1.13, 1.37) 1.98 (1.76, 2.23) 1.25 (1.13, 1.38) 
1997 1.38 (1.26, 1.51) 1.46 (1.29, 1.64) 1.46 (1.32, 1.61) 
1998 0.95 (0.85, 1.05) 1.05 (0.92, 1.20) 0.96 (0.86, 1.07) 
1999 0.98 (0.89, 1.08) 0.92 (0.80, 1.05) 1.01 (0.91, 1.13) 
2000 - - - 
2001 0.89 (0.81, 0.98) 0.67 (0.59, 0.77) 0.92 (0.84, 1.02) 
2002 0.85 (0.78, 0.93) 0.63 (0.56, 0.72) 0.88 (0.80, 0.97) 
2003 0.79 (0.72, 0.86) 0.55 (0.49, 0.63) 0.82 (0.75, 0.90) 
2004 0.70 (0.64, 0.76) 0.53 (0.47, 0.60) 0.74 (0.67, 0.81) 
2005 0.64 (0.59, 0.70) 0.44 (0.39, 0.50) 0.67 (0.61, 0.74) 
2006 0.61 (0.56, 0.67) 0.41 (0.36, 0.47) 0.64 (0.58, 0.71) 
2007 0.48 (0.44, 0.53) 0.33 (0.28, 0.38) 0.51 (0.46, 0.56) 
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7.5.7.2 Exclusion of PYFU between HIV diagnosis and first CD4 
cell count 
Estimates of incidence were slightly lower throughout the period when the 
analysis was repeated with exclusion of PYFU between HIV diagnosis and first 
CD4 cell count (Figure 7.17). However, the incidence rate ratios for the various 
factors were inconsequentially different than those in the original model (Table 
7.7).  
    Square root of CD4 cell count 0.82 (0.82, 0.83) 0.80 (0.79, 0.80) 0.82 (0.82, 0.83) 
    
    PYFU within first six months 
                          after HIV diagnosis 
   
No -   
Yes 5.79 (5.58, 6.02) 11.31 (10.68, 11.97) 5.44 (5.22, 5.66) 
    
    Region    
Outside London 1.09 (1.05, 1.13) 1.31 (1.24, 1.37) 1.08 (1.04, 1.12) 
London -   
    
    Age, per additional 10 years 1.16 (1.14, 1.18) 1.16 (1.13, 1.19) 1.15 (1.13, 1.18) 
    
   Risk group    
MSM - - - 
Heterosexual men 0.99 (0.93, 1.05) 0.94 (0.86, 1.02) 0.96 (0.90, 1.03) 
Heterosexual women 0.96 (0.91, 1.02) 0.95 (0.87, 1.03) 0.94 (0.88, 1.01) 
Heterosexual women 
 (diagnosed antenatally) 
0.49 (0.42, 0.57) 0.37 (0.28, 0.49) 0.52 (0.45, 0.61) 
IDU 0.99 (0.90, 1.09) 0.77 (0.67, 0.88) 0.99 (0.89, 1.09) 
Recipients of blood products 0.61 (0.51, 0.71) 0.59 (0.47, 0.75) 0.56 (0.47, 0.67) 
    
   Ethnicity    
White  - - - 
Black African 1.11 (1.05, 1.18) 1.05 (0.97, 1.14) 1.12 (1.05, 1.19) 
Black Caribbean 0.97 (0.87, 1.08) 0.83 (0.71, 0.98) 0.94 (0.84, 1.05) 
Black Other 0.89 (0.77, 1.02) 0.94 (0.77, 1.14) 0.89 (0.76, 1.03) 
Indian\Pakistani\Bangladeshi 1.44 (1.25, 1.66) 1.41 (1.16, 1.70) 1.49 (1.28, 1.72) 
Other Asian 1.42 (1.23, 1.64) 1.62 (1.34, 1.96) 1.36 (1.16, 1.59) 
Other/mixed 0.96 (0.87, 1.07) 1.06 (0.92, 1.23) 0.97 (0.87, 1.08) 
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7.5.7.3 Termination of all follow-up at the end of 1999 
Estimates of incidence were very similar in 1996, 1997 and 1998 to those in the 
original model when the analysis was repeated with termination of all follow-up 
at the end of 1999. However, incidence was estimated to be higher in 1995 and 
1999 in this model. The multivariable analysis reflected this as the estimated 
rate in 1998 was lower than that in 1999 (IRR 0.81; 95% CI 0.73, 0.89) and the 
rate for 1996 was no longer significantly higher than that in 1999 (IRR 1.07; 
95% CI 0.98, 1.18). The rate for heterosexual women diagnosed antenatally 
was no longer significantly different to that for MSM, likely due to small numbers 
before 2000 due to under-ascertainment of pregnancy status (IRR 0.71; 95% CI 
0.41, 1.24). The latter may also have been the cause for other heterosexual 
women to be significantly less likely than MSM to be diagnosed with AIDS in 
this model (IRR 0.83; 95% CI 0.74, 0.93). Differences in the rate ratios between 
the models for the other factors were minor. 
7.6 Discussion 
The overall incidence of death was 18.5 per 1,000 PYFU and the overall 
incidence of AIDS was 93.0 per 1,000 PYFU in E,W&NI between 1995 and 
2007. There were marked declines in the incidence of both AIDS and death 
through the early HAART era, which then continued more slowly between 1998 
and 2007. These declines in incidence reflected the population effect of 
combination therapy with nucleoside reverse transcriptase inhibitors and 
protease inhibitors365;449. After taking improvements in CD4 cell counts and 
other factors into account, reductions in mortality and AIDS incidence were less 
marked between 1995 and 1998, though still statistically significant. The 
incidence of AIDS and death changed little between 1998 and 2000 but 
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declined again after 2000/2001. The reasons for these trends cannot be 
determined from this population-based observational study. Suggested 
hypotheses may be the introduction of boosted protease inhibitors and new 
classes of ART, by providing new effective treatment options for patients, the 
availability of simpler ART regimens, by supporting improved adherence, or 
increasing potency with time since initiation450. Also, changes in reporting in 
2000, which improved HIV reporting detail, may have reduced AIDS reporting. 
Importantly, the incidence of both AIDS and death was continually high at low 
CD4 cell counts and the absolute PYFU with CD4 cell counts below 100 
cells/mm3 changed little over the period. This was despite marked declines in 
the proportion of overall PYFU spent with CD4 cell counts below 100 cells/mm3 
(falling from 26.0% in 1995 to 2.7% in 2007 in the analysis of death, and from 
12.9% in 1995 to 1.7% in 2007 in the analysis of AIDS). An increasing 
proportion of these PYFU were contributed by individuals recently diagnosed 
and might be reduced by earlier HIV testing (Chapter 6). 
These results show the high burden of AIDS and death at the time of HIV 
diagnosis. AIDS within the first six months of HIV diagnosis accounted for half 
of the total number of AIDS and deaths within the first six months of HIV 
diagnosis accounted for one in seven of the total number of deaths. After 
adjusting for other factors, the overall incidence of AIDS within six months of 
diagnosis was almost six times higher than that among patients followed more 
than six months after diagnosis. The equivalent figure for the incidence of death 
was 35%. However, the respective incidence rates were seven and a half times 
and 54% higher overall when taking into account the interaction between 
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calendar year and PYFU within the first six months after HIV diagnosis. These 
results fit with those of the analyses of late diagnosis and consequent mortality 
(Chapter 6). Other cohort studies have acknowledged this association because 
they have excluded patients with low CD4 cell counts at enrolment or the period 
shortly after diagnosis to remove their effect on the results of analyses451-453. 
However, there do not appear to be any published studies that have focused on 
the period shortly after HIV diagnosis as a particular period of high risk of AIDS 
or death for comparison. The explanation for a higher risk of AIDS or death 
within the first six months after HIV diagnosis cannot be known from these data. 
It can be hypothesised that this may be due the impact of treatment and care, 
which do not always start immediately after diagnosis and were not adjusted for 
in this population-level analysis. This would include prophylactic treatment such 
as the antibacterial cotrimoxazole, antiretroviral treatment and its impact on viral 
load, and routine clinical review to detect and intervene against opportunistic 
infections and other clinical conditions. 
There was also little evidence of published literature comparing the population 
incidence of AIDS and death among HIV-infected individuals between ethnic 
groups after controlling for risk groups454. Studies have shown similar survival 
rates for black/African and white/European individuals but have not 
simultaneously considered the effect of risk groups79-82;455. These results 
indicate that ethnicity seems to have had little effect on mortality after adjusting 
for other determining factors. However, black Africans, 
Indian/Pakistani/Bangladeshi individuals and other Asians experienced higher 
AIDS incidence than white individuals in E,W&NI between 1995 and 2007 even 
after adjusting for other factors. This may have been due to higher background 
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rates of AIDS defining illnesses and particularly tuberculosis among these 
population groups207;456. Further investigation of the incidence of specific AIDS-
defining illnesses by ethnic group is warranted but may be limited in E,W&NI by 
the under-reporting of AIDS to HARS. This appeared to be a particular limitation 
for AIDS diagnoses that occurred after the time of HIV diagnosis and is likely to 
be a consequence of the integrated CHR form and a failure of some clinicians 
to appreciate that AIDS is still a useful epidemiological marker, even if less 
important clinically. Overall estimates of the incidence of all first AIDS 
diagnoses were available through integration of data from SOPHID but specific 
AIDS-defining illnesses were not available from this surveillance system. 
Restriction of these analyses to only first AIDS diagnoses minimised the need to 
consider competing risks, but death remains a competing risk for first AIDS457. 
Mortality was substantially different between risk groups. There was lower 
mortality among heterosexuals compared to MSM even after controlling for all 
other factors. This may suggest that not all of the pertinent determining factors 
were included in this analysis, such as ongoing access to care and differences 
in uptake of ART between groups. However, other studies have not had data on 
ethnicity or sufficiently large ethnic groups to detect differences between risk 
groups after adjustment for ethnicity. The low mortality of pregnant women is 
likely to be due to them having been diagnosed early due to antenatal 
screening. This effect has not previously been shown to be an added benefit to 
the reduced transmission of infection from mother to infant and may be further 
strong evidence for the expansion of HIV testing among relatively low-risk 
populations (Section 6.5). As other studies have shown, IDUs had a higher 
mortality than all other groups (more than double that of MSM)458-460. Other 
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studies have shown that this is largely due to non-HIV related causes of deaths 
among IDUs461-464. 
AIDS incidence, in contrast to mortality, was only lower for heterosexual women 
diagnosed antenatally and recipients of blood/blood products than for MSM. 
The reasons for this cannot be determined from this analysis but the routine 
monitoring of the health of these individuals may potentially have played some 
part in the prevention of illness among these groups. 
The results indicate similar trends in the incidence of AIDS and death 
365;451;457;465-473 and a similar effect of CD4 cell counts on the incidence of AIDS 
and death360;365;451;471;473-479 as large observational cohorts. The results also 
describe the effects of demographic factors. Incidence of both AIDS and death 
fell by about 20% for each doubling in CD4 cell counts. Each 10 year increase 
in age was associated with a 37% increase in mortality and a 16% increase in 
AIDS incidence. Also, previous AIDS diagnoses were associated with more 
than a doubling in mortality rates as previously reported450;480. 
CD4 cell counts are very strong markers for the risk of AIDS and death but 
improvements in CD4 cell counts over time did not account for the entire 
declines in incidence as noted in other studies. One hypothesis put forward is 
that HAART has a clinical benefit over and above that measured by the usual 
laboratory markers365;474;478;480. Others have stated that residual confounding 
due to measurement error in laboratory markers may explain this observation 
481. Allocation of PYFU to CD4 counts can also lead to variations in incidence 
rates though these have been shown to be minor448. Another limitation of this 
analysis is that laboratory markers other than CD4 cell counts were not 
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considered as they were not available from surveillance data. Although 
longitudinal viral loads could be considered in the future now that they are 
reported to SOPHID, this may not affect the results significantly as other studies 
have concluded that the inclusion of viral loads and other laboratory markers in 
models of incidence was unlikely to substantially affected trends365. 
This analysis shows that surveillance data can be used to create a pseudo-
cohort with very large numbers of patients (nearly 50,000) and PYFU (over 
200,000 years) comparable to analyses of pooled data from multi-centre 
cohorts250;449;452;470;471;476;482-491. The use of CD4 cell counts to define person-
years ensured that patients were under follow-up, which may otherwise be a 
limitation of using surveillance data. The cut-off of 365 days accounted for the 
small proportion of individuals who were temporarily LTFU for longer (Section 
5.4.3.3) and ensured that follow-up time was appropriately allocated to a level of 
risk/CD4 cell count. Changing the censoring definition of temporary LTFU had 
little effect on the trends in mortality observed. Indeed, very similar results were 
obtained from all sensitivity analyses on the mortality data, indicating that 
interpretations were robust. There was negligible effect of the use of CD4 cell 
count categories or either the square root or logarithm of CD4 cell counts on the 
trends over time. And, although the total number of PYFU and deaths was 
reduced, when either only the first continuous phase of follow-up was 
considered or when follow-up after 59 years of age was excluded, this had little 
effect on the overall estimates of incidence or the rate ratios. Analysis of 
mortality with follow-up split one year after HIV diagnosis instead of after six 
months, reduced the rate ratio for PYFU during this period in comparison to 
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subsequent follow-up because the incidence of death fell rapidly after HIV 
diagnosis due to the impact of treatment. 
There was a marked decline in the proportion of first AIDS diagnoses that were 
reported to HARS. HARS reports accounted for a large majority of records with 
AIDS diagnoses in 1995 but only a third of all such records in 2007 and the 
trend was greater for AIDS diagnoses that occurred more than six months after 
an HIV diagnosis. The change in reporting methods in 2000 and the lower 
emphasis of the importance of reporting AIDS diagnoses492 appear to have 
reduced the ascertainment of the HARS surveillance system. Estimates of 
incidence that excluded SOPHID reports of AIDS were less than half that when 
all reports were used (40.1 compared to 93.0 per 1,000 PYFU). Additionally, 
AIDS was only collected in SOPHID reports since 2005, and therefore much of 
these data were retrospectively collated (although prospectively collected locally 
in patient notes) and would be incomplete for individuals not reported to 
SOPHID since 2005 due to either death or LTFU. Although the shape of the 
trend over time was similar between models, adjustment for CD4 cell counts 
and other factors had little effect on this shape when only HARS reports of AIDS 
were considered, which may be due to under-reporting of AIDS to HARS. There 
were also some significant differences in the rate ratios for other factors when 
only AIDS diagnoses reported to HARS were considered. In particular, the 
effect of PYFU within the first six months of HIV diagnosis was exaggerated, but 
also IDU, black Caribbeans and individuals accessing care in London were 
relatively less likely to be reported as having AIDS. 
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I attempted to link all CD4 cell counts for the same patient even if these were 
reported from different laboratories but some lack of identifiers may have 
resulted in gaps in the dataset. The linkage of records from different people and 
the inaccurate recording of information should have been minimised in the 
development of the integrated dataset and was not believed to have resulted in 
any significant bias because follow-up time, AIDS and deaths were aggregated 
at a specific level of risk/CD4 cell count. Inclusion bias may have substantially 
affected the results because individuals included in the integrated dataset were 
less likely to have AIDS or die than other individuals, and particularly at the time 
of HIV diagnosis. In particular, the lower incidence of death among 
heterosexuals may be an artefact, there may have been an undetected higher 
incidence of AIDS among heterosexuals than among MSM, and the higher 
incidence of AIDS among black Africans may have been underestimated. 
Censoring may have affected the results for 1995 and 2007 particularly. For 
example, there was some evidence of an increase in mortality from 1995 to 
1996, which may have been due to biased data for 1995. This may also have 
exaggerated the decline between 2006 and 2007.  
Surveillance information about HAART, HIV-related but non-HAART treatment 
and prophylaxis was limited at the time of these analyses, which therefore could 
not directly account for the independent effect of HAART. However, this 
population should have similar access to therapy (as recommended by national 
guidelines133) and therefore comparisons of incidence rates are justified in this 
population-level analysis adjusted for period of HIV diagnosis493.  
 381 
 
7.7 Conclusion 
In conclusion, the incidences of AIDS and death declined substantially in 
E,W&NI from the pre-HAART to the HAART era and continued to decline 
throughout the HAART era. However, individuals diagnosed late benefited less 
and increasingly experienced disproportionate morbidity and mortality. The 
integrated dataset demonstrated that changes in the surveillance of AIDS in 
E,W&NI since 2000 decreased the completeness of AIDS diagnoses in HARS 
(especially those occurring after HIV diagnosis) and this limited analysis of the 
incidence of specific AIDS-defining illnesses. However, analysing the overall 
incidence of AIDS and the incidence of deaths using integrated surveillance 
data can be an important public health tool for monitoring the population 
effectiveness of treatment and complements randomised clinical trials of the 
individuals effectiveness of treatment493.  
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Chapter 8. Estimating ART start dates 
8.1  Introduction 
Determining the date that an HIV-infected individual started ART (startART) is 
vital when analysing longitudinal data, such as the integrated dataset, because 
the progression of infection changes dramatically. Generally, viral loads 
decrease, CD4 cell counts increase, and the risk of progression to AIDS and 
death decrease with sufficient adherence and in the absence of viral resistance. 
The date of starting ART is essential for determining whether patient follow-up 
occurred whilst the patient was on or off therapy but is not available in the 
HARS or CD4 Surveillance datasets. For example, CD4 cell counts used to 
calculate rates of decline before ART and rates of increase after ART need to 
be separated accordingly to minimise misclassification and underestimation of 
trends485;494. Good knowledge of the date of starting ART can also be used to 
identify the CD4 cell count just prior to starting treatment and therefore 
investigate whether individuals start treatment as recommended and/or whether 
rates of CD4 increase are determined by these baseline CD4 counts485;495-500. 
StartART has been requested in the SOPHID survey since 2005. However, 
these data were incomplete and some sites had difficulty in extracting 
information from their records. Also, collection of startART could not include 
individuals who had died, left the country or stopped attending HIV services 
before 2005. This is problematic because these individuals may have been 
more likely to start ART at low CD4 counts, which could bias results. 
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Information about when people start ART is also available as a combination of 
the date last seen for HIV care during a SOPHID survey period and the level of 
ART (number of independently-acting drugs) at that time. The earliest of these 
dates with ART reported, provides the earliest date in a calendar year when a 
patient can be assumed to be on ART (approxART) (Figure 8.1). It is probable 
that a patient started ART between the start of the survey period and 
approxART because it is unlikely that an individual started ART during a 
previous survey period without that being reported. However, approxART could 
not be determined for individuals on therapy in 1997 or 1998 with reports from 
previous years because the level of ART was not collected in 1995 or 1996 and 
appeared to be incomplete in 1997, the first year of collection of these data (for 
59% of those with approxART in 1998 and startART reported, startART 
occurred before 1998 indicating that approxART had not been reported in 1997 
[Section 8.4.1]).  
Figure 8.1. Schematic showing the information reported to SOPHID 
2003 20042002
Date last seen in 2003 
and on ART in 2003
CD4
CD4
CD4
CD4
CD4CD4
CD4
CD4
CD4
Date last seen in 2002  
and noton ART in 2002
Date last seen in 2001  
- not on ARV in 2001
Last report not on ART approxART
startART
(if reported)
First report
Reported data
Derived information
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In this chapter, CD4 cell counts in the integrated dataset were investigated to 
determine whether they could be used to determine a reasonably accurate 
estimate of the date of starting ART (estART) that was closer to startART than 
approxART (therefore occurring between the start of the survey period and 
approxART). CD4 cell count measurements were used because i) they were the 
only source of information available from surveillance data that were more 
regular than SOPHID surveys, and ii) there is an overall downwards trend in 
CD4 cell counts among untreated patients, which is generally reversed following 
the initiation of treatment485. It was recognised that although immunological 
response to ART is usually rapid, CD4 counts may take some time to increase 
or may even decline after the start of effective treatment364;499;501-503. There is 
also substantial variability in CD4 counts such that slopes can fluctuate over the 
short-term while showing a smoother long-term trend. 
The goal of the work described in this chapter was to evaluate the feasibility of 
developing an algorithm that could be applied to the integrated dataset to 
estimate estART for individuals without a reported startART. Potential 
algorithms were considered that defined estART based on an initial increase in 
CD4 counts and/or a change in slope from negative to positive.  
8.2  Aims 
a) To investigate a number of possible algorithms, based on changes in CD4 
cell counts, to enable a simple, practical, and reasonably accurate 
estimation of estART for individuals known to have started ART in any 
particular year (known approxART), but for whom the exact date (startART) 
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was unknown. The date of each CD4 cell count was considered to 
potentially be a close estimate of the date of startART. 
b) To validate the most promising algorithms using reported startART and to 
use this information to select the optimal algorithm. 
c) To use the optimal algorithm to determine estART for individuals without a 
reported startART and use it to supplement the integrated dataset. 
8.3  Methods 
The methods evaluated for determining estART were a set of algorithms 
developed to detect changes in CD4 cell count measurements that often occur 
first at the time of starting ART. These were: a nadir; CD4 cell counts below the 
level at which guidelines recommend that treatment should be started; an 
increase in CD4 cell counts; a preceding decrease and subsequent increase in 
CD4 cell counts; a positive slope in CD4 cell counts; and a preceding negative 
slope and subsequent positive slope in CD4 counts. A simple smoothing 
technique was used to assess whether the removal of some natural or 
measurement variability would improve the accuracy of the algorithm. 
EstART was defined as the date on which the CD4 cell count, selected by the 
algorithm, was measured. Only dates of CD4 count measurements earlier than 
approxART but in the same year were considered for the determination of 
estART because it was unlikely for patients to have started ART during a 
previous survey (which must not have been reported). 
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8.3.1 Data preparation 
Where more than one startART was reported for an individual (383) the earliest 
reported startART was used for analysis (assuming individuals had changed 
clinics and each clinic had only reported the date they had started ART). For 
individuals on treatment but without startART reported, the date last seen for 
care (approxART) when first reported to be prescribed ART was considered to 
be the earliest date that an individual was known to be on ART (Figure 8.1). 
Initial investigation of the integrated dataset showed that some individuals had a 
reported startART date after approxART. This was assumed to be either due to 
coding errors or a change of clinics with earlier clinics not reporting startART. 
Therefore, dates of startART after approxART were ignored in this analysis.  
8.3.2 Defining and evaluating the algorithms 
For each individual, the date of the first CD4 count to meet specified criteria for 
each algorithm was used to define estART. For four of the algorithms these 
criteria required a change in CD4 counts above a threshold, which was varied to 
determine the optimal level. An accurate estART was defined as one within 31 
days of startART (the median time between startART and the preceeding CD4 
count was 21 days (Section 8.4.2)). A random sample of 70% of individuals was 
used to develop the algorithms, with the remainder used for validation504. 
First, the algorithms were described by considering CD4 cell count changes at 
startART. This provided descriptive information to develop criteria for each 
algorithm. Then, cut-off values were tested for their sensitivity and specificity in 
categorising estART. For each cut-off value: 
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2003 2004
approxART
-50
-40 +160
+20
1st CD4 with CD4 increase > threshold 
is within 31 days of startART
startART
 true positives had estART within 31 days of startART (Figure 8.2a) 
 false positives were where estART was not within 31 days of startART 
(Figure 8.2b) 
 true negatives were where no estART could be estimated and no CD4 
counts measured within 31 days of startART (Figure 8.2c) 
 false negatives were where no estART could be estimated but there were 
CD4 counts measured within 31 days of startART (Figure 8.2d). 
Summary tables of sensitivity, specificity and likelihood ratios were created to 
assess the performance of different cut-off values for each algorithm. The cut-
off with the highest likelihood ratio was considered as the threshold likely to 
provide the best combination of sensitivity and specificity. 
Figure 8.2. a, b, c, d). Examples of how patients were determined to be true 
positives, false positives, true negatives and false negatives: 
a) A true positive was an individual whose first CD4 count with a subsequent 
increase greater than the threshold was measured within 31 days of startART. 
In this example, the red cross depicts the first CD4 count with a subsequent 
increase (the yellow arrow) of greater than 150 cells/mm3. That CD4 count is 
within 31 days date of startART (the bracket) so the patient was considered to 
be a true positive. 
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b) A false positive was an individual whose first CD4 count with a subsequent 
increase greater than the threshold was not measured within 31 days of 
startART. In this example, the patient does have an increase greater than the 
threshold (red cross and subsequent yellow arrow) but this does not fall within 
31 days of startART (bracket) so the positive result falsely identifies startART. 
2003 2004
approxART
-50
-40 +160
+20
startART
1st CD4 with CD4 increase > threshold 
is <> 31 days of startART
 
 
c) A true negative was an individual who had no CD4 counts with a subsequent 
increase greater than the threshold and no CD4 counts measured within 31 
days of startART. In this example without the CD4 count shown by the red 
cross, there is no CD4 count with a subsequent increase greater than 150 
cells/mm3 and no CD4 counts measured within 31 days of startART. Therefore, 
it is true to say that there are no CD4 counts that correctly identify startART. 
 
2003 2004
approxART
-50
+120
+20
No CD4 with CD4 increase > threshold 
and no CD4 within 31 days of startART
startART
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d) A false negative was an individual with a CD4 count measured within 31 days 
of startART but without any CD4 counts with a subsequent increase greater 
than the threshold. In this example, the red cross depicts a CD4 count within 31 
days of startART, which would be expected to be the first CD4 count with a 
subsequent increase greater than the threshold of 150 cells/mm3. However, the 
subsequent increase of 60 cells/mm3 is less than the threshold and therefore, 
falsely, no startART is identified for this patient. 
2003 2004
approxART
-50 +60
+60
+20
startART
CD4 within 31 days of startART but not 
with CD4 increase > threshold
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8.3.3 Algorithms 
Seven algorithms were considered, which could simply and practicably be 
applied to a large proportion of individuals in the integrated dataset. As 
algorithms were based on changes in CD4 counts, they could only be applied to 
individuals for whom a sufficient number of CD4 cell counts had been reported. 
This number varied between the algorithms and is described below (Section 
8.4.3 and Table 8.2). For algorithms 3-7,  
 
The algorithms evaluated were as follows: 
1. The first time an individual meets the recommended criteria for starting ART: 
CD4 threshold or AIDS 
Published guidelines recommending the initiation of ART based on CD4 cell 
counts among people with established HIV infection have changed over time 
(Section 1.3.6). Guidelines have also recommended that people with primary 
HIV infection should be included in clinical trials, that people with 
symptomatic HIV infection or AIDS should start ART and that other factors in 
addition to CD4 cell count should be taken into account (including viral load, 
rate of CD4 cell count decline and age)123.  
In light of these guidelines, a CD4 cell count below a threshold (350 
cells/mm3 in 1999 and 2000 and 200 cells/mm3 between 2001 and 2007) or a 
recent AIDS diagnosis was used to identify the first CD4 cell count in the year 
of approxART that should have prompted ART initiation130-135;505. 
 391 
 
a. EstART was determined as the first CD4 cell count below the 
recommended threshold for starting ART 
2003 2004
approxARTstartART
CD4
CD4
CD4
CD4
220
180
340
380
CD4
360
CD4
410CD4
430
estART
 
or 
 
b. EstART was determined as the first CD4 cell count after a reported AIDS 
diagnosis (within the same or preceding month) 
2003 2004
approxARTstartART
CD4
CD4
CD4
CD4
220
180
340
380
CD4
360
CD4
410CD4
430
AIDS
estART
 
 
 
 
 392 
 
2. The date of the CD4 nadir (lowest CD4 cell count) 
2003 2004
approxARTstartART
CD4
CD4
CD4
CD4
220
180
340
380
CD4
360
CD4
410CD4
430
estART
 
EstART was determined as the date of the lowest CD4 cell count, as long as it 
was earlier than, but in the same year as approxART (the earliest date was 
selected if there were two or more measurements with the same values). 
3. An absolute increase immediately following a CD4 count 
2003 2004
approxART
-40
+160
+40
startART
CD4
CD4
CD4
CD4
220
180
340
380
CD4
360
CD4
410CD4
430
-210
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EstART was determined as the earliest CD4 cell count measurement where the 
difference between two consecutive CD4 cell counts exceeded the threshold. 
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4. An absolute increase immediately following a CD4 count after using a 
smoothing mechanism to remove some variability 
2003 2004
approxART
0
+120
startART
CD4
CD4
CD4
CD4
360
220
340
CD4
360
CD4
410CD4
-140
CD4
220
CD4
380
+40
180
430
estART
 
The running median of each three consecutive CD4 cell counts was used 
instead of the reported CD4 count to remove some variation. In this example, 
the CD4 count of 430 cells/mm3 (dotted) and subsequent fall of 210 cells/mm3 
was replaced by a smoothed CD4 count of 360 cells/mm3 (in red) and a drop of 
140 cells/mm3 (highlighted). Similarly, the CD4 cell count of 180 cells/mm3 
(dotted) was replaced by a smoothed count of 220 cells/mm3 (in red), indicating 
no change before it and an increase of 120 cells/mm3 after it (instead of -40 
cells/mm3 before and +160 cells/mm3 after). estART was determined as the 
earliest date where the difference between two consecutive smoothed CD4 cell 
counts exceeded the threshold. 
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5. A preceding decrease and subsequent increase in CD4 counts 
2003 2004
approxARTstartART
CD4
CD4
CD4
CD4
220
180
340
380
CD4
360
CD4
410CD4
430
-(-40) + (160) = 200
estART
 
EstART was defined as the earliest CD4 count that was immediately preceded 
by a decrease and followed by an increase, such that the combined magnitude 
of change around the central measurement exceeded the threshold. 
 
6. A preceding decrease and subsequent increase in smoothed CD4 counts 
2003 2004
approxART
0
+120
startART
CD4
CD4
CD4
CD4
360
220
340
CD4
360
CD4
410CD4
CD4
220
CD4
380
180
430
estART
 
CD4 counts were smoothed using the median of three consecutive counts as 
before (dotted counts replaced). Where this occurred, the change between the 
smoothed count and one of the adjacent CD4 counts will be zero. EstART was 
determined as the earliest CD4 count that was preceded by no change and 
followed by an increase that exceeded the threshold. 
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7. A positive slope in CD4 counts 
2003 2004
approxARTstartART
CD4
CD4
CD4
CD4
220
180
340
380
CD4
360
CD4
410CD4
430
Slope =   -350               -802            376                380              109
(cells per mm3 per year)
estART
 
Both the adjacent CD4 cell counts were considered to determine the slope 
through each set of three consecutive CD4 cell counts (using the least squares 
method – see equation below). EstART was determined as the earliest CD4 
count with a positive slope that exceeded the threshold. 
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8. A preceding negative slope and subsequent positive slope in CD4 counts 
2003 2004
approxARTstartART
CD4
CD4
CD4
CD4
220
180
340
380
CD4
360
CD4
410CD4
430
Combined slope =         (-350,376)=726     (-802,380)=1,182
(cells per mm3 per year)
estART
 
 The figure shows the slopes through each set of three consecutive CD4 cell 
counts (around the specific CD4 count itself). EstART was determined as the 
earliest CD4 count with a preceding negative slope and subsequent positive 
slope with the sum of the magnitude of those slopes exceeding the threshold. 
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8.4  Results 
8.4.1 Describing startART and approxART 
Of 50,167 patients in the integrated dataset, there were 28,095 (56.0%) 
individuals who had startART reported and 34,974 (69.7%) with approxART 
(Figure 8.3). Of the 25,263 individuals with startART equal to or earlier than 
approxART: 
  startART was in the same year as approxART for 19,276 (76.3%). The 
median difference between these dates was 84 days (IQR 32, 147); 
 startART was in a year before approxART for 5,987 (23.7%). Almost half 
(2,698 [45.1%]) of these individuals had approxART in 1997 or 1998 
(number of ARV drugs was not reported before 1997 and may have 
been incomplete in 1997). Of the latter, 68.6% had startART in 1995, 
1996 or 1997 (Figure 8.4).  
Individuals with startART in a year before approxART accounted for the 
majority of individuals with approxART in 1997 and 1998 (Figure 8.4) 
suggesting that most of these individuals probably started therapy in previous 
years but did not have that information captured by SOPHID (as assumed).  
There were 14,875 individuals who had no reported startART and who had 
never been reported to be on ART (no approxART). There were 7,197 
individuals with approxART who had no reported startART but only 318 who 
had not been reported to have received ART but who had startART reported. 
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Figure 8.3. Flow diagram showing the reporting of approxART and startART 
and the chronological association between them. 
50,167 records in the 
integrated dataset
27,777 startARTand 
approxART reported
14,875 no startART
reported and no 
approxART reported
318 startART reported 
but approxART not 
reported
25,263 startARTequal 
to or earlier than 
approxART
3,557 startART after 
approxART
7,197 approxART
reported but startART
not reported
19,276 startART in the 
same year as 
approxART
5,987 startART in a 
year before approxART
2,698 approxART in 
1997 or 1998
3,289 approxARTsince 
1998
 
Figure 8.4. Year in which ART was started based on startART stratified by the 
year of approxART. 
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8.4.2 Describing the time between CD4 counts and startART 
There were 15,567 individuals with approxART after 1998, with startART earlier 
and in the same year as approxART, and with at least one CD4 cell count 
earlier than approxART and in the same year. 
There were 23,492 individuals who had a CD4 count before startART (where 
startART was not after approxART), among whom the median time from the last 
CD4 count before startART to startART was 21 days (IQR 8, 42). Almost a third 
of these individuals (29.8% [7,010]) started ART more than 30 days after a CD4 
count and 7.4% (1,735) started more than 91 days after a CD4 count. 
There were 23,555 individuals who had a CD4 count after startART (where 
startART was not after approxART). The median time from startART to the next 
CD4 count was 39 days (IQR 21, 92) and 877 individuals had more than 91 
days between startART and the next CD4 count. For 18,870 of these individuals 
who also had CD4 counts before startART, the median time from the last CD4 
count before startART to startART was 21 (IQR 8, 41) days. The median time 
from the first CD4 count after startART to the subsequent CD4 count was 56 
days (IQR 29, 91) for 18,361 individuals with subsequent CD4 counts. 
There were 14,887 individuals whose CD4 cell count closest to startART was in 
the same year as both startART and approxART, before approxART and after 
1998. The time between this CD4 count and startART varied from 0 days to 352 
days (median 14 days [IQR 5, 26]) and there were 12,466 (83.7%) individuals 
with their closest CD4 count within 30 days of startART. 
 400 
 
10,897 eligible individuals with 
38,213 CD4 counts
11,390 (29.8%) counts
more than 31 days before 
startART or not last count
6,918 (18.1%) last count
before startARTand
within 31 days
Median 230
(IQR 153, 306)
cells per mm3
Median 168
(IQR 73, 254)
cells per mm3
19,905 (52.1%) counts
after startART
Median 250
(IQR 147, 370)
cells per mm3
8.4.3 Evaluating the use of CD4 counts to determine estART 
among a sample of individuals with startART reported 
There were 15,567 individuals with approxART after 1998, startART earlier than 
approxART and in the same year and at least one CD4 cell count measured 
earlier than approxART and in the same year. 
The random sample of 70% used to develop the algorithm consisted of 10,897 
of the 15,567 eligible individuals. These individuals had 38,213 CD4 cell counts 
measured earlier than approxART and in the same year and 8,933 (82.0%) 
individuals had CD4 counts within 31 days of startART. 
8.4.3.1 Evaluating the first time an individual met the 
recommended criteria for starting ART: CD4 threshold or AIDS 
All 10,897 individuals had a CD4 cell count earlier than approxART and in the 
same year. Of their 38,213 CD4 cell counts, 9,427 (24.7%) were the last before 
startART and 6,918 (18.1%) of these were within 31 days of startART (Figure 
8.5). There were 2,113 individuals with 3,113 CD4 counts within 31 days of an 
AIDS diagnosis. The median of these was 71 [IQR 23, 160] cells/mm3. 
Figure 8.5. Distribution of CD4 counts in relation to startART 
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There were 526 individuals who started ART before the guidelines changed in 
2000. Of these, 444 (84.4%) had CD4 counts below the threshold of 350 
cells/mm3 (of whom, 301 had CD4 counts less than 200 cells/mm3) and 13 
(2.5%) had CD4 counts of 350 cells/mm3 or more but a previous AIDS 
diagnosis. Among the 10,371 individuals who started ART after 1999, 6,422 
(61.9%) had CD4 counts below the threshold of 200 cells/mm3 and 428 (4.1%) 
had CD4 counts of 200 cells/mm3 or more but a previous AIDS diagnosis (a 
further 2,648 [25.5%] individuals had CD4 counts of 200-350 cells/mm3 but no 
previous AIDS diagnosis). 
The earliest CD4 cell count at which the individual fulfilled the criteria for starting 
ART identified estART within 31 days of startART for 3,834 (35.2%) individuals 
(Figure 8.6). There were 3,397 (31.2%) individuals with ‘incorrect’ estART, and 
3,666 (33.6%) individuals with no estART because they did not have CD4 cell 
counts that met the criteria. This algorithm correctly identified estART within 31 
days of startART with a sensitivity of 40.2% and a specificity of 45.1%. A 
substantial percentage of false positives identified the last CD4 count before 
startART or the first CD4 count after startART (Figure 8.6). This occurred most 
frequently when an individual did not have a CD4 count measured within 31 
days of startART. 
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Figure 8.6. Distribution of estART in relation to startART 
  
The analysis was also repeated considering CD4 cell counts in the sample that 
were the only CD4 cell count before approxART to define estART in addition to 
those defined by the guidelines. There were 3,549 individuals with only one 
CD4 cell count before approxART, of which the median was 113 cells/mm3 [IQR 
39, 210]. The median difference between estART and startART for these 
individuals was 19 days [IQR 9, 32] and 73.6% (2,613/3,549) had estART within 
31 days of startART. This percentage was only slightly higher among those who 
fit the criteria for starting ART (76.1% [2,039/2,678]) than among those who 
didn’t (65.9% [574/871]), which was statistically significant (p<0.01). Including 
the only CD4 cell count before approxART in the algorithm along with those 
defined by the guidelines resulted in estART correctly identified within 31 days 
of startART for 40.2% (4,381) of individuals, with a sensitivity of 46.0% and a 
specificity of 36.0%. 
10,897 eligible individuals 
with 38,213 CD4 counts
True positives
3,834 (35.2%) estART within 
31 days of startART
True negatives
899 (8.2%) no estART and 
no CD4 within 31 days of 
startART
False positives
3,397 (31.2%) estART not
within 31 days of startART
For 2,949 (86.8%), estART
identified a CD4 count 
before startART
For 448 (13.2%), estART
identified a CD4 count after 
startART
344 (76.8%) of these were 
the first CD4 count after 
startART
933 (31.6%) of these were 
the last CD4 count before 
startART
False negatives
2,767 (25.4%) no estART
but CD4 within 31 days of 
startART
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To account for the flexibility in the guidelines, this analysis was repeated using: 
1) thresholds of 400 cells/mm3, 350 cells/mm3 and 250 cells/mm3;  2) thresholds 
of 450 cells/mm3, 350 cells/mm3 and 300 cells/mm3 respectively for people with 
approxART in 1999, 2000 and 2001 onwards. AIDS was still considered as a 
prompt for ART initiation. The number of true positives, false positives, true 
negatives and false negatives were: 1) 4,134, 4,496, 601, 1,666 and 2) 4,423, 
5,252, 385, 1,017 respectively. The sensitivities and specificities of these 
algorithms were 1) 43.4% and 30.2%, and 2) 44.5% and 19.3% respectively. 
Of the overall 27,270 individuals with approxART after 1998, 2,503 (9.2%) 
individuals could not be categorised using this algorithm because they did not 
have a CD4 count before approxART and in the same year as approxART. 
8.4.3.2 Evaluating the earliest CD4 nadir 
The 10,897 individuals used to evaluate this algorithm were the same as those 
included in the analysis above. The median difference between estART (date of 
CD4 nadir) and startART was 16 days [IQR 0, 40]). The nadir CD4 count 
correctly identified estART within 31 days of startART for 6,054 (55.6%) 
individuals (Figure 8.7). By definition, there were no individuals without estART 
(as all individuals had at least one CD4 cell count and hence a nadir value) and 
no negative results from the algorithm; therefore, there were no true negative 
results. A substantial percentage of false positives identified the last CD4 count 
before startART or the first CD4 count after startART (Figure 8.7) and most 
frequently when an individual did not have a CD4 count measured within 31 
days of startART. 
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Figure 8.7. Distribution of estART in relation to startART 
 
8.4.3.3 Evaluating a single increase in CD4 counts 
There were 10,673 individuals (97.9% of the random sample) who had more 
than one CD4 cell count measured before or on the same date as approxART 
and in the same year (Figure 8.8). These individuals contributed a total of 
36,758 pairs of consecutive CD4 counts, of which 6,698 (18.2%) spanned 
startART (where the first was measured within 31 days of startART). However, 
there was substantial overlap in the range of increases in CD4 counts between 
the three categories, indicating probable misclassification using this algorithm. 
10,897 eligible individuals 
with 38,213 CD4 counts
True positives
6,054 (55.6%) estART within 
31 days of startART
True negatives
None - no individuals
without estART
False positives
4,843 (45%) estART not
within 31 days of startART
For 3,448 (71.2%), estART
identified a CD4 count 
before startART
For 1,395 (28.8%), estART
identified a CD4 count after 
startART
717 (51.4%) of these were 
the first CD4 count after 
startART
1,628 (47.2%) of these were 
the last CD4 count before 
startART
False negatives
None - no individuals
without estART
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Figure 8.8. Distribution of CD4 counts in relation to startART 
 
Using this algorithm, the sensitivity decreased and the specificity increased as 
the cut-off increased. Overall, however, the percentage correctly classified fell 
from 55.0%, with a cut-off of 20 cells/mm3, to 21.6% with a cut-off of 300 
cells/mm3. There was a peak in the likelihood ratios of 0.860 at 150 cells/mm3 
with a sensitivity of 23.3% and specificity of 72.9% (highlighted in Table 8.1).  
10,673 eligible individuals with 
36,758 CD4 counts
11,263 (30.6%) counts
more than 31 days before 
startART or not last count
6,698 (18.2%) last count
before startARTand within 31 
days
Median change 0
(IQR -44, 49)
cells per mm3
Median increase 64
(IQR 14, 131)
cells per mm3
18,797 (51.1%) counts
after startART
Median increase 20
(IQR -20, 70)
cells per mm3
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Table 8.1. Summary table for a single increase in CD4 counts 
Cut-off for 
change in 
CD4 counts 
/ cells/mm
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0 10,190 5,390 483 257 62% 13% 53% 0.714 
20 9,739 5,479 934 330 63% 19% 55% 0.788 
40 8,971 5,147 1702 396 60% 26% 53% 0.810 
60 7,895 4,619 2778 465 54% 36% 50% 0.842 
80 6,791 3,975 3,882 538 46% 45% 46% 0.837 
90 6,243 3,646 4,430 645 42% 49% 44% 0.835 
100 5,686 3,343 4,987 743 39% 54% 42% 0.836 
110 5,113 3,008 5,560 840 35% 58% 39% 0.839 
120 4,631 2,717 6,042 918 31% 62% 37% 0.837 
130 4,200 2,461 6,473 1,008 29% 66% 36% 0.842 
140 3,787 2,218 6,886 1,095 26% 70% 34% 0.851 
150 3,400 2,010 7,273 1,193 23% 73% 33% 0.860 
160 3,044 1,790 7,629 1,273 21% 76% 31% 0.849 
170 2,728 1,592 7,945 1,349 18% 78% 30% 0.825 
180 2,448 1,421 8225 1,424 16% 80% 29% 0.815 
190 2,166 1,252 8,507 1,488 15% 82% 27% 0.822 
200 1,952 1,117 8,721 1,542 13% 84% 27% 0.807 
210 1,750 1,006 8,923 1,584 12% 85% 26% 0.785 
220 1,575 906 9,098 1,628 10% 87% 25% 0.790 
230 1,420 799 9,253 1,680 9.3% 88% 24% 0.761 
240 1,277 718 9,396 1,713 8.3% 89% 24% 0.764 
250 1,155 641 9,518 1,737 7.4% 90% 23% 0.739 
260 1,042 575 9,631 1,769 6.7% 91% 23% 0.727 
270 938 515 9,735 1,792 6.0% 92% 22% 0.708 
280 854 467 9,819 1,818 5.4% 92% 22% 0.717 
290 781 432 9,892 1,835 5.0% 93% 22% 0.745 
300 711 389 9,962 1,853 4.5% 94% 22% 0.741 
1
 positives were where estART was estimated using the algorithm 
2
 true positives were where estART was within 31 days of startART 
3
 negatives were where no estART could be estimated 
4
 true negatives were where no estART could be estimated and no CD4 counts measured within 31 days of startART. 
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Using the cut-off of 150 cells/mm3, there were 2,010 (18.8%) individuals with 
estART within 31 days of startART, 1,390 (13.0%) individuals with ‘incorrect’ 
estART, and 7,273 (68.1%) individuals with no estART because they did not 
have CD4 counts that met the criteria (Figure 8.9). There were 224 individuals 
with no estART because they had CD4 cell counts before approxART and in the 
same year as approxART but which weren’t followed by another CD4 count. 
The median difference between estART and startART was 7 days [IQR -21, 
27]). Of the 1,390 individuals with ‘incorrect’ estART, 719 (51.7%) had estART 
more than 31 days before startART with a median difference of 53 [IQR 40, 85] 
days and 671 (48.3%) had estART more than 31 days after startART with a 
median difference of 80 [IQR 50, 121] days. Yet estART identified the last CD4 
count before startART or the first CD4 count after startART for a substantial 
percentage of false positives (Figure 9). 
Figure 8.9. Distribution of estART in relation to startART 
 
10,673 individuals with 
36,758 CD4 counts followed 
by another CD4 count
True positives
2,010 (18.8%) estART within 
31 days of startART
True negatives
1,488 (13.9%) no estART
and no CD4 within 31 days 
of startART
False positives
1,390 (13.0%) estART not
within 31 days of startART
For 719 (51.7%), estART
identified a CD4 count 
before startART
504 (70.1%) of these were 
the last CD4 count before 
startART
False negatives
5,785 (54.2%) no estART
but CD4 within 31 days of 
startART
671 (48.33%), estART
identified a CD4 count after 
startART
233 (34.7%) of these were 
the first CD4 count after 
startART
224 individuals with CD4 
counts not followed by 
another CD4 count
 408 
 
Of the overall 27,270 individuals with approxART after 1998, 3,203 (11.7%) 
could not be categorised using this algorithm because they did not have a CD4 
count before approxART and in the same year as approxART that was followed 
by another CD4 count. 
8.4.3.4 Evaluating other algorithms 
The structure of the results from evaluation of algorithms 4-8 was very similar to 
the single increase in CD4 cell counts and therefore figures and tables specific 
to the other algorithms are presented in Appendix C. Table 8.2 below 
summarises the results for all algorithms investigated. 
The number of individuals and CD4 cell counts included in the analysis 
decreased and the overall number of individuals who could not be categorised 
by the algorithm increased as the number of CD4 cell counts required for the 
algorithm increased. For example, determination of whether CD4 counts meet 
the recommended criteria for starting ART and determination of CD4 nadir 
require only one CD4 cell count before approxART and in the same year, and 
have the lowest overall percentages (9.2%) who could not be categorised. In 
contrast, the preceding decrease and subsequent increase in smoothed CD4 
counts and the preceding negative slope and subsequent positive slope in CD4 
counts require two CD4 cell counts before and two CD4 cell counts after each 
CD4 cell count used in the algorithm. An overall percentage of 40% of 
individuals could not be categorised using these algorithms. 
The percentage of true positives and true negatives varied substantially such 
that the percentage correctly classified, with this selection of cut-offs, varied 
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from 30%, when using the preceding decrease and subsequent increase in 
smoothed CD4 cell counts and a cut-off of 130 cells/mm3 per year, to 56% 
when using the CD4 nadir. However, the positive predictive value is a more 
appropriate indicator of the usefulness of an algorithm for determining a reliable 
estART (and therefore increasing the proportion of individuals with this 
information for analysis). Among these algorithms with this selection of cut-offs, 
the positive predictive value varied from 46%, when using the preceding 
decrease and subsequent increase in CD4 cell counts, to 68% when using the 
positive slope in CD4 cell counts. The absolute percentage of true positives 
must also be considered as an indicator of the usefulness of an algorithm – this 
varied from 3.6%, when using the preceding decrease and subsequent increase 
in smoothed CD4 cell counts, to 56% when using the CD4 nadir.  
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Table 8.2. Summarised results for all algorithms 
 Algorithm 
 
1) First CD4 to 
meet criteria for 
starting ART 
2) CD4 nadir 
3) Single CD4 
increase 
4) Increase in 
smoothed CD4 
counts 
5) Preceding 
decrease and 
subsequent 
increase in CD4 
counts 
6) Preceding 
decrease and 
subsequent 
increase in 
smoothed CD4 
counts 
7) Positive 
slope in CD4 
counts 
8) Preceding 
negative slope and 
subsequent 
positive slope in 
CD4 counts 
Cut-off 
350 
cells/mm
3
/200 
cells/mm
3
/AIDS 
n/a 150 cells/mm
3
 110 cells/mm
3
 150 cells/mm
3
 130 cells/mm
3
 
800 cells/mm
3
 
per year 
800 cells/mm
3
 per 
year 
Number of individuals 
included in evaluation, n (%) 
10,897 
(100%) 
10,897 
(100%) 
10,673 
(97%) 
8,945 
(82%) 
9,284 
(85%) 
7,513 
(69%) 
9,284 
(85%) 
7,513 
(69%) 
Number of counts included in 
evaluation, n 
38,213 38,213 36,758 28,933 30,401 23,499 30,401 23,499 
Median time from estART to 
startART (IQR) / days 
24 (7, 49) 16 (0, 40) 7 (-21, 27) 0 (-35, 18) 14 (-26, 43) 5 (-21, 29) -14 (-30, 2) 15 (-2, 40) 
True positives, n (%) 3,834 (40%) 6,054 (56%) 2,010 (18%) 1,190 (11%) 1,409 (13%) 394 (4%) 1,508 (14%) 1,001 (9%) 
False positives, n (%) 3,397 (31%) 4,843 (44%) 1,390 (13%) 823 (8%) 1,680 (15%) 313 (3%) 701 (6%) 880 (8%) 
True negatives, n (%) 899 (8%) n/a 1,488 (14%) 2,212 (20%) 1,994 (18%) 2,890 (27%) 2,351 (22%) 2,783 (26%) 
False negatives, n (%) 2,767 (25%) n/a 5,785 (53%) 4,720 (43%) 2,043 (39%) 3,916 (36%) 4,724 (43%) 2,849 (26%) 
Correctly classified, n (%) 4,733 (43%) 6,054 (56%) 3,498 (32%) 3,402 (31%) 3,403 (31%) 3,284 (30%) 3,859 (35%) 3,784 (35%) 
Positive predictive value (%) 53% 56% 59% 59% 46% 56% 68% 53% 
Overall number that could not 
be categorised, n (%) 
2,503 (9%) 2,503 (9%) 3,203 (12%) 7,630 (28%) 6,896 (25%) 10,897 (40%) 6,896 (25%) 10,897 (40%) 
 411 
 
8.4.3.5  Selecting the most appropriate algorithm 
Having investigated a number of possible algorithms there were two 
approaches to achieve the aim of estimating a reasonably accurate estART for 
individuals known to have started ART in any particular year (known 
approxART), but in whom startART was unknown: 
1. Use a single algorithm and select one with an acceptable sensitivity and 
specificity. 
The use of recommended criteria for starting ART and the CD4 nadir were 
not considered to have sufficient specificity. The algorithm using the slope 
through three consecutive CD4 cell counts and the cut-off of 800 cells/mm3 
per year had high sensitivity at specificities of close to 80% and 90% (Table 
8.3). Additionally, the number of individuals who could not be categorised 
using this algorithm (6,896 [25%]) was not as great as that for the algorithm 
requiring a preceding negative slope and subsequent positive slope (10,897 
[40%]), which had similar sensitivity. Therefore, this algorithm with the cut-off 
of 800 cells/mm3 per year was selected as the most appropriate to achieve 
the aim of estimating estART for as many individuals as possible with 
reasonable accuracy (sensitivity of 23% and specificity of 91%). This 
correctly identified estART for 1,508 individuals, incorrectly identified estART 
for 701 individuals and left 8,688 individuals with approxART as the best 
estimate (1,613 because they did not have a CD4 count before approxART 
and in the same year that was both preceded and followed by other CD4 
counts). 
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Table 8.3. Comparative sensitivities, specificities and percentages 
uncategorised for different algorithms (two sets of thresholds that produced 
specificities closest to 90% [panel 1] and 80% [panel 2] were used for 
comparison of sensitivity and percentages uncategorised]) 
Algorithm number and description Sensitivity Specificity 
Overall percentage 
uncategorised 
Using thresholds producing specificities closest to 90% for comparison 
3) Single increase in CD4 counts 7.4% 90% 12% 
4) Increase in smoothed CD4 counts 14% 90% 28% 
5) Decrease then increase in CD4 counts 8.0% 89% 25% 
6) Decrease then increase in smoothed CD4 counts 18% 89% 40% 
7) Positive slope through CD4 counts 23% 91% 25% 
8) Negative then positive slope through CD4 counts 24% 90% 40% 
Using thresholds producing specificities closest to 80% for comparison 
3) Single increase in CD4 counts 16% 80% 12% 
4) Increase in smoothed CD4 counts 26% 80% 28% 
5) Decrease then increase in CD4 counts 18% 79% 25% 
6) Decrease then increase in smoothed CD4 counts 31% 79% 40% 
7) Positive slope through CD4 counts 37% 79% 25% 
8) Negative then positive slope through CD4 counts 33% 78% 40% 
 
2. Use the best algorithm for individuals with sufficient CD4 cell counts followed 
by an inferior algorithm that can be applied to additional individuals and 
using an increased cut-off to maintain specificity with this algorithm. 
a. The first algorithm selected used the slope through three consecutive 
CD4 counts and a cut-off of 800 cells/mm3 per year. This had a 
specificity of 91%, sensitivity of 23, and 25% remained uncategorised. 
b. The next algorithm selected used a single increase in CD4 cell counts 
only for the 25% (6,896) of the 27,270 individuals with an approxART 
after 1998 who did not have enough CD4 counts to calculate a slope. A 
cut-off of 250 cells/mm3 was selected because this had a similarly high 
specificity of 90% (although the sensitivity was only 7.4%).  
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The sensitivity of these two combined algorithms was slightly lower than 
that of the slope used alone (20% versus 23%) although the specificity 
remained at 90%. However, the combined algorithms performed 
markedly better than the single increase in CD4 counts alone. There 
were 1,389 additional individuals categorised including 178 true 
positives and 99 false positives compared to using the slope alone. Of 
the sample of 10,897 individuals, there remained 2.1% (compared to 
15% using the slope alone) where the combined algorithm could not 
estimate an estART and the best estimate of startART was approxART. 
There remained 3,203 (12%) individuals who could not be categorised 
using this combined algorithm (compared to 6,896 [25%] using the 
slope alone) because of insufficient CD4 counts. 
The investigation of a number of possible algorithms and combinations of 
algorithms indicated that the ‘best option’ for determining an accurate estART 
for individuals without startART reported was to use the combination of 
algorithms described above. This provided the best sensitivity with reasonable 
specificity compared to the other algorithms while also minimising the number of 
individuals who could not be categorised because of insufficient CD4 counts. 
8.4.4 Validation of the ‘combined’ algorithm 
The ‘combined’ algorithm was validated on the 30% (4,670) of individuals who 
were not included in the 70% sample used above. There were 4,583 (98%) of 
these individuals who had at least two CD4 cell counts so that the algorithm 
could be applied. The combined algorithm identified estART for 1,049 (22%) of 
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all the individuals. estART was a median of 83 [IQR 42, 133] days before 
approxART with a range of 0-343 days. There were 716 (15%) individuals with 
estART within 31 days of startART, 333 (7%) individuals with ‘incorrect’ estART, 
and 3,534 (78%) individuals with no estART.  
There were 130 (39%) individuals with an ‘incorrect’ estART that was more than 
31 days before startART with a median difference of 60 [IQR 41, 83] days, and 
203 (59%) individuals where estART was more than 31 days after startART with 
a median difference of 57 [IQR 42, 84] days. Yet estART identified the last CD4 
count before startART for 73 (56%) of these individuals and the first CD4 count 
after startART for 67 (33%) of these individuals respectively. 
8.4.5 Applying the algorithm to individuals without startART  
There were 7,197 individuals with approxART who had no reported startART, of 
whom 4,862 had approxART after 1998. Of these, 4,162 individuals had CD4 
cell counts earlier but in the same year as approxART and 3,889 (54%) had 
sufficient CD4 cell counts to determine single increases in CD4 cell counts for 
the algorithm.  
The algorithm identified estART for 578 (15%) of the 3,889 individuals. EstART 
was a median of 91 [IQR 35, 153] days before approxART with a range of 0-344 
days. However, approxART remained the most reliable estimate of the date of 
starting ART for the majority of patients. 
 415 
 
8.4.6 Combination of reported and estimated ART start dates 
There were 27,270 individuals with approxART after 1998 of whom 22,408 
(82.2%) had a startART reported and a further 578 (2.1%) had an estART 
determined by the algorithm. A remaining 4,284 (15.7%) individuals had 
approxART as the best estimate of startART. Of these: 
 339 (7.9%) had no reported CD4 count prior to approxART 
 361 (8.4%) had a CD4 count reported prior to approxART but not within 
the same calendar year 
 273 (6.4%) had a CD4 count reported prior to approxART and within the 
same year but did not have sufficient CD4 counts to determine the 
algorithm 
 3,311 (77.3%) had a CD4 count reported prior to approxART and within 
the same year and sufficient CD4 counts to determine the algorithm but 
the algorithm failed to identify an estimated ART start date. 
The conclusion was that the algorithm was not sensitive and specific enough to 
accurately identify startART for a sufficient number of individuals to justify the 
introduction of the additional methodology and the additional false positive 
results. 
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8.4.7 Sensitivity analysis – evaluation of the combined algorithm 
with startART in the 70% sample considering CD4 counts in 
the same year as approxART and the year before approxART 
Inclusion of CD4 counts in the year before approxART increased slightly the 
number of individuals that could be included in the sensitivity analysis (Table 
8.4). The number correctly classified, sensitivity and specificity decreased 
(although negligibly) but the reduction in the overall percentage that could not 
be classified (from 12% to 10%) was insufficient to consider use of this version 
of the algorithm. 
Table 8.4. Summarised results for the combined algorithm considering CD4 cell 
counts in the same year as approxART and the year before approxART 
compared to the combined algorithm considering only CD4 cell counts in the 
same year as approxART. 
  
Only CD4 counts 
in same year as 
approxART 
CD4 counts in 
same year and year 
before approxART 
   
Number of individuals included in evaluation n (%) 10,673 (98%) 10,753 (98%) 
Number of counts included in evaluation / n 36,758 40,912 
Median time from estART to startART (IQR) / days -10 (-28, 10) -7 (-28, 13) 
True positives / n (%) 1,686 (16%) 1,680 (15%) 
False positives / n (%) 800 (7%) 863 (8%) 
True negatives / n (%) 1,839 (17%) 1,831 (17%) 
False negatives / n (%) 6,348 (59%) 6,299 (57%) 
Correctly classified / n (%) 3,525 (33%) 3,511 (33%) 
Overall number that could not be categorised / n (%) 3,203 (12%) 2,708 (10%) 
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8.5  Discussion 
This chapter aimed to produce a robust estimate of the date of starting ART for 
individuals missing this crucial piece of information. This information is regularly 
used to assess incidence rates of events or CD4 trajectories before and after 
starting ART, for assessing when people start therapy and as a baseline in 
studies of response to ART. The HPA has now started to collect dates of 
starting ART to monitor important public health outputs and indicators. This is a 
prime example of surveillance developing in association with public health data 
needs – in this case, together with the performance monitoring and quality 
assurance aspects of the developing commissioning role in the NHS. 
A surprising conclusion from these analyses was that the algorithm based upon 
treatment guidelines was not even reasonably accurate in determining the date 
of starting ART even when various sensitivity analyses were considered. The 
majority of the false positive results identified CD4 cell counts more than 31 
days before the date of starting ART indicating delays between the 
recommended time to start ART and the actual date of initiation. Similar findings 
have been published raising public health interest for further 
investigation325;495;506;507. In the UK, during the period analysed, there were no 
guidelines for the timeliness of ART initiation. Subsequent guidelines, which 
may partly reflect previous practice, state that clinicians should assess patients’ 
readiness to start therapy and allow them to make decisions about their 
therapy. Yet, that ART should be started immediately for patients with certain 
AIDS diagnoses, co-morbidities or very low CD4 counts and within two weeks 
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for other patients with AIDS, serious bacterial infections or CD4 counts less 
than 200 cells per mm3 128. Therefore, it is reasonable to expect most patients 
to have started ART within 31 days after becoming eligible by CD4 count or by 
AIDS diagnosis, as in this analysis. Hence, reasons for substantially delayed 
ART initiation should be determined and addressed to reduce this period when 
patients are at high risk of AIDS and death. Additionally, a third of individuals 
starting ART after 1999 did not meet the eligibility criteria, which should also be 
investigated further as it could reflect inappropriate advice provided to patients. 
The analyses showed that almost a third of CD4 nadirs occurred more than 31 
days before starting ART and 13% occurred more than 31 days after starting 
ART. This finding was not useful for the determination of an estimated date of 
starting ART. However, it may be useful for researchers analysing longitudinal 
data because it may indicate that additional validation is necessary before the 
use of a single CD4 count as a baseline measure of immunosuppression prior 
to ART233;234. This was recognised in UK treatment guidelines in 2008123 (but 
not re-stated in 2012 guidance128). Among the sample of 9,488 where baseline 
CD4 was the one closest to and within 31 days of startART, the median 
difference between the CD4 nadir and the baseline CD4 count was 0 (IQR 0, 
41) cell per mm3 but the difference was greater than 50 cells/mm3 for 22.6% 
(n=2,145) and greater than 100 cells/mm3 for 11.8% (n=1,124). These results 
also suggest further analysis of factors associated with CD4 counts declines 
after the start of ART among 13% of individuals. However, this would also 
require assessment of the effects of natural and measurement variability, further 
validation of the data and consideration of statistical techniques494. 
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CD4 cell counts change due to pregnancy among non-HIV-infected women 
(Section 1.3.2) but studies show no significant change among HIV-infected 
women508-510. Therefore, there is no difference in the recommendation for 
therapy by CD4 cell count for pregnant and non-pregnant women according to 
guidelines135 and CD4 counts during pregnancy can be considered to 
accurately reflect levels of immunosuppression and CD4 nadirs for use in these 
algorithms. 
In this study, the median increase between two consecutive CD4 cell counts 
that spanned the start of ART was 64 cells/mm3 and the median subsequent 
increase was 20 cells/mm3. Less than a third of individuals had single CD4 
count increases that exceeded the cut-off of 150 cells/mm3 and more than two-
fifths of those did not occur within 31 days of starting ART. Similar increases in 
CD4 cell counts of a median 130 cells per mm3 within six months of starting 
ART and 176 cells per mm3 within a year are reported in the literature511. 
However, there are no published data on the proportion of individuals who do 
not experience an increase or the proportion that experience similar increases 
before they start ART. The only relevant information published comes from 
cohort studies on treatment-naïve individuals, which indicate that a quarter do 
not experience increases greater than 24 cells/mm3 512 or 51 cells/mm3 498 after 
six months. The only range published was a 12 months increase, among 
individuals who controlled their viraemia, which showed that decreases of up to 
200 cells/mm3 occurred364.  
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The algorithm using a preceding decrease and subsequent increase in CD4 
counts performed worse than the one using a single increase in CD4 counts. 
The sensitivities and specificities were similar but a higher percentage of 
individuals did not have sufficient data to be categorised. Only a fifth of 
individuals exceeded the cut-off within 31 days of starting ART, whilst more than 
half of those occurred after more than 31 days. The literature has focused on 
quantifying decreases in CD4 counts before starting ART and increases in CD4 
counts after starting ART but overlooked quantification of the combination of the 
two and the proportions that do/do not experience declines before and 
increases after, which could help describe the progression of HIV infection485. 
The algorithm based on a positive slope in CD4 counts performed best but was 
still not sufficient for the estimated date of starting ART to be used in 
subsequent analyses. It was clear that many individuals did not have a 
substantial positive slope at the time of starting ART but that many individuals 
experienced such increases even before ART was started. False positive 
results accounted for 29% of all positives even when the cut-off rate was 1,600 
cells/mm3 per year (double the cut-off selected). High rates of increase shortly 
after starting ART are known, with published rates of of 11 cells/mm3 per week 
during the first 8 weeks among all treatment-naïve individuals513 and 30 
cells/mm3 per month before the fourth month514 and 97 cells/mm3 per month 
during the first month364 among individuals who controlled their viraemia. 
Furthermore, the data showed that a fair proportion of the false positives were 
the last CD4 count before starting ART or the first CD4 count after starting ART 
even though these did not occur within 31 days of starting ART.  
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Some ART regimens may be more effective than others at increasing CD4 
counts* and this may have resulted in a differential bias of identifying estART for 
individuals on those regimens515;516. This would possibly bias the results of 
subsequent analyses based on estART towards inclusion of individuals on 
those regimens. However, ART regimens are not available in the integrated 
dataset to quantify this potential bias as they are not reported to surveillance 
and other variations in rates of increase of CD4 counts are much more 
substantial. Therefore, this was not believed to be among the most important 
limitations of these analyses. 
It is possible that a proportion of the false positives were due to reporting errors 
in the date of starting ART or due to CD4 measurement errors. Studies to 
develop these investigations would need to examine a sample of false positives 
for verification. Even when slopes both before and after each CD4 cell count 
were considered or a smoothing mechanism was employed, the specificity was 
even lower and did not exclude the false positives.  
Some individuals did not have CD4 cell counts within 31 days of starting ART 
but the algorithms did identify many of the last CD4 counts before starting ART 
or the first CD4 counts after the date of starting ART for these individuals. A 
recent CD4 count should be available for all individuals to inform the initiation of 
ART and the lack of this for all individuals could be investigated further for 
                                            
*
 Of the order of 10-15% higher CD4 count after 48 weeks for ritonavir-boosted PI regimens 
than PI or NNRTI regimens and 24% higher than for NRTI-only regimens. 
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public health interest although the possibility of unlinked records would have to 
be excluded.   
8.6  Conclusion 
Overall, this analysis indicates that the assumption that most individuals will 
experience a CD4 cell count below the threshold recommended by guidelines or 
AIDS at the time of starting ART, and not before, is not valid. Neither is the 
assumption that most individuals will experience a CD4 nadir at the time of 
starting ART and not before. Furthermore, individuals may experience 
substantial increases in CD4 counts, positive slopes in CD4 counts or even 
preceding decreases/subsequent increases in CD4 counts more than a month 
before the time of starting ART. 
While the outcome of these analyses did not determine an algorithm that could 
be used to estimate dates of starting ART, the results were very informative 
about CD4 cell count changes around the time of starting ART. Additionally, for 
individuals who only have an approximate date of starting ART available for 
analyses, these results will still inform the allocation of patient follow-up and 
CD4 counts (as prior to or after starting ART) and the identification of CD4 
counts that are highly likely to reflect levels of immunosuppression just prior to 
starting ART. However, the methods used for censoring patient follow-up and 
assigning baseline CD4 counts prior to the estimated date of starting ART will 
have to be evaluated. Finally, these analyses also provide methodological 
options for detecting potential clerical errors that could be used to improve 
surveillance data.  
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Chapter 9. Rates of change of CD4 cell counts after starting ART 
9.1 Introduction 
Effective ART reduces the risk of morbidity and mortality among HIV-infected 
individuals by reducing the viral load and increasing the CD4 cell count. Current 
CD4 counts remain a predictor of morbidity and mortality among HIV-infected 
individuals on ART and so the rate at which they increase after starting ART is 
clinically important360;517-519. The literature shows that the immunological 
response to ART is biphasic but reasonably linear in each phase with CD4 
counts increasing rapidly during the first 3-18 weeks of ART, followed by slower 
increases364;513;514;520-525. CD4 counts may return to levels similar to those of 
non-HIV-infected individuals if effective ART can be maintained for a sufficient 
length of time526. Yet, some individuals do not achieve or maintain virological 
suppression due to poor adherence or drug resistance527. CD4 cell count 
increases are rare without at least transient or partial virological suppression528. 
However, CD4 cell counts may decline for some individuals on ART even if 
viraemia is controlled (indicating adherence to ART and no resistance) 364;499;503. 
Analyses of rates of change of CD4 cell counts after starting ART have helped 
to further understand responses to ART and determine rates of increase and 
maximum CD4 cell counts that may be aimed for and achieved 
364;498;513;522;526;529;530. The integrated dataset was therefore used in this chapter 
to provide population-level information on rates of change of CD4 cell counts 
after starting ART in E,W&NI and associated factors. Baseline factors 
 424 
 
associated with slower rates may indicate unmet need among population 
groups that could be addressed to improve public health outcomes. 
9.2  Aims 
a) To use the integrated dataset to investigate baseline factors that were 
associated with rates of change of CD4 counts: 
a. During the first three months after starting ART; 
b. After the first three months after starting ART. 
b) To determine the length of time that baseline CD4 cell counts were 
associated with rates of increase in CD4 cell counts after starting ART. 
9.3  Methods 
The time of starting ART used as the baseline in this analysis was taken as: 1) 
startART where there was no evidence of previous ARV use; or 2) estART, 
where there was no startART but evidence of ARV use, or evidence of ARV use 
before startART. Records from the integrated dataset were included in analyses 
for individuals starting ART after 1998 and with no evidence of starting ART 
before diagnosis in the UK.  
Rates of change of CD4 cell counts for each individual were analysed from the 
time of starting ART (baseline). To reduce bias in the baseline CD4 cell count 
due to natural and measurement variability, the mean of the last two CD4 cell 
counts within the three months before startART or estART were used unless 
only one was available. Individuals without a CD4 cell count during the three 
months before starting ART were excluded from the analysis. EstART was 
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included in the main analysis (but excluded from the sensitivity analysis) to 
maximise the number of individuals included in the analysis and evaluate the 
use of estART. Although the algorithm did not produce a good yield or 
sensitivity, and was therefore not effective for identification of startART among 
all individuals, good specificity was achieved. Therefore, relatively few false 
positives would be included in the analysis but also a fair proportion of these 
were either the last CD4 count before starting ART or the first CD4 count after 
starting ART even though these did not occur within 31 days of starting ART. 
Follow-up time was split into the period during the first three months after 
starting ART and the subsequent period (Figure 9.1). This was because CD4 
cell count increases are known to be much greater during the first few months 
than subsequently498;515;520;523. Additionally, CD4 cell count increases during the 
first three months are likely to be substantially affected by error in the estimation 
of estART due to the nature of the integrated dataset (Figure 9.2). This is not 
applicable to other studies of longitudinal CD4 counts where the date of starting 
ART is known. 
Linear mixed-effects models were used for analysis with overall mean CD4 cell 
counts considered to be linear over time but allowing for a random intercept and 
random slope at the individual level. Random intercepts allowed for each 
individual’s vertical shift from overall means and random slopes allowed for 
each individual’s deviation in linear rate of CD4 change from overall mean linear 
rates of CD4 change. The model allowed for different rates of CD4 increase in 
those with different baseline characteristics through the inclusion of interactions 
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between each baseline factor and the time from starting ART. Factors analysed 
in the analyses were: ethnicity, risk group, age group at baseline, year of 
starting ART, baseline CD4 cell count category, previous AIDS (prior to 
startART or estART), and whether treatment was started in London or not. 
These were all, except for region, shown in previous analyses to be associated 
with CD4 responses to ART (ethnicity498;513;516; risk group531; age516, 
year498;515;531, CD4 count515, previous AIDS531;532. Region was included for 
consistency throughout the thesis and to test geographic generalisability. 
Figure 9.1. Schematic showing how baseline CD4 cell counts and rates of 
increase in CD4 cell counts were defined  
 
A number of sensitivity analyses were carried out using i) excluding all 
individuals who started ART with baseline CD4 counts greater than 349 
cells/mm3; ii) excluding all women; iii) using only the last CD4 count before 
starting ART to define the baseline; iv) using the mean of all CD4 counts in the 
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*
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three months before starting ART to define the baseline; v) using only records 
from individuals who had a specific date of starting ART (startART) reported. 
The exclusion of individuals with baseline CD4 cell counts greater than 349 
cells/mm3 and, separately, women were to determine the effects of excluding 
pregnant women who started ART solely to prevent mother-to-infant 
transmission and may have subsequently interrupted ART. Individuals with one 
or more CD4 cell counts before starting ART were differentiated, primarily, to 
investigate whether there were indications of different degrees of bias in the 
baseline CD4 cell counts arising from regression to the mean. The analysis 
limited to individuals with startART was to exclude the systematic bias of 
estART dates being later than the actual dates of starting ART.  
In the stratified analysis of long-term follow-up by year to investigate the 
duration of effect of baseline factors on increases in CD4 cell counts separate 
linear mixed-effects models were used to determine the association between 
the baseline factors and the mean rate of increase in CD4 cell counts for each 
year of follow-up.  
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* Baseline CD4 cell count was the average of the last two CD4 cell counts 
before startART/estART where available, otherwise the last CD4 cell count 
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Figure 9.2. Schematic showing how rates of increase in CD4 cell counts were 
calculated for each year after starting ART 
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9.4  Results 
9.4.1 Rates of increase of CD4 cell counts during the three 
months after starting ART 
There were 25,727 individuals who started ART between 1999 and 2007, of 
whom 21,203 had a baseline CD4 cell count followed by a median of one 
subsequent CD4 cell count (range 0, 8) during the three months after starting 
ART. These 21,203 individuals included in the analysis (those with baseline 
CD4 cell counts) were not representative of all individuals starting ART (Table 
9.1). In multivariable analysis, there were marked differences in proportions 
included for all factors. Individuals starting ART in more recent years, in 
London, or with a previous AIDS diagnosis were more likely to be included in 
the analysis. Individuals were also more likely to be included if they were MSM 
or middle-aged (40-44 years). Individuals were less likely to have baseline CD4 
cell counts, and therefore less likely to be included, if they were 
Indian\Pakistani\Bangladeshi. 
Overall, the mean rate of change of CD4 counts during the first three months of 
ART was 120 (95% CI 117, 123) cells/mm3 (Table 9.2). The reference group for 
analyses was white MSM aged 40-44 years who had a baseline CD4 cell count 
of 200-249 cells/mm3 and no previous AIDS diagnosis when they started ART in 
1999 in London. This reference group had a rate of change of 149 (95% CI 132, 
166) cells/mm3. All factors except a previous AIDS diagnosis were significantly 
associated with the initial rate of increase in CD4 counts in multivariable 
analysis (Table 9.2). There was no significant difference in the initial rate of 
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increase in CD4 counts between 1999 and 2004 but the rates of increase were 
a quarter to two-fifths higher between 2005 and 2007 (p<0.01). Baseline CD4 
counts of 250 cells/mm3 or more were associated with slower initial rates of 
increase in CD4 counts (p<0.01). In contrast, individuals with baseline CD4 cell 
counts of 50-99 cells/mm3 had faster initial rates of increase than the reference 
group (p=0.01). Having a treatment provider in London was associated with a 
faster initial rate of increase in CD4 counts (p<0.01). Individuals aged 15-24 
years or 25-29 years had significantly faster rates of increase than individuals 
aged 40-44 years (p<0.01 and p=0.05 respectively). IDU and heterosexuals had 
significantly slower initial rates of increase in CD4 counts compared to MSM 
(p<0.01) except for heterosexual women diagnosed antenatally, who had faster 
rates of increase (p<0.01). Compared to white individuals, black Africans, other 
black individuals and ‘Other Asians’ had significantly slower initial rates of 
increase in CD4 counts (p<0.01, p=0.03 and p=0.04).  
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Table 9.1. Individuals included in analysis of initial rates of increase in CD4 cell 
counts (i.e. individuals with baseline CD4 cell counts) as a proportion of all 
individuals who started ART between 1999 and 2007. 
 
Number of  individuals 
included in analysis 
Proportion of all 
individuals starting 
ART (%) 
Multivariable odds ratio 
for inclusion in analysis                  
(95% confidence interval) 
    Calendar year of starting 
ART 
   
1999 1,353 73.3 - 
2000 1,495 76.3 1.19 (1.02 , 1.37) 
2001 1,763 79.3 1.44 (1.24 , 1.66) 
2002 2,034 73.7 1.06 (0.93 , 1.22) 
2003 2,841 83.8 1.99 (1.73 , 2.29) 
2004 2,875 84.6 2.13 (1.85 , 2.45) 
2005 3,017 87.7 2.76 (2.38 , 3.20) 
2006 2,922 85.2 2.21 (1.92 , 2.55) 
2007 2,903 88.7 2.98 (2.56 , 3.47) 
    
   Previous AIDS diagnosis    
No 16,624 82.4 - 
Yes 4,579 82.4 1.12 (1.04 , 1.22) 
    
   Site of care    
Outside London 8,874 82.0 0.90 (0.84 , 0.96) 
London 12,329 82.7 - 
    
   Age group    
15-24 1,487 80.3 0.76 (0.65 , 0.88) 
25-29 3,295 81.2 0.85 (0.75 , 0.96) 
30-34 4,940 82.6 0.95 (0.84 , 1.06) 
35-39 4,661 83.1 0.98 (0.87 , 1.09) 
40-44 3,134 84.0 - 
45-49 1,725 82.1 0.86 (0.75 , 0.99) 
50-54 930 82.7 0.94 (0.79 , 1.13) 
>54 1,031 80.7 0.81 (0.69 , 0.96) 
    
   Risk group    
MSM 8,019 84.2 - 
Heterosexual men 4,443 81.3 0.79 (0.71 , 0.88) 
Heterosexual women 6,588 81.4 0.80 (0.72 , 0.90) 
Heterosexual women 
 (diagnosed antenatally) 
1,577 84.1 0.98 (0.84 , 1.16) 
IDU 437 74.6 0.56 (0.46 , 0.68) 
Recipients of blood products 139 78.5 0.78 (0.54 , 1.13) 
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   Ethnicity    
White  9,300 82.9 - 
Black African 9,464 81.9 0.98 (0.88 , 1.09) 
Black Caribbean 713 80.9 0.91 (0.75 , 1.09) 
Black Other 410 83.8 1.09 (0.84 , 1.41) 
Indian\Pakistani\Bangladeshi 270 78.3 0.76 (0.58 , 0.99) 
Other Asian 341 84.8 1.17 (0.88 , 1.55) 
Other/mixed 705 84.9 1.16 (0.95 , 1.42) 
    
    Total 21,203 82.4 - 
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Table 9.2. Results from linear mixed-effects analysis of the association between 
each factor and the initial rate of increase of CD4 counts during the first three 
months of ART. 
 
Initial rate of increase of CD4 
count estimated from 
univariable regression 
(95% CI) 
/cells/mm
3
 
Multivariable 
regression 
coefficient 
(95% CI) 
Multivariable 
p value 
    
    Calendar year of starting ART    
1999 102 (91 , 113) - - 
2000 106 (95 , 116) -1.4 (-18.3 , 15.4) 0.87 
2001 109 (99 , 119) 3.0 (-13.4 , 19.3) 0.72 
2002 106 (97 , 115) 2.6 (-13.1 , 18.4) 0.74 
2003 110 (103 , 118) 8.5 (-6.4 , 23.5) 0.26 
2004 113 (106 , 121) 10.8 (-4.1 , 25.7) 0.16 
2005 132 (125 , 139) 28.8 (14.0 , 43.6) <0.01 
2006 138 (131 , 145) 35.6 (20.8 , 50.5) <0.01 
2007 141 (133 , 149) 39.3 (24.0 , 54.6) <0.01 
    
    Baseline CD4 count category 
(cells/mm
3
) 
   
0-49 121 (113 , 129) -9.4 (-21.0 , 2.3) 0.12 
50-99 151 (141 , 160) 16.7 (4.3 , 29.0) <0.01 
100-149 145 (136 , 154) 8.0 (-3.9 , 19.9) 0.19 
150-199 147 (139 , 155) 4.6 (-6.5 , 15.7) 0.42 
200-249 146 (138 , 154) - - 
250-299 130 (121 , 140) -17.4 (-29.3 , -5.4) <0.01 
300-349 123 (111 , 135) -26.2 (-40.6 , -11.9) <0.01 
350-499 99 (88 , 109) -52.1 (-65.2 , -39.0) <0.01 
>499 15 (3 , 27) -140.0 (-154.4 , -125.6) <0.01 
    
    Previous AIDS diagnosis    
No 123 (120 , 126) - - 
Yes 118 (113 , 124) -5.6 (-13.5 , 2.3) 0.17 
    
    Site of care    
Outside London 115 (111 , 119) -9.6 (-15.9 , -3.3) <0.01 
London 124 (120 , 127) - - 
    
    Age group    
15-24 129 (118 , 139) 19.8 (5.3 , 34.2) <0.01 
25-29 121 (114 , 128) 11.5 (0.2 , 22.8) 0.05 
30-34 119 (113 , 125) 5.8 (-4.4 , 16.0) 0.26 
35-39 119 (113 , 125) 3.6 (-6.6 , 13.7) 0.49 
40-44 119 (112 , 126) - - 
45-49 117 (108 , 127) -4.6 (-17.7 , 8.6) 0.50 
50-54 121 (108 , 135) -2.0 (-18.5 , 14.5) 0.82 
>54 124 (112 , 137) -0.1 (-16.0 , 15.8) 0.99 
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    Risk group    
MSM 139 (134 , 143) - - 
Heterosexual men 101 (95 , 107) -26.2 (-37.1 , -15.4) <0.01 
Heterosexual women 105 (100 , 110) -16.0 (-26.7 , -5.2) <0.01 
Heterosexual women 
 (diagnosed antenatally) 
134 (124 , 145) 35.4 (20.0 , 50.8) <0.01 
IDU 90 (70 , 110) -44.5 (-67.3 , -21.8) <0.01 
Recipients of blood products 88 (53 , 124) -32.0 (-71.7 , 7.8) 0.12 
    
    Ethnicity    
White  135 (131 , 139) - - 
Black African 103 (99 , 107) -33.1 (-43.3 , -22.8) <0.01 
Black Caribbean 125 (110 , 140) -5.9 (-24.4 , 12.6) 0.53 
Black Other 111 (90 , 131) -26.8 (-50.9 , -2.8) 0.03 
Indian\Pakistani\Bangladeshi 103 (78 , 127) -23.5 (-51.6 , 4.6) 0.10 
Other Asian 118 (98 , 139) -25.0 (-48.8 , -1.1) 0.04 
Other/mixed 137 (122 , 152) -0.9 (-18.4 , 16.5) 0.92 
    
    Overall 120 (117 , 123) - - 
    Comparison group* - 149.0  (132.3 , 165.7) - 
 
 * The comparison group was white MSM aged 40-44 years who had been diagnosed for more 
than 730 days and had a baseline CD4 cell count between 200 and 249 cells/mm
3
 and no 
previous AIDS diagnosis when they started ART in 1999 in London. 
 
Excluding individuals who started ART with CD4 cell counts greater than 349 
cells/mm3 reduced the number of individuals included in the model to 17,520. 
The effect of the year of starting ART was greater than in the main model such 
that initial rates of CD4 count increases in 2003 and 2004 were also significantly 
faster than in 1999 (p=0.04 and p<0.01 respectively) (Table 9.3). Individuals 
starting ART with a baseline CD4 count of 0-49 cells/mm3 experienced a 
statistically slower rate of increase than those starting ART with CD4 counts of 
200-249 cells/mm3 (p=0.01). The effects of age group, heterosexual women 
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diagnosed antenatally and ‘Black other’ ethnicity were no longer associated with 
statistically different rates of increase than the comparison group.  
Excluding women from the analysis reduced the number of individuals included 
in the model to 13,038 but had little effect on the results compared to the main 
model (Table 9.3). However, age group and ‘Black other’ ethnicity were no 
longer associated with different rates of increase in CD4 cell counts. 
The analysis was repeated using different methods of calculating the baseline 
CD4 cell count (no change in the number of individuals included in the 
analysis). The baseline CD4 cell count categories changed for 14.4% (3,049) of 
individuals when only the last CD4 cell count was used and for 3.4% (721) of 
individuals when the mean of all CD4 cell counts in the last three months before 
ART was used. As the number of CD4 cell counts included in the calculation of 
the baseline value increased, there was an overall increase in the baseline CD4 
count for individuals with CD4 counts below 250 cells/mm3 and an overall 
decrease in the baseline CD4 count for individuals with CD4 counts of 250 
cells/mm3 or more such that there was a slight decrease in the mean and a 
reduced variance in baseline CD4 cell counts (from 226.2 cells/mm3/34,160 
when using only the last CD4 count, to 225.0 cells/mm3/32,798 when using the 
mean of the last two CD4 counts where available, and to 224.7 
cells/mm3/32,469 when using the mean of all CD4 counts – all within the three 
months before starting ART). 
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Table 9.3. Results from linear mixed-effects analysis of the association between 
each factor and initial rates of increase of CD4 counts during the first three 
months of ART: sensitivity analyses of models i) excluding individuals starting 
ART with CD4≥350 cells/mm3 and ii) excluding women. 
 
i) Excluding individuals starting   
ART with CD4≥350 cells/mm3 
 
N = 17,520 
ii) Excluding women 
 
N = 13,038 
 
Regression 
coefficient 
(95% CI) 
p value 
Regression 
coefficient 
(95% CI) 
p value 
     
    Calendar year of starting ART     
1999 - - - - 
2000 1.6 (-15.8 , 19.0) 0.86 0.1 (-20.1 , 20.4) 0.99 
2001 6.9 (-9.9 , 23.7) 0.42 7.5 (-12.4 , 27.4) 0.46 
2002 13.7 (-2.4 , 29.9) 0.10 7.0 (-12.3 , 26.2) 0.48 
2003 16.0 (0.6 , 31.4) 0.04 13.2 (-5.2 , 31.7) 0.16 
2004 23.6 (8.3 , 38.9) <0.01 17.2 (-1.1 , 35.5) 0.07 
2005 39.9 (24.8 , 55.1) <0.01 39.5 (21.3 , 57.6) <0.01 
2006 47.0 (31.8 , 62.3) <0.01 37.6 (19.5 , 55.7) <0.01 
2007 48.4 (32.8 , 64.0) <0.01 47.3 (28.8 , 65.8) <0.01 
     
    Baseline CD4 count category 
(cells/mm
3
) 
    
0-49 -14.0 (-24.8 , -3.2) 0.01 -5.8 (-20.9 , 9.3) 0.45 
50-99 14.3 (3.0 , 25.6) 0.01 21.4 (5.4 , 37.3) <0.01 
100-149 7.4 (-3.5 , 18.4) 0.18 13.3 (-2.2 , 28.7) 0.09 
150-199 3.5 (-6.6 , 13.7) 0.49 10.1 (-4.1 , 24.3) 0.17 
200-249 - - - - 
250-299 -17.5 (-28.4 , -6.5) <0.01 -19.7 (-34.8 , -4.6) 0.01 
300-349 -24.1 (-37.2 , -10.9) <0.01 -26.9 (-45.8 , -8.0) <0.01 
350-499   -56.2 (-73.7 , -38.6) <0.01 
>499   -165.5 (-184.7 , -146.2) <0.01 
     
    Previous AIDS diagnosis     
No - - - - 
Yes -0.4 (-8.0 , 7.2) 0.92 -9.0 (-19.0 , 1.1) 0.08 
     
    Site of care     
Outside London -6.4 (-12.6 , -0.1) 0.05 -11.9 (-20.1, -3.7) <0.01 
London - - - - 
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* The comparison group was white MSM aged 40-44 years who had been diagnosed for more 
than 730 days and had a baseline CD4 cell count between 200 and 249 cells/mm
3
 and no 
previous AIDS diagnosis when they started ART in 1999 in London. 
 
In multivariable analysis, there was no meaningful difference between the 
models that used the mean of the last two (where available) CD4 cell counts or 
all CD4 cell counts within the previous three months (Table 9.4). Results from 
the model that used just the last CD4 count before ART indicated that the initial 
rates of increase in CD4 cell counts from baselines of 100-149 cells/mm3 were 
    Age group      
15-24 10.0 (-5.0 , 25.0) 0.19 5.2 (-16.4 , 26.9) 0.64 
25-29 5.6 (-5.7 , 16.9) 0.33 8.4 (-6.8 , 23.5) 0.28 
30-34 7.3 (-2.7 , 17.3) 0.15 11.4 (-1.3 , 24.1) 0.08 
35-39 1.9 (-8.0 , 11.8) 0.71 5.3 (-7.1 , 17.6) 0.40 
40-44 - - - - 
45-49 -3.9 (-16.7 , 8.9) 0.55 -3.1 (-18.6 , 12.4) 0.69 
50-54 -6.2 (-22.0 , 9.7) 0.45 -3.2 (-22.7 , 16.3) 0.75 
>54 2.3 (-13.2 , 17.9) 0.77 4 (-14.4 , 22.4) 0.67 
     
   Risk group     
MSM - - - - 
Heterosexual men -26.6 (-37.3 , -15.9) <0.01 -31.4 (-44.4, -18.3) <0.01 
Heterosexual women -19.4 (-30.1 , -8.6) <0.01   
Heterosexual women 
 (diagnosed antenatally) 
8.9 (-8.0 , 25.7) 0.30   
IDU -39.7 (-62.4 , -17.1) <0.01 -43.9 (-67.3 , -20.5) <0.01 
Recipients of blood products -34.7 (-74.3 , 4.9) 0.09 -34.0 (-75.2 , 7.1) 0.11 
     
   Ethnicity     
White  - - - - 
Black African -32.5 (-42.8 , -22.3) <0.01 -29.3 (-43.9 , -14.7) <0.01 
Black Caribbean -8.7 (-27.2 , 9.7) 0.35 -6.0 (-30.4 , 18.3) 0.63 
Black Other -15.2 (-38.9 , 8.4) 0.21 -14.2 (-49.1 , 20.8) 0.43 
Indian\Pakistani\Bangladeshi -8.1 (-35.5 , 19.3) 0.56 -19.6 (-54.0 , 14.8) 0.27 
Other Asian -26.1 (-49.6 , -2.6) 0.03 -39.9 (-71.7 , -8.0) 0.01 
Other/mixed 0.2 (-17.1 , 17.6) 0.98 -5.8 (-26.7 , 15.0) 0.58 
     
  Comparison group* 145.6  (129.0 , 162.3) - 145.2  (125.1 , 165.2) - 
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statistically faster than the increases from baselines of 200-249 cells/mm3 in 
contrast to the main model (Table 9.4). There was little change in the initial rate 
of increase for any of the other variables. 
The analysis was repeated using data for only the 15,509 individuals who had 
startART reported. These individuals had lower baseline CD4 cell counts 
(median 182 [IQR 90, 266] cells/mm3) than the 5,694 individuals with estART 
but no startART reported (median 247 [IQR 136, 389] cells/mm3) (p<0.01). For 
individuals with startART, the rate of change during the first three months of 
ART was 138 (95% CI 135, 141) cells/mm3 compared to 58 (95% CI 52, 65) 
cells/mm3 for those with estART. In comparison with the main model, there was 
no longer a significant association between age group and initial rates of CD4 
cell count increases although the regression coefficients changed little. In 
contrast, the effect of site of care was no longer significant and the regression 
coefficient became close to zero. (Table 9.4). There was no change in the 
associations between risk group or ethnicity and initial rates of CD4 count 
increases. There was a weaker association with the year of starting ART and 
the baseline CD4 cell count category. Additionally, individuals with baseline 
CD4 counts less than 50 cells/mm3 had significantly slower initial rates of 
increase, and individuals with baseline CD4 counts of 50-99 cells/mm3 no 
longer had statistically different initial rates of increase, than the comparison 
group. However, a previous AIDS diagnosis was weakly associated with faster 
initial rates of CD4 cell count increase in this model (p=0.05). 
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Table 9.4. Results from linear mixed-effects analysis of the association between 
each factor and the rate of increase of CD4 counts during the first three months 
of ART: sensitivity analyses of models i & ii) varying the definition of baseline 
CD4 cell count and iii) only including individuals with startART reported. 
 
 
i) Single baseline CD4  
cell count 
 
N = 21,203 
ii) Mean of all CD4 cell  
counts during the last 
 three months 
 
N = 21,203 
iii) Individuals with 
startART only 
 
N = 15,509 
 
Regression 
coefficient 
(95% CI) 
p value 
Regression 
coefficient 
(95% CI) 
p value 
Regression 
coefficient 
(95% CI) 
p value 
       
    Calendar year of  
                        starting ART 
      
1999 - - - - - - 
2000 -1.8 (-19.1 , 15.4) 0.83 -1.0 (-17.8 , 15.7) 0.90 2.1 (-19.0 , 23.1) 0.85 
2001 2.8 (-13.9 , 19.6) 0.74 2.7 (-13.5 , 19.0) 0.74 -4.2 (-24.6 , 16.3) 0.69 
2002 2.8 (-13.4 , 18.9) 0.74 2.7 (-13.0 , 18.4) 0.74 -3.7 (-23.3 , 15.9) 0.71 
2003 9.4 (-5.9 , 24.7) 0.23 8.9 (-6.0 , 23.7) 0.24 1.8 (-16.9 , 20.5) 0.85 
2004 9.6 (-5.7 , 24.9) 0.22 11.0 (-3.9 , 25.8) 0.15 8.5 (-10.0 , 27.0) 0.37 
2005 28.9 (13.7 , 44) <0.01 29.3 (14.6 , 44.0) <0.01 14.9 (-3.2 , 33.1) 0.11 
2006 35.3 (20.1 , 50.5) <0.01 35.8 (21.1 , 50.6) <0.01 23.7 (5.5 , 41.9) 0.01 
2007 40.2 (24.6 , 55.8) <0.01 39.5 (24.3 , 54.6) <0.01 20.7 (2.3 , 39.0) 0.03 
       
     Baseline CD4 count 
           category (cells/mm
3
) 
      
0-49 -6.5 (-18.5 , 5.5) 0.29 -10.8 (-22.4 , 0.8) 0.07 -25.8 (-38.5 , -13.1) <0.01 
50-99 15.9 (3.3 , 28.4) 0.01 14.4 (2.2 , 26.7) 0.02 9.4 (-4.0 , 22.8) 0.17 
100-149 15.8 (3.7 , 28.0) 0.01 6.4 (-5.5 , 18.3) 0.29 1.5 (-11.6 , 14.5) 0.83 
150-199 4.3 (-7.2 , 15.8) 0.47 3.9 (-7.1 , 14.9) 0.49 1.9 (-10.2 , 14.0) 0.76 
200-249 - - - -   
250-299 -20.2 (-32.7 , -7.7) <0.01 -19.6 (-31.4 , -7.8) <0.01 -13.1 (-26.3 , 0.1) 0.05 
300-349 -33.4 (-48.1 , -18.8) <0.01 -29.1 (-43.3 , -14.9) <0.01 -7.3 (-23.9 , 9.3) 0.39 
350-499 -54.2 (-67.5 , -40.9) <0.01 -48.0 (-61.0 , -35.0) <0.01 -41.3 (-56.8 , -25.7) <0.01 
>499 -159.0 (-173.6 , -144.4) <0.01 -138.2 (-152.5 , -123.8) <0.01 -118.3 (-136.0 , -100.5) <0.01 
       
   Previous AIDS diagnosis       
No - - - - - - 
Yes -7.4 (-15.5, 0.7) 0.07 -5.2 (-13.1 , 2.7) 0.20 9.0 (0.0 , 18.1) 0.05 
       
   Site of care       
Outside London -9.2 (-15.6, -2.7) <0.01 -9.7 (-16.0 , -3.5) <0.01 -0.5 (-7.6 , 6.6) 0.89 
London - - - - - - 
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* The comparison group was white MSM aged 40-44 years who had been diagnosed for more 
than 730 days and had a baseline CD4 cell count between 200 and 249 cells/mm
3
 and no 
previous AIDS diagnosis when they started ART in 1999 in London. 
 
    Age group        
15-24 22.8 (8.0 , 37.6) <0.01 19.3 (4.9 , 33.7) <0.01 13.3 (-3.1 , 29.6) 0.11 
25-29 13.4 (1.8 , 25) 0.02 11.2 (-0.1 , 22.4) 0.05 7.0 (-5.6 , 19.6) 0.27 
30-34 6.5 (-3.9 , 16.9) 0.22 5.5 (-4.6 , 15.6) 0.29 5.3 (-6.0 , 16.5) 0.36 
35-39 3.7 (-6.7 , 14.1) 0.48 3.6 (-6.5 , 13.7) 0.49 1.5 (-9.7 , 12.7) 0.80 
40-44 - - - - - - 
45-49 -4.1 (-17.5 , 9.4) 0.55 -4.6 (-17.6 , 8.5) 0.49 -8.5 (-23.1 , 6.1) 0.25 
50-54 -1.1 (-18 , 15.8) 0.90 -1.5 (-17.9 , 15.0) 0.86 -6.8 (-25.1 , 11.6) 0.47 
>54 -0.5 (-16.8 , 15.8) 0.95 0.1 (-15.7 , 15.9) 0.99 -5.3 (-23.0 , 12.3) 0.56 
       
  Risk group       
MSM - - - - - - 
Heterosexual men -27.3 (-38.4 , -16.2) <0.01 -26.0 (-36.8 , -15.2) <0.01 -23.7 (-35.8 , -11.6) <0.01 
Heterosexual women -16.8 (-27.8 , -5.9) <0.01 -15.6 (-26.3 , -4.9) <0.01 -17.0 (-28.9 , -5.2) <0.01 
Heterosexual women 
 (diagnosed antenatally) 
38.5 (22.8 , 54.2) <0.01 34.2 (18.9 , 49.5) <0.01 23.3 (6.0 , 40.6) <0.01 
IDU -45.6 (-68.8 , -22.3) <0.01 -44.6 (-67.2 , -22.0) <0.01 -33.7 (-60.6 , -6.8) 0.01 
Recipients of blood products -31.8 (-72.5 , 8.8) 0.13 -32.6 (-72.1 , 7.0) 0.11 -8.6 (-57.4 , 40.3) 0.73 
       
  Ethnicity       
White  - - - - - - 
Black African -33.9 (-44.4 , -23.5) <0.01 -32.9 (-43.0 , -22.7) <0.01 -33.2 (-44.6 , -21.9) <0.01 
Black Caribbean -6.3 (-25.2 , 12.6) 0.52 -6.4 (-24.8 , 11.9) 0.49 -17.1 (-37.3 , 3.1) 0.10 
Black Other -26.1 (-50.7 , -1.6) 0.04 -26.4 (-50.3 , -2.5) 0.03 -29.7 (-56.8 , -2.5) 0.03 
Indian\Pakistani\Bangladeshi -23.9 (-52.7 , 4.9) 0.10 -22.9 (-50.8 , 5.1) 0.11 -4.2 (-35.8 , 27.3) 0.79 
Other Asian -23.8 (-48.3 , 0.6) 0.06 -25.3 (-49.0 , -1.6) 0.04 -29.8 (-55.8 , -3.8) 0.03 
Other/mixed -1.5 (-19.4 , 16.4) 0.87 -0.7 (-18.0 , 16.6) 0.94 0.4 (-18.5 , 19.3) 0.97 
       
  Comparison group* 151.8  (134.7 , 168.8) - 149.0  (132.5 , 165.6) - 166.9  (146.8 , 187.0) - 
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9.4.2 Rates of change of CD4 counts after the first three months 
of ART 
Of the 21,203 individuals with baseline CD4 cell counts who started ART 
between 1999 and 2007, there were 18,657 (88.0%) who had CD4 cell counts 
after the first three months of ART (median 10 [IQR 5, 17; range 1, 71]). As in 
the previous analysis, these individuals were not representative of the 25,727 
individuals starting ART (Table 9.5). In contrast to the previous analysis, 
however, individuals starting ART in 2007 were significantly less likely to be 
included in this analysis due to insufficient CD4 counts after the first three 
months of ART. Indian\Pakistani\Bangladeshi individuals were no longer 
significantly less likely to be included in the analysis whereas black Africans 
were significantly less likely to be included. Other differences in the factors 
associated with inclusion between the analyses were minor. 
The overall mean rate of increase in CD4 counts after the first three months of 
ART was 43 (95% CI 42, 44) cells/mm3 per year. This rate increased with year 
of starting ART but slowed with increasing baseline CD4 counts (Table 9.6). 
Individuals aged 15-24 years (p<0.01) and those aged 55 years or older 
(p<0.01) had slower rates of increase than those aged 40-44 years. Care in 
London (p<0.01) and a previous AIDS diagnosis (p<0.01) were associated with 
faster rates of increase in CD4 cell counts. Heterosexual men, heterosexual 
women diagnosed antenatally and IDU all had slower rates of increase than 
MSM whereas other heterosexual women had faster rates of increase than 
MSM. The only significant association with ethnicity was that black Africans had 
slower rates of increase in CD4 cell counts than white individuals. 
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Table 9.5. Individuals included in analysis of rates of increase in CD4 cell 
counts after the first three months after starting ART as a proportion of all 
individuals who started ART between 1999 and 2007.  
 
Number of  
individuals included 
in analysis 
Proportion of all 
individuals starting 
ART (%) 
Multivariable odds ratio 
for inclusion in analysis                  
(95% confidence interval) 
    Calendar year of  
                         starting ART 
   
1999 1,288 69.8 - 
2000 1,416 72.3 1.15 (1.00 , 1.32) 
2001 1,650 74.2 1.31 (1.14 , 1.50) 
2002 1,925 69.7 1.07 (0.94 , 1.21) 
2003 2,676 78.9 1.77 (1.55 , 2.02) 
2004 2,701 79.5 1.85 (1.62 , 2.11) 
2005 2,848 82.7 2.29 (2.00 , 2.62) 
2006 2,692 78.5 1.72 (1.51 , 1.96) 
2007 1,461 44.6 0.37 (0.33 , 0.42) 
    
   Previous AIDS diagnosis    
No 14,300 72.1 - 
Yes 4,357 74.0 1.11 (1.03 , 1.19) 
    
   Site of care    
Outside London 7,650 71.0 0.85 (0.80 , 0.90) 
London 11,007 73.6 - 
    
   Age group    
15-24 1,288 69.5 0.83 (0.72 , 0.94) 
25-29 2,888 71.2 0.90 (0.81 , 1.00) 
30-34 4,415 73.8 1.03 (0.94 , 1.14) 
35-39 4,169 74.4 1.06 (0.96 , 1.17) 
40-44 2,719 72.9 - 
45-49 1,509 71.8 0.95 (0.84 , 1.08) 
50-54 793 70.6 0.87 (0.75 , 1.01) 
>54 876 68.6 0.77 (0.66 , 0.88) 
    
   Risk group    
MSM 7,133 74.9 - 
Heterosexual men 3,861 70.6 0.80 (0.72 , 0.88) 
Heterosexual women 5,797 71.6 0.85 (0.77 , 0.94) 
Heterosexual women 
 (diagnosed antenatally) 
1,362 72.6 0.89 (0.77 , 1.02) 
IDU 379 64.7 0.55 (0.46 , 0.66) 
Recipients of blood products 125 70.6 0.83 (0.59 , 1.16) 
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   Ethnicity    
White  8,264 73.7 - 
Black African 8,274 71.6 0.89 (0.81 , 0.97) 
Black Caribbean 635 72.1 0.94 (0.80 , 1.12) 
Black Other 339 69.3 0.85 (0.68 , 1.05) 
Indian\Pakistani\Bangladeshi 238 69.0 0.83 (0.65 , 1.06) 
Other Asian 302 75.1 1.11 (0.87 , 1.42) 
Other/mixed 605 72.9 0.93 (0.79 , 1.10) 
    
    Total 18,657 72.5 - 
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Table 9.6. Results from linear mixed-effects analysis of the association between 
each factor and the rate of increase of CD4 counts after the first three months of 
ART (cells/mm3 per year). 
 
Rate of increase of CD4 
count estimated from 
univariable regression 
(95% CI) 
/cells/mm
3
 per year 
Multivariable 
regression 
coefficient 
(95% CI) 
Multivariable 
p value 
    
     Calendar year of starting ART    
1999 23 (21, 26) - - 
2000 28 (25, 31) 3.1 (-0.4 , 6.6) 0.08 
2001 35 (32, 37) 9.9 (6.5 , 13.3) <0.01 
2002 40 (37, 42) 14.4 (11.0 , 17.7) <0.01 
2003 46 (44, 48) 21.5 (18.3 , 24.8) <0.01 
2004 56 (54, 59) 31.1 (27.7 , 34.5) <0.01 
2005 66 (63, 69) 39.3 (35.4 , 43.2) <0.01 
2006 79 (74, 85) 52.4 (46.1 , 58.7) <0.01 
2007 90 (61, 119) 63.6 (35.6 , 91.7) <0.01 
    
      Baseline CD4 count category 
(cells/mm
3
) 
   
0-49 62 (59, 64) 14.2 (10.8 , 17.6) <0.01 
50-99 55 (52, 58) 9.5 (6.0 , 13.1) <0.01 
100-149 50 (47, 52) 5.4 (2.0 , 8.8) <0.01 
150-199 50 (48, 53) 3.6 (0.3 , 6.9) 0.03 
200-249 46 (44, 49) - - 
250-299 42 (40, 45) -1.8 (-5.4 , 1.7) 0.31 
300-349 31 (27, 35) -10.6 (-14.7 , -6.4) <0.01 
350-499 17 (14, 20) -23.3 (-27.0 , -19.5) <0.01 
>499 -11 (-14, -8) -49.2 (-53.2 , -45.3) <0.01 
    
    Previous AIDS diagnosis    
No 39 (38, 40) - - 
Yes 53 (51, 55) 5.8 (3.6 , 8.0) <0.01 
    
    Site of care    
Outside London 45 (44, 46) 2.2 (0.8 , 3.6) <0.01 
London 41 (40, 42) - - 
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     Age group     
15-24 28 (24, 31) -6.9 (-11.1 , -2.6) <0.01 
25-29 36 (34, 38) -2.8 (-6.0 , 0.5) 0.10 
30-34 44 (42, 46) 1.7 (-1.2 , 4.6) 0.26 
35-39 46 (44, 48) 1.0 (-2.0 , 3.9) 0.52 
40-44 47 (45, 50) - - 
45-49 49 (45, 52) 1.3 (-2.5 , 5.2) 0.50 
50-54 43 (39, 48) -3.6 (-8.4 , 1.1) 0.14 
>54 39 (35, 44) -9.1 (-13.7 , -4.4) <0.01 
    
   Risk group    
MSM 42 (41, 44) - - 
Heterosexual men 45 (43, 47) -4.6 (-7.7 , -1.6) <0.01 
Heterosexual women 50 (49, 52) 4.6 (1.6 , 7.6) <0.01 
Heterosexual women 
 (diagnosed antenatally) 
8 (4, 12) -24.4 (-28.9 , -19.9) <0.01 
IDU 26 (19, 32) -18.3 (-24.6 , -12.1) <0.01 
Recipients of blood products 35 (24, 46) 1.7 (-8.8 , 12.1) 0.76 
    
   Ethnicity    
White  41 (40, 42) - - 
Black African 44 (43, 45) -3.9 (-6.8 , -1.0) <0.01 
Black Caribbean 49 (43, 54) 4.3 (-0.9 , 9.4) 0.10 
Black Other 49 (42, 56) 0.8 (-6.1 , 7.7) 0.83 
Indian\Pakistani\Bangladeshi 43 (35, 52) 0.5 (-7.5 , 8.6) 0.90 
Other Asian 46 (39, 54) -2.9 (-10.2 , 4.4) 0.44 
Other/mixed 43 (38, 48) -1.0 (-6.1 , 4.1) 0.70 
    
   Total 43 (42, 44) - - 
   Comparison group* - 28.1  (24.0, 32.3) - 
* The comparison group was white MSM aged 40-44 years who had been diagnosed for more 
than 730 days and had a baseline CD4 cell count between 200 and 249 cells/mm
3
 and no 
previous AIDS diagnosis when they started ART in 1999 in London. 
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Exclusion of those starting ART with CD4 cell counts greater than 350 
cells/mm3 (leaving 15,487 individuals in the dataset) had little effect on the 
results except that there was a more marked effect of year of starting ART and 
individuals aged 15-24 years no longer had significantly slower rates of increase 
(p=0.17). Exclusion of women (leaving 11,498 men in the dataset) also resulted 
in a more marked effect of the year of starting ART but reduced some of the 
effect of baseline CD4 cell counts.  Men aged 15-24 years no longer had 
significantly different rates of increase than men aged 40-44 years (p=0.75) but 
men aged 50-54 years had significantly slower rates of increase (p=0.02). There 
was no longer any significant difference between the rates of increase for 
heterosexual men and MSM in the model that excluded women (p=0.19). 
There was little change in the effect of any of the factors on the rate of increase 
when the analysis was repeated using either the last CD4 count before starting 
ART or the mean of all the CD4 counts in the last three months before starting 
ART as the baseline CD4 count. 
The analysis was repeated using only the records from individuals with 
startART. In this analysis of 14,045 individuals, the rate of change of CD4 
counts after the first three months of ART was 47.2 (95% CI 46.1, 48.2) 
cells/mm3 per year (compared to 29.7 (95% CI 27.8, 31.6) cells/mm3 per year 
for individuals without startART reported). There was little difference between 
this model and the model including all individuals. Yet, there was no longer any 
significant difference between the rate of increase for heterosexual men and 
MSM (p=0.07) or between individuals treated at different sites of care (p=0.48).  
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Number of years after starting ART
9.4.3 How long after starting ART do baseline factors impact on 
CD4 cell count increases? 
The 21,203 individuals with baseline CD4 cell counts who started ART post-
1998 were included in this analysis. The number of individuals contributing to 
each separate analysis decreased from 21,203 for the first year of follow-up to 
1,759 for the seventh year of follow-up (Figure 9.3). 
The mean rate of increase declined progressively over the first five years after 
starting ART but subsequently remained fairly stable and positive (Figure 9.3). 
The mean increase in CD4 cell counts was: 147 (95% CI 144, 149) cells/mm3, 
57 (95% CI 54, 60) cells/mm3, 40 (95% CI 36, 43) cells/mm3, 33 (95% CI 29, 
38) cells/mm3, 25 (95% CI 19, 30) cells/mm3, 23 (95% CI 16, 30) cells/mm3, 29 
(95% CI 20, 37) cells/mm3, and 29 (95% CI 16, 42) cells/mm3 in years 0, 1, 2, 3, 
4, 5, 6 and 7, respectively. 
Figure 9.3. Estimated mean (95% CI) rate of CD4 cell count increase per year 
and number of individuals in follow-up by year after starting ART. 
Number of individuals 
Mean annual rate of CD4 count increase per year 
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Separate multivariable analysis for each year of follow-up indicated that, for the 
reference group who started ART in 1999 with CD4 counts of 200-249 
cells/mm3, the rate of increase declined from 178 (95% CI 163, 192) cells/mm3 
in the first year to 29 (95% CI 8, 50) cells/mm3 in the fourth year, after which 
only the increase in the seventh year was significant (Table 9.7).  
Many of the significant associations in multivariable analysis were observed 
during the first year after starting ART, which may reflect effects during the first 
three months. Individuals with baseline CD4 counts of 300 cells/mm3 or more 
experienced slower rates of increase during the first three years after starting 
ART. This association appeared to remain longer for individuals with baseline 
CD4 counts of 500 cells/mm3 or more. IDU tended to have slower rates of 
increase than MSM although the regression coefficients fluctuated between 
positive and negative and were only significant (negative) in the first, second 
and fifth years after starting ART. Heterosexual women diagnosed antenatally 
and recipients of blood products did not have faster rates of increase than MSM 
in any year after starting ART. Other heterosexuals had slower rates of increase 
in the first year but this was not maintained. Initiation of ART after 1999 was 
generally associated with faster rates of increase in CD4 cell counts although, 
during the first year after starting ART, rates appeared to be slower for 
individuals starting ART between 2000 and 2003 and faster after 2003. Black 
Africans appeared to experience slower rates of increase than white individuals 
although the difference was only significant during the first and fifth year after 
starting ART. In the first year after starting ART, there was some evidence that 
individuals aged 15-39 years had faster rates of increase in CD4 counts than 
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individuals aged 40-44 years and that individuals aged 45 years or older had 
slower rates of increase but there were no consistent associations in other 
years. There were other significant rates of change in CD4 counts in varied 
groups and varied years but no other consistent trends. 
Table 9.7. Results from multivariable linear regression analysis of the 
association between each factor and the rate of increase of CD4 counts in each 
year of follow-up after starting ART.  
 Regression coefficient (cells/mm3), p value 
Number of years after 
starting ART 
0 1 2 3 4 5 6 7 
         
    Calendar year of  
                starting ART 
        
1999 - - - - - - -  
2000 -16,  0.03 7,  0.33 1,  0.92 0,  0.99 16,  0.06 11,  0.21 3,  0.80 -24,  0.20 
2001 -12,  0.09 16,  0.02 12,  0.10 5,  0.56 14,  0.11 23,  <0.01 -14,  0.42  
2002 -15,  0.03 1,  0.87 2,  0.75 16,  0.05 17,  0.04 25,  0.10   
2003 -11,  0.10 16,  0.02 3,  0.68 15,  0.05 14,  0.28    
2004 4,  0.56 12,  0.06 16,  0.02 7,  0.53     
2005 10,  0.12 18,  <0.01 -10,  0.37      
2006 27,  <0.01 9,  0.33       
2007 81,  <0.01        
         
    Baseline CD4 count                   
     category (cells/mm
3
) 
        
0-49 10,  0.07 15,  0.01 3,  0.65 6,  0.49 5,  0.66 -4,  0.78 -10,  0.60 40,  0.16 
50-99 -1,  0.86 5,  0.46 4,  0.63 1,  0.88 3,  0.80 8,  0.60 -15,  0.47 42,  0.18 
100-149 -1,  0.86 -3,  0.58 -4,  0.58 5,  0.58 5,  0.66 -5,  0.72 -24,  0.20 34,  0.25 
150-199 4,  0.48 -4,  0.53 -1,  0.88 -12,  0.18 4,  0.72 -3,  0.82 -21,  0.27 15,  0.62 
200-249 - - - - - - - - 
250-299 -11,  0.06 -8,  0.18 -4,  0.60 4,  0.67 4,  0.73 -14,  0.34 -4,  0.82 3,  0.91 
300-349 -46,  <0.01 -19,  0.01 -17,  0.05 -7,  0.50 -21,  0.11 17,  0.30 -41,  0.06 63,  0.06 
350-499 -79,  <0.01 -39,  <0.01 -15,  0.05 -13,  0.20 11,  0.38 13,  0.39 8,  0.67 42,  0.16 
>499 -154,  <0.01 -98,  <0.01 -43,  <0.01 -21,  0.04 -3,  0.85 -30,  0.05 -48,  0.02 22,  0.49 
         
    Previous AIDS         
No - - - - - - - - 
Yes 5,  0.19 9,  0.03 -4,  0.34 -7,  0.19 6,  0.4 8,  0.32 6,  0.58 -4,  0.81 
         
    Site of care         
Outside London -5,  0.07 -1,  0.85 8,  0.04 12,  0.01 -1,  0.81 -4,  0.62 -1,  0.89 -15,  0.32 
London - - - - - - - - 
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Significant differences in the first year after starting ART were similar to those 
during the first 91 days (Section 9.4.1). There were greater rates of increase in 
later years, among younger individuals and among MSM. In addition, there 
were slower rates of increase among individuals with higher baseline CD4 
counts, among IDU and heterosexuals (not women diagnosed antenatally), and 
among individuals of black African ethnicity in both models. However, in 
contrast, the region of care was not significantly associated with rates of 
increase in CD4 cell counts after starting ART in this model. 
    Age group   
15-24 9,  0.17 -6,  0.40 -15,  0.12 -2,  0.83 20,  0.16 26,  0.16 -70,  <0.01 -51,  0.16 
25-29 15,  <0.01 0,  0.98 -18,  0.01 -8,  0.35 6,  0.54 23,  0.09 -31,  0.08 -21,  0.42 
30-34 9,  0.06 4,  0.40 -5,  0.42 -11,  0.14 16,  0.09 33,  <0.01 -6,  0.70 -9,  0.68 
35-39 9,  0.05 0,  0.96 2,  0.74 -9,  0.27 2,  0.80 31,  0.01 -29,  0.07 7,  0.77 
40-44 - - - - - - - - 
45-49 -12,  0.06 9,  0.17 -6,  0.46 -3,  0.73 11,  0.39 34,  0.03 7,  0.73 -49,  0.10 
50-54 -14,  0.06 -19,  0.03 -5,  0.60 -10,  0.4 21,  0.15 34,  0.07 -14,  0.55 15,  0.66 
>54 -12,  0.10 -9,  0.29 -23,  0.02 -14,  0.23 -26,  0.08 14,  0.45 23,  0.36 7,  0.85 
         
    Risk group         
MSM - - - - - - - - 
Heterosexual men -32,  <0.01 1,  0.92 7,  0.30 4,  0.58 0,  0.97 -4,  0.77 32,  0.04 57,  0.01 
Heterosexual women -11,  0.02 13,  0.02 10,  0.13 4,  0.61 10,  0.30 4,  0.73 37,  0.02 85,  <0.01 
Heterosexual women 
 (diagnosed antenatally) 
10,  0.18 -14,  0.09 -10,  0.32 6,  0.64 -12,  0.45 -18,  0.39 -4,  0.90 86,  0.17 
IDU -52,  <0.01 -26,  0.03 -3,  0.80 20,  0.26 -56,  <0.01 18,  0.45 -21,  0.52 -17,  0.70 
Recipients of blood  
products 
-26,  0.14 21,  0.30 -14,  0.52 -31,  0.24 18,  0.57 -6,  0.88 69,  0.08 74,  0.24 
         
    Ethnicity         
White  - - - - - - - - 
Black African -19,  <0.01 -2,  0.70 -3,  0.63 0,  1.00 -18,  0.05 -14,  0.24 -10,  0.53 -41,  0.07 
Black Caribbean -4,  0.60 11,  0.24 15,  0.18 38,  <0.01 12,  0.48 -33,  0.12 1,  0.98 -32,  0.47 
Black Other -14,  0.20 32,  0.01 -3,  0.81 14,  0.42 -73,  <0.01 -6,  0.84 -37,  0.33 -118,  0.02 
Indian\Pakistani\ 
Bangladeshi 
-8,  0.52 -15,  0.28 33,  0.05 -20,  0.36 -40,  0.11 -74,  0.02 -58,  0.17 -12,  0.83 
Other Asian -13,  0.24 -12,  0.38 6,  0.69 5,  0.79 -52,  0.02 47,  0.14 34,  0.36 -25,  0.67 
Other/mixed -3,  0.70 -4,  0.64 12,  0.29 16,  0.22 -20,  0.23 -36,  0.06 3,  0.92 -35,  0.36 
    Overall 178,  <0.01 50,  <0.01 40,  <0.01 29,  <0.01 10,  0.43 -6,  0.69 48,  0.01 2,  0.93 
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9.5  Discussion 
These analyses describe the population-level effect of ART on CD4 cell counts 
in the UK as a mean rate of increase of 120 cells/mm3 during the first three 
months of ART and a subsequent rate of increase of 43 cells/mm3 per year. 
Multivariable analyses indicated that there were statistically significant 
differences in the rate of increase between groups during the first three months 
of ART but sensitivity analysis using only data from individuals with startART 
reported suggested that many of these effects could be due to bias in the 
estimations of baseline CD4 cell counts at estART. In that analysis, baseline 
CD4 cell count, risk group, ethnicity and no previous AIDS diagnosis were 
significantly associated with CD4 cell count increases. Furthermore, it should be 
noted that combinations of factors could actually result in a decrease in CD4 
cell counts during the first three months after starting ART in all models.  
Analysis of the data stratified by year of follow-up indicated that the overall 
mean rate of increase remained greater than zero up to eight years after 
starting ART but declined with more years of follow-up. However, there was an 
inherent bias towards faster CD4 count increases because some of those who 
died or were lost to follow-up would be a result of poor response to therapy or 
disengagement with care. Furthermore, the representativeness of the data 
decreases with length of follow-up because only individuals starting ART more 
than five years ago, for example, can inform the five-year trend and these 
individuals will probably receive a different treatment history and different 
clinical care than individuals starting in 2007. 
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Rates of increase in CD4 counts of 120 cells/mm3 during the first three months 
after ART were of the same order but slightly higher than those reported in the 
literature. This was despite the systematic bias from estimation of dates of 
starting ART, which was likely to have excluded some of the period when CD4 
cell counts were rising most rapidly for many individuals. A systematic overview 
of 53 clinical trials determined a weighted mean increase in CD4 counts after 24 
weeks of ART of 130 cells/mm3 515. Cohort studies that followed ART-naïve 
individuals reported median increases in CD4 counts of 88 cells/mm3 during the 
first eight weeks513; 80 cells/mm3 during the first three months529; 114 cells/mm3 
during the first six months498; and 119 cells/mm3 during the first six months512. 
As the best estimate of the inflection point after the period of rapid increase is 
ten weeks (among ART-experienced, but HAART-naïve, individuals) it is likely 
that about half of the follow-up time in the studies which determined increases 
over the first six months of ART was not during the period of rapid increase523.  
The rate of increase in CD4 counts after the first three months of ART in this 
analysis was 43 cells/mm3 per year. This compares to an increase of 94 
cells/mm3 per year in a cohort study498. However, that was observed during a 
median follow-up of 2.5 years and studies which split the follow-up time indicate 
that the rate of increase slows over time364;516;529. For example, cohort data 
show that increases slowed from 172 cells/mm3 during the first year after ART 
to 80, 63, 28, and 27 cells/mm3 during the second to fifth years after ART529. 
Similarly, in the integrated dataset, the increase in CD4 counts slowed from 147 
cells/mm3 during the first year after ART to 57 cells/mm3 in the second year, 
and then more gradually to around 25 cells/mm3 in years 5-8. 
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Comparison of the results of these analyses with the literature is complicated 
because some publications focus on the effect of HAART and include, but do 
not adjust for, a high proportion of individuals who were pre-treated with non-
HAART regimens533;534. Additionally, some studies focused on individuals who 
maintained low viral loads on ART rather than the entire population364;514;516. 
Studies also varied in the factors considered, the number of individuals 
monitored and the time periods after ART that were included in analyses, which 
may explain some of the differences in the associations found. 
Consistent with these analyses, older age has previously been found to be 
associated with slower rates of increase of CD4 cell counts over both the 
short516;531 and long-term513;516;532;533 (although not when baseline CD8 cell 
counts were considered498). However, my analysis only showed a clear 
association with age in the short-term. Age may be biologically associated with 
CD4 cell count response to ART but it may also reflect other characteristics of 
the population, such as adherence. 
Only one other study has clearly shown a reduced immunological response for 
IDU531 although this does not seem to be refuted by other studies that exclude 
pre-treated individuals and is consistent with other information about reduced 
adherence, irregular attendance and poorer clinical outcomes among IDU124. 
These analyses have identified significant differences between MSM and 
heterosexuals that have not been reported in the literature. Heterosexual 
women diagnosed antenatally appeared to have greater increases in CD4 cell 
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counts during the first three months, which may have been due natural 
increases after delivery for women who started ART during pregnancy57;509;535. 
However, these were not sustained and overall rates of increase after the first 
three months were even slower than among MSM. This may have been due to 
interruption of therapy among women who were indicated ART solely for the 
prevention of mother-to-child transmission, or who interrupted for other reasons 
after giving birth. Other heterosexuals had slower rates of increase in CD4 
counts than MSM during the first three months and the first year after starting 
ART but this did not appear to continue in the medium term. Explanations for 
this require further investigation although differential adherence and differential 
virulence of subtypes may be implicated (sections 1.3.3 and 1.3.6 respectively). 
Results from the literature differed in the effect of baseline CD4 cell counts on 
the immunological response during the short-term after ART. Some studies 
indicated no effect of baseline CD4 count486;498;513, whereas others observed an 
association between lower baseline CD4 counts and increased rates of 
change515;531;532. Results have also been inconclusive during long-term 
ART498;533. However, different authors adjusted for many different factors, which 
may have substantially affected the results and made them less comparable*. 
Most studies demonstrated no effect of sex on the immunological response to 
ART498;531;533. Two studies did find an association but did not consider risk 
                                            
*
 Including time-updated viral loads, drug classes included in the treatment regimen at baseline, 
baseline CD8 cell counts, and time from seroconversion. 
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group as a factor513;516. One of these also found no effect of ethnicity over the 
short-term513 whereas another study found that rates of increase of CD4 cell 
counts were higher among white individuals than non-white individuals during 
the first 3 months of ART but not subsequently498. These findings are supported 
by my analyses. The results of the latter study indicated that the difference 
between ethnicities was not due to a lower baseline viral load among black 
African individuals, which may have been a biological hypothesis. Black 
Africans were the only ethnic group in the integrated dataset to have 
significantly weaker immunological response after the first three months of ART, 
but it is likely that this may be due to unmeasured confounders such as 
differential adherence or virulence of subtypes. 
Results from studies have also differed as to whether rates of increase of CD4 
cell counts have increased over time or not515;531. This may be because there is 
no effect of when individuals started ART on the immunological response during 
the first 3 months of ART but that this has had a significant effect after the first 3 
months of ART498. Recent calendar years were associated with greater rates of 
increase over the short-term in my main analysis but not in the sensitivity 
analysis considering only records with startART. This suggests that the 
observed effect of calendar year over the short-term was due to bias in the 
estimation of estART. Except for 1999, there did not appear to be a strong 
effect of baseline calendar year over the long term. 
An AIDS diagnosis prior to starting ART was associated with rates of increase 
in the sensitivity analysis excluding records with estART but not in the main 
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analysis of the first three months after ART and there were also conflicting 
reports in the literature531;532. Interestingly, a previous AIDS diagnosis was 
associated with greater increases in CD4 cell counts rather than poorer 
immunological responses, which may reflect greater preventative adherence 
among individuals who have experienced an HIV-related illness. 
There have not been any published results describing whether immunological 
response to ART varies across the UK but there have been some suggestions 
(also refuted) that treatment in tertiary centres by specialist clinicians who care 
for large cohorts of HIV-infected individuals and who have greater and earlier 
experience with new drugs due to involvement in clinical trials may result in 
improved prognosis536-540. In these analyses, individuals who were treated in 
London had greater rates of CD4 cell count increase during the first three 
months after starting ART but there were no longer-term regional differences. 
However, the regional difference detected may be a result of bias due to less 
complete reporting of startART from outside London as there was no significant 
difference by region of treatment when excluding records with estART. 
There were several factors that have been associated with the immunological 
response to ART but are not within the scope of these analyses. Most 
significantly, higher baseline viral loads are associated with greater CD4 cell 
count increases both in the short and long-term498;513;516;531;533. Although a 
systematic overview found a faster rate of CD4 increase among individuals 
treated with a boosted PI, the authors acknowledged that they may not have 
been able to fully differentiate the baseline characteristics of those initiating 
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different regimens, and most other studies have found no effect of the initial 
treatment regimen on CD4 response481;498;513;515;531;532. Lower pre-HAART CD8 
cell counts, pre-treatment slopes and a higher baseline naïve/memory CD4 cell 
count ratio have also been associated with a greater increase in CD4 
counts485;498;513;533. The effectiveness of treatment after initiation also affects 
CD4 count responses and discontinuation of treatment and virological failure 
result in significantly less benefit486;541;542.  
The analysis of rates of increase in CD4 cell counts during the first three 
months after ART was likely to have been affected by inclusion bias because 
the analysis included an unrepresentative 82.4% of all individuals who started 
ART during the period. It is not possible to know how individuals included in 
each population group differed from those excluded, according to this outcome 
of CD4 changes after ART initiation, so interpretation must be based on the 
assumption that they are similar in this regard. White individuals, MSM and 
Londoners were more likely to be included in the integrated dataset and more 
likely to have CD4 counts for analysis than other groups. These groups also 
had faster CD4 count increases than other groups indicating that the overall 
population results would be significantly biased in this direction. Older 
individuals were less likely to be included in the integrated dataset, were less 
likely to have CD4 counts for this analysis, and had slower CD4 count increases 
than other groups, which would also add to this bias and result in 
overestimation of the overall rate of increase of CD4 cell counts. Therefore, 
exclusion bias may partly account for the slightly higher rates of increase in 
CD4 cell counts during the first three months after starting ART. 
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Selection bias may have been slightly greater in the analysis after the first three 
months of ART because individuals without CD4 cell counts more than three 
months after starting ART were not included in that analysis (72.5% versus 
82.4%). This particularly resulted in under-representation of individuals starting 
ART in 2007 who were more likely to have faster CD4 count increases. Black 
Africans were also particularly less likely to be included in this analysis and 
were already under-represented in the integrated dataset and shown to have 
slower CD4 cell count increases. MSM and Londoners were again over-
represented in the dataset and shown to have faster CD4 count increases than 
other groups. The balance of these effects was likely to be that the overall 
results were biased towards a faster increase in CD4 counts. 
 The factors associated with inclusion in the analyses suggest that unmeasured 
factors also added to the bias. Individuals more likely to be included were more 
likely to have been monitored more frequently than other individuals (chapter 5), 
which may be due to their care-seeking behaviour, their risk of disease 
progression, their risk of clinical problems such as toxicity or the clinical practice 
of their doctor. All of these unmeasured factors are likely to be confounders due 
to their association with adherence and treatment response. 
Informative drop-out (associated with the outcome) due to death may have 
occurred if those who died and were not included had poorer immunological 
responses to ART than other individuals. This may have resulted in over-
estimation of the rates of CD4 cell count increases in all sub-groups in the 
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analysis and particularly for those with higher mortality rates, such as older 
individuals, IDU and individuals with low baseline CD4 cell counts. 
The interruption of ART by women who had used it solely to reduce mother-to-
child transmission may have biased the results, particularly in the longer-term, 
because their CD4 cell counts would subsequently be expected to fall. 
Exclusion of all women in sensitivity analysis (because pregnancy status was 
only known at the time of HIV diagnosis) reduced some of the effects such that 
the results were similar to the analysis excluding individuals with estART. 
Error in the determination of the dates of starting ART (chapter 7) is likely to 
have had a substantial impact on the analysis during the first three months of 
starting ART. The effects of many factors were no longer statistically significant 
in the sensitivity analysis that excluded records without startART. 
Misclassification could have reduced or inflated the estimates of the rates of 
increase and may have biased the estimates of the regression coefficients for 
the factors investigated (Figures 9.4 a-c. An accurate schematic from a record 
with startART is shown in Figure 9.4a). Errors in the determination of estART 
were likely to have biased rates of CD4 increases because they would likely to 
be calculated using the wrong CD4 cell counts; for example, those after the 
initiation of ART (Figure 9.4b). Greater errors were likely if the baseline CD4 cell 
count could only be estimated from one CD4 count before estART rather than 
averaged between that CD4 count and a CD4 count closer to the true baseline 
(Figure 9.4c).  
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Figure 9.4a. Schematic showing the estimation of the slope during the first three 
months of ART for an individual with startART. 
 
Figure 9.4b. Schematic showing the estimation of the slope during the first three 
months of ART for an individual with estART and more than one CD4 cell count 
before estART. 
 
 
 
 
 
* Baseline CD4 cell count was the average of the last two CD4 cell counts 
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Figure 9.4c. Schematic showing the estimation of the slope during the first three 
months of ART for an individual with estART and only one CD4 cell count 
before estART. 
 
A common source of error in studies of the immunological response to ART is 
regression to the mean, introduced by natural and measurement variability of 
the baseline CD4 cell counts43;242;499;543-545. For example, one study that 
included follow-up before and after treatment found that the decrease in CD4 
cell counts prior to ART was significantly associated with subsequent increases 
to three and six months post-ART but not after that, but this may have been due 
to regression to the mean529. In these analyses, regression to the mean was 
likely to have affected the observed rate of increase during the first three 
months after starting ART and during the first year of ART because the baseline 
CD4 cell count was used in the calculation of the rate. In these analyses, the 
effect will have been greatest for individuals with baseline CD4 cell counts in the 
highest and lowest categories because the variability was more likely to have 
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acted in one direction (assuming that it was random and normally distributed) 
546. For example, individuals with observed baseline CD4 cell counts between 0 
and 49 cells per mm3 may have had true baseline CD4 cell counts greater than 
49 cells per mm3 but cannot have had true baseline CD4 cell counts below 0 
cells per mm3.  The true overall rate of increase for this category of individuals 
was therefore expected to be slower than observed such that it was significantly 
slower than for individuals with baseline CD4 counts of 200-249 cells per mm3. 
Use of the mean of the last two CD4 cell counts during the three months prior to 
starting ART was intended to reduce the effects of natural and measurement 
variability and regression to the mean546. As the number of CD4 cell counts 
included in the calculation of the baseline value increased, there was an 
increase in the baseline CD4 count for individuals with low CD4 counts and a 
decrease in the baseline CD4 count for individuals with high CD4 counts. This 
supported the assumption that there was an effect of regression to the mean. 
Because CD4 counts would be expected to be decreasing over time prior to 
starting ART, use of the mean of the last two measurements before starting 
ART may have systematically overestimated baseline values. In fact, there was 
a marginal increase in the overall medians when using the mean of the last two 
CD4 cell counts before ART (196 cells/mm3) and the mean of all CD4 cell 
counts in the last three months before ART (197 cells/mm3) compared to using 
just the last CD4 cell count before ART (195 cells/mm3). However, this was 
likely to have less impact than regression to the mean and negligible impact on 
the relative effects of the baseline CD4 count categories.  
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Confounding by indication probably affected the results because individuals 
starting ART with CD4 cell counts below 200 cells/mm3 should have been 
recommended initiation of ART according to treatment guidelines134;426. The 
unmeasured characteristics of these individuals were therefore likely to differ 
from those of individuals who started ART at higher CD4 cell counts. 
In the stratified analysis of long-term follow-up, there may have been insufficient 
numbers of sub-groups of individuals to achieve statistical significance after the 
first three years (although overall numbers in the seventh year still exceeded 
3,000). This was suggested by the fact that the slower rates of change for IDU 
and individuals aged 55 years or more continued throughout the eight years of 
follow-up but with decreasing significance.  
Finally, it should be noted that more experienced statisticians may have used 
more complex techniques to analyse the data in a single random effects model. 
Inclusion of join points would have allowed for changes in the rate of increase in 
CD4 cell counts and changes in interactions between each baseline factor and 
the time from starting ART. A join point after 3 months on ART could have been 
used to merge the two formal models that were analysed, and multiple joins at 
each year after starting ART could have been used to formally test the effects of 
baseline covariates over time. 
9.6  Conclusion 
Advantages of analysing immunological responses using data from the 
integrated HIV surveillance systems were that the numbers of individuals 
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starting ART were substantially greater than numbers included in cohort 
analyses in the literature and that follow-up was prospective, extensive and 
continuing. This enabled multivariable analysis of factors such as ethnicity and 
risk group together with narrow CD4 cell count categories and calendar year of 
starting ART. Areas for improvement of surveillance data included more 
accurate dates of starting ART, pregnancy status as a reason for starting ART, 
dates of stopping or interrupting ART and viral loads at the time of starting ART. 
These analyses identified the disadvantageous effect of black African, 
Indian/Pakistani/Bangladeshi and Other Asian ethnicity on the rate of increase 
of CD4 counts during the first three months after starting ART in E,W&NI. The 
consistency of this finding through sensitivity analyses and confirmation with the 
literature498 indicate that it was unlikely to be due to the limitations of data. 
Wider research is required to investigate whether this is due to lower adherence 
during this time, which may be due to language barriers reducing understanding 
of clinical guidance, greater perception of stigma or competing priorities. 
Other findings of this population-level analysis confirmed those in the literature. 
These include the overall short and long-term rates of change of CD4 cell 
counts, which increase rapidly during the first three months after starting ART 
and continue to increase at a slower rate for eight years  (although biased by 
loss to follow-up, stopping treatment and death). The results of these analyses 
may help to clarify the population groups that may expect CD4 cell counts to 
recover to levels observed among uninfected individuals and to identify those 
that may require enhanced adherence or other support such as IDU. 
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The results showed that immunological responses were slower at higher CD4 
counts and that the threshold at which rates of increase slowed varied 
according to sensitivity analyses. Maintaining higher CD4 counts reduces 
morbidity and mortality in the short-term but the optimal threshold at which to 
start ART is not yet known. Therefore, the randomised control trial, ‘START’127, 
is underway to determine whether deferral of ART can be clinically beneficial. 
The results suggest an improved immunological response over time, and 
particularly in the long-term, but also highlight the need to ascertain accurate 
dates of starting ART for all individuals for increased reliability of results. This 
and the previous chapter demonstrate that this key piece of epidemiological 
data cannot be adequately determined by proxy from other surveillance data. 
The methodology used in this analysis of surveillance data provides potential for 
the routine monitoring of the rate of increase of CD4 cell counts as a 
performance indicator of high quality clinical care. Increased awareness of the 
factors associated with slower rates of increase and direct feedback of these 
results could lead to changed protocols to address these issues. Furthermore, 
further analysis could quantify associations between slower rates of 
immunological increase and subsequent mortality. 
In conclusion, understanding of the rates of increase of CD4 cell counts after 
starting ART and their determining factors in E,W&NI may be used by clinicians 
to benchmark patient-specific immunological responses to therapy. The public 
health benefits of this may be improved outcomes for HIV-infected patients. 
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Chapter 10. Conclusion 
10.1 Summary 
The rationale behind this thesis was to develop robust methodologies to realise 
some of the untapped public health potential of HIV surveillance data. Case-
based HIV surveillance in E,W&NI is very comprehensive but analysis is limited 
because it consists of three complementary but independent systems due to the 
complexity of the epidemic and the separate primary sources of data. 
Therefore, the pivotal aim of this thesis was to develop a robust method to fully 
integrate data from these systems into a single national HIV surveillance 
database containing a complete and consistent description of each individual 
with a coherent sequence of events. The secondary aim was to apply statistical 
techniques, more commonly used in cohort study research, to the integrated 
database to demonstrate the full public health potential of the data. 
Reliable analysis and astute interpretation of the data was dependent upon a 
thorough understanding of the HIV epidemic, its development over time, and the 
mechanisms through which the data are collected and processed. Chapter 1 
describes the clinical and epidemiological background to HIV surveillance and 
chapter 2 details the three case-reporting systems and provides summary 
context of HIV surveillance systems in other countries with similar epidemics. 
Chapters 3 and 4 describe the complex processes that were developed over a 
long period of time to achieve a single, national, integrated HIV surveillance 
database. After characterisation of patient-specific information in each system, I 
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created bilateral, deterministic record linkage algorithms that reliably matched 
patient records between HARS and SOPHID and between SOPHID and CD4 
Surveillance. This demonstrated a degree of coding errors in the data and that a 
substantial number of records could not be automatically linked. This informed 
the selection of records for the triangulation process of Chapter 4 but raised 
issues of inclusion bias, data quality, disharmonised surveillance systems, 
under-reporting and loss to follow-up. I concluded that at least two of soundex, 
date of birth and local patient ID number should match for record linkage to be 
accepted without further manual review. Outcomes of these analyses were that 
adjustments for under-reporting are no longer used in E,W&NI to prevent over-
counting, SOPHID uses integrated patient and report tables that facilitate 
analyses and data completeness, record linkage is used to reduce the follow-up 
needed for missing information, and record linkage is incorporated into data 
processing procedures to validate HIV case reports as they are received. 
Chapter 3 also demonstrated that there is a need for care when combining 
reports from parallel surveillance systems (including the development of novel 
systems as for the surveillance of recent HIV infections) because of the 
potential creation of additional duplicates. Results of this chapter can inform 
record linkage processes that are likely to be increasingly used in both 
surveillance and research because they permit new analyses without additional 
and duplicated data collection. The minimal additional resources required at 
national level could be offset by reductions in data collection and entry 
resources at all levels by reducing duplication. 
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Due to tripartite HIV case reporting systems, triangulation and rationalisation of 
common data variables was necessary to create the final integrated dataset as 
described in chapter 4. For consistency throughout this thesis, I chose to only 
use data that were linked across all three surveillance systems, which limited 
analyses to individuals alive in 1995 and reported to SOPHID and did not 
provide a complete historical picture. This would not be necessary for future 
analyses that do not require data points from all three systems. The resulting 
integrated dataset utilized and combined information from each surveillance 
system to reduce missing information and expand the dataset. Furthermore, the 
integrated dataset also identified additional data inconsistencies raising the 
question of whether redirection of resources could significantly improve data 
quality at minimal cost to data completeness. The final integrated dataset had a 
large sample size equivalent to multinational cohort collaborations, potential 
follow-up from HIV diagnosis to death, good information on ethnicity and 
national representativeness. Lessons learnt could inform the development of 
national cohorts for what could be termed ‘3rd generation HIV surveillance’ as 
pioneered by the Netherlands and Austria. 
A thorough understanding of any dataset is needed before analyses can be 
appropriately carried out and results can be interpreted. Some understanding of 
the integrated dataset was developed during the processes of record linkage, 
triangulation and rationalisation but these also raised issues of potential bias. 
Chapter 5 described the analyses of the integrated dataset undertaken to 
investigate potential sources of bias. Strengths of the integrated dataset were 
that inclusion bias could be specifically characterised as it was a subset of 
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national surveillance data, in which loss to follow-up may have been largely 
limited to death and emigration rather than transfer between clinics, and that 
follow-up started from the time of HIV diagnosis. A weakness was that record 
linkage incorporated additional errors into the data suggesting that 
misclassification bias may have affected these data more than clinical cohort 
data. Left and right censoring were shown to have substantial potential to affect 
subsequent analyses because numerous events occurred shortly after HIV 
diagnosis, those with and without CD4 cell counts at HIV diagnosis differed, 
loss to follow-up did not occur randomly and was associated with factors that 
were independently associated with progression. In addition to identification of 
all of these potential sources of bias, 91 days was determined as the most 
appropriate cut-off for the definition of CD4 cell counts at the time of HIV 
diagnosis and 365 days after a CD4 cell count was determined as the most 
appropriate cut-off for the definition of temporary loss to follow-up. 
The analysis of late HIV diagnosis and consequent mortality, described in 
chapter 6, provided the highest impact public health messages from this thesis. 
The results demonstrated that individuals diagnosed late were approximately 
ten times more likely to die within a year of diagnosis than comparable 
individuals who were not diagnosed late. Furthermore, deaths within a year of 
HIV diagnosis accounted for over a quarter of all deaths among HIV-infected 
individuals between 2001 and 2007. I concluded that a reduction in late 
diagnoses could prevent substantial mortality and the literature suggests that 
this would be accompanied by a reduction in transmission. Factors associated 
with increased risk of late diagnosis and consequent mortality were identified, 
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indicating groups that should be offered targeted HIV testing. Due to the 
morbidity, mortality, financial cost and transmission potential associated with 
late diagnoses, guidelines in E,W&NI now recommend consideration of 
opportunistic screening in a variety of healthcare settings and operational 
research is addressing the geographical targeting of increased HIV testing in 
high prevalence areas. These will need to consider acceptable methods to 
increase demand for HIV testing among target groups as well as methods to 
improve the accessibility of HIV tests from a variety of health services. Late 
diagnosis is now monitored and reported annually by the HPA at the national 
and Primary Care Trust level to inform public health action. Late diagnosis is 
also now a priority indicator for routine monitoring at the European level by the 
European Centre for Disease Control. 
Chapter 7 demonstrates the potential of analyses of longitudinal HIV 
surveillance data to describe the progression of infection among individuals to 
either AIDS or death as if they were being monitored as a prospective cohort. I 
described the absolute and proportional person years of follow-up at different 
levels of risk determined by CD4 cell count categories to show that the absolute 
time at high risk changed little over time despite marked declines in the 
proportion of time at high risk. The incidence of AIDS and death declined 
markedly during the early era of combination therapy but more slowly 
subsequently reflecting the immunological improvements in the population and 
the population effect of combination therapy. However, the incidence of AIDS 
and death were both continually high at low CD4 cell counts throughout the 
study period. AIDS within the first six months of HIV diagnosis accounted for 
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half of the total number of AIDS, and deaths within the first six months of HIV 
diagnosis accounted for one in seven of the total number of deaths. The 
incidence of these events during the first six months after HIV diagnosis was 
significantly higher than during subsequent follow-up. I believe this analysis was 
also the first to provide robust evidence of the effect of ethnicity on the 
incidence of AIDS and death after HIV diagnosis in E,W&NI. All ethnic groups 
had similar mortality rates but AIDS incidence was higher among black Africans, 
Indian/Pakistani/Bangladeshi individuals and other Asians than white 
individuals. This requires further investigation before the public health 
implications can be determined but this may depend on the improvement of 
surveillance systems to capture specific AIDS-defining illnesses (particularly 
after the time of HIV diagnosis). Heterosexual women diagnosed antenatally 
had lower mortality than other risk groups which may be an added benefit to the 
reduced transmission of infection from mother to infant and may be further 
strong evidence for the expansion of HIV testing among relatively low-risk 
populations. The disproportionately high mortality among IDUs apparent from 
these analyses has long been acknowledged but is not often prioritised for 
tertiary prevention. The routine dissemination of incidence rates in surveillance 
reports may highlight these outcomes and encourage public health action. 
Chapters 8 and 9 focussed on utilisation of dates of starting ART that had been 
recently included in SOPHID. This was an essential addition to the data 
dictionary because it could be used, among other things, to determine whether 
follow-up was while the patient was on or off therapy. Chapter 8 investigated 
whether the date of starting ART could be reliably estimated for individuals with 
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only an approximate date of starting ART. CD4 cell count measurements were 
the only date-specific source of information available from surveillance data that 
were plausibly related to patients’ initiation of ART.  Unfortunately, none of the 
algorithms investigated could substantially enhance the surveillance data, either 
because the natural and measurement variability in CD4 cell counts was too 
great or because other unmeasured factors were stronger factors associated 
with initiation of therapy. The analysis showed that some individuals 
experienced a CD4 cell count below the threshold recommended by guidelines, 
or AIDS, before the time of startART. There may be a delay between the 
measurement of the CD4 cell count that stimulates the recommendation of ART 
and the actual date of initiation, which should be further investigated to 
determine any public health implications, causes and necessary remedial 
actions.  
Chapter 9 describes the rate of increase of CD4 cell counts after starting ART, 
which is of interest as a predictor of morbidity and mortality among HIV-infected 
individuals on ART. Specific studies and cohort analyses have quantified 
immunological responses to ART and indicated CD4 cell counts that may be 
attainable for HIV-infected patients. However, these analyses of the integrated 
dataset show the population-level immunological response to ART in the 
E,W&NI and associated factors. The analysis should be repeated on more 
recent data with more complete information of the exact date of starting ART 
collected prospectively in order to clarify the findings from the first three months 
after starting ART. This is because of the likely bias introduced by either using 
the approximate date of starting ART or excluding those with only an 
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approximate date of starting ART. The slower rates of increase in CD4 cell 
counts among heterosexual men, heterosexual women (not those diagnosed 
antenatally) and IDU in comparison to MSM during the first three months may 
suggest additional adherence support needs among the former groups but 
requires clarification before public health interventions are initiated. 
Heterosexual men and IDU also had slower rates of increase in CD4 cell counts 
than MSM after the first three months of ART, which may again reflect 
adherence support needs with less likelihood of bias from approximate dates of 
starting ART. Data indicated that CD4 cell counts tended to continue to increase 
for up to eight years after starting ART although this was only statistically 
different for the first three years. Individuals starting ART with higher CD4 cell 
counts had slower rates of increase but this may have been outweighed by a 
reduced risk of AIDS and death. Determination of rates of increase of CD4 cell 
counts after starting ART in E,W&NI may provide benchmarks to help identify 
patients with slower immunological responses, for clinical action, or those with  
greater immunological responses for further public health research. 
In summary, I have conducted a number of analyses that may help to inform 
public health responses to the HIV epidemic. These either have been, or I hope, 
will be integrated into national surveillance and public health processes. 
Lessons have been learnt for surveillance methodology with regards sharing 
information and ensuring that data are representative of the whole population.  
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10.2 Suggestions for further work  
Firstly, further work should focus on issues that are likely to further validate the 
data to increase the reliability of results. This could include follow-up 
investigation of samples of i) non-linked records, ii) multiply-linked records, and 
iii) inconsistent records for a deeper understanding of data collection and 
reporting. This could also include further investigation of diagnosis before first 
presentation in the UK, the under-reporting of AIDS, and detection of 
seroconversion at HIV diagnosis. Furthermore, record linkage to the National 
Study of HIV in Pregnancy and Childhood dataset could assess and maximise 
the completeness of data on pregnancies among HIV-infected women. 
A few of the analyses I would like to conduct on the data include: i) an 
investigation of individuals with discordant virological and immunological 
responses to ART including the identification of cases and controls for more in-
depth study; ii) analyses of factors associated with different causes of death; iii) 
a repeat of some of these analyses on randomised control trial data or clinical 
cohort data to investigate whether similar results are apparent from datasets 
that do not require integration; iv) investigation with clinical case note review to 
assess whether multiple CD4 cell counts prior to treatment improve clinical 
decision-making due to more accurate determination of immunosuppression; v) 
survival analysis of the integrated dataset for follow-up time post diagnosis and 
pre-ART and separately for follow-up time post ART; vi) logistic regression of 
factors associated with virological response to ART. 
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Finally, I would like to investigate the possibility of conducting nested research 
studies on samples of patients drawn from the national cohort. This could utilise 
the national surveillance dataset as a patient-specific denominator for 
extrapolation of results to the national level for enhanced policy-making. 
10.3 Recommendations for surveillance 
The limitations of the work for this thesis indicated some recommendations for 
surveillance. The first of these was to improve routine data validation as records 
are added to the databases by record linkage. This should maximise the 
accuracy and internal consistency of patient records and include validation of 
longitudinal data for coherence, including rates of change of CD4 cell counts. 
Secondly, to investigate and address the fact that pregnancy status and AIDS at 
HIV diagnosis have been under-reported since 2000 if no clinician HIV report 
form is received.  
Most importantly, I believe that we should enhance the monitoring of outcomes 
of HIV treatment and care in E,W&NI. Firstly, this would involve improvement of 
AIDS surveillance to capture first and subsequent AIDS diagnoses and specific 
AIDS-defining illnesses post HIV diagnosis. This should inform whether certain 
population groups are at disproportionate risk of, or certain factors are potential 
factors associated with progression to, specific opportunistic infections. 
Secondly, continue and improve the collection of treatment start and stop dates 
and viral loads to routinely monitor individual-level responses to treatment for 
research and performance management. 
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Finally, I suggest that the incorporation of complex indicators, such as AIDS and 
death incidence and the immunological response to ART, should be included in 
routine surveillance analyses and reports to better inform public health action. 
10.4 Closing remarks 
Through studying for this thesis, I developed an in-depth knowledge of HIV 
epidemiology, HIV datasets and mechanisms by which epidemiological data are 
collected and processed including a thorough understanding of the literature. I 
learnt more about potential sources of bias and methods to characterise bias in 
order to better interpret results of analyses. I used statistical techniques on 
longitudinal patient data that can be applied to other epidemiological data from 
either surveillance or research. I will be able to apply this knowledge to the 
development of surveillance systems and improvement of public health 
information to help address disease monitoring.  
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Appendix A: Supplementary background information 
A.1 Legislation protecting the confidentiality of patient 
information 
Voluntary and ‘pseudonymised’ HIV surveillance is included with other 
communicable disease surveillance as a part of the cover afforded to the Health 
Protection Agency by the Secretary of State granted under Section 251 
regulations of the NHS Act 2006 (previously Section 60 of the Health and Social 
Care Act 2001 [in conjunction with Statutory Instrument 1438 approved in June 
2002])547. Approvals made under these powers for the provision of data to 
support essential NHS services are overseen by the independent Ethics and 
Confidentiality Committee (previously Patient Information Advisory Group), 
which is a subcommittee of the National Information Governance Board (NIGB). 
Communicable disease surveillance, including HIV surveillance, has approval 
(renewed each year) under Section 251 with NIGB approval. Even with these 
regulations (which cover potential litigation around the common law duty of 
confidence) the HPA is still subject to all the requirements of the Data 
Protection Act. 
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A.2 AIDS Case Definition 
Table A.1. Clinical diagnoses forming the 1993 European AIDS Case Definition+. 
AIDS indicator disease (definite or presumed) 
At date of AIDS indicator disease 
No HIV 
test* 
HIV test 
positive
$ 
Never tested positive 
and currently negative
* 
Candidiasis: trachea, bronchi, lungs Def   with CD4<400 
Candidiasis: oesophageal 
Def   with CD4<400 
Pres    
Cervical carcinoma: invasive Def  since 93  
Coccidioidomycosis: extrapulmonary Def    
Cryptococcosis: extrapulmonary Def   with CD4<400 
Cryptosporidiosis: with diarrhoea>1  month    with CD4<400 
Cytomegalovirus (CMV) retinitis 
Def   with CD4<400 
Pres    
CMV disease: not in liver spleen or nodes Def   with CD4<400 
Encephalopathy (dementia) due to HIV Def    
Herpes simplex: ulcers for >1month or 
bronchitis, pneumonitis, oesophagitis 
Def   with CD4<400 
Histoplasmosis: 
disseminated/extrapulmonary 
Def    
Isosporiasis: with diarrhoea >1month Def    
Kaposi’s sarcoma 
Def age<60  with CD4<400,age<60 
Pres    
Lymphoma: Burkitt’s or equivalent Def    
Lymphoma: immunoblastic or equivalent Def    
Lymphoma: primary in brain Def age<60  with CD4<400,age<60 
Mycobacterium avium: extrapulmonary 
Def   with CD4<400 
Pres    
Mycobacterium tuberculosis: pulmonary 
Def   since 93  
Pres   since 93  
Mycobacterium tuberculosis: extrapulmonary 
Def    
Pres    
Mycobacterium: other, unidentified or 
disseminated 
Def    
Pres    
Pneumocystis pneumonia 
Def    
Pres    
Pneumonia, recurrent within 12 months 
Def   since 93  
Pres   since 93  
Progressive multifocal leukoencephalopathy Def   with CD4<400 
Salmonella septicaemia, recurrent Def    
Toxoplasmosis of the brain 
Def   with CD4<400 
Pres    
Wasting syndrome due to HIV Def    
+
 In those aged > 13 at date of diagnosis 
* In absence of other non-HIV cause of immunodeficiency e.g. immunosuppressive therapy, other 
immunodepressive disease or genetic or acquired immunodeficiency syndrome atypical of HIV. 
$
 For indicator disease diagnoses requiring HIV positivity for the case definition to be satisfied, e.g. 
Presumptive oesophageal candidiasis, the date of the HIV test should be known, and no later than the 
date of indicator disease diagnosis.  If patient is still being treated for tuberculosis (TB) at time of HIV test, 
can be regarded as still having TB.                                                                                        
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A.3 UK postcodes 
UK postcodes are alphanumeric codes between five and eight characters long 
including a single space. This space separates the part of the postcode that 
identifies the postal district from the part of the postcode that identifies the 
group of residences (e.g. the postcode for The HPA Centre for Infections is 
NW9 5EQ: ‘NW’ is the postal area of ‘North West London’, ‘NW9’ is the postal 
district, ‘NW9 5’ is the postal sector and ‘NW9 5E’ is the postal sector+). A 
house or flat name or number is usually required to identify a specific place of 
residence. Postcodes are required to allocate individuals to a NHS Primary care 
Trust (PCT) of residence for planning, prevention and commissioning purposes. 
Postcodes are requested because many data reporters do not have the facilities 
to allocate the PCT of residence themselves. However, once the postcode 
information has been used to allocate a PCT of residence and used to link 
records from the same individual, it is encrypted along with an anonymous 
record number and stored separately on a secure server in a locked room. This 
means that it can be recalled if necessary but that the databases remain 
‘pseudonymised’ (for example, postcodes were recently accessed so that the 
place of residence for every record in the database could be reassigned 
following changes in the structure of the NHS). 
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A.4 Soundex coding 
The first letter of a surname is always retained and followed by three digits 
according to eight rules: 
1. The first letter of the surname is always retained, followed by three digits 
selected as follows: 
 A, E, I, O, U, Y, H and W are not given a code number. 
 B, F, P, V   Code 1 
 C, G, J, K, Q, S, X, Z Code 2 
 D,T    Code 3 
 L    Code 4 
 M, N    Code 5 
 R    Code 6 
2. Consonants after the initial letter are coded to the numbers above in the 
order in which they occur. 
e.g.  Holmes  H-452  Adomomi  A-355 
3. The code never has more than three digits, so further consonants in long 
names are ignored. Zeros are used for the remaining digits in short names. 
e.g.  Vonderlehr  V-536   Bailey  B-400    Shaw  S-000 
4. Double consonants and adjacent consonants from the same letter group are 
ignored. 
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e.g.  Ball   B-400   Jackson  J-250 
5. A consonant immediately following a surname initial from the same letter 
group is ignored. 
e.g.  Scanlon  S-545 
6. Abbreviated prefixes are coded as if they were spelt out in full. 
e.g.  McIlhaney = Macilhaney  M-245  St John = Saint John  S-532 
7. An apostrophe is ignored and the whole of double-barrelled names are 
coded as a single name. 
e.g. O’Neill  O-540  El Eryan  E-465  King-Smith  K-525 
8. Consonants from the same letter group separated only by W or H are only 
coded once. 
e.g. Booth-Davis = B-312   
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A.5 Algorithm for the hierarchical categorisation of 
exposures 
1 sex between men 
2 IDU 
3  transfer of blood, tissue or blood products such as blood factor 
3.1 exposure abroad 
3.2 exposure in the UK 
4 heterosexual sex 
4.1  exposure to ‘high-risk’ partner(s) i.e. to partner presumed 
infected through sex between men, IDU, or transfer of blood, 
tissue or blood products 
4.2 exposure to presumed heterosexually infected partner(s) 
4.2.1 exposure abroad 
4.2.1.1 Africa 
4.2.1.2 Latin America/Caribbean 
4.2.1.3 Asia 
4.2.1.4 North America 
4.2.1.5 Europe 
4.2.1.6 Australasia 
4.2.1.7 Country(ies) not known 
4.2.2 exposure in the UK 
4.2.2.1 to a partner infected outside Europe 
4.2.2.2 to a partner infected in Europe 
4.3 partner(s) exposure category undetermined 
5 occupational (healthcare), nosocomial and other blood contact 
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An individual who had potentially acquired infection via heterosexual sex in the 
UK with a partner presumed to have been heterosexually infected outside 
Europe would be assigned to the category numbered 4.2.2.1 in the schematic 
above. If that individual was thought to have acquired infection via heterosexual 
sex abroad with a partner presumed to have been heterosexually infected in 
Africa they would be assigned to the category numbered 4.2.1.1. 
The hierarchy does not distinguish between risks within each category 
determined by factors including sexual behaviour, transmissibility of the virus, 
and host factors. 
 484 
 
A.6 Development of HARS databases 
At the establishment of AIDS reporting in 1982, coded data from AIDS and 
death reports were double entered into an in-house database and archived 
monthly. In 1985, with the advent of surveillance for HIV diagnoses, an EPI-
INFO database was set up to collate reports of positive results from HIV tests. 
Data were not double entered to this database. In 1995 a unified patient-based 
Microsoft ACCESS ‘95 database was created in which each HIV-infected 
individual was recorded only once and linked to reports of HIV diagnoses and 
AIDS diagnoses using patient identifiers. This refined the data processing 
system and allowed for future volume and support of the database. In addition, 
individuals with an AIDS report but no HIV report could be regarded as HIV-
infected because HIV was then accepted as being the cause of AIDS. Minor 
programming changes were made to the Microsoft ACCESS ‘95 database 
between 1995 and 2000 to accommodate adaptations of the reporting forms 
and in 2000 the database was upgraded to Microsoft ACCESS ’97. This 
upgrade added fields to the patient table and a form for use with the CHRs used 
by clinicians to report newly diagnosed HIV infections.  A further upgrade from 
Microsoft ACCESS ’97 into Microsoft SQL Server was undertaken in January 
2005 to consolidate the functionality, simplify maintenance and development, 
and increase the stability and responsiveness of the database.  
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A.7 ‘XLatest’: the HARS archive table 
Table A.2. List of fields in ‘XLatest’: the HARS archive table* 
* includes data from Scotland and from the Institute of Child Health.  
Field name Data Type Description Field name Data Type Description 
Patient ID Number 
Internal ID of patient in its source 
dataset 
Viral Load Number 
Viral load (at time of clinician's 
report of new diagnosis) 
Soundex Text Soundex of surname Date VLoad Date/Time Date Viral Load assessed 
Init Text Initials of patient Has AIDS Number Has AIDS = 1 
DOB Date/Time Date of Birth Date AIDS Diag Date/Time Date AIDS Diagnosed 
Sex Number Sex Date AIDS Rep Date/Time Date of first AIDS Report 
HIV Type Number HIV 1, 2, ...... Age AIDS Number Age at AIDS 
Infection Route Number Risk group SHA AIDS Rep Text 
Strategic health authority of 
AIDS report 
Risk (Hetero) Number Heterosexual Risk Factor Reg AIDS Rep Text New region of AIDS report 
Exp Number Exposure Reg AIDS Name Text 
Name of new region of AIDS 
report 
ExpC Number Exposure of Contact Was Reg AIDS Rep Text 
Pre-PCT region of AIDS 
report 
Inf Loc Number Infection Location Country AIDS Text Country AIDS 
InfC Loc Number Infection Location of Contact Clin Number Clinical Diagnosis 
Date Last Neg Date/Time Date Last Negative WHO Diagnosis 1 Number WHO coding of Diagnosis 
Date Pos Date/Time Date first HIV+ WHO Diagnosis 2 Number WHO coding of Diagnosis 
Ethnic Gp Number Ethnic Group WHO Diagnosis 3 Number WHO coding of Diagnosis 
Date LKA Date/Time Date Last known alive WHO Diagnosis 4 Number WHO coding of Diagnosis 
Source LKA Number Source of Last known alive Is Dead Number Is Dead = 1 
Resident Number UK Resident=1 Date Death Rep Date/Time Date of Death Report 
Has Lab Number Has HIV lab report = 1 Date Death Date/Time Date of Death 
Date Lab Rep Date/Time Date of first HIV (lab) Report Age Death Number Age at Death 
Date Lab Spec Date/Time Date of specimen of lab report Pre-AIDS Death Number Pre-AIDS death 
Age Lab Number Age at HIV (lab) report Reg Death Text New region of death 
SHA Lab Rep Text 
Strategic health authority of HIV 
(lab) report 
Reg Death Name Text Name of (new) region of death 
Reg Lab Rep Text New region of HIV (lab) report Was Reg Death Text Pre-PCT region of death 
Reg Lab Name Text 
Name of new region of HIV (lab) 
report 
Status of Death Number Status of Death information 
Was Reg Lab 
Rep 
Text Pre-PCT region of HIV (lab) report Child Inf Status Number Infection status for a child 
Country Lab Text Country HIV (lab) report Year earliest Event Date/Time Date of first event 
Has CHR Number Has Clinician's report = 1 Year earliest Report Date/Time Date of first report 
Date CHR Spec Date/Time 
Date of CHR diagnosis (date of 
specimen on which clinician's 
diagnosis based) 
Earliest 
Organisation 
Text 
Organisation ID of earliest 
report - currently only 
available for HARS data 
Date CHR Rep Date/Time Date of first clinician's report Earliest SHA Text 
First strategic health authority 
of report (code) 
Age CHR Number Age at CHR Earliest SHA Name Text 
Name of first strategic health 
authority of report 
SHA CHR Rep Text 
Strategic health authority of 
clinician's report 
Earliest Reg Text 
First region of report - coded 
to new regions 
Reg CHR Rep Text New region of CHR report Earliest Reg Name Text 
Name of first (new) region of 
report 
Reg CHR Name Text Name of new region of CHR report Age at earliest Event Number Age at earliest event 
Was Reg CHR 
Rep 
Text Pre-PCT region of CHR report Earliest Event Code Number 
1 - HIV lab report; 2 - CHR 
report;  3 - AIDS report; 4 - 
Death; 9 - unknown. 
Country CHR Text Country CHR report Latest Date Date/Time Date of most recent event 
Cbirth Number Country of Birth (only from CHR) Latest Rep Date/Time Date of most recent report 
Year of Arrival Number 
(For patients not born in UK) year of 
arrival as recorded on CHR report 
Latest Reg Text 
Last region of report - coded 
to new regions 
CD4 count Number 
CD4 count (at time of clinician's 
report) 
Latest Reg Name Text 
Name of last (new) region of 
report 
Date CD4 Date/Time Date of CD4 count at HIV diagnosis    
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A.8 Methodology for deduplication of HARS records 
Routine deduplication occurred when new reports are added to the database. 
Only records that had at least a fully matched soundex or date of birth as well 
as the same sex and scores above 60 were considered as possible duplicates 
and were assessed subjectively by users. The weighting score was loosely 
based upon the inverse frequency at which the data occurred in the database in 
December 1995 (Table A.3). Exact matches were given more weighting than 
fuzzy matches (those with some matching and some discordant data). Missing 
values had no effect on the scoring system. 
Table A.3. Multiplicative scoring system for identifying possible duplicate reports 
Variable Match Weighting 
Number of 
different 
values* 
Range of 
frequency of 
values* 
Date of birth Exact 25 
11,212 1 – 14 
 Fuzzy 
2 if only the years match, 7 if 2 
of day, month or year match 
Soundex Exact 10 
2,997 1 – 262 
 Fuzzy 
5, 7.5 or 8.3 depending on 
whether first, second or third 
digit is the first discordant one 
(the surname initial must agree) 
Sex  
2 if both male, 4 if both female, 
0.5 if discordant 
2 3,231 – 22,512 
First initial Exact 2 (1
st
 initial only) 26 1 – 1,639 
Route of infection Exact 3 8 27 – 16,696 
Ethnic group Exact 4 7 171 – 12,442 
* Frequency at which variables occurred among cumulative new diagnoses in England and Wales reported 
to end of December 1995 as defined by year of earliest report. December 1995 was used to reflect the 
integration of the HIV and AIDS patient databases. 
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The maximum score of 6,000 could be obtained if all variables matched, 
whereas a score of 20 would result from a match between two records that had 
the same soundex, male sex and same route of infection (would therefore not 
be assessed). 
Supporting evidence for a true match included the following: the soundex 
beginning with infrequent letters (I, Q, U, X, Y or Z); matching dates of death; 
matching GUM clinic identifiers; matching locations of diagnosis (town or city 
outside London, hospital or clinic within London). 
Information from possible duplicate records is presented on the screen to help 
users decide whether they should be linked. The data shown are: local patient 
ID number, soundex, initials, date of birth, sex, source hospital of HIV diagnosis, 
source hospital of AIDS diagnosis, date of death, likelihood of match score, 
route of infection, country of infection, ethnicity, earliest date of diagnosis in the 
UK. Duplicate scores are presented in descending order with the highest score 
representing the most likely match. Further details on previously entered 
records are viewed for clarification and, if necessary, the original forms are 
examined for further notes. The user entering the data must decide whether to 
link the new report to any of the previously entered records. A different user 
must confirm this deduplication before it is stored as such in the database.  
In addition to the routine deduplication that occurs when new reports are added 
to the database, quarterly deduplication is also carried out on the whole 
database to identify duplicate records that have not previously been detected. 
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Dates of birth, sex and forename initial are used to identify potential duplicate 
records from the same individual that have been reported with different soundex 
codes. The process is similar to deduplication as described above. Data 
presented to aid the decision are: local patient ID number, soundex, initials, 
date of birth, sex, health authority of HIV diagnosis, date of diagnosis, date of 
last negative test, route of infection, country of infection, ethnicity and any 
comments.  
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A.9 Methodology for deduplication of CD4 Surveillance 
records  
Patient records are annually deduplicated such that all CD4 counts from 
duplicate records are attributed to a master record. Information such as 
soundex code, date of birth, sex, laboratory location, and local patient ID 
number are used to search for matches within the database. Information not 
used in the searching process such as initials, date of death and CD4 counts 
can be assessed to determine which of the possible matches should be linked. 
All punctuation is removed from patient identifiers to ensure comparability. 
A.9.1 Deduplication process before 2005 
The CD4 Surveillance application provided options of search modes (Figure 
A.1a and Table A.4), which when run, searched the database and presented 
the number of matches found, flagging those that were selected as true 
matches due to additional matching information. All of the potential duplicates in 
each search mode were stored in a temporary dataset and had to be browsed 
individually (Figure A.1b). The user had to decide whether to retain the decision 
made by the program or change that decision. Once all of the potential 
duplicates had been assessed the user updated the database with the 
decisions made. The first reported patient record was considered a ‘master 
record’ and the CD4 count data of its duplicates were transferred to this record. 
The duplicates were marked as ‘not genuine’ patients and were also marked 
with the record number of their master records. Patient information, such as 
soundex code, date of birth, sex and date of death that were missing from the 
master record were transferred from the duplicate record.  
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Figure A.1. Deduplication process a) search modes b) decision-making 
a)      b) 
 
 
 
 
 
 
Thousands of potential duplicate records were individually checked each year to 
ascertain which records were to be deduplicated and which should not. Only 
3.1% (572/18,284) of the potential duplicates identified in April 2002 were 
considered to be true matches. 
Table A.4. Results of the deduplication process, April 2002 
Soundex 
Date of 
birth 
Patient ID number 
Possible 
duplicates 
Flagged 
as real 
Deduplicated 
exact exact ignore 658 580 294 
fuzzy* exact ignore 4,261 286 68 
exact fuzzy* ignore 5,831 225 21 
ignore ignore primary = secondary 208 1 179 
ignore ignore fuzzy primary* - - - 
ignore ignore fuzzy secondary* 7,296 0 10 
Total 18,284 1,092 572 
* fuzzy matches are those with slightly differing soundex codes or dates of birth 
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A.9.2 Deduplication process since 2005 
An algorithm was developed to improve the efficiency of the deduplication 
process based on the algorithm developed for record linkage between the CD4 
Surveillance and SOPHID databases (Section 3.6). This process employed a 
hierarchical algorithm of queries to extract potential matches according to 
certain criteria (Table A.5). Some of the database queries behind this process 
were split even further to allow more specific subsets of the matches to be 
linked without manual inspection. This process was a successful development 
of the earlier application because 80% (7,561/9,433) of the potential duplicates 
identified were considered to be true matches and it linked many patient records 
that were missing soundex codes in CD4 Surveillance. 
Matches 4-15 were not repeated after 2005 because they were not greatly 
productive and subsequent matches were expected to pick up any valid links.  
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Table A.5. Results of the hierarchical deduplication process used in 2005 
(records deduplicated sequentially and therefore not considered in subsequent 
matches) 
Level 
Local patient ID 
number 
Laboratory 
Date of 
birth 
Soundex Sex 
Matches 
found 
Deduplicated 
1      27 26 
2      45 45 
3      755 752 
4      88 16 
5  1     322 33 
6 minus 1
st
 character     114 94 
7 minus 1
st
 character     31 31 
8 minus 1
st
 character     4 1 
9 minus 1
st
 character     819 23 
10 minus first 2 characters     122 46 
11 minus first 2 characters     8 8 
12 minus first 2 characters     6 4 
13 minus first 3 characters     73 0 
14 minus first 3 characters     0 0 
15 minus first 3 characters     0 0 
16 excluding any zeros     182 182 
17 substring of six
2
     1,831 1,686 
18 substring of five
2     306 242 
19      2,748 2,748 
20      118 116 
21      1,004 971 
22      196 167 
23      18 18 
24    
minus last 
character  515 314 
25    3  7 7 
26   Americanised
4
   94 31 
Total 9,433 7,561 
1
 local patient ID number must be longer than four characters 
2
 an exact match between any six/five consecutive characters of the local patient ID number 
3
 and same firstname initial  
4
 switched day and month of birth  
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A.10 Methodology for record linkage between HARS and 
CD4 Surveillance  
A.10.1 Record linkage to HARS before 2004 
Record linkage was carried out in a similar manner to the deduplication process 
in CD4 Surveillance before 2005 (Appendix A.9.1). However, search modes 
(Figure A.2a and Table A.6), allowed the user to browse a temporary dataset of 
matches between the HARS and CD4 database. The user was presented with 
an abbreviated set of demographics (Figure A.2b) and other information from 
each database and had to select true matches as in the deduplication process. 
The user’s decisions were aided by the frequency of the soundex code and date 
of birth from auxiliary tables. The results of the decision-making process were 
used to update records in CD4 Surveillance with the patient ID number from 
HARS. 
Figure A.2. Record linkage process a) search modes b) decision-making 
Table 11. b) 
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 Of the 12,346 records that were considered as possible matches between the 
HARS (March 2002 archive) and CD4 databases, 2,636 (21%) were judged to 
be true matches. The majority of these were matched with exact soundex and 
date of birth or with patient ID numbers. 
Table A.6. Record linkage to HARS, April 2002 
Soundex Date of birth Patient ID number 
Possible 
matches 
Flagged as 
true 
Linked 
exact exact ignore 1,684 1,499 1,396 
ignore ignore exact secondary 574 0 269 
ignore ignore exact primary 1,248 0 844 
fuzzy exact ignore 3,132 184 37 
exact fuzzy ignore 4,543 173 42 
ignore ignore fuzzy primary 75,490* - - 
ignore ignore fuzzy secondary 598 0 0 
exact 
Date/month 
swap 
ignore 9,394* 19 - 
exact 
soundex + 
initial + sex 
Date/month 
swap 
ignore 567 19 48 
Total 12,346 1,875 2,636 
* these possible matches were not assessed as the yield was judged to be too low for the time required 
A.10.2 Record linkage to HARS since 2004 
As with deduplication (Appendix A.9.2), an algorithm was developed to improve 
the efficiency of record linkage to HARS based on the algorithm developed for 
record linkage between the CD4 Surveillance and SOPHID databases (Section 
3.6). A key change to that process was that soundex codes and dates of birth 
missing from reports to CD4 Surveillance but identified from record linkage to 
SOPHID, were included in CD4 record linkage to HARS. Results indicated that 
there was a high degree of record linkage between CD4 Surveillance and 
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SOPHID (Chapter 3), which was expected as these reports should be received 
concurrently for the same individuals and with the same local patient ID 
numbers. It was expected that greater completion of soundex codes and dates 
of birth in CD4 Surveillance would improve record linkage to HARS, which was 
more likely to have different local patient ID numbers associated with the time of 
diagnosis. 
The hierarchical algorithm originally considered all criteria that might result in 
possible matches between the CD4 Surveillance and HARS databases (Table 
A.7). Records linked were excluded from subsequent matches. This ensured 
that only the strongest link would be retained if there was more than one 
potential match to the same record. 
The results of the original process showed that there were relatively small 
numbers of records that matched at the lower levels and that this did not 
substantially improve the record linkage. Possible matches at levels 15, 16 and 
19-21 (italicised) were therefore not included in subsequent record linkage as 
they were judged to be insufficiently specific. 
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Table A.7. Results of the hierarchical record linkage process used in 2004 (records linked sequentially) 
Level Date of birth Soundex Sex 
Local patient ID 
number 
Exposure Ethnicity Location Records linked 
1    X    21,098 
2        11,060 
3    substring of five1    2,625 
4        41 
5        516 
6        353 
7        62 
8    substring of five1    248 
9    substring of five1    140 
10        72 
11        27 
12        23 
13        8 
14  fuzzy 2      111 
15  fuzzy 3      277 
16        26 
17  fuzzy 2    missing  157 
18 fuzzy 
4
       77 
19 fuzzy 
5
       45 
20 fuzzy 
6
       1,868 
21 fuzzy 
6
       141 
Total 38,975 
1
 an exact match between any five consecutive characters of the local patient ID number 
2
 the first three characters of the soundex code are the same 
3
 the first character of the soundex code is the same or the numeric characters of the soundex code are the same 
4
 Americanised: switched day and month of birth 
5
 flipped day or month or year (e.g. 12 versus 21) 
6
 same day and year but different year, or same month and year but different day or same day and month but different year 
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A.11 Areas of residence reported to SOPHID  
The NHS is organised into regional and local organisations with responsibility 
for the provision of healthcare for their residents. Data were first collected for 
SOPHID in 1996 (for 1995) when 97 new District Health Authorities for England 
had just been created from the Area Health Authorities for England and Wales. 
These existed with minor boundary changes until 2001 when 303 PCTs were 
created. However, in 2005 the number of PCTs was reduced and after a period 
of change, 152 PCTs have remained since 1st October 2006. About 70% of 
these PCTs are co-terminous with local authorities, which are responsible for 
the provision of social care. In Wales, five Health Authorities were created in 
1998 from the previous Area Health Authorities for England and Wales. These 
were reorganised in 2003 into 22 local health boards to be coterminus with local 
authorities. Northern Ireland has four Health and Social Services Boards. 
In SOPHID, Health Authority of residence was collected in 1995 and 1996 but 
postcodes were added to the data request in 1997 to validate the allocation of 
Health Authorities and allocate Health Authorities where data providers could 
not do so themselves. To ensure data continuity, both Health Authority and PCT 
of residence were requested in 2001 (since the second half of 2001 in London). 
Once data continuity was assured, Health Authority was no longer requested in 
the national survey but PCT of residence continues to be collected. Internal 
consistency between these residence-based data are validated on receipt of the 
data and checked with data providers as necessary. To provide consistent 
trends over time by area of residence, PCTs have been retrospectively 
allocated, and these data are reasonably complete from 2001 onwards. 
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A.12 Data collected by the SOPHID surveys. 
Table A.8. List of fields collected by the SOPHID surveys (data dictionary sent to data providers). 
Field Name Details Description Format/Coding 
SDEX Soundex
 
code of surname Used to  link reports from the same patient (soundexing program available on request) e.g. A123  
INITIAL Initial of first name 
Used to link reports from the same patient and to identify individuals with the same soundex and      
date of birth (e.g. twins) 
dd/mm/yyyy 
DOB Date of birth Used to link reports from the same patient and to calculate age dd/mm/yyyy 
SEX Sex Male or female Numeric code (see field codes) 
CLINID Patient’s identification code within the clinic Used to link reports from the same patient E.g. alpha-numerical code 
PCTres PCT of residence Primary Care Trust Code – where postcode not available (first collected in the 2001 survey)  
LA/UAres LA/UA of residence Local/Unitary Authority Code – where postcode not available  
HAres HA of residence Health Authority of residence (not collected after the 2001 national survey )  
POSTCODE Full (unit) postcode 
Used for derivation of  LA, PCT and SHA of residence and to summarise spatial distribution  
of residents within a health district 
e.g. NW9 5EQ 
SITE  Site of care Place where patient attended for treatment 
e.g. St Mary’s London, or codes 
with allocation stated  e.g. SML=St 
Mary’s London 
PEXP Infection route How infection was probably acquired Numeric code (see field codes) 
CLIN Clinical stage of infection Most advanced clinical stage patient has ever reached Numeric code (see field codes) 
DATEAIDS Date of most recent AIDS Date of diagnosis of most recent AIDS defining illness (this should not be defined by CD4 count) dd/mm/yyyy 
ETHN Ethnic group Ethnic group classification (NHS classification can be accepted) Numeric code (see field codes) 
ARV Antiretroviral therapy Level of antiretroviral therapy prescribed by your clinic/site when last seen Numeric code (see field codes) 
ARVSTART Date of start of ARV 
Date this patient first ever started a course of antiretroviral therapy – may not be HAART  
and may not necessarily be at your clinic/site (please estimate if exact date not known) 
dd/mm/yyyy 
CD4 CD4 cell count Most recent CD4 cell count in the survey period (per microlitre) Number e.g. 357 
VL Viral load Most recent viral load  in the survey period (number of copies per millilitre) Number e.g. 35000 
VLDATE Date of viral load Date of most recent viral load in the survey period dd/mm/yyyy 
PREVCARE Previous HIV care at another site 
Did the patient ever receive HIV treatment or care elsewhere before attending at your clinic/site? 
Include previous care abroad. N.B. do not include those who have had a first test and then been 
instantly transferred to your centre. 
Y/N/NK or numeric code (see field 
codes) 
DATEPOS 
Date positive on site or date of 
first
 
attendance 
If PREVCARE = ‘N’ or 1, enter date of patient’s first positive test/diagnosis (include ‘immediate’ 
referrals such as individuals diagnosed at a GP and referred directly to you), or 
If PREVCARE = ‘Y’ or  0, enter date of patient’s first attendance at your clinic/site 
If PREVCARE = ‘NK’ or 9, enter the earliest date you have for that patient at your clinic/site. 
dd/mm/yyyy 
DLSEEN 
Date patient last seen at this site 
or date of death in the survey period 
Date patient was last seen for care within the survey period  OR date of death if the person is known 
to have died within the period 
dd/mm/yyyy 
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A.13 Comparison of SOPHID deduplication algorithms. 
Table A.9. Comparison of SOPHID total counts of adults per year according to 
the traditional SOPHID deduplication algorithm and the algorithm used to create 
the report table. 
Year 
SOPHID totals based on 
exact soundex, date of 
birth and sex matching 
SOPHID totals based on the 
record linkage algorithm  
shown in Table 11 
Difference 
1995 13,499 13,408 91 
1996 13,608 13,484 124 
1997 14,873 14,521 352 
1998 16,560 16,126 434 
1999 18,659 18,146 513 
2000 21,061 20,549 512 
2001 24,596 23,903 693 
2002 29,338 28,490 848 
2003 34,263 33,392 871 
2004 39,064 38,253 811 
2005 44,430 43,319 1,111 
2006 48,991 48,103 888 
2007 53,231 52,453 778 
Overall 89,076 79,596 9,480 
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A.14 Descriptive analysis of factors associated with 
record linkage between HARS and SOPHID  
 Table A.10. Proportions of records linked between HARS and SOPHID by first 
letter of surname, month and day of birth  
 
Proportion of linked 
HARS patients      
(total number)  
n (%) 
 
Proportion of linked 
HARS patients      
(total number)  
n (%) 
 
Proportion of linked 
HARS patients      
(total number)  
n (%) 
               
First letter of 
surname 
 
Month of 
birth 
 
Day of 
birth 
 
A 1,788  (76) 1 3,286  (77) 1 1,641  (75) 
B 3,169  (79) 2 2,954  (77) 2 1,306  (78) 
C 2,921  (78) 3 3,436  (80) 3 1,265  (78) 
D 1,869  (78) 4 3,233  (77) 4 1,205  (80) 
E   670  (77) 5 3,453  (78) 5 1,289  (77) 
F 1,167  (78) 6 3,433  (78) 6 1,364  (78) 
G 1,751  (78) 7 3,284  (78) 7 1,287  (78) 
H 2,219  (80) 8 3,290  (78) 8 1,251  (79) 
I 237  (76) 9 3,191  (77) 9 1,197  (77) 
J 1,062  (75) 10 3,248  (78) 10 1,422  (79) 
K 1,963  (77) 11 3,160  (78) 11 1,199  (78) 
L 1,604 (77) 12 3,281  (78) 12 1,390  (78) 
M 5,235  (80)   13 1,190  (79) 
N 1,759  (79)   14 1,271  (78) 
O 1,056  (77)   15 1,477  (78) 
P 1,649  (77)   16 1,223  (78) 
Q 67  (78)   17 1,272  (79) 
R 1,607  (76)   18 1,221  (80) 
S 3,148  (77)   19 1,237  (77) 
T 1,468  (79)   20 1,353  (78) 
U 101  (81)   21 1,227  (77) 
V 385  (74)   22 1,262  (78) 
W 1,945  (80)   23 1,290  (77) 
X 22  (36)   24 1,275  (77) 
Y 160  (81)   25 1,422  (80) 
Z 227  (69)   26 1,213  (76) 
    27 1,211  (78) 
    28 1,322  (78) 
    29 1,158  (78) 
    30 1,158  (77) 
    31 651  (80) 
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Appendix B: HARS reporting forms  
B.1 Laboratory forms 
Originally, in 1984, microbiologists reported newly diagnosed HIV infections 
individually on the pre-existing ‘Form 30’ for the reporting of ‘Individual 
infections with virus, chlamydia, rickettsia or mycoplasma’ or ‘Form 30C’ that 
was a ‘Composite form for viruses – not hepatitis’ (Table B.1 and Form B.1a/b). 
Guidance for completion was provided on an accompanying sheet. The 
initiation of HIV serosurveillance in March 1985 led to use of ‘Form 30A’, the 
‘Composite form for HTLV 3/LAV’, which allowed the reporting of up to 9 cases 
per sheet and was accompanied by an HIV-specific guide for completion (Form 
B.1c). To prevent the segregation of HIV reporting from the standard laboratory 
reporting of infections, HIV was reported on ‘Form 2 – Communicable Disease 
Reporting' from 1989 to 1993, a form that was also used to report other viral 
and bacterial infections (Form B.1d).  In September 1993, the first dedicated 
HIV form with accompanying guidance sheet was introduced and this continued 
with minor modifications until 2000 (variations of ‘Form L’ and ‘Form D’ – Form 
B.1e and B.1f). There was a brief trial of a form that included an additional sheet 
that microbiologists could return to clinicians for further details along with the 
request for the confirmatory specimen. However, this was not found to be 
sufficiently utilised to justify the additional complication. After the introduction of 
clinician reporting of newly diagnosed HIV infections in January 2000 
laboratories were asked to continue reporting newly diagnosed HIV infections 
on ‘Form L0001’ (Form B.1g), which changed only marginally to the end of 2007 
(Forms B.1h and B.1i). 
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Table B.1. Data collected on laboratory report forms 
 
Form 
30 
Form 
30 C 
Form 
30 A 
Form  
2 
1
 
Form  
D 93 
Form  
D 95 
Form 
L0001 
Form 
L3 
Form 
L4 
Data field           \          Period of use 
pre 
1985 
pre 
1985 
1985 - 
1989 
1989 -
1993 
1993 - 
1995 
1995 - 
2000 
2000 - 
2001 
2001 - 
2004 
2004 -
2008 
Source hospital or clinic     X X X X X 
Reference lab. X X X  X X  
2 2 
Clinician/consultant who requested the test       X X X 
Patient soundex or surname X A A or C A or C X X X X X 
Forename X B or C B or C B or C      
Initial(s)     X X X X X 
Clinic/Hospital patient identifying number   C or A C or A X X X X X 
Laboratory patient identifying number X  C or A C or A X X X   
Age X D or E X D or E      
Date of birth    E or D X X X X X 
Sex X X X X X X X X X 
Pregnant X    
5 5 
   
HIV type     X X X X X 
Date of specimen X X X X X X X X X 
Ethnic group     
4 4 
X X X 
Has patient been tested in this lab. before?       X   
If yes, result:       X   
If yes, when       X   
Has patient been anti-HIV tested before?     X X  X X 
If yes, result:     X X  X X 
If yes, date of last negative test        X X 
If yes, place of last negative test        X X 
If yes, when     X X    
If yes, where     X X    
Has patient been HIV-diagnosed before? X      X X X 
If yes, when X      X X X 
If yes, where       X X X 
Details of any recent seroconversion     X X    
Facility where specimen taken     X X X X X 
Clinical features at date of specimen X X X X X X    
Infection contributed to death? X   X      
Died? X  X       
Date of death     
5 5 
   
Main reason for request X  X  X X    
Exposure(s) of patient   X X X X X X X 
Probable country(ies) of infection of patient     
4 4 
X 
3
 X 
3
 X 
Exposure(s) of partner     X X X 
3
 X 
3
 X 
Probable country(ies) of infection of partner       X 
3
 X 
3
 X 
Comment:     X X X X X 
Reported by X X X X X X X X X 
Date report sent X X X    X X X 
Reporting laboratory X X X X X X X X X 
A = surname or soundex of surname, B = forename, C = clinic or laboratory patient ID number, D = age, E = date or year of birth 
1
  Form 2 also collected the ‘Organism and subtype’, ‘Date of onset of illness’, ‘Organism identified in: Specimen type’,  
‘Organism detected by: Isolation, Direct fluorescent microscopy, ELISA, Specific immunoglobulin, Serology: X4 rise OR single titre’ 
but these fields were not related to HIV infections. 
2
 only requested if HIV-2 positive 
3
 only requested for individuals exposed through heterosexual intercourse 
4
 only requested if infected abroad 
5
 requested in comment field
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Form B.1a. ‘Form 30’ for the reporting of ‘Individual infections with virus, 
chlamydia, rickettsia or mycoplasma’ 
 
 
 504 
 
Form B.1b. ‘Form 30C’ – ‘Composite form for viruses – not hepatitis’  
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Form B.1c.‘Form 30A’, the ‘Composite form for HTLV 3/LAV’ 
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Form B.1d. ‘Form 2’ – ‘Communicable Disease Reporting' 
 509 
 
 
 510 
 
 
 511 
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Form B.1e. ‘Form L 09.93’ – first dedicated laboratory HIV reporting form 
 513 
 
 
 514 
 
Form B.1f. ‘Form D 03.95’ – Laboratory HIV reporting form 
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                                                                                   CDSC use only 
Laboratory report of newly identified  
anti HIV positive specimen CONFIDENTIAL 
   week no Serial No 
 
Consultant/clinician who requested the test 
 
 Clinic/ward/hospital/practice result returned to 
 
  Patient Soundex or Surname 
 
Initial(s)  Clinic/Hospital No.  Date of Birth 
____/____/____ 
 Sex  Date of specimen 
____/____/____ 
  Lab. No. 
 PLEASE CHECK BOX IF YOU DO NOT WISH US TO CONTACT THE REQUESTING CLINICIAN FOR FURTHER INFORMATION   
   Results:    HIV 1/2 specific testing not done           HIV-1 Pos     Neg           HIV-2 Pos     Neg        
      Has the patient been tested in this laboratory before?         YES     NO  
           If YES Date of most recent previous diagnosis  ___/___/___  Result  POS          NEG           INDETERMINATE  
      Has the patient had HIV diagnosed elsewhere?                   YES            NO            NK  
           If YES:  when?   (mm/yy)  ___/___    where? ………………………………………………………………………..………………. 
   ETHNIC GROUP (if known) 
   1White    5Black-Caribbean    6Black-African     7Black-Other      8Indian/Pakistani/Bangladeshi    4Other/Mixed       
   FACILITY WHERE SPECIMEN COLLECTED 
       1  GUM Clinic 
       2  Antenatal Clinic 
       3  Other out Patient (specify) ……………………………………………………………………………………………………………………….. 
       4  In Patient 
       5  GP 
       6  Drug dependency unit 
       7  Blood Transfusion Service 
       8  Accident and Emergency 
          Post mortem Specimen 
          Other: specify …………………………………………………………………………………………………………………………………………… 
 
   EXPOSURE(S) OF PATIENT, IF KNOWN FROM REQUEST FORM (please tick all that apply) 
         Homosexual intercourse 
         Heterosexual intercourse: please give risk factor(s) of partner(s) and possible countries of infection in COMMENT 
         Injecting Drug Use 
         Child of HIV infected mother 
         Haemophilia  
         Blood / tissue recipient 
  Other: specify …………………………………………………………………………………………………………………………………………… 
  Not Known 
COM COMMENT 
 
 
Reported by: Date Reporting Laboratory 
 
 
 
       PHLS Communicable Disease Surveillance Centre                                                                   Form L0001 
 
Form B.1g. ‘Form L0001’ – Laboratory HIV reporting form 
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PLEASE REPORT ALL INDIVIDUALS WHEN THEY ARE FIRST 
IDENTIFIED AS HIV POSITIVE IN YOUR LAB, EVEN IF THERE IS A 
HISTORY OF THEM HAVING BEEN PREVIOUSLY FOUND POSITIVE 
ELSEWHERE 
 
 
In January 2000 there was a change in the surveillance of new diagnoses of HIV 
infection in England, Wales and Northern Ireland.  Previously surveillance of HIV 
diagnoses relied solely on microbiologists reporting the HIV positives identified in their 
laboratory, while the clinicians treating people with HIV infection were only asked to 
report those who developed AIDS.  The introduction of more effective antiretroviral 
therapy from 1995 onward led to a rapid decline in the number of AIDS cases in those 
treated.  As a result AIDS was no longer a largely unbiased marker of disease 
progression and clinicians were reporting a decreasing proportion of the patients in their 
care.  In response to this change clinicians have been asked to report all HIV infected 
patients at their first UK diagnosis.  Because of their direct contact with patients, 
clinicians can provide additional information to that available in the laboratory. 
 
Despite the change outlined above, laboratory reporting remains vital to the surveillance 
of HIV infection for three reasons: 
 To provide continuity with the previous 15 years of reporting, 
 To indicate the diagnoses for which clinicians’ reports would be expected, 
 To provide basic information when clinician reporting is delayed or inappropriate. 
  
LABORATORY REPORTING OF NEW DIAGNOSES OF HIV INFECTION 
REMAINS ESSENTIAL TO NATIONAL SURVEILLANCE. 
 
Because of the changed situation the laboratory report form was simplified.  
Reporters are asked  to complete only as much of the form as they can from 
information available in the laboratory at the time of making the diagnosis.  We do, 
however, ask for information which will allow us to contact the doctor who 
requested the test unless the laboratory reporter asks us not to do so.   
 
Circumstances  in which the reporter will be routinely contacted for further 
information: 
 
 If the fields identifying the requesting doctor and the “clinic/ward/ hospital/practice 
result returned to” have not been completed 
 If the report does not give enough information (soundex code and date of birth or 
clinic or hospital number) to identify the patient at the place where they are 
receiving care 
 If the date of the specimen is not given 
 If the route of infection is not recorded and the form asks us not to contact the 
clinician providing care 
 
PLEASE SEND COMPLETED FORMS  “IN STRICT MEDICAL CONFIDENCE” TO: 
The Director PHLS CDSC, 61 Colindale Avenue, London NW9 5EQ 
(PHLs use DX6530002 Colindale NW) 
For more forms, details of soundex coding or help with any queries ring: 
020-8200-6868, ext 4406, or 4455 
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                                                                                   CDSC use only 
CONFIDENTIAL  
Laboratory report of new HIV diagnosis  
   week no Serial No 
 
Consultant/clinician who requested the testing 
 
 Clinic or ward and hospital/practice result returned to 
 
  Patient Soundex or Surname 
 
Initial(s)  Clinic/Hospital No.  Date of Birth 
____/____/____ 
 Sex  Date of specimen 
____/____/____ 
  Lab. No. 
 PLEASE CHECK BOX IF YOU DO NOT WISH US TO CONTACT THE REQUESTING CLINICIAN FOR FURTHER INFORMATION   
Results:   HIV positive – type not known            HIV-1 Pos     Neg           HIV-2 Pos     Neg   
               If HIV-2 Positive please state confirmatory lab, or test used         …………………………………………………………………………… 
Had patient ever had an HIV test prior to this diagnosis?         YES     NO     NK            If YES:- 
  Date and place of last negative HIV test (if any)       ___/___/___        …………………………………………………………………………… 
  Date and place of earliest HIV diagnosis              ___/___/___        …………………………………………………………………………… 
  (if any previous to this one) 
ETHNIC GROUP (if known) 
   1White    5Black-Caribbean    6Black-African     7Black-Other      8Indian/Pakistani/Bangladeshi    
4Other/Mixed       
FACILITY WHERE SPECIMEN COLLECTED 
      1  GUM Clinic 
      2  Antenatal Clinic 
      3  Other out Patient (specify) ……………………………………………………………………………………………………………………….. 
      4  In Patient 
      5  GP 
      6  Drug dependency unit 
      7  Blood Transfusion Service 
      8  Accident and Emergency 
         Post mortem Specimen 
         Other: specify …………………………………………………………………………………………………………………………………………… 
 
EXPOSURE(S) OF PATIENT, IF KNOWN FROM REQUEST FORM (please tick all that apply) 
      1  Homosexual intercourse 
      6  Heterosexual intercourse:please give risk factor(s) of partner(s) and possible countries of infection in COMMENT 
      2  Injecting Drug Use 
      8  Child of HIV infected mother  
      4  Haemophilia 
      5  Blood / tissue recipient 
         Other: specify …………………………………………………………………………………………………………………………………………… 
         Not Known 
CDSC use only                
CC    
    
 
Reported by: Date Reporting Laboratory 
 
 
 
       HEALTH PROTECTION AGENCY 
       Communicable Disease Surveillance Centre                                                                        Form L3 
 
COMMENT 
Form B.1h. ‘Form L3’ – Laboratory HIV reporting form 
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PLEASE REPORT ALL INDIVIDUALS TO THE HIV/AIDS REPORT SECTION 
(HARS) AT CDSC WHEN THEY ARE FIRST IDENTIFIED AS HIV POSITIVE IN 
YOUR LAB, EVEN IF THERE IS A HISTORY OF THEM HAVING BEEN 
PREVIOUSLY FOUND POSITIVE ELSEWHERE 
 
In January 2000 there was a change in the surveillance of new diagnoses of HIV 
infection in England, Wales and Northern Ireland.  Previously surveillance of HIV 
diagnoses relied solely on microbiologists reporting the HIV positives identified in 
their laboratory, while the clinicians treating people with HIV infection were only 
asked to report those who developed AIDS.  The introduction of more effective 
antiretroviral therapy from 1995 onward led to a rapid decline in the number of AIDS 
cases in those treated.  As a result AIDS was no longer a largely unbiased marker 
of disease progression and clinicians were reporting a decreasing proportion of the 
patients in their care.  In response to this change clinicians have been asked to 
report all HIV infected patients at their first UK diagnosis.  Because of their direct 
contact with patients, clinicians can provide additional information to that available 
in the laboratory. 
 
Despite the change outlined above, laboratory reporting remains vital to the 
surveillance of HIV infection for three reasons: 
 To provide continuity with the previous 15 years of reporting, 
 To indicate the diagnoses for which clinicians’ reports would be expected, 
 To provide basic information when clinician reporting is delayed or 
inappropriate. 
  
LABORATORY REPORTING OF NEW DIAGNOSES OF HIV INFECTION 
REMAINS ESSENTIAL TO NATIONAL SURVEILLANCE. 
 
Because of the changed situation the laboratory report form was simplified.  
Reporters are asked  to complete only as much of the form as they can from 
information available in the laboratory at the time of making the diagnosis.  
We do, however, ask for information which will allow us to contact the doctor 
who requested the test unless the laboratory reporter asks us not to do so.   
 
Circumstances  in which the reporter may be contacted for further 
information: 
 
 If the fields identifying the requesting doctor and the “Clinic or ward and 
hospital/practice result returned to” have not been completed 
 If the report does not give enough information (soundex code and date of birth 
or clinic or hospital number) to identify the patient at the place where they are 
receiving care 
 If the date of the specimen is not given 
 If the route of infection is not recorded and the form asks us not to contact the 
clinician providing care 
 
PLEASE SEND COMPLETED FORMS “IN STRICT MEDICAL CONFIDENCE” TO: 
 
HEALTH PROTECTION AGENCY,  
Communicable Disease Surveillance Centre, 
HARS Section, 61 Colindale Avenue, London NW9 5EQ 
 
For more forms, pre-paid labels, details of soundex coding or help with any 
queries ring: 
020-8200-6868, ext 4406, or 4455 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 519 
 
  
       CDSC use only 
CONFIDENTIAL  
Laboratory report of new HIV diagnosis  
   week no Serial No 
 
Consultant/clinician who requested the testing 
 
 Clinic or ward and hospital/practice result returned to 
 
  Patient Soundex or Surname 
 
Initial(s)  Clinic/Hospital No.  Date of Birth 
____/____/____ 
 Sex  Date of specimen 
____/____/____ 
  Lab. No. 
 
  Ethnic group  
 
  1White     5Black-Caribbean     6Black-African      7Black-Other       8Indian/Pakistani/Bangladeshi      4Other/Mixed    
PLEASE TICK BOX IF YOU DO NOT WISH US TO CONTACT THE REQUESTING CLINICIAN FOR FURTHER INFORMATION   
RESULTS    
HIV positive – type not known            HIV-1 Pos     Neg           HIV-2 Pos     Neg   
If HIV-2 positive please state confirmatory lab, or test used         …………………………………………………………………………………… 
 
Had patient ever had an HIV test prior to this diagnosis?         YES     NO     NK            If YES:- 
  Date and place of last negative HIV test (if any)      ___/___/___        …………………………………………………………………………… 
   Date and place of earliest positive HIV diagnosis   ___/___/___        …………………………………………………………………………… 
 
 
 
FACILITY WHERE SPECIMEN COLLECTED 
 
5  GP 
     1  GUM Clinic 11 Prison 
 2  Antenatal Clinic 6  Drug dependency unit 
 8  Accident and Emergency 
 
7  Blood Transfusion Service 
 3  Other out Patient: specify …………………………………………………    Post mortem specimen 
      4  In Patient    Other: specify …………………………………………………..…… 
 EXPOSURE(S) OF PATIENT  
 6  Heterosexual intercourse (please give risk factor(s) for partner(s) in COMMENT) 
 1  Homosexual intercourse 4  Haemophilia 
 2  Injecting Drug Use 5  Blood / tissue recipient 
8  Child of HIV infected mother 9  Not known 
        Other: specify………………………………………………………………………………………………………….………………………………………………………………… 
 
Patient’s probable country of infection………………………………………………………………………………………………………….……………………… 
 
 
 
 
Partner’s probable country of infection (if known) ………………………………………………………………………………….…………………….…… 
 
Reported by: Date Reporting Laboratory 
 
 
Communicable Disease Surveillance Centre                   L4                                                               
Form B.1i. ‘Form L4’ – Laboratory HIV reporting form 
 
 
COMMENT
CC
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PLEASE REPORT HIV POSITIVE INDIVIDUALS WHEN THEY ARE FIRST IDENTIFIED 
IN YOUR LAB, EVEN IF PREVIOUSLY DIAGNOSED ELSEWHERE 
 
Laboratory reporting of new diagnoses of HIV infection is essential to national 
surveillance of HIV infection.  
Since the beginning of the UK’s HIV epidemic laboratories have been reporting diagnoses 
of HIV infection to CDSC. Clinician HIV reporting was introduced in 2000 to supplement 
laboratory reporting of HIV by collecting additional information, such as country of birth, 
behavioral data and treatment information which is not readily available in laboratories. 
Despite the introduction of clinician HIV reporting, laboratory reporting remains vital to HIV 
surveillance because: 
 ● in many cases it provides the only record of a new diagnosis, particularly for diagnoses 
made in non GU settings such as GPs, non GU departments, prisons and at post mortem 
 ● it provides continuity with reporting before 2000, when laboratory reporting was the only 
source of information on new HIV diagnoses  
 
Reporters are asked to complete as much of the form as possible from information 
available in the laboratory at the time of diagnosis. 
However, there are some fields that must be completed so we can determine whether we 
already know about a previous diagnosis in an HIV-infected individual: 
 ● soundex code* of surname 
 ● date of birth 
 ● sex 
 ● date of diagnosis (within the UK) 
If any one of these is missing from a report, we cannot immediately enter the form onto the 
surveillance database and will have to therefore contact the clinician for the information.  
 
Electronic reporting of new HIV diagnoses may be possible if your laboratory 
records are computerised. 
Please contact us to discuss the possibility of electronic reporting. 
 
PLEASE SEND COMPLETED FORMS “IN STRICT MEDICAL CONFIDENCE” TO: 
 
HARS, CDSC, Health Protection Agency, 61 Colindale Avenue, London NW9 5EQ 
 
 
*For more forms, pre-paid postage labels, details of soundex coding or help with any 
queries ring: 020-8200-6868 ext 4406 or 4455 
 
Thank you for your continuing support 
 
 
 
 521 
 
B.2 AIDS forms 
Table B.2. Data collected on AIDS forms 
 Period of use 
Data field 
pre 
1985 
1985 - 
1987 
1987 - 
1989 
1989 -
1993 
1993 - 
1996 
1996 - 
1997 
1997 - 
1998 
1998 - 
1999 
Newly diagnosed AIDS or death without AIDS      X X X 
Patient soundex or surname X X X X X X X X 
Forename(s) X X X      
Initial(s)     X X X X 
Date of birth X X X X X X X X 
Clinic/Hospital patient identifying number      X X X 
Name of hospital if patient hospitalised X X       
Location of hospital if patient hospitalised X X       
Sex X X X X X X X X 
Age X X       
Occupation of patient X  X X X X X X 
Patient’s usual address  X X X X X X X 
Town or postal district X X X X X X X X 
Full postcode   X X X X X X 
Health District/Authority (if not town/postal district)   X X X X X X 
Local Authority (if not town/postal district)    X X X X X 
Is patient overseas visitor intending to return home   X X X X X X 
If yes, country of residence   X X X X X X 
If immigrant, from what country  X       
Country(s) (if patient has lived abroad)   X X X X X X 
Date from (if patient has lived abroad)   X X X X X X 
Date to (if patient has lived abroad)   X X X X X X 
Country of birth (if patient has lived abroad)     X X X X 
Ethnic group X X X X X X X X 
Country of origin (if African, Caribbean or other) X X       
Marital status X X X X X X X X 
Sexuality X X X X X X X X 
Exposure(s) of patient X
1
 X
1
 X
2
 X
3
 X
4
 X
4
 X
4
 X
4
 
Non-injecting drug use  X       
Any further details about likely exposure(s)   X X X X X X 
Sexual contacts with Americans/Caribbeans X X       
Date of last negative HIV test   X X X X X X 
HIV antibody positive   X X X X X X 
HIV antigen/culture positive   X X     
Date of first positive test   X X X X X X 
Where? (first positive test)      X X X 
HIV-2 positive     X X X X 
Cause of immunodeficiency if patient not HIV+   X X X X X X 
Date of AIDS diagnosis (mm/yy)   X X     
AIDS indicator disease (table xx.xxx) X X X X X X X X 
Date of onset of AIDS indicator disease X X X X X X X X 
Definitive or presumptive diagnosis    X X X X X 
Site of illness X X X      
Method of diagnosis X X X X     
Signs and symptoms of illness X X X  X    
Unusual or interesting clinical features    X     
Date of onset of signs and symptoms X X X  X    
Date of first presentation for medical advice X X       
Presence of serious underlying condition  X X       
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Did patient donate blood in 5 years prior to illness  X X       
Is this case related to any other known cases X X       
Previously, did patient have infection/vaccination X
5
 X
5
  X
6
     
Has patient had surgery since Dx or in last 5 years X        
Details of HTLV III serology X        
Lowest total white blood cell count  X       
% of lymphocytes corresponding to the above  X       
% of T cells corresponding to the above  X       
CD4 count at time of AIDS diagnosis    X X    
Date of CD4 count     X    
Other immunological test results  X X      
Was patient on ARV before AIDS diagnosis     X X X X 
If yes, what was the most intensive level of ARV       X X 
What drugs were prescribed at that time        X 
Was the patient still on ARV at AIDS diagnosis       X X 
Date of first starting ARV treatment (mm/yy)      X X X 
Did patient get Pneumocystis pneumonia (PCP) 
prophylaxis before AIDS Dx 
    X X X X 
Date of first starting PCP prophylaxis (mm/yy)      X  X 
Did patient get other prophylaxis before AIDS Dx     X X X X 
Has the patient died X X X X X X X X 
If yes, date of death X X X X X X X X 
Cause of death   X  X X X X 
Name and address of notifying doctor X X       
Name and address of notifying consultant X X       
Name of reporting consultant/GP   X X X X X X 
Address   X X X X X X 
Telephone number X X X X X X X X 
Completed by   X X X X X X 
Position    X X X X X 
Date of report  X X X X X X X 
1
 IV drug use and which drugs; did the patient have a blood transfusion; did the patient receive blood products 
 
2
 misused drugs by injection, had any injection abroad, had blood transfusion, had blood products, had surgical procedures, 
been sexually active abroad (homo/hetero), had other known exposure to a HIV+ve person, other possible exposure. For 
all, when and whether in the UK or abroad 
3
 injected drugs for recreational use, had a blood transfusion, had blood products for a coagulation disorder, had sexual 
relations abroad (homo/hetero), had sexual relations with any of the following: IDU, bisexual man, person with 
haemophilia/coagulation disorder, person with AIDS or known to be HIV-infected. For all, when and whether in the UK or 
abroad 
4
 sexual intercourse between men, sexual intercourse between men and women – including possible country of infection, 
IDU, child of HIV-infected mother, haemophilia/coagulation disorder, blood/tissue recipient – including country and reason. 
For all, approximate dates 
5
 YES/NO/UNKNOWN. How many times? Year of last infection. For gonorrhea, syphilis, non-gonococcal urethritis, genital 
herpes simplex, amoebiasis, giardiasis, hepatitis A (infectious), hepatitis B (serum), vaccination against hepatitis B 
6
 YES/NO. Month and year of first diagnosis. For herpes zoster, pulmonary tuberculosis, acute hepatitis B, syphilis, 
gonorrhoea, non-specific gonococcal infection 
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Form B.2a. ‘AIDS form 83-85’ – ‘Questionnaire for surveillance of A.I.D.S. 
 524 
 
 
 525 
 
 
 526 
 
 
 527 
 
 
 528 
 
 
 529 
 
Form B.2b. ‘AIDS form 85-87’ – ‘Questionnaire for surveillance of A.I.D.S. and 
Kaposi’s Sarcoma 
 530 
 
 
 531 
 
 
 532 
 
 
 
 533 
 
 
 534 
 
 
 535 
 
Form B.2c. ‘AIDS form 87-89’ – ‘AIDS surveillance: clinical report’ 
 536 
 
 
 537 
 
 
 538 
 
Form B.2d. ‘AIDS form 89-93’ – ‘AIDS surveillance and HIV death clinical report’ 
 539 
 
 
 540 
 
 
 541 
 
 
 542 
 
Form B.2e. ‘AIDS form 93-96’ – ‘AIDS surveillance and HIV death clinical report’ 
 543 
 
 
 544 
 
 
 545 
 
 
 546 
 
Form B.2f. ‘AIDS form 96-97’ – ‘AIDS surveillance and HIV death clinical report’ 
 547 
 
 
 548 
 
Form B.2g. ‘AIDS form 97-98’ – ‘AIDS surveillance and HIV death clinical report’ 
 549 
 
 
 550 
 
Form B.2h. ‘AIDS form 98-99’ – ‘AIDS surveillance and HIV death clinical report’ 
 551 
 
 
 552 
 
 
 553 
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B.2 Clinician HIV Reporting forms 
Table B.3. Data collected on CHR forms 
 Form number 
Data field C0001  C2 C3 
Confidential report of:    
Newly diagnosed HIV infection X X  
     and/or AIDS diagnosis X X  
     and/or death without AIDS in an HIV-infected person X X  
First UK diagnosis of HIV infection   X 
     and/or first UK diagnosis of AIDS    X 
     and/or death without AIDS in an HIV-infected person   X 
To be completed on all reports:    
Reporting consultant X X X 
Hospital/centre X X X 
Department/ward  X X 
Telephone number X X X 
Patient soundex or surname X X X 
Initial(s) X X X 
Date of birth X X X 
Sex X X X 
Clinic/Hospital patient identifying number X X X 
If in UK temporarily, usual country of residence X X X 
Country of birth X X X 
     If not UK, year of first arrival in UK X X X 
Ethnicity X X X 
Probable route of HIV infection:    
     Sex between men X X X 
          Year of first sex between men X X X 
          In last year, estimated no. of male partners X X X 
          In last year, estimated no. of female partners X X X 
          Does the patient believe himself to be infected through oral sex  X X 
     Injecting drug use X X X 
          Year first injected X X X 
          Year last injected X X X 
          Ever used needle exchange X   
     Sex between men and women (had sex with) X X  
     Sex between men and women (patient probably infected by)   X 
          Bisexual male X X X 
          Injecting drug user X X X 
          Partner presumed heterosexually infected X X X 
               If yes, partner’s likely country of infection X X X 
     Other (please specify) X X X 
     Not known X X X 
     Comment field for other information X X X 
Patient presumed infected in the UK X X X 
     If no, in which country(ies) X X X 
Previously tested  X X 
First ever negative HIV test (date and place) X X  
Last negative HIV test (date and place) X X X 
First positive test (date and place) X X X 
HIV-1 X   
HIV-2 X   
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HIV+ (type not known) X   
Pregnant at diagnosis X X X
1
 
     If yes, estimated date of delivery X X X
1
 
Previous live births since 1980 (year and country of each) X X X 
Complete only for HIV diagnoses made after 01/01/2000 X X  
Patients not previously diagnosed HIV positive in the UK   X 
HIV diagnosing laboratory X X X 
Date of current diagnosis  X X 
Any evidence of HIV-2  X X 
Date of laboratory report (mm/yy) X   
Reason for test X X X 
Pregnant at diagnosis   X
1 
     If yes, estimated date of delivery   X
1
 
Ever attended STD clinic before HIV diagnosis X X  
     If yes, year of first attendance X X  
Symptoms (at HIV diagnosis, pre-treatment) X X X 
CD4 count (at HIV diagnosis, pre-treatment) X X X 
Date of CD4 count (at HIV diagnosis, pre-treatment) X X X 
Viral load (at HIV diagnosis, pre-treatment) X X X 
Date of viral load (at HIV diagnosis, pre-treatment) X X X 
Complete for AIDS diagnosis, or death without AIDS in a HIV+ person:    
AIDS indicator disease X X X 
Definitive or presumptive diagnosis X X X 
Date of diagnosis (mm/yy) X X X 
Any non-HIV related cause of immunodeficiency X X X 
Was patient ever on ARV therapy (before AIDS/death without AIDS) X X X 
     If no, reason  X X 
     If yes, approximate duration of pre-AIDS/death without AIDS treatment   X 
Date stopped ARV therapy (mm/yy)   X 
Reason stopped   X 
Highest level of ARV prescribed (before AIDS/death without AIDS) X X  
     Date started at that level (mm/yy) X X  
     ARV drugs prescribed at that time X X  
     Was this level of ARV maintained to AIDS/death without AIDS X X  
          If yes, factors contributing to compliance X X  
          If no, reasons X X  
Did the patient receive prophylaxis for PCP X X  
Did the patient receive prophylaxis for any other opportunistic infection X X  
Complete for all reports:    
Has the patient died X X X 
     If yes, date of death (dd/mm/yy) X X X 
     Cause of death X X X 
     If no, date of last contact X X X 
Completed by X X X 
     Position X X X 
     Date of report X X X 
Updated by X X X 
     Position X X X 
     Date of report X X X 
1
 moved from section for all reports to section for patients not previously diagnosed HIV positive in the UK 
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Form B.3a. ‘Form C0001’ – ‘HIV, AIDS or HIV Death report’ 
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Form B.3b. ‘Form C2’ – ‘HIV, AIDS or HIV Death report’ 
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Form B.3c. ‘Form C3’ – ‘HIV, AIDS or HIV Death report’ 
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Appendix C: Supplementary data on evaluating algorithms to 
determine estART 
C.1 Evaluating a smoothed increase in CD4 counts 
After the smoothing mechanism was applied, the evaluation of the algorithm 
included 8,945 (82.1%) of the random sample of 10,897 individuals (Figure C.1). 
There was a peak in the likelihood ratios and the cut-off of 110 cells/mm3 had the 
highest likelihood ratio (highlighted in Table C.1) and was selected to produce the 
results. 
Figure C.1. Distribution of CD4 counts in relation to startART  
 
8,945 eligible individuals with 
28,933 CD4 counts
6,561 (22.7%) counts
more than 31 days before 
startART or not last count
5,387 (18.6%) last count
before startARTand within 31 
days
Median change 0
(IQR -22, 10)
cells per mm3
Median increase 29
(IQR 0, 80)
cells per mm3
16,985 (58.7%) counts
after startART
Median increase 12
(IQR 0, 48)
cells per mm3
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Table C.1. Summary table for a single increase in smoothed CD4 counts 
Cut-off for 
change in 
CD4 counts 
/ cells/mm
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0 8,650 3,903 295 168 61% 7% 46% 0.655 
20 6,866 3,811 2,079 944 60% 37% 53% 0.945 
40 5,595 3,170 3,350 1,343 50% 52% 50% 1.041 
60 4,344 2,458 4,601 1,672 39% 65% 46% 1.102 
80 3,282 1,886 5,663 1,921 30% 75% 43% 1.168 
100 2,408 1,404 6,537 2,127 22% 83% 39% 1.271 
110 2,013 1,190 6,932 2,212 19% 86% 38% 1.331 
120 1,472 1,028 7,473 2,261 16% 88% 37% 1.330 
130 1,492 885 7,453 2,304 14% 90% 36% 1.328 
140 1,284 756 7,661 2,336 12% 91% 35% 1.288 
160 930 544 8,015 2,390 8.5% 93% 33% 1.200 
180 657 386 8,288 2,445 6.1% 95% 32% 1.218 
200 482 282 8,463 2,478 4.4% 96% 31% 1.199 
 
 
C.2 Evaluating a preceding decrease and subsequent 
increase in CD4 counts 
The evaluation of the algorithm included 9,284 (85.2%) of the random sample of 
10,897 individuals (Figure C.2). Of their 30,401 CD4 cell counts, 8,479 (27.9%) 
were preceded by a decrease and followed by an increase in CD4 counts. The 
remaining 21,922 CD4 counts were not preceded by a decrease and followed by 
an increase in CD4 counts: 9,688 were preceded and followed by increases, 7,937 
were preceded by an increase and followed by a decrease, 4,206 were preceded 
and followed by decreases, and 91 were preceded and followed by no change. 
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With this algorithm the likelihood ratios changed little using the different cut-offs. 
The cut-off of 150 cells/mm3 (highlighted in Table C.2) was selected to produce the 
results. 
Figure C.2. Distribution of CD4 counts in relation to startART  
 
9,284 eligible individuals with 
30,401 CD4 counts
6,693 (22.0%) counts
more than 31 days before 
startART or not last count
5,700(18.7%) last count
before startARTand 
within 31 days
1,849 (27.6%) counts were 
preceded by a decrease and 
followed by an increase 
2,791 (49.0%) counts were 
preceded by a decrease and 
followed by an increase
18,008 (59.2%) counts
after startART
3,839 (21.3%) counts were 
preceded by a decrease and 
followed by an increase
Overall combined median 
magnitude change 123
(IQR 73, 195)
cells per mm3
Overall combined median 
magnitude change 155
(IQR 91, 245)
cells per mm3
Overall combined median 
magnitude change 116
(IQR 65, 191)
cells per mm3
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Table C.2. Summary table for a preceding decrease and subsequent increase in 
CD4 counts 
Cut-off for 
change in 
CD4 counts 
/ cells/mm
3
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0 6,249 2,706 3,035 1,320 40% 51% 43% 0.824 
10 6,227 2,696 3,057 1,323 40% 51% 43% 0.822 
20 6,140 2,660 3,144 1,345 40% 52% 43% 0.826 
30 6,015 2,590 3,269 1,376 39% 53% 43% 0.825 
40 5,826 2,509 3,458 1,416 38% 55% 42% 0.826 
50 5,593 2,419 3,691 1,473 36% 57% 42% 0.837 
60 5,345 2,310 3,939 1,527 35% 59% 41% 0.839 
70 5,099 2,204 4,185 1,571 33% 61% 41% 0.835 
80 4,873 2,121 4,411 1,616 32% 62% 40% 0.841 
90 4,612 2,039 4,672 1,678 30% 65% 40% 0.863 
100 4,349 1,934 4,935 1,738 29% 67% 40% 0.876 
110 4,077 1,825 5,207 1,799 27% 69% 39% 0.890 
120 3,824 1,724 5,460 1,853 26% 71% 39% 0.902 
130 3,572 1,607 5,712 1,905 24% 73% 38% 0.904 
140 3,326 1,510 5,958 1,943 23% 75% 37% 0.899 
150 3,089 1,409 6,195 1,994 21% 77% 37% 0.911 
160 2,872 1,304 6,412 2,028 19% 78% 36% 0.893 
170 2,684 1,223 6,600 2,057 18% 79% 35% 0.883 
180 2,471 1,134 6,813 2,102 17% 81% 35% 0.894 
190 2,274 1,038 7,010 2,146 16% 83% 34% 0.898 
200 2,106 963 7,178 2,177 14% 84% 34% 0.895 
220 1,942 886 7,342 2,204 13% 85% 33% 0.881 
240 1,788 812 7,496 2,227 12% 86% 33% 0.858 
260 1,665 754 7,619 2,251 11% 87% 32% 0.852 
280 1,532 684 7,752 2,273 10.2% 88% 32% 0.826 
300 1,413 636 7,871 2,294 9.5% 88% 32% 0.822 
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C.3 Evaluating a preceding decrease and subsequent 
increase in smoothed CD4 counts 
The evaluation of the algorithm included 7,513 (68.9%) of the random sample of 
10,897 individuals (Figure C.3). There were 5,063 CD4 counts that were preceded 
by a decrease or no change and followed by an increase in smoothed CD4 counts. 
The remaining 18,436 CD4 counts were not preceded by a decrease and followed 
by an increase in smoothed CD4 counts: 7,123 were preceded and followed by 
increases, 5,230 were preceded by an increase and followed by a decrease, 4,715 
were preceded and followed by decreases, and 1,368 were preceded and followed 
by no change.  
There was a clear but minor peak in the likelihood ratios with this algorithm and 
the cut-off of 130 cells/mm3 had the highest likelihood ratio (highlighted in Table 
C.3) and was selected to produce the results. 
Figure C.3. Distribution of CD4 counts in relation to startART  
7,513 eligible individuals with 
23,499 CD4 counts
5,509 (23.4%) counts
more than 31 days before 
startART or not last count
3,859 (16.4%) last count
before startARTand 
within 31 days
849 (15.4%) counts were 
preceded by a decrease and 
followed by an increase 
1,673 (43.4%) counts were 
preceded by a decrease and 
followed by an increase
14,131 (60.1%) counts
after startART
2,541 (18.0%) counts were 
preceded by a decrease and 
followed by an increase
Overall combined median 
magnitude change
40 (IQR 19, 78)
cells per mm3
Overall combined median 
magnitude change
68 (IQR 30, 120)
cells per mm3
Overall combined median 
magnitude change
42 (IQR 20, 80)
cells per mm3  
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Table C.3. Summary table for a preceding decrease and subsequent increase in 
smoothed CD4 counts 
Cut-off for 
change in 
CD4 counts 
/ cells/mm
3
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0 4,320 2,030 3,193 1,950 45% 64% 53% 1.27 
10 4,006 1,902 3,507 2,053 42% 68% 53% 1.31 
20 3,561 1,732 3,952 2,176 39% 72% 52% 1.37 
30 3,145 1,571 4,368 2,305 35% 76% 52% 1.46 
40 2,745 1,398 4,768 2,408 31% 79% 51% 1.51 
50 2,362 1,225 5,151 2,511 27% 83% 50% 1.58 
60 2,065 1,082 5,448 2,599 24% 86% 49% 1.68 
70 1,777 943 5,736 2,652 21% 87% 48% 1.67 
80 1,538 817 5,975 2,701 18% 89% 47% 1.66 
90 1,315 720 6,198 2,763 16% 91% 46% 1.79 
100 1,154 620 6,359 2,790 14% 92% 45% 1.72 
110 962 526 6,551 2,837 11.7% 93% 45% 1.80 
120 829 456 6,684 2,864 10.2% 94% 44% 1.81 
130 707 394 6,806 2,890 8.8% 95% 44% 1.84 
140 607 335 6,906 2,905 7.5% 96% 43% 1.75 
150 525 288 6,988 2,925 6.4% 96% 43% 1.77 
 
 
C.4 Evaluating a positive slope in CD4 counts 
The evaluation of the algorithm included 9,284 (85.2%) of the random sample of 
10,897 individuals (Figure C.4). Using this algorithm the specificity approached 
100% as the cut-offs increased and there was no peak in the likelihood ratios. 
Therefore, the cut-off of 800 cells/mm3 per year (highlighted in Table C.4) was 
selected as it resulted in a similar sensitivity (22.5%) as the previous algorithms. 
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Figure C.4. Distribution of CD4 counts in relation to startART  
9,284 eligible individuals with 
30,401 CD4 counts
6,693 (22.0%) counts
more than 31 days before 
startART or not last count
5,700 (18.7%) last count
before startART
(within 31 days)
Median slope
-122 (IQR -288, 15)
cells per mm3 per year
Median slope
162(IQR -22, 461)
cells per mm3 per year
18,008 (59.2%) counts
after startART
Median slope
196(IQR 16, 465)
cells per mm3 per year
 
 
Table C.4. Summary table for a slope in CD4 counts 
Cut-off for 
change in 
CD4 counts 
/ cells/mm
3
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100 7,880 4,486 1,404 640 67% 25% 55% 0.89 
200 6,791 4,023 2,493 1,109 60% 43% 55% 1.05 
300 5,635 3,462 3,649 1,531 52% 59% 54% 1.26 
400 4,659 2,944 4,625 1,824 44% 70% 51% 1.48 
500 3,837 2,493 5,447 2,061 37% 79% 49% 1.81 
600 3,171 2,109 6,113 2,182 32% 84% 46% 1.98 
700 2,651 1,796 6,633 2,276 27% 88% 44% 2.19 
800 2,209 1,508 7,075 2,351 23% 91% 42% 2.41 
900 1,844 1,283 7,440 2,410 19% 93% 40% 2.70 
1,000 1,569 1,088 7,715 2,445 16% 94% 38% 2.83 
1,100 1,337 927 7,947 2,472 14% 95% 37% 2.95 
1,200 1,130 786 8,154 2,495 12% 96% 35% 3.08 
1,300 977 690 8,307 2,512 10% 97% 34% 3.26 
1,400 850 597 8,434 2,518 9% 97% 34% 3.05 
1,500 728 508 8,556 2,533 8% 98% 33% 3.23 
1,600 629 446 8,655 2,546 6.7% 98% 32% 3.60 
1,700 552 393 8,732 2,552 5.9% 98% 32% 3.63 
1,800 489 354 8,795 2,559 5.3% 99% 31% 3.92 
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C.5 Evaluating a preceding negative slope and subsequent 
positive slope in CD4 counts 
The evaluation included 7,513 (68.9%) of the sample of 10,897 individuals (Figure 
C.5). There were 7,448 counts that were preceded by a negative slope and 
followed by a positive slope. Of the remaining 16,051 counts: 8,223 were 
preceded and followed by positive slopes, 4,845 were preceded by a positive 
slope and followed by a negative slope, 2,979 were preceded and followed by 
negative slopes, and 4 were preceded and followed by slopes of zero. 
Using this algorithm the specificity approached 100% as the cut-offs increased and 
there was no peak in the likelihood ratios. Therefore, the cut-off of 800 cells/mm3 
per year (highlighted in Table C.5) was selected as it resulted in a similar 
sensitivity (22.4%) as the previous algorithms. 
Figure C.5. Distribution of CD4 counts in relation to startART  
7,513 eligible individuals with 
23,499 CD4 counts
5,509 (23.4%) counts
>31 days before startART
3,859 (16.4%) last count
before startART
(within 31 days)
2,174 (39.5%) counts were 
preceded by a decrease and 
followed by an increase 
2,526 (65.5%) counts were 
preceded by a decrease and 
followed by an increase
14,131 (60.1%) counts
after startART
2,748 (19.4%) counts were 
preceded by a decrease and 
followed by an increase
Overall combined median 
magnitude change
552 (IQR 314, 991)
cells per mm3 per year
Overall combined median 
magnitude change
645 (IQR 386, 1080)
cells per mm3 per year
Overall combined median 
magnitude change
490 (IQR 261, 916)
cells per mm3 per year  
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Table C.5. Summary table for a preceding negative slope and subsequent positive 
slope in CD4 counts 
Cut-off for 
change in 
CD4 counts 
/ cells/mm
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100 4,459 1,637 3,054 1,947 37% 64% 48% 1.02 
200 4,146 1,591 3,367 2,080 36% 69% 49% 1.13 
300 3,741 1,522 3,772 2,243 34% 74% 50% 1.30 
400 3,331 1,456 4,182 2,382 33% 78% 51% 1.51 
500 2,897 1,365 4,616 2,529 30% 83% 52% 1.83 
600 2,518 1,255 4,995 2,634 28% 87% 52% 2.12 
700 2,143 1,091 5,370 2,724 24% 90% 51% 2.38 
800 1,881 1,001 5,632 2,783 22% 92% 50% 2.69 
900 1,653 905 5,860 2,834 20% 93% 50% 3.05 
1,000 1,440 814 6,073 2,867 18% 94% 49% 3.28 
1,100 1,243 720 6,270 2,900 16% 96% 48% 3.61 
1,200 1,071 640 6,442 2,920 14% 96% 47% 3.77 
1,300 929 577 6,584 2,943 13% 97% 47% 4.25 
1,400 817 513 6,696 2,960 11% 98% 46% 4.64 
1,500 716 459 6,797 2,971 10% 98% 46% 4.86 
1,600 627 399 6,886 2,978 8.9% 98% 45% 4.74 
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